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Abstract 
Background: Lung function tests (LFT) provide valuable insights into respiratory 
physiology, and have been proven to be useful outcome measures in both clinical 
research and the clinical management of children with lung disease.  Standardised 
methods and appropriate interpretation are, however, essential if these measurements 
are to be applied reliably. The aims of this thesis were to improve the application and 
interpretation of LFT’s in children and to determine the extent to which ethnic 
differences in lung function (LF) occurred between healthy Black and White children 
after adjusting for height, sex and age. 
Methods: A series of investigations using four commercially available LFT (Impulse 
oscillometry (IOS), specific airways resistance (sRaw), plethysmographic lung volumes, 
and spirometry) involving 400 healthy children (214 Black and 186 White) aged 4-12y 
were undertaken.  Upon determining the most appropriate methods for interpreting LF 
in health, the LFT’s and a respiratory health questionnaire were applied to children with 
Sickle Cell Disease (SCD) to determine the extent to which each outcome measure 
identified LF abnormalities in these children. 
Results: Reference data for measurements of sRaw in children were developed as well 
as recommendations for interpreting spirometry and plethysmography in Black children. 
Despite the relatively high proportion of respiratory symptoms reported in SCD, the 
proportion of children with LF results falling outside the limits of normal was relatively 
small, and a pattern of restrictive lung disease was observed.   Of the outcomes 
assessed in this thesis, spirometry appeared to be the most robust outcome measure 
for routine assessment of LF in SCD. 
Conclusions: Results from this thesis contribute to the literature that SCD is primarily 
associated with restrictive lung disease.  Furthermore, the new interpretation strategies 
developed during the work for this thesis prevented significant misinterpretation of LF in 
Black children, and improved the standards for using these LFT’s in children.   
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1 Introduction 
1.1 Aim of the thesis 
Lung function tests provide valuable insights into respiratory physiology, and have 
been proven to be useful outcome measures in clinical research as well as valuable 
adjuncts in the clinical management of children with lung disease.  Standardised 
methods and appropriate interpretation are however, essential if these measurements 
are to be applied reliably.  The broad aim of this thesis is to evaluate the methods and 
interpretation of paediatric lung function measurements in children aged 4 to 12 years.  
Prior to considering this aim, this introduction chapter will briefly review basic 
respiratory physiology in health and disease; evaluate the literature on the methods of 
assessing and interpreting lung function in children (at inception of this thesis in 2008), 
and identify the lung function tests selected for evaluation in this thesis.  This chapter 
will conclude with a summary of the different methods of interpretation, the aim of the 
thesis and the hypotheses. 
1.2 Respiratory physiology 
The principle function of the lungs is to transport oxygen from the atmosphere to the 
lungs and to release carbon dioxide from the bloodstream into the atmosphere.  The 
structure of the lung is perfectly designed for this function; during inspiration, air flows 
into the lung as a consequence of pressure changes within the lung (brought about by 
the action of the “respiratory pump,” that is, the diaphragm, intercostal and accessory 
muscles, operating on the thoracic cage).   While expiration is generally a passive 
process measures of forced expiration can provide information about the mechanical 
properties of the lung.  This section will describe the functional anatomy of the lung, 
respiratory mechanics, and forced expiratory flows in health and lung disease. 
1.2.1 Functional anatomy  
The respiratory system comprises the upper airways (the nasal cavity, pharynx and 
larynx), the lower airways (trachea, primary bronchi and bronchial tree) and the small 
bronchioles and alveoli within the lung tissue (Figure 1-1a). Each alveolus is closely 
associated with a network of capillaries.  Expansion of the lungs (i.e. inspiration) affects 
all its components, but mainly increases the surface area of alveoli and, in doing so 
facilitates the exchange of gas across the alveolar-capillary membrane.   
 
 
Figure 1-1: a) Anatomy of the respiratory system. b) muscles used for ventilation 
Adapted from “Human Physiology” by Dee Unglaub Silverthorn. ISBN10: 0321590899 
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The main muscles involved in breathing are shown in Figure 1-1b.  Breathing is largely 
driven by the diaphragm, which is innovated by the phrenic nerve.  Upon contraction, 
the diaphragm descends downwards pulling the ribcage with it.  Concurrently the 
external intercostal muscles contract and the ribcage rises, thus the thorax is elongated 
and widened.  Since the lungs are connected to the thoracic wall by the pleural 
membranes they also expand.  This results in increasing the volume, and decreasing 
the pressure within the lungs, causing air to flow into the airways along the pressure 
gradient.  The “mechanical work” required to expand the lungs, and overcome the 
impedance to movement of the lungs, chest wall and abdomen is described in section 
1.2.3. 
 
The framework of the lungs is made up of bundles of elastic and collagen fibres that 
extend from the large airways down to the alveoli and across to the pleura and blood 
vessels.  The constituent fibres are relatively indistensible but they can move in relation 
to each other so the bundles of fibres lengthen and uncurl and alter their relative 
positions.  The force required to maintain inflation of the lung is provided by the chest 
wall and diaphragm, which are in turn recoiled inward by the pull of the lungs. The 
lung–chest system thus acts as two opposed coiled springs, the length of each of 
which is affected by the other, and ultimately determines the lung volume.  
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1.2.2 Determinants of lung volume 
The amount of gas in the lungs at different levels of inflation is represented as volumes 
when consisting of single components, and capacities when they comprise two or more 
components.  The partitioned lung volumes are labelled in the spirogram (Figure 1-2). 
 
Figure 1-2: Spirogram identifying different lung volume levels.  
Legend: IRV = Inspiratory Reserve Volume; VT  = Tidal Volume; ERV = Expiratory Reserve Volume;  
IVC = Inspiratory Vital Capacity; RV = Residual Volume; IC = Inspiratory Capacity; FRC = Functional 
Residual Capacity; TLC = Total Lung Capacity 
 
Lung volumes are governed by a balance of forces of different mechanisms relating to 
respiratory muscle activity, chest wall function, airway size and tone, and the elastic 
recoil properties of the lung.  In the absence of movement, the extent of lung inflation 
reflects a balance between the elastic recoils of the lungs and chest wall, gravitational 
force and tension in the respiratory muscles.  This “resting lung volume” is termed 
Functional Residual Capacity (FRC) and occurs when the inward pull of the lung is 
balanced by the outward pull of the chest wall.  Movement occurs when the equilibrium 
is disturbed and is influenced by the strength of the applied force, the elasticity of the 
lung and chest wall, the resistance to movement and the inertia of the thoracic cage, 
lung tissue and volume of gas contained in the lung.  At Total Lung Capacity (TLC) and 
Residual Volume (RV) the inspiratory and expiratory muscles have reached the limit of 
their ability to oppose the elastic recoil. These concepts are described in detail in the 
following section (section 1.2.3).  
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1.2.3 Respiratory mechanics 
The mechanical work required to ventilate the lungs is expressed over an entire 
breathing cycle comprising inspiration and expiration.  Air is moved in or out of the 
lungs whenever the sum of the pressures developed by the passive recoil of the 
respiratory system and by the respiratory muscles is different from zero.  Work is 
required to expand the lungs and overcome the impedance to movement of the lungs, 
chest wall and abdomen.  To produce air movement, the driving pressure of the 
respiratory muscles must overcome the forces opposing the movement of gas flow.  
The mechanics of the respiratory system are governed by the following forces: 
1.2.3.1 Impedance 
Impedance (Z) in electronics terms is a measure of the overall opposition of a circuit to 
current, in other words: how much the circuit impedes the flow of current. The concept 
of impedance with respect to the lungs is the total opposition to breathing/airflow, and 
represents the net sum forces that must be overcome to generate flow which 
encompass the resistive, inertive and the visco-elastic forces that oppose respiration. 
1.2.3.2 Resistance 
Resistance (R) means opposition to movement and is caused by the forces of friction 
that occurs between the gas molecules within the airways.  In general it represents the 
sum of viscous resistances of which airway resistance is the most significant.  
Measurement of resistance to flow of air is calculated by Ohm’s Law which states: 
Resistance is equal to pressure (P) divided by flow (V’).   
Resistance is a familiar parameter in conventional pulmonary function, and is described 
further in section 1.2.5. 
1.2.3.3 Inertance  
Inertance (I) is the force required to overcome the inertia (the tendency of an object to 
resist a change in motion) of the lungs and acceleration of gas (volume of air) into and 
out of the lung. It therefore describes the relationship between pressure and volume 
acceleration (speed of gas flow). 
1.2.3.4 Elastance 
During inspiration, contraction of respiratory muscles stretches the elastic and collagen 
tissue network of the lungs and pleura.  The work that is done in stretching the lung is 
not however, dissipated as heat, instead it is stored in the structures which have been 
stretched, and used to drive the subsequent expiration (i.e. by recoiling back to 
previous volume).  The force required to overcome the elastic properties to expand the 
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lung during inspiration is termed elastance (E), and is directly related to lung volume.  
As the lung volume increases during inspiration, the elastic recoil pressure of the lung 
(Pel) increases. The reciprocal of elastance (1/E) is the compliance (C) of the lung and 
represents the change in volume per unit change of pressure.  Pel can be regarded as 
the driving force of the expired gas since it overcomes the friction in the airways and 
the remaining pressure is used to accelerate the expired gas.   
 
Figure 1-3 illustrates the interactions between the elastic properties of the lung and 
chest wall.  At FRC the elastic recoil of the lung (pulling inwards) is balanced by the 
elastic recoil of the chest (pulling outwards), thus the transmural pressure is 0 cmH2O 
(0 kPa).  At every lung volume, the overall transmural pressure is the sum of the lung 
and chest wall pressures measured separately.  The compliance (determined by the 
volume change for a particular pressure change) of the respiratory system (lung+chest 
wall) is large at low/moderate lung volumes (i.e. large volume changes occur as a 
result of small increases in pressure), but low at high lung volumes (i.e. large pressure 
changes cause minimal volume changes) (Figure 1-3). 
 
Figure 1-3: Pressure-volume curve of the lung and chest wall. 
Legend: Elastic properties of the lung and chest wall can be examined by determining 
pressures over the entire range of volumes that the lung can contain.  The elasticity of the lung 
and chest wall are opposing forces, and the overall compliance of the lungs is dependent upon 
the lung volume. Unit conversion: 1cmH2O = 0.1kPa. 
Illustration adapted from: “Respiratory Physiology” by West (ISBN: 0683089374) 
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1.2.4 Pressure changes throughout the breathing cycle 
Airflow occurs as a consequence of pressure changes throughout the breathing cycle 
as illustrated in Figure 1-4.   
 
Figure 1-4: Alveolar and Intrapleural pressure changes during the respiratory cycle. 
Legend: Pressures given in kPa.  Ppl remains negative throughout the breathing cycle, whereas 
Palv =Patm when there is no flow (end-expiration (a & e) and end-inspiration (c)), but is negative 
during inspiration (b) and positive during expiration (d).   
Illustration adapted from “Infant respiratory function testing” by J Stocks et al. ISBN: 
0471076821 
 
  
31 
 
During inspiration, the volume of the lung increases, hence the pressure within the 
alveoli (Palv) reduces.  Since Palv is more negative than atmospheric pressure (Patm), a 
driving pressure is established and airflow occurs along the pressure gradient.  The 
increase in volume is brought about partly by contraction of the diaphragm, and partly 
by the action of the intercostal muscles.  Since the lung is elastic, during passive 
expiration the lungs and chest wall return to their original state, thus decreasing the 
volume of the lung and increasing the pressure within the lungs, such that Palv is 
greater than Patm and air moves out of the lungs.  At the end of expiration or end of 
inspiration Palv = Patm hence there is no flow and Patm, and/or pressure measured at the 
airway opening (Pmouth) is zero.   
Pleural pressure (Ppl) is the pressure difference between inside and outside the lung 
(within the pleural space), and is generally negative (in relation to Patm) due to the 
elastic recoil of the lungs.  Ppl  increases (i.e. becomes more negative) as the lung is 
stretched and its volume increases during inspiration. During the expiratory phase of 
the respiratory cycle, the inspiratory muscles relax and Ppl becomes less negative with 
respect to Patm.  The elastic recoil pressure of the lung tissue then compresses the 
alveolar gas and raises its pressure above that at the mouth (Pmouth) and air flows out of 
the mouth or nose. 
 
The continuous pressure changes throughout the breathing cycle are intrinsically 
related to the mechanical properties of the lung.  Knowledge of these pressure 
changes allow us to make measurements and assumptions about the function of the 
lungs.     
1.2.4.1 Phase relationship of acceleration, flow and volume 
The principles of respiratory mechanics are often based on the assumption of a linear 
behaviour of the pulmonary-thoracic system and are described in relation to flow, 
volume and acceleration under defined physiological conditions.  However, changes in 
flow are in fact the direct result of pressure changes within the system and not 
synchronous with time.  During inspiration, the fall in Palv precedes airflow, and volume 
is maximal at a time when flow is zero. Hence there is a phase (timing) difference 
between flow (V’) and pressure (P) with the pressure leading the flow.  This phase 
difference is determined by the elastic and the inertive properties (the resistance to 
acceleration of a volume of gas) of the lung (Figure 1-5).  
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Figure 1-5: Phase relationship between volume, flow and acceleration.   
Legend: 1) Elastic forces are overcome to achieve lung expansion and hence increase in lung 
volume.  2) The change in lung volume creates a pressure gradient in which flow can occur, 
however resistive forces have to be overcome to allow airflow.  3) Simultaneously inertial forces 
(the force acting against the acceleration of a mass of air) are overcome. 
 
Figure 1-5 illustrates the phase relationship between volume flow and acceleration.  
Inspiration is initiated by contraction of the diaphragm and intercostal muscles, which 
are the driving force to overcome the elastic forces within the lung.  Lung volume 
increases thereby creating a pressure gradient between the airway opening (which is 
equal to Patm (0 kPa)) and the alveoli (Palv, which is negative pressure with respect to 
Patm).  Airflow occurs along the pressure gradient once it has overcome the forces 
opposing the movement of gas flow: i.e. the resistance offered by the airways to the 
flow of gas, and by the viscous properties of the tissues resisting their deformation, and 
by the inertia of the gas and tissues which undergo acceleration.  If a line is drawn 
through the point of zero flow, it will intersect with the trough of the volume waveform 
and the peak of the acceleration waveform (Figure 1-5).  Thus it can be seen that flow 
leads volume by a ¼ of a cycle or 900 and that it lags acceleration by the same amount.  
Volume and acceleration are opposite in phase (or 1800 out of phase) with each other. 
The various components of resistance, both in-phase with flow (also termed “real”) and 
out-of-phase with flow (also termed “imaginary”) and pressure changes throughout the 
breathing cycle are described in section 1.2.3 and can be measured with specialised 
lung function tests (described in section 1.5).  
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1.2.5 Airways resistance 
The unique structure of the lungs facilitates gas exchange.  The progressively 
subdividing system of bronchi and bronchioles offers resistance to flow, which is 
essential to allow adequate time and surface area for gas exchange, in addition to 
allowing heating and humidification of air in to the lungs.  Measurement of resistance to 
flow of air is calculated by Ohm’s Law which states: 
Resistance is equal to pressure (P) divided by flow (V’).   
The resistance to the flow of air into and out of the lung is determined by Poiseuille's 
Law which states:  R α8nl/πr4 
Where  n= gas viscosity 
 l= length of the tube 
 r = radius of the tube. 
Poiseuille’s Law states that in a straight circular tube resistance is proportional to the 
length of the tube and inversely proportional to the fourth power of the radius.  This 
means that if the length of the tube is halved, the resistance is halved, however if the 
radius is halved, the resistance would increase by 16 fold.  As the airways get 
progressively narrower, the resistance within the individual airways increases, however 
the number of airways increases exponentially, such that the cross-sectional area of 
the lungs increases towards the periphery where overall resistance decreases (Figure 
1-6).    
 
Figure 1-6: Cross-sectional area and subsequent airways resistance  
Illustration adapted from: “Respiratory Physiology” by West (ISBN: 0683089374) 
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In the presence of lung disease, resistance in the peripheral airways (defined as 
bronchioles <2mm in diameter) is likely to increase due to significant peripheral airway 
oedema, inflammation, secretions and/or bronchoconstriction, such that airways 
resistance in the peripheral airways increases relative to the central airways.   
 
“Resistance” can be divided into three categories: 
Airways resistance (Raw): Relates to changes in alveolar pressure (Palv) to airflow.  
Since during normal breathing frequencies, the pressures producing acceleration of 
flow are negligible, flow resistance of the airways may be measured by recording the 
pressure difference between appropriate points (e.g. at end inspiration or end 
expiration) in time simultaneously with airflow.  Measurement of airways resistance is 
discussed further in section 1.7.  
Pulmonary (lung) resistance (Rlung): Comprises the lung tissue resistance plus the 
airways resistance.  Lung tissue resistance refers to the resistance offered by the lung 
tissue as it expands, and varies with lung volume:  The airways are surrounded by and 
attached to the alveoli.  At high lung volumes, the alveoli are more distended and the 
elastic recoil tension in their walls is higher, thus the lumen of the airways are pulled 
open by the high tension in the distended alveolar walls.  The increased airway calibre 
results in a reduction in airways resistance (Raw) and resistance within the airways is 
decreased.  
At lower lung volumes, the elastic recoil tension in the alveolar wall is less and thus 
reducing airway calibre in turn contributes more to airway resistance.  Pulmonary 
resistance is calculated from changes in transpulmonary pressure. 
Total respiratory resistance (Rrs): Comprises the total resistance (airway resistance + 
lung tissue resistance + chest wall resistance) to air flow in and out of the respiratory 
system.  It includes the inertia of the respiratory system, the tissue resistance of the 
lungs and chest wall, and airways resistance.   
1.2.5.1 Impact of flow on airways resistance 
The principles of airways resistance are based on Poiseuille’s Law which is based on 
“straight circular tubes.”   The lungs however are a series of branching tubes, in which 
the pressure difference depends on the rate and pattern of flow (Figure 1-7). 
  
35 
 
 
Figure 1-7: The different types of flows that can be generated.  
Legend: A) Laminar flow: flow is stream lined and parallel to the sides of the tube.  B) 
Transitional flow: unsteadiness in the flow, especially at the branches.  C) Turbulent flow: 
Complete disorganisation of stream lines.  
Illustration adapted from: “Respiratory Physiology” by West (ISBN: 0683089374) 
 
Resistance can only be described as linearly increasing pressure with increasing flow 
as long as the flow type is laminar (which occurs at low flow).  At high flows (turbulent 
flows) there is complete disorganisation of stream lines and resistance may be 
described in relation to Rohrer’s law: ∆P = k1• V’ +k2 • V’’ 
Rohrer’s law describes airflow in the airways during tidal breathing from laws on fluid 
mechanics and states that: The change in pressure is equal to a constant (K1) 
multiplied by flow (V’) plus another constant (K2) multiplied by flow acceleration (V’’).  It 
suggests that pressure changes become more dependent on gas density (rather than 
viscosity) and V’’ (rather than flow (V’)) and implies that Raw will increase as flow 
increases e.g. on exercise, due to increased turbulence.  This implies that breathing 
pattern has important implications when measuring Raw. 
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1.2.6 Forced expiratory flow  
Quiet expiration is a passive process due to the elastic properties of the lungs.  
However forced expiration is an active process requiring contraction of expiratory 
muscles (oblique and transverse abdominus muscles, internal intercostals, and the 
latissimus dorsi).  During a forced expiration the pressure distribution inside the 
bronchial tree depends on lung volume, gas properties, flow, and airway calibre.  Thus 
the mechanics of the airways and that of airflow are closely linked.  Measurements of 
forced expiratory flow are thought to reflect the integrated mechanical properties of the 
lungs and airways. 
 
Analysis of both flow-volume and pressure-flow curves gives important indications on 
the physiology of the lungs.  The maximum expiratory flow-volume (MEFV) curve has 
characteristic features that reflect the properties of the lungs.  During inspiration, flow is 
maximal at mid-volume.  It varies directly with the applied pleural pressure, therefore it 
is effort dependent.  During maximal expiration from a position of full inspiration the 
flow rises to a peak early in the manoeuvre (generated mainly by the expiratory 
muscles), and then exhibits a gradual decline as the volume in the lungs diminishes 
(dependent mainly on elastic recoil, and not from expiratory muscles) (Figure 1-8). The 
relationship of flow to time during inspiration and expiration is therefore different, with 
differing shapes on the inspiratory and expiratory flow-volume curve.  
 
Figure 1-8: Flow-Volume curve during maximal expiration and maximal inspiration. 
 
MEFV curves are largely reproducible, because, beyond a critical level of effort, the 
expiratory flow is independent of Ppl.  This independence of effort, taken together with 
the observed dependence of maximum flow on lung volume, suggests that there is a 
lung mechanism which limits the expiratory flow (see section 1.2.7.1). 
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1.2.7 Airflow limitation 
Airflow limitation is the condition in which, at a given lung volume, flow is independent 
of the pressure difference between the airway opening and the alveoli (assuming the 
pressure difference is sufficiently large to allow maximal flow).  The difference extends 
to the relationship of flow to applied pressure and is demonstrated with the iso-volume 
pressure-flow curve. 
1.2.7.1 Iso-Volume Pressure-Flow (IVPF) curve 
An iso-volume pressure-flow (IVPF) curve can be constructed by repeating inspiratory 
and expiratory flow manoeuvres at gradually increasing effort (greater Ppl and Palv) and 
recording flow, Palv and the total thoracic gas volume (TGV) (Figure 1-9).  Intra-thoracic 
pressures are measured with an oesophageal catheter and are plotted against 
expiratory flows measured at the mouth at specific lung volumes.  The IVPF curve 
demonstrates that, with the exception of the highest lung volumes, expiratory flow 
becomes limited or effort independent at relatively modest positive intra-thoracic 
pressures. 
 
 
Figure 1-9: Iso-volume pressure flow curve 
Legend: Repeated maximal inspiratory and expiratory flow-volume curves at gradually 
increasing effort (greater Ppl and Palv) and recording flow, alveolar pressure and TGV, 
demonstrates that there is a plateau of flow even with increasing effort (increased driving 
pressure) so the lung limits flow (not respiratory muscles).  Flow  therefore said to be effort 
independent.  Illustration adapted from “Physiology and Practice of Pulmonary Function” by 
Mike Hughes. 
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The pressure-flow relationship at a constant lung volume is informative:  At the start of 
expiration a rise in Ppl, together with the positive recoil pressure of the lungs, increases 
Palv and initiates expiratory flow.   However once a threshold pressure has been 
generated, a further increase in pressure does not augment the flow (seen by the 
plateau on the IVPF curve (Figure 1-9). The existence of flow limiting mechanisms has 
the effect that beyond a threshold level of effort the maximal expiratory flow reflects 
mainly the intrinsic mechanical properties of the lungs, not expiratory effort.  These 
mechanical properties can be described further by the wave speed theory and the 
development of the equal pressure point (EPP) or choke point.   
1.2.7.2 Wave speed theory  
Wave speed (velocity) is the maximal speed at which a pulse wave of gas molecules 
can be transmitted along an airway and is calculated by the formula: 
V’ws = [1/δ∙(∆Ptransmural/∆A)∙A]
1/2∙A 
Where:  A = cross-sectional area 
V’ws = Wave speed 
  δ=gas density 
  ∆Ptransmural = transmural pressure difference 
  ∆A = change in cross-sectional area. 
 
Thus, the less dense the gas, the stiffer the tube wall, and the larger its cross-sectional 
area, the higher the wave speed and hence, the higher the flow that can theoretically 
pass the tube.  According to this theory, for compressible tubes such as the airways, 
the maximum velocity is determined by an interaction between the velocity, the 
compliance of the airway wall and the convective acceleration of the gas.  The maximal 
flow therefore is the product of the velocity and the cross-sectional area of the tube, 
and the mean flow cannot exceed the speed at which the pressure driving the flow is 
propagated along the tube.   
 
The lungs consist of a series of airways each with their own wave speed flows that 
depend on a number of factors and vary with lung inflation.  Flow limitation will occur at 
the point along the bronchial tree at which local wave speed flow is minimal for a given 
lung volume and this point is called the equal pressure point (EPP) (or choke point).  At 
this location, airflow can increase until local wave speed flow is reached, however if 
more energy is added (more effort exerted), it may be converted to noise (wheeze), but 
not to increase flows.   
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1.2.7.3 Equal pressure point 
During forced expiration, the driving pressure forcing flow from the lungs is the sum of 
the pressure actively applied to the pleural space plus the lung recoil pressure.  
Throughout forced expiration, flow-related frictional and convective accelerative 
intrabronchial pressure losses occur.  At some point along the airways downstream 
from the alveoli to the mouth, flow-related pressure losses will equal the elastic recoil 
pressure and the difference between intrabronchial and extrabronchial pressure losses 
will be zero.  This point is referred to as the equal pressure point (EPP). Distal to this 
point, further intrabronchial airway pressure losses result in lower pressures within the 
airways than around them and leads to dynamic compression of downstream airways 
(i.e. towards the mouth). 
 
During forced expiration, EPPs move due to changes to the many factors that 
determine wave speed flow.  At high lung volumes, the level of the bronchial tree with 
the smallest total cross-sectional area is in the trachea.  In the smaller airways, the 
cross-sectional area is large at high lung volumes and decreases steadily as forced 
expiration proceeds to lower lung volumes.  Peripheral airway resistance thus 
increases steadily with decreasing lung volume.    Both increases in resistive losses 
and declining lung elastic recoil pressure diminish intra-airway pressures as exhalation 
proceeds.  As a result, the EPP and the location where airways are dynamically 
compressed move toward the alveoli as lung volume decreases.  Thus, the site of flow 
limitation during a forced expiratory manoeuvre occurs initially in the trachea or central 
airways in normal subjects and moves progressively upstream towards the alveoli as 
forced exhalation proceeds. 
 
An increase in resistance in the peripheral airways (e.g. due to inflammation) 
exaggerates the flow limiting mechanism because it magnifies the pressure drop along 
the airways.  Low lung volume and reduced recoil pressure (e.g. loss of elasticity, such 
as emphysema) would also exaggerate the flow-limiting mechanism (Figure 1-10). 
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Figure 1-10: Maximal Flow-Volume curves. 
A) Health,  B) moderate airway obstruction, C) severe airway obstruction  
Legend:  Reduction in forced expiratory flows are indicative of airways obstruction.  In severe 
airways obstruction (C) a reduction in vital capacity also occurs due to the airway closure. 
 
In summary, maximal flow-volume curves have a distinctive shape which provides 
important information regarding airway mechanisms and airflow limitation.  On 
inspiration, no intrapulmonary flow limitation develops as the airways are dynamically 
distended by the negative Ppl.  The entire MIFV curve and the upstroke of the MEFV 
curve are therefore dependent on the speed and force of contraction of the expiratory 
and inspiratory muscles and the flow resistance at each lung volume.  At the start of 
expiration however, the speed of airflow is limited by the rate at which the expiratory 
muscles are able to contract, until wave speed flow is reached and flow limitation is 
established.  Flow is then limited and is independent of effort. 
  
A   B        C 
41 
 
1.3 Lung function in health 
Lung function in health is significantly influenced by a number of factors including age, 
body size, genetic factors such as sex and ethnicity, socio-economic factors, family 
history of asthma and atopy, and environmental exposures including cigarette 
smoke.1,2  The previous section (1.2) has described the structure and function of the 
lung and the physiology of respiration.  A comprehensive understanding of lung 
physiology and knowledge of normal growth and development of the lung in childhood 
is essential if lung function tests are to be interpreted appropriately.  
1.3.1 The growing lung 
While the function of the lungs remains the same throughout life, it is important to note 
that children’s lungs are not simply smaller versions of adult lungs.  Significant 
structural and functional changes occur with growth primarily due to the different 
patterns of airway and parenchymal development (dysanaptic growth).  The full adult 
compliment of conducting airways and a blood-gas barrier sufficient to sustain life is 
present by 27 weeks gestation; however the airways and gas-exchanging surface area 
continue to develop after birth and throughout early childhood.  This rapid alveolar 
development stage increases lung volume at a greater rate than airway development.  
Evidence of this dysanaptic growth can be seen in Figure 1-11 where the FEV1/FVC 
ratio (an indication of airway dimension relative to lung volume) decreases with age.  
The “kink” occurring in puberty is thought to be related to differing changes in stature 
and muscle strength in relation to the pubertal growth spurt. 
 
 
Figure 1-11: The decline in FEV1/FVC throughout life. 
Adapted from Quanjer et al, ERJ 2010
3
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During early childhood there is an almost linear lung and airway growth pattern, where 
alveolar expansion, airway elongation and enlargement occur at a similar rate.  By the 
start of puberty lung function is equal in males and females of equal height, however by 
the end of puberty lung function in males is up to 25% higher than females of the same 
height.  These differences relate to differences in the growth of the thoracic cage and 
respiratory muscle strength.  Lung growth stops when the thoracic cage stops growing, 
and during adulthood there are further structural changes whereby the elastic recoil of 
the lung reduces with advancing age, and the lungs are more compliant.   
 
The continuous structural changes of the lungs throughout life have important 
implications.  Figure 1-12 depicts the increase in lung growth throughout childhood, 
and the steady decrease after the peak lung function at around 21-25 years of age.  
When measuring lung function, age and growth need to be taken into account when 
interpreting lung function results.  
 
Figure 1-12: Changes in FEV1  occurring throughout life.   
Legend: There is a steady increase in FEV1 throughout childhood which peaks at around 21 
years for males (~18 years for females), after which there is a steady decline. 
Adapted from Quanjer et al, ERJ 2010
3
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Growth and age play a key role in determining lung volumes.  During childhood, in 
addition to the overall growth of the lungs and thorax, there are significant changes in 
functional anatomy which needs to be considered when interpreting partitioned lung 
volumes:  Ossification of the rib cage begins in utero and continues until around 25 
years of age, thus the chest wall is more compliant in younger children resulting in a 
different balance between the outward chest recoil and inward lung recoil.  In addition 
to the changes in the chest wall, younger children also have lower muscle strength 
which also impacts on the partitioned lung volumes.  Since FRC reflects a balance 
between the elastic recoils of the lungs and chest wall, gravitational force and tension 
in the respiratory muscles, the functional implications of the growing (stiffening) chest 
wall, and developing respiratory muscles need to be considered when measuring and 
interpreting lung volumes in children. 
1.3.2 Ethnic differences in lung function 
The previous section highlighted the importance of considering growth and 
development when attempting to interpret lung function in children; however another 
important consideration is the impact of ethnic origin.  Anthropometric differences have 
been observed in different ethnic groups, in particular the trunk: leg ratio has been 
shown to be higher in White European children in comparison to children of Black 
origin.   Furthermore ethnic differences in lung function have been observed, with 
spirometric forced expiratory volumes and lung volumes being larger in White children 
compared to Black children4-8 (Figure 1-13). 
 
Figure 1-13: Predicted FEV1 values for three ethnic groups.  
Legend: Lower limit of normal (LLN) denoted by the dotted line.  
Adapted from Quanjer et al, ERJ 2010
3
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The observed ethnic differences in lung function have been attributed to the 
anthropometric differences, although chest wall dimensions are also thought to 
contribute to these differences.9  Several studies have reported lung function to vary 
from 10% to 25% between ethnic groups.10 The ATS/ERS has suggested adjustment 
factors of ~12% for TLC, FEV1 and FVC and ~7% for FRC when interpreting results 
from Black children.2  Previous attempts however, to correct for ethnic differences in 
lung function have been shown to be over-simplistic,7,8 and further work in interpreting 
ethnic differences is required. 
1.4 Lung disease in children 
Paediatric respiratory disease represents a major health issue, with asthma care and 
services alone costing the NHS almost £900 million per year (MRC-Asthma UK centre).  
In addition, there is evidence that much adult lung disease can be traced back to 
childhood.11,12  Therefore the importance of identifying, monitoring and treating 
childhood lung disease cannot be over-estimated.  This section will provide a broad 
overview of lung disease in children and the rationale for the lung diseases selected for 
further analysis in this thesis. 
1.4.1 Overview of lung disease 
In general, lung diseases can be categorised into those which cause an obstructive 
ventilatory defect, those which cause a restrictive ventilatory defect, and those which 
have a mixed obstructive/restrictive pattern.  Some of these defects are illustrated in 
Figure 1-14, and lung function tests have been shown to offer an insight into defining 
these ventilatory defects.2 
 
Figure 1-14: Schematic view of the differing mechanisms which cause lung disease. 
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An obstructive ventilatory defect is defined by a disproportionate reduction of 
maximal airflow from the lung in relation to the maximal volume (i.e. airflow limitation).  
In adults it is characterised by a reduced FEV1/FVC ratio,2 TLC may be normal, but RV 
is generally increased. 
A restrictive ventilatory defect is defined by a restriction on the expansion of the 
lung, resulting in a lower lung volume (reduced FVC, reduced FEV1, reduced TLC, 
however normal/increased FEV1/FVC), increased work of breathing and inadequate 
ventilation. 
 
A mixed obstructive/restrictive ventilatory defect is characterised by the 
coexistence of obstruction and restriction, and is defined by a reduced FEV1/FVC and 
reduced TLC. 
   
There are many paediatric conditions with significant respiratory symptoms and 
complications, some of which are listed in Table 1-1.  Lung function tests (LFT’s) offer 
a role in identifying obstructive or restrictive lung function abnormalities and monitoring 
respiratory status and response to intervention in these conditions. 
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Table 1-1: Common medical conditions that cause lung abnormalities in children. 
 Description Obstructive Restrictive Mixed 
Asthma Caused by a combination of genetic suspectability and environmental exposures.   
Symptoms include coughing, wheezing, chest-tightness and shortness of breath.
13
 
 
  
Sickle cell disease 
(SCD) 
Genetic blood disorder causing abnormal form of haemoglobin within the blood cells which 
then stick together causing obstructions within the blood vessels.
14
 
  
 
Cystic fibrosis (CF) Genetic disease caused by a mutation in the gene for the protein cystic fibrosis 
transmembrane conductance regulator (CFTR), which is required to regulate transfer of salt 
at the surface membranes of the lungs and pancreas.  The inability to excrete salt from the 
lungs results in a build-up of mucus, which contributes to airway obstruction, frequent 
infections and scarring of the lung.
15
 
 
  
Bronchopulmonary 
dysplasia (BPD) 
A chronic lung disorder that is common among preterm children with low birth weights and 
received prolonged mechanical ventilation.  It is characterised by inflammation and scarring 
of the lungs and long-term respiratory morbidity has been described.
16
 
  
 
Congenital lung 
abnormalities 
An incomplete development of the lungs in utero will result in an abnormally low number or 
size of alveoli
17
 
 
 
 
Chest deformities e.g. Scoliosis: A condition in which the spine is curved and can restrict the movement of the 
thorax
18
 
 
 
 
Neuromuscular 
weakness 
Weakness in the respiratory muscles prevents adequate expansion of the lungs
19
  
 
 
Interstitial lung 
diseases (ILD) 
ILD are a group of diseases that inflame or scar the lungs. Resulting in pulmonary fibrosis 
which limits the expansion of the lungs
20
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1.4.2 Rationale for patient group under investigation: Sickle Cell Disease 
Sickle Cell Disease (SCD) is an inherited blood disorder in which the red blood cells 
contain an abnormal form of haemoglobin (Hb), causing them to become misshaped 
(sickle shaped). The sickle-shaped cells stick together and to the lining of the blood 
vessels and cause obstructions (infarcts) in the blood stream.  SCD is one of the most 
prevalent genetic diseases with around 1 in 200 Afro-Caribbean children in the UK and 
1 in 400 Afro-Caribbean children in the USA born with SCD.21  It is associated with 
many pulmonary complications,14 as well as having a strong association with asthma.22  
Acute complications include pneumonia, thromboembolism, fat embolism and acute 
chest syndrome (ACS), whilst chronic complications include sickle cell chronic lung 
disease with death usually occurring within seven years of diagnosis.23  Thus SCD can 
result in significant respiratory morbidity,14 with studies to suggest that SCD progresses 
from an obstructive lung defect in childhood24 to a predominantly restrictive defect in 
adulthood.25  Lung function measurements in children with SCD could therefore 
potentially play an important role in the clinical management of children with SCD, 
however interpretation can be challenging without ethnic specific lung function 
reference equations.  Consequently, a group of healthy control children from the same 
ethnic background will also be investigated as part of this thesis. 
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1.5 Lung Function Tests  
Lung Function Tests (LFT’s) are used in both clinical care and research projects and, 
when applied in combination with a clinical history and other diagnostic tests, can be 
used: 
 to confirm/exclude the presence of abnormality/disease  
 as a guide to assess disease severity/progression  
 to distinguish between obstructive and restrictive defects  
 to monitor the course of disease or the effects of treatment   
 
An accurate LFT may be the first and indispensable step in the process of clinical 
management.  However, unlike with the situation with regards to drugs, which undergo 
rigorous testing and are registered with the Food and Drug Association (FDA), there 
are no formal requirements that lung function tests need to meet in order to be 
accepted or retained as a routine part of healthcare.  Hence careful evaluations of 
LFT’s are required before attempting to use them either in clinical management or as 
objective outcomes in research, and the following criteria should be considered:  
 Patient group (i.e. age, suspected underlying pathology, ability to follow 
instructions (co-ordination and co-operation)), 
 Equipment (i.e. whether there is commercialised equipment available and the 
ease of set-up and maintenance of this equipment),  
 Environment to be used in (i.e. specialised laboratory, ward, outpatients, school 
or other “field” environment),  
 Methods of data collection and analysis (i.e. whether tests are standardised for 
use in that particular patient group, and if adhered to equipment specifications),  
 Within-subject variability for the age/patient group being investigated, and  
 Availability of appropriate reference data.   
In addition, financial implications (e.g. the cost of equipment, consumables, time, 
expertise, and the number of technicians required) and manufacturer’s support 
(software guidance/upgrade and data handling) can have important implications.   
 
Although LFT’s are thought to be a valuable adjunct to the clinical management of 
respiratory disease, appropriate methods and interpretation are essential to optimise 
their use.  Assessments of data quality control, knowledge of the normal variability of 
the LFT, and appropriate use of reference data should be evaluated prior to making 
any clinical interpretation.  These three broad categories are described briefly here, 
and further discussed in relation to the LFT’s under investigation in sections 1.6 to 1.9. 
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1.5.1 Application and Interpretation of lung function tests 
1.5.1.1 Quality control 
Validated equipment and standardised methods are the first steps to ensuring accurate 
assessments are achieved.  LFT’s however, may involve recording tidal breathing 
patterns which are inherently difficult to standardise, or maximal expiratory manoeuvres 
which are effort dependent.  Thus the very nature of LFT’s means that considerable 
variation can occur due to a number of issues (e.g. artefact, irregular breathing pattern, 
poor co-operation, etc.).  All lung function results therefore need to undergo some level 
of quality control (QC) to determine if they are technically satisfactory.  These QC 
assessments give an indication of how reliable data are, such that, if the data do not 
meet the QC criteria, less confidence can be placed on the result.  For some LFT’s 
there are well defined QC criteria, whereas others may need more attention towards 
standardisation of quality control, particularly in children. 
1.5.1.2 Repeatability  
After assessing the quality of data and determining the test is an “acceptable” measure, 
the within-test variability of the LFT should be assessed.  All LFT’s are repeated a 
number of times and, depending on the type of test, the “best” (highest, mean or 
median) of a number of trials are reported.  An ATS/ERS task force defined 
Repeatability as “the closeness of agreement between the results of successive 
measurements of the same item carried out subject to all of the following conditions: 
same method, same observer, same instrument, same location, same condition of use, 
and repeated over a short space of time”; Whereas the term reproducibility should be 
used only if conditions have changed.26  Variability may be expressed as within-subject 
standard deviation or the coefficient of variation (CV) which is the standard deviation 
expressed as a percentage of the mean, and can be assessed in several ways (e.g. 
within-test repeatability, between-test repeatability, or long term reproducibility) and is 
dependent on the LFT applied and the age group assessed.  
 
Within-test, within-subject repeatability reflects the consistency of the subject “effort”, 
the stability of intrinsic biological factors (i.e. the subject’s breathing pattern) and the 
precision of the LFT device used.  It is used to assess flow-limitation and to ensure that 
maximum effort has been achieved, or that a stable resting lung volume (FRC) has 
been established.  For some measures the within test repeatability is defined within the 
guidelines of an “acceptable test session” however others may be less well defined.   
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Between-test repeatability (i.e. short term repeatability within a 15 minute period) is 
also important, as this allows the determination of whether an apparent change over 
time in response to an intervention is clinically significant.  Between-test repeatability 
may be influenced by disease and biological variability in lung function, the stability of 
the LFT device and the technical consistency of the subject.  If the between test 
repeatability is very low, subtle changes from this baseline measure can be detected.  
However, if the between test repeatability is large, then any “clinically significant 
change” must be something over and above that seen in the between test repeatability.  
The threshold for a significant  bronchodilator response (BDR) can be determined by 
establishing the within-subject between-test repeatability, whereby a response greater 
than twice the average baseline CV can be considered positive.1   
 
Long-term reproducibility (i.e. variability over several weeks or months) can be also be 
assessed, however this is beyond the remit of this thesis.   
1.5.1.3 Compare to reference data 
Once a LFT has undergone QC and the repeatability of the measure has been 
confirmed, the result should be compared to a known reference to determine if it is a 
“normal” or “atypical” result.  In the simplest terms the subject can act as their own 
reference to determine if there has been a significant change from baseline (e.g. the 
effect of an intervention, or change over time).  This method, however, does not give 
an indication of whether the child differs from the normal population, and is further 
limited in growing children as it does not take into account the effect of growth and 
development.  Recruitment of a prospective control group with similar characteristics as 
the index group allows the determination of group differences; however a more 
comprehensive approach is to compare results with published normative reference 
data. 
 
The principles behind normative reference data are based upon the theory that a 
summary measure of values obtained from “normal” individuals will represent the range 
of values expected in a healthy population.27  Thus the reference range selected to 
interpret results should be derived from a similar “normal” population from which the 
test subjects come from, using the same equipment and methodologies as those 
applied.28  It is not feasible for every individual lung function laboratory to generate their 
own reference ranges as the sample size needs to be large enough to ensure that the 
extreme limits of “normal” can be estimated with reasonable precision.  Furthermore, 
despite the ATS/ERS guidelines which recommend validating reference equations to 
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ensure they match the healthy population,26 this is not feasible in the majority of lung 
function laboratories.  Many investigators simply rely on software defaults within their 
lung function equipment, and a recent survey of lung function laboratories found that up 
to 25% of laboratories are not aware which reference equations were used in their 
centre and only one third had selected equations that are applicable to their own 
population.29,30  Inevitably there will be differences between the predicted values in 
different studies, and the choice of reference equation has been shown to have 
important implications on interpretation.31   
 
Alongside the challenges faced with selecting appropriate reference data, expressing 
results in a meaningful way has its own challenges.  Interpretation of reference data 
are based on the assumption that the values observed in the population are normally 
distributed (i.e. fit the Gaussian distribution) such that 95% of the values will fall within 
approximately two standard deviations (SD) of the mean.  Results can then be 
expressed as Z scores (or SD scores) which are calculated as: 
[observed-predicted)/(SD-predicted)].   
Z scores quantify how far from the mean an individual observation is.  Depending on 
outcome, lower or upper limits of normality (LLN or ULN) may be defined either as 
those encompassing 90% of the healthy population, in which case the LLN and ULN 
are based on the 5th and 95th centiles (i.e. ±1.64 SD) or alternatively encompassing 
95% of the population, whereby the LLN and ULN represent the 2.5th and 97.5th 
centiles (±1.96 SD) respectively.  Values that fall outside this range do not necessarily 
indicate abnormality, rather that further investigation (i.e. repeat or additional 
assessments in combination with clinical history) is warranted. 
 
Percent predicted is another method of expressing lung function results.  This is 
calculated as: [(observed/predicted)*100]  
Percent predicted is a common outcome which is easily understood by both clinicians 
and patients.  The limitation of percent predicted is that it does not take into 
consideration the variability of values around the mean, and the LLN is based on a 
constant proportion of the mean.  The implications of this are that in younger children 
and the elderly in whom greater variability around the mean is observed, fixed percent 
predicted cut-offs may over-estimate abnormality.32  The debate on expressing 
predicted values has been on-going for some time,33 however, as long as the SD of the 
population is available, both methods can be utilised. 
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There is a wide variety of LFT’s available, however this thesis will be limited to the 
evaluation of four commercially available LFT’s that are used currently for both clinical 
and research purposes: Impulse Oscillation (IOS); Specific Airways Resistance (sRaw); 
spirometry and plethysmographic lung volumes (literature as of inception of thesis: 
2008). 
1.6 Oscillometry 
Oscillometry is an effort independent measurement which gives an assessment of total 
respiratory resistance. 
1.6.1 Principles of oscillometry 
The fundamental assumption of oscillometry is that respiratory mechanics can be 
measured by superimposing external pressure oscillations on the respiratory system 
during resting breathing, and analysing the resulting pressure and flow response.  The 
spectral ratio of the amplitude of the pressure wave signal to the resulting flow signal 
constitutes the impedance of the total respiratory system (Zrs), through which the total 
resistance (Rrs) and reactance (Xrs) of the total respiratory system is calculated.   Zrs 
can be conceived as a generalisation of Rrs since it embodies the in-phase and out-of-
phase relationships between pressure (P) and flow (V’).   
 
Rrs (the in-phase portion) describes the dissipative mechanical properties of the 
respiratory system, and Xrs (the out-of-phase (imaginary) portion) is related to the 
energy storage capacity and is thus determined jointly by the elastic properties 
dominant at low oscillation frequencies and the inertive properties which become 
progressively more important with increasing frequency (see Figure 1-5, section 0). 
 
Depending on the condition of the lungs, a characteristic ratio between impulse 
pressure and flow can be recorded that is dependent on the frequency of oscillation 
applied to the lung.  If a high frequency is applied, the amplitude of such a movement 
remains predominantly within the upper part of the airways, and will not penetrate down 
to the peripheral part of the lungs. Therefore the reflected waves at high frequency 
(>20Hz) only carry information about the upper airways (central airway resistance 
(R20)).  In contrast, low frequencies penetrate down to the peripheral parts of the lungs, 
and the reflected waves carry information from both the peripheral and the central parts 
of the lungs. Thus, the low frequencies (5Hz) carry the sum of both peripheral as well 
as central airway resistance and the difference between values at 5Hz and 20Hz (R5 
and R20) represents the peripheral airway resistance (Figure 1-15).   
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Figure 1-15: Multiple frequencies are applied to the respiratory system.  
High frequencies remain in the upper airways, whereas low  frequencies penetrate the 
peripheral airways. 
1.6.2 Equipment specification for the oscillation technique 
The advantages of oscillometry are that it is a non-invasive, versatile method which 
demands minimal patient cooperation, and is well supported theoretically.  The full 
protocol and equipment set up can be found in the methods (section 2.6.4).  The 
equipment is commercially available (costing ~£10k), requires minimal calibration and 
is portable (can be wheeled from one location to another).  Historically there have been 
several methods of measuring oscillation mechanics, originating in 1956 by DuBois et 
al, with fixed frequency or monotonic / monofrequency measurements.34  This is the 
simplest measurement in which one frequency, which usually ranges from between 2-
4Hz to 30-35Hz, is applied at an individual time.  Whilst the information obtained from 
this technique is valid, it is a time-consuming technique and there is no assessment of 
the frequency response of impedance (Zrs).  It cannot therefore differentiate between 
resistive and visco-elastic elements of the respiratory system.  
 
The limitations associated with mono-frequency measurements were overcome as 
computer software improved, and the development of Fast Fourier Transformation 
(FFT).  FFT allowed multiple frequencies to be analysed at once, allowing better 
definition of the signals from the out-of-phase portion of the respiratory cycle.35 The 
continuous / multi-frequency harmonic oscillation measurement utilises computer 
driven forced pressure oscillations, including a wide range of frequencies applied in a 
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single burst, commonly between 2 and 48Hz.  This is referred to as Pseudo Random 
Noise (PRN) Forced Oscillation Test (FOT), and is a method in common use.36,37  PRN 
allows Zrs to be estimated simultaneously at a number of frequencies, thus providing 
insight into the frequency-dependent mechanics of the respiratory system. 
 
Time discrete, Impulse Oscillation is a step further on from PRN and works by 
superimposing many frequencies, and adding them together to generate a so-called 
“rectangular pulse”.  “Impulse Oscillometry” (IOS) is performed by applying this 
rectangular pulse signal to the airways with a pressure step wave every 200 
milliseconds through a loudspeaker / pulse generator to the airway opening via a 
mouthpiece. The superimposed pressure oscillations during normal spontaneous 
breathing are composed of several frequencies allowing assessment (by Fast Fourier 
analyser) of Rrs and Xrs at several frequencies simultaneously.  Since all frequencies 
are applied in just one rectangular pulse, the measurement time is reduced whilst 
maintaining a very low noise to signal ratio.  Furthermore, continuous curves are 
generated rather than values at discrete frequencies.38   
 
Different oscillation techniques and instrumentation vary significantly, with most 
published data prior to the mid-1990s being collected from “home-made” devices.  
Currently commercially available equipment includes the SensorMedics ROS, the 
12M:Chess Medical which utilises PRN, and Jaeger IOS, which utilises rectangular 
wave “pulses”.  The limited number of studies comparing the accuracy of IOS to FOT 
generally suggests similar, but not identical measures of Rrs and Xrs.
39  Hellinckx et al 
compared the Jaeger IOS with the SensorMedics FOT system in a random order in 49 
subjects (age range 8 to 70 years) with a variety of respiratory diseases.  The wide 
range of resistances made a reliable comparison and found that the two techniques to 
be closely correlated (r2 = 0.83), with Rrs values measured by IOS being slightly higher 
than those measured with FOT at all frequencies, whereas Xrs tended to be smaller 
with IOS.40  Similar results were found in a pilot study of adults with COPD.38 
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1.6.3 Application and interpretation of the oscillation technique 
1.6.3.1 Quality Control for IOS 
As with all LFT’s, IOS QC criteria can be checked both during and after the 
measurement.  During the measurement the operator must coax the subject to adopt a 
quiet, relaxed breathing pattern free from artefact such as swallowing, coughing, 
chewing, talking and tongue movement which can cause airflow leak.  It is the 
operator’s responsibility to optimise data quality by observing the real-time volume/time 
display to identify data corruption (i.e. airflow leak) as described in the FOT 
recommendations by Oostveen et al.39  If artefact/airflow leak is detected, the decision 
on whether to exclude the entire measurement as suggested by some investigators,36 
or to select a time segment free from artefact which meets a minimum time 
specification (e.g. 20 seconds)41 needs to be made.  Guidance for identifying artefacts, 
and selecting “acceptable” segments has been provided by Goldman et al,38 but as yet 
there is no international consensus on quality control.  Selecting “acceptable” sections 
on the results can be subjective since there is no method of quantifying airflow leak; 
this subjective analysis could therefore lead to increased inter-observer variability.42    
 
Standardised guidelines for IOS are limited.  In 2003 some guidelines for FOT were 
published by Oostveen et al39, however the IOS and FOT are not directly comparable 
and discrepancies in QC have already been highlighted.  Further work on standardising 
QC for IOS in children is required.  
1.6.3.2 Repeatability in IOS 
The coefficient of variation (CV) has been recommended to be used as the main index 
of the reliability and repeatability of Zrs data
39 and has been described in a limited 
number of studies with conflicting results:  In one study the repeatability of replicate 
IOS measures at a single sitting, and serial data over three consecutive days, in 
adolescent subjects (n=24, mean age (SD) 12.7 (1.8) years) with well-controlled 
asthma found that in contrast to spirometry, significant day-to-day differences 
occurred.43  The within-day CV was substantially less than day-to-day variability, such 
that day-to-day changes in these parameters for each individual were more than twice 
the within-day CV for the same individual.  They concluded that 60% of the adolescent 
asthmatic subjects tested demonstrated day-to-day variability in R5 and AX that were in 
the order of 15-35%, variations were thought to reflect real physiological changes 
rather than random differences.43   Another study evaluated IOS outcomes (R5, R20 and 
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X5) in triplicate at baseline and after a placebo in 33 asthmatic preschool children (aged 
3 to 6 years) and found the baseline CV for R5 to be 4.1%.
44 
 
In summary, the short-term CV (between-test repeatability) of Rrs derived by various 
oscillation techniques has been reported to range between 5-15% which is 
comparable, but always slightly larger than the variability of other lung function 
methods.39,45  The within-test and between-test CV in oscillation may be related to the 
technique employed (e.g. CV appears to be lower for FOT than IOS) and the methods 
of analysis (CV can be reduced when a reliability index is applied) and may also be 
influenced by the parameters investigated (i.e. the lowest oscillation frequencies have 
the greatest variability because this is closer to the natural harmonics of tidal 
breathing), and the subjects tested (the examples above investigated lung disease, but 
the variability may be different in health or in different disease states).  These factors 
need to be taken into account when determining thresholds for significant change in 
lung function or the response to an intervention and further investigation is required. 
1.6.3.3 IOS and the Bronchodilator Response 
Several studies have demonstrated a BDR with IOS in healthy children: Houghton et al 
demonstrated a mean reduction in R5 of 7.9% in 12 healthy children, but a significantly 
larger reduction of 11.3% in 12 asthmatics.46  Nielsen et al had a larger group (37 
healthy controls and 55 asthmatic subjects) and also found that healthy children 
showed significant improvements post BD compared to placebo (5.1%, and 9.5% 
reduction in R5 post placebo and BD respectively), although the BDR in asthmatic 
children was significantly greater (17.7% reduction).47  A larger BDR was demonstrated 
in 4 year old children in the Childhood Asthma Prevention Study where the BDR in 
health and asthma for R5 was 17% vs. 27% respectively.48  Statistically significant BDR 
in both healthy children and those with lung disease measured with PRN FOT have 
also been reported.37 
 
Given that BDR has been observed in health, there are discrepancies in what 
constitutes a significant BDR and which parameter should be used to determine this.  
Suggestions of “meaningful” reductions in R5 have ranged from 20-25%,
47,48 up to 
40%,49 whilst expected changes in R10 are a little lower, ranging from 15-20%
48 up to 
30%.50  In contrast, changes of up to 65% have been recommended for AX,37 which 
may be due to baseline variability or low absolute numbers.  There is an urgent need 
for consensus on the threshold for a significant BDR for each outcome (specific to 
equipment) to be established. 
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1.6.3.4 Oscillometry in health 
Studies on healthy children are essential to characterise the pattern of oscillation 
results, establish the normal variability expected within and between tests, develop 
reference equations specific to children, and to determine significance of therapeutic 
interventions. Several studies have demonstrated frequency dependence of resistance 
(Fdr) of resistance in young children: Stanescu et al, 1979, measured Rrs in 130 
subjects aged 3 to14 years using forced oscillations between 4 and 9 Hz and found Fdr 
(R4-R9) in children at all ages, which decreased with increasing height (r = -0.50).
51  
They found that during growth, peripheral resistance decreased and Rrs become less 
Fdr, such that by the age of 15 to 16 years Rrs was relatively independent of frequency, 
with no statistical difference between boys and girls.51  In 1987, Clement et al extended 
the age range (4 to 20 years) and the number of healthy subjects (n=403) and 
demonstrated a relationship between Rrs and Xrs with age, height, and weight which 
differed between the sexes.52  During growth, Fdr of Rrs decreased while Xrs increased, 
and the magnitude of the Fdr was related to age with those <10 years demonstrating a 
decrease in R4-R16Hz of about 10%, this Fdr disappeared at about 13.5 years, and 
adult values for Rrs and Xrs were attained by around 15 years of age in girls and 18 
years in boys.52 
 
Subsequently Cuijpers et al, (1993) measured FOT in 371 healthy children, aged 5 to 
12 years and also demonstrated a reduction in Rrs with increasing height, and the 
negative Fdr decreased with growth, however the sex differences reversed once 
children reached 140 cm in height, with girls having higher R8 <140 cm, and boys 
having greater R8 above it.
53  In summary, Fdr of Rrs occurs in normal healthy children 
up to the age of about 13 years, and may be more pronounced in boys; this Fdr of Rrs 
is likely to represent developmental changes rather than implicate pulmonary 
pathology, and should be considered when interpreting results. 
1.6.3.5 Reference Data in IOS 
The ERS taskforce on “The Forced Oscillation in Clinical Practice” in 2003 reported 
reference FOT data in adults to be virtually stable and frequency-independent, with 
mean Rrs in females being slightly higher than males (0.31 kPa∙L
-1.s vs. 0.25 kPa∙L-1.s). 
The same review reported on 11 reference equations on FOT in children published 
between 1979 and 1993 which all revealed a negative correlation between Rrs and 
height, a Fdr of resistance which became less pronounced with increasing height, and 
a high resonant frequency (Fres) in small children (up to 20Hz), which decreased as Xrs 
became less negative with growth.  The authors concluded that “despite lack of 
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standardisation in measuring procedures and equipment, reasonably good agreement 
amongst the reference equations have been observed.”39 
 
More recently the 2007 ATS/ERS Official Statement on Pulmonary Function Testing in 
Preschool Children highlighted eleven reference equations for FOT in children,1 seven 
of which were mentioned in the 2003 report.39  The equations were published between 
1979 and 2002, and showed similar agreement with Rrs decreasing with height (Figure 
1-16).1  The clear outlier (highest Rrs values) comes from the Klug and Bisgaard 
dataset.  These investigators used modified facemasks which potentially could have 
introduced additional upper airway compliance or nasal breathing.54  Only three of the 
equations presented in the official statement had included multiple frequencies that 
were taken from more than one measurement,50,55,56 and none of these equations 
related to measurements obtained using the Jaeger IOS system.  Although FOT and 
IOS are similar, the results obtained using these techniques should not be regarded as 
interchangeable.40 
 
Figure 1-16: Rrs at different frequencies according to published reference data. 
Legend: The lines represent the following published reference equations (numbers represent 
cited ref in original publication: 174=Klug and Bisggard,54 190=Solyman et al,57 186=Mamberg 
et al,
50
 189=Hordvik et al,
55
 188=Lebecque et al,
58
 193=Hellinckx et al,
49
 194=Stanescu et al,
51
  
295=Hantos et al,
59
 195=Ducharme et al,
60
 and 5=Mazurek et al.
61
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In addition to the ATS/ERS preschool statement, a limited number of independent IOS-
specific reference equations for children have been produced:  In 2005, Frei et al 
generated reference equations from 222 White North American children aged 3 to 10 
years (height 100-150cm),62 while in 2006, Dencker et al collated IOS data from two 
populations: 109 Finnish pre-school children aged 2 to 7 years, and 251 Swedish 
children aged 7 to11 years and calculated reference equations from all 360 children 
(90-160cm).41  Ethnic specific reference equations have also been developed for 
Chinese children63 and Iranian children,64 while the largest collection of IOS healthy 
data to date comes from a Polish population of 626 children aged 3 to 19 years.65  All 5 
studies reported similar trends in Rrs and Xrs. 
 
In summary, a variety of reference data are available for FOT and IOS, however 
reference equations developed for FOT may not be appropriate for IOS.  Similarly 
reference equations collected in White subjects may not be appropriate for African 
American and Asian subjects, where ethnic differences in lung function have been 
described.66  There is an urgent need for age, sex and ethnic specific reference data 
for each type of commercial equipment along with appropriate guidelines for their use. 
1.6.3.6 Oscillometry in lung disease 
Resistance measurements have shown higher mean values in populations of asthmatic 
children compared to healthy young children.47 However, wide inter-subject variability 
of baseline measures limit the extent to which baseline abnormalities can be detected 
and there is little consensus on which threshold should be used to define an abnormal 
value.  Despite this, several studies have successfully utilised oscillation techniques in 
conjunction with a bronchial challenge to assess airflow obstruction in children45,67,68 
and adults.69-71  These techniques have also proved useful in the assessment of 
BDR.37,49,72,73   
 
Several studies have demonstrated lung function abnormalities, and in particular 
asthma-like characteristics in SCD,22,74,75 however only one study has utilised IOS (as a 
secondary) outcome:  Santoli et al studied lung function and acute chest syndrome in 
49 children with SCD, and demonstrated an increased Rrs that was associated with 
reduced expiratory flows and an increase in the number of ACS episodes.76 
 
In summary, IOS has proved to be a potentially useful outcome measure in the 
assessment of airflow obstruction and asthma, however there has been limited use of 
IOS in the investigation of children with SCD. 
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1.7 Specific airways resistance (sRaw) 
Lung function techniques that can be applied during tidal breathing are particularly 
pertinent in young children where active cooperation and understanding may be 
reduced.1  Plethysmographic Specific Airways Resistance (sRaw) is a measurement of 
airflow resistance, corrected for lung volume and can be used to identify airflow 
obstruction in subjects who are unable to perform a maximal forced expiratory 
manoeuvre.2  It is measured during tidal breathing when the relationship between 
simultaneous measurements of airflow and the change in plethysmographic pressure is 
assessed without the need for any special breathing manoeuvres against an airway 
occlusion.77  It is therefore ideally suited for young children.78   
1.7.1 Principles of sRaw 
sRaw is the product of Functional Residual Capacity (FRC) and Airways Resistance 
(Raw).  It can be calculated from the relationship of plethysmographic box pressure 
(Pbox) to flow during spontaneous breathing.  Derivation of sRaw occurs as follows: 
1) Raw  = (Vbox_spontaneous / flow) / (Vbox_occlusion / Pmouth) 
2) FRC = (Vbox_occlusion / Pmouth) x (Pamb – PH20) 
Where 
 Vbox_spontaneous = change in box volume during spontaneous breathing 
Vbox_occlusion   = change in box volume during efforts against the airway occlusion 
(shutter) 
 Pmouth   = change in mouth (alveolar) pressure during efforts against the airway 
occlusion 
Pamb = ambient pressure 
PH2O = water vapour pressure 
 
Equations (1) and (2) are then combined: 
3) sRaw  =  Vbox_spontaneous / flow  ∙  Vbox_occlusion  ∙  (Pamb-PH2O) 
   Vbox_occlusion / Pmouth          Pmouth 
And simplified, thereby avoiding need for an airway occlusion with which to calibrate 
box pressure changes in terms of alveolar pressure changes. 
4) sRaw =   Vbox_spontaneous / flow  ∙  (Pamb-PH2O) 
 
In the simplest form, sRaw can be derived from the tangent of the slope of box 
Pressure/Flow.  Since Raw has a strong inverse relationship to lung volume, sRaw 
provides a relatively stable index with which to distinguish effects of disease from those 
of growth and development.34,77 
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1.7.2 Equipment specification for sRaw 
sRaw can only be measured within the body plethysmograph which is a large “body 
box”, approximately 160cm in height, 100cm wide and 78cm deep, and weighs around 
40kg.  It is therefore not portable and, although commercially available, it is more 
expensive than other lung function equipment (costing ~£30k) and therefore limited to 
specialised respiratory laboratories.  Furthermore, there is a lack of consensus with 
regards to equipment, measurement conditions, data collection, analytical strategies 
and reference data.  Consequently, reported values of sRaw have been collected under 
a variety of differing measurement conditions: In the past, changes in temperature and 
humidity throughout the breathing cycle79 have been compensated with either re-
breathing bags or panting technique to achieve body temperature, pressure, and water 
vapour saturated (BTPS) conditions80 whereas, in recent years,  quiet tidal breathing 
with subsequent electronic compensation has been utilised.  The application of a digital 
(electronic) ‘thermal correction’ factor during calculation of sRaw
79 has been shown to 
produce systematically higher results than those collected under BTPS conditions,81 
thus even healthy subjects will appear to have abnormally elevated sRaw if results are 
interpreted using BTPS-derived normative data. 
 
In addition to the differing equipment specifications (NB: assumptions of 
plethysmography are described in section 1.8.1.1), measurements have been 
performed with modified facemasks82 and mouthpieces,83 with or without bacterial 
filters, which potentially vary the deadspace within the system.  Each manufacturer has 
produced different software, and the relationship between plethysmographic (box) 
pressure and airflow  can be analysed in a variety of ways, thus resulting in numerous 
different outcome measures for sRaw, including: ‘effective resistance’ (sReff); ‘total 
resistance’ (sRtot); ‘peak resistance’ (sRpeak) and resistance measured over a fixed 
range of flow (e.g. between 0-0.5 L.s-1 i.e. sR0.5).  In children the most common 
outcomes are sReff and sRtot, whilst measures of sR0.5 have been discouraged in 
children due to potential age-related effects.84  sRtot is a simple outcome measured 
between points of maximum plethysmographic (box) pressure, however sReff may be a 
better reflection of airway mechanics as it is calculated from multiple points throughout 
the breathing cycle (the integration method)6,85 (see Chapter 2, section 2.6.5.3 for 
further details).   
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1.7.3 Application and interpretation of sRaw 
1.7.3.1 Quality Control for sRaw 
The use of sRaw as a valid outcome measure in clinical management has been limited 
by the lack of consensus with regard to equipment, measurement conditions, data 
collection, analytical strategies and reference data.  Results may be influenced by:  
a) the extent to which operator QC is used, either to exclude pressure-flow loops due to 
poor phasing/irregular breathing patterns, or manually adjust the automatically 
generated tangents for such loops;  
b) the number of breaths per epoch or ‘trial’ and the number of  trials used to 
summarise data, and  
c) whether results are expressed as the median of all data86 or the weighted mean of 
data selected after extensive quality control.87  
There are no standardised guidelines for QC applicable to sRaw measurements. 
1.7.3.2 Repeatability in sRaw 
Within-subject SD and between-subject SD in healthy young children (aged 3 to 7 
years) have been reported to range from 0.086 to 0.109 kPa∙s and 0.19 to 0.20 kPa∙s, 
respectively.78  This equates to a within-subject coefficient of variation of 8-11%.  
Repeatability has been shown to be independent of age.54  
1.7.3.3 sRaw in health  
Dab and Alexander first described the technique in 197677 and subsequently 
determined no significant change in sRaw  with body size for normal children between 3 
and 16 years of age.84  In 2001, Manzke et al measured 187 girls and 213 boys aged 6 
to 16 years and also found that sRaw  remained constant throughout childhood and 
adolescence, however they found a statistically significant difference between boys and 
girls and therefore recommended separate reference values for each sex.6  More 
recently, Bisgaard et al measured 121 healthy 2 to 7 year olds (61 boys) with 
approximately 20 children in each age year and found sRaw to be independent of height 
and gender.78  These studies suggest that sRaw remains fairly constant throughout 
childhood, with possibly some sex differences in older children. 
1.7.3.4 Reference Data for sRaw 
sRaw is the product of Functional Residual Capacity (FRC) and Airways Resistance 
(Raw) (section 1.7.1).  Since Raw has a strong inverse relationship to lung volume,
77 
sRaw provides a relatively stable index with which to distinguish effects of disease from 
those of growth and development.  sRaw reference data to date, therefore quotes a 
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single reference value: Bisgaard et al, suggests a normal mean (SD) value of 1.3 (0.1) 
kPa∙s for both sexes and all ages (2 to 7 years),78 whilst the Carefusion software 
(which does not include data by Bisgaard et al)  simply has a default value called 
“Jaeger-kids” for children aged 4 to 18 years, and “Jaeger” for those >18 years.  These 
equations are based on unpublished data collected under BTPS conditions over 30 
years ago80 which are known to be systematically lower than those collected under 
electronic conditions.81 The ‘Jaeger-kids’ predicted values for both sReff and sRtot are 
0.51 kPa·s for girls and 0.53 kPa·s for boys.  There after follows by a sudden (and 
physiologically implausible) increase in predicted values to 0.96 kPa·s for females and 
1.18 kPa∙s for males from 18 years of age onwards.  These default equations 
significantly under-estimate the actual values observed in healthy children, and if 
results were interpreted with these equations, a serious over-estimation of the degree 
of airway obstruction in children with lung disease would occur.   
 
There is some evidence to suggest that there are age and/or gender differences in 
sRaw in young children,
6,88 and updated reference data are urgently required. 
1.7.3.5 sRaw in lung disease 
Researchers at Copenhagen University, Denmark, have investigated the use of sRaw in 
children with asthma/wheeze and demonstrated that sRaw is significantly increased 
compared to healthy children in groups of 2 to 6 year old asthmatic children.47,89-92  The 
same investigators evaluated the association between anti-asthma medication and 
sRaw and concluded that sRaw is a useful outcome measure to distinguish controlled 
from uncontrolled asthma.89  Lowe et al also assessed sRaw in 463 three year olds and 
repeated these measurements in the same children as well as some additional children 
at 6 years (n=690).  In this group of pre-schoolers, they found that sRaw could 
differentiate between persistent and transient wheezers and between wheezing and 
non-wheezing children, and that the deficit in lung function was considerably greater in 
persistent wheezers.60-64 
 
In summary, measurements of sRaw have proved to be a feasible and useful outcome 
measure in clinical research studies of preschool children with cystic fibrosis and 
wheezing disorders, but their usefulness in Sickle Cell Disease has yet to be 
determined. 
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1.8 Plethysmographic Lung Volumes 
Measurements of lung volumes are the gold standard for identifying restrictive lung 
defects2  and although not mandatory to identify obstructive defects, they may help to 
identify underlying pathophysiology. Reduced RV, FRC, TLC and RV/TLC ratio are 
commonly seen with restrictive disorders, whereas an increase in RV, FRC, TLC, 
and/or increased RV/TLC ratio denotes air trapping or hyperinflation associated with an 
obstructive pattern. 
1.8.1 Principles of measuring lung volume assessments 
Plethysmographic measurements are based on Boyle’s Law which states that: under 
isothermal conditions, when a constant mass of gas is compressed or decompressed, 
the changes in gas volume and pressure are inversely proportional, such that the 
product of volume and pressure at any given moment is constant. 
 
The subject is seated inside the plethysmograph and asked to breathe normally.  Once 
stable tidal breathing has been established, an occlusion at the airway opening is made 
by closing a shutter to temporarily stop airflow (resulting in a fixed mass of gas in the 
lungs).  Inspiratory efforts against the occlusion cause an increase in the volume in the 
lung and a decrease in alveolar pressure (Palv) which equilibrates throughout the 
respiratory system (providing no airflow occurs) such that Palv can be measured at the 
airway opening (measured as: change in mouth pressure: (Pmouth)).  Simultaneously, 
the expansion of the thorax compresses the gas in the plethysmograph resulting in a 
decrease in box volume (Vbox) and an increase in box pressure during an inspiratory 
effort and the opposite during an expiratory effort.   
 
FRC can be then be calculated:  (Vbox / Pmouth) x  (Pamb – PH2O) 
Where: Vbox: is the change in lung volume (calculated from change in box volume)  
Pmouth: is the change in alveolar pressure (calculated from Pmouth changes) 
   Pamb : Ambient pressure. 
Maximal inspiratory and expiratory manoeuvres post release or airway occlusion allow 
the calculation of absolute lung volumes whereby  
RV = FRC-ERV 
TLC = RV + VC 
 
The large volume of the plethysmograph box undergoes very small pressure changes 
during compression and decompression of TGV, thus the plethysmographic pressure 
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transducer must be very sensitive and stable.  The plethysmographic transducer is 
calibrated in terms of changes in TGV by injecting and withdrawing a fixed volume of 
air (generally 30 or 50 mL) in and out of the plethysmograph using a motor-driven 
syringe to simulate the changes in TGV that occur during decompression and 
compression of thoracic gas during inspiratory and expiratory phases of the respiratory 
cycle.  After such calibration, the measured changes in plethysmographic gas pressure 
reflect the change in TGV due to decompression and compression of thoracic gas.  
Changes in calibrated plethysmographic gas pressure are recorded in terms of volume 
change. 
Since calibration of the plethysmograph is normally carried out without a subject in the 
plethysmograph, the calibration must be corrected for the subjects body volume (i.e. 
body weight must be entered prior to testing). 
1.8.1.1 Assumptions of plethysmography 
During plethysmographic measurements the airway opening is briefly occluded to hold 
the lung at a constant volume (normally at end expiration, i.e. FRC).  Respiratory 
efforts that compress and rarefy the thoracic volume are recorded.  By relating changes 
in Palv (reflected by pressure changes at the airway opening during periods of no 
airflow) to changes in thoracic gas alveolar volume (reciprocal to pressure changes in 
the plethysmograph), thoracic gas volume at the moment of the occlusion can be 
calculated.  There are however a number of assumptions relating to this technique: 
1.8.1.1.1 Pressure-volume changes in the body are isothermal 
An underlying assumption of the technique is that the pressure–volume changes in the 
body are isothermal.  During inspiration, air is warmed and humidified to body 
temperature and pressure under saturated conditions (BTPS), and air is cooled during 
expiration.  It is assumed that any heat generated by warm, expired air is 
instantaneously lost to the surrounding tissue, such that changes of alveolar volume 
will occur under isothermal conditions.  However, during rarefaction and compression 
of gas within the plethysmograph, heat may or may not be lost through the walls of the 
container (i.e. conditions within the plethysmograph are not isothermal).  The 
plethysmograph must therefore be calibrated at an appropriate frequency to mimic 
respiratory efforts.  The plethysmograph is also open to the atmosphere via a small 
leak with a mechanical time constant of between 5 and 25s.  This controlled leak 
minimises slowly occurring pressure changes that are not related to respiratory 
manoeuvres, such as thermal drift (heating) caused by the presence of a subject 
breathing and body heat within a closed chamber. 
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1.8.1.1.2 Linear behaviour between changes in Pmouth and Palv 
The respiratory system comprises both elastic recoil forces and resistance forces, thus 
a pressure change in the respiratory system will take a finite time to come to 
equilibrium.  This time constant (τ) of the respiratory system is a function of the 
elastance/compliance and resistance of the system and is the time taken for 63% of a 
step change to stabilise.   
Defined as: τ=1/Elastance * Resistance Or: τ=compliance * resistance. 
Stiff lungs (low compliance) with a low resistance will therefore have a short τ and 
empty and fill rapidly, whereas lungs with normal/high compliance and high airways 
resistance will have a long τ and will empty/fill more slowly.  The main assumption of 
body plethysmography is that changes in Pmouth closely approximate changes in Palv 
during respiratory efforts against an occlusion (i.e. there is equilibration), however in 
airflow obstruction (where there is a long τ) the Pmouth and Palv may not have time to 
equilibrate, hence the change in Pmouth may potentially under-estimate the changes in 
Palv in the presence of airways obstruction and over-estimate total thoracic gas volume. 
1.8.1.1.3 Pressure-volume changes are limited to the volume of gas within the thorax  
Another assumption of body plethysmography is that changes in body volume during 
respiratory efforts against the occlusion are essentially only those of TGV, and that 
abdominal gas is negligible.  Guidelines therefore recommend avoiding consumption of 
fizzy drinks prior to plethysmographic measurements, since increased abdominal gas 
and/or pressure swings could be a potential source of error.93  Significantly, 
plethysmographic FRC measures all the total gas volume (TGV) in the lungs at end 
expiration, including any gas trapped behind closed airways.  This contrasts to gas 
washout or dilution techniques (e.g. nitrogen washout) which rely on gas mixing, and 
only measure communicating ventilated areas of the lungs and not gas trapped in 
poorly or non-ventilated areas.   
1.8.1.1.4 Pressure changes applied to the lung are homogeneous within the pleural 
space 
Finally, the principles of body plethysmography are based on the assumption that 
pressure changes applied to the lung are homogeneous within the pleural space.  The 
significant chest distortion observed in some infants with respiratory disease may be 
associated with inhomogenous pleural pressure swings during airway occlusion. 
Similarly, in the presence of marked ventilation inhomogeneity, ∆Pmouth may not reflect 
mean changes in Palv, potentially resulting in either over- or under-estimation of FRC. 
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1.8.2 Equipment specifications for lung volume measurements 
Guidelines for equipment specifications have been developed.94  The body 
plethysmograph used for the measurement of lung volumes was identical to that used 
for the measurement of sRaw.   
1.8.3 Application and interpretation of plethysmographic lung volumes  
1.8.3.1 Quality Control for Lung Volume assessments 
Measurements of absolute and partitioned lung volumes are technically more 
challenging than other LFT’s and are therefore limited to older children.  International 
guidelines for their use have been developed.94  Three to five measurements are 
recommended to achieve at least three FRC values that agree within 5% of the highest 
value.   A technically acceptable FRC is described as “a series of almost superimposed 
straight lines separated by only a small thermal drift on the pressure–volume plot.”94  
These guidelines are based on adults, and while there is no evidence to suggest these 
guidelines are not feasible in children, at present there are no guidelines specific to 
children. 
1.8.3.2 Repeatability in Lung Volume assessments 
Guidelines state that within-test repeatability should be within 5%.94 The same 
guidelines suggest that between-test repeatability in healthy subjects should not differ 
significantly (i.e. no greater than 10% for FRC and TLC and 20% for RV) from 
previously established means for measurements on the same subject, however 
absolute volume differences are not defined, and this doesn’t growth into account.  A 
study by Halvorsen et al measured 35 healthy children with a mean (SD) age 10.6 (0.4) 
years and 46 healthy children aged 17.8 (1.2) years and found the within-test 
repeatability (maximum value – minimum value) for FRC, TLC and RV to be 0.16 L, 
0.13 L and 0.14 L respectively.  They found no significant difference in the variance 
between gender, age or asthma status.95 
 
Plethysmographic lung volumes have been successfully used as a BDR outcome 
measure in asthmatic children,96 however it is a technically demanding measurement 
and time-consuming and therefore infrequently used as an outcome measure for BDR. 
1.8.3.3 Lung volumes in health  
Lung volumes are related to body size, with standing height being the most important 
determinant.94  In children and adolescents, lung growth appears to lag behind the 
increase in standing height during the growth spurt, and there is a shift in relationship 
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between the lung volume and height during adolescence.  Quanjer et al collated lung 
volume data from 2,253 children aged 4 to 20 years and analysed the pattern of 
anthropometric growth and changes in lung volumes.3  TLC was a function of sex, age 
and height, and they found TLC to be 8% larger in males compared to females.  
RV/TLC ratio fell by about 5% in childhood until the start of adolescence where it 
increased about 2% during puberty, then decreased to the adult levels.  This curvilinear 
pattern of RV/TLC ratio from childhood to adulthood can be explained by differences in 
the development of airway properties, body dimensions, chest shape and respiratory 
muscle function during growth, such that lung volume (size and number of alveoli) 
increase more rapidly than airway calibre during childhood.3  Ethnic differences in lung 
volumes were also noted in this study, although limited numbers and differing 
methodologies prevented the group from presenting reference data.  Ethnic differences 
have also been investigated by Sylvester et al, who studied 80 healthy Black children 
with a median age of 9 years and demonstrated significantly lower lung volumes than 
those values predicted from White reference ranges,7 however they did not make a 
direct comparison between Black and White healthy children.  Further work 
investigating the link between ethnic differences in lung function and somatic growth is 
required. 
1.8.3.4 Reference Data in Lung Volumes 
Lung volume reference data in children are limited and ethnic differences in such data 
are not well defined.2   In the USA, the Zapletal equations are the most commonly used 
reference data,97 whereas in the UK, the British Thoracic Society recommend reference 
equations by  Rosenthal et al.98  Zapletal’s equations were based on a very small White 
population of 86 boys and 87 girls aged 6 to 17 years using out-dated (pre-electronic 
thermal compensation) equipment.  The Rosenthal equations were based on modern 
equipment and a larger sample size (772) and included the calculation of Z scores.  
There are two equations (one pre-puberty and one post-puberty) for each outcome and 
each sex.  The impact of these somewhat arbitrary pubertal break points are discussed 
further in the spirometry section below.  Discrepancies in these equations in healthy 
children have been demonstrated previously.16,99 To date, no lung volume equations 
specifically for Black children have been published, and previous attempts to correct for 
ethnic differences in lung function have been shown to be over-simplistic.7,8   
1.8.3.5 Lung volumes in lung disease 
SCD is thought to progress from an obstructive lung defect in childhood24 to a 
predominantly restrictive defect in adulthood.25  Several groups have identified a 
possible association of asthma and airways obstruction and SCD and recognised the 
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potential use of lung volume assessments to identify obstructive lung disease in 
children with SCD.24,25,100,101  A study of 64 children with SCD and 64 ethnic-matched 
controls, aged 5 to16 years, which investigated whether children with SCD have 
restrictive lung function abnormalities revealed that children with SCD have significantly 
reduced lung volumes compared with healthy controls.  These results suggest that 
restrictive abnormalities may become more prominent with increasing age.10 The same 
group studied 20 children with SCD who had suffered acute chest syndrome (ACS) 
episodes and 20 children with SCD without ACS episodes, and found RV to be 
elevated (and a reduction in FEV1 and flows) in those children who had suffered 
ACS.102  This suggests ACS episodes predispose children to increased airway 
obstruction, and provides more evidence regarding the clinical usefulness of assessing 
lung volumes in children with SCD. 
 
In summary, plethysmographic lung volume assessments are potentially useful 
outcome measures for distinguishing between restrictive and obstructive lung disease.2 
A brief review of the application of lung volumes in SCD has been summarised here.  
In addition, lung volumes have been proven to be useful in the assessment of children 
with asthma,103 CF104 and BPD.16  
1.9 Spirometry  
Spirometry is the most common lung function test available with well established 
guidelines for both adults105 and children.1  It is an effort dependent test which requires 
maximal inspirations and forced expirations, thus full subject cooperation is required 
and the potential for fatigue is greater than when using effort-independent tests such 
IOS and sRaw.   
1.9.1 Principles of Spirometry 
Spirometry is the measurement of volume and/or flow of air inhaled or exhaled.  Whilst 
measures of tidal volume can be recorded with spirometry, measures of maximal 
inspiratory and expiratory flow-volume are most informative. Details of airflow limitation 
which can be detected with spirometry assessments have been presented in section 
1.2.7.   
1.9.2 Equipment specification for spirometry 
Spirometry can be performed using commercially available equipment that is portable.  
This test can be applied in both the hospital environment and in the field.  The 
ATS/ERS re-issued equipment specifications and standardised guidelines in 2005.105  
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1.9.3 Application and interpretation of spirometry data 
Spirometry is invaluable as a screening test of general respiratory health.  In patients 
with respiratory disorders, several factors that influence the mechanical properties of 
the lung give rise to the distinctive shape of the flow-volume curves.  Hence, inspection 
of the curves can contribute to clinical diagnosis.  Forced expiratory flow has been 
discussed previously (section 1.2.6).  Spirometry measurements are a cardinal feature 
for the assessment of respiratory conditions such as asthma and SCD.  A vast body of 
evidence supports the applications of spirometry.105-108 
1.9.3.1 Quality Control in Spirometry 
Quality control guidelines are well established in adults105 and young children1 and 
laboratory based measures remain the "gold-standard" in both clinical and research 
practice.109  Published evidence of disparity between practice and hospital services and 
the quality of spirometry performed110 has fuelled the debate regarding the 
appropriateness of such measurements outside specialised facilities, however, with 
appropriate training and QC, spirometry can be equally feasible in the field 
environment.111 
 
Recent ATS/ERS guidelines recommend a six second exhalation and no change in 
volume (i.e <25mL) in the last 1s of the forced expiratory manoeuvre in subjects >10 
years, with a three second duration stipulated for younger children.105  However, 
previous ERS recommendations did not stipulate a forced expired time (FET) for 
children as it was appreciated that many healthy young children may empty their lungs 
in less than three seconds.112 In the recent EPICure study, modifications to current 
guidelines were made.111  Recommendations included that all spirometry software 
should allow visual QC which can be coded for QC criteria as “second line QC”, thus 
allowing a more objective over-read of paediatric data.111  In addition, the same study 
recommended spirometry software to display critical outcome measures with respect to 
QC, such as time to reach Peak Expiratory Flow, back extrapolation volume (BEV) as 
both absolute and %FVC, the % and absolute difference between best and 2nd best 
manoeuvres, the end of test volume (EOTV) and the FET, all of which were potentially 
adaptable but have not yet been implemented.  Despite spirometry being the most 
commonly applied lung function test in adults and children, there are still unanswered 
questions regarding appropriate QC guidelines, particularly with respect to children.  
The Global Lungs Initiative (www.lungfunction.org) are currently updating these 
guidelines.  
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1.9.3.2 Repeatability in Spirometry 
Repeatability in spirometry has been thoroughly investigated.  International guidelines 
for within-test and between-test repeatability have been defined as <0.15L in FVC and 
FEV1 between best and second best efforts, with a slightly lower criteria of 0.10L if the 
FVC is <1.0L.105  These criteria have been shown to relatively lenient in adults, where a 
review of 18,000 consecutive patients, aged 20 to 90 years revealed that 90% of 
subjects were able to reproduce FEV1 to within 120 mL (i.e. within 6.1%), and FVC 
within 150 mL (5.3%).113  Similarly, a review of 4000 children aged 9 to 18 years 
revealed that most met these criterion.114 In addition, in the more recent EPICure study, 
where repeatability criteria was more liberal (highest FEV1 and FVC values were within 
10% of each other) to allow for the potential neurological deficits in the extremely pre-
term children assessed, the vast majority of children (aged 10 to 11 years) met the 
repeatability guidelines.111  Preschool guidelines state that adult criteria are not suitable 
for young children and suggest repeatability within 0.1L or 10%,1 however it is 
important to note that since spirometers only have accuracy to ~100mL it is difficult to 
impose closer repeatability criteria with confidence. 
1.9.3.3 Reference Data in Spirometry 
A plethora of spirometry reference data in children are available115,116 with the most 
comprehensive reference data to date being the All-Age equations.117 These equations 
are based on 7209 measurements from White subjects aged 4 to 80 years and updates 
on these equations are in progress (www.lungfunction.org).  
For Black children, the only reference data available are those by Wang et al.5  These 
were created from the 6 cities study which included 989 Black children aged 6 to 18yrs 
who underwent a total of 6,324 annual examinations (NB. Equations derived from 1630 
White children are also available for this study).  The outcomes were regressed on a 
logarithm of height, and reference equations were created which were sex and age 
specific (i.e. a separate equation for each sex and age group).  The equations were 
limited to children aged 6 to 18 years thus a change in reference data to NHANES III is 
required when progressing to adulthood.107   To date there are no Black-specific 
equations available for children <6 years. 
1.10 Other LFT’s (not used) 
The LFT’s which have been selected for this thesis do not comprise all the LFT’s 
available for use in children.  Other LFT’s include the Multiple Breath Washout 
technique (MBW),118 Oesophageal manometry,119 Resistance measured by the 
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interrupter technique (Rint),1 Diffusion capacity with carbon monoxide (DLCO)
120 and 
measurements of exhaled nitric oxide.121,122 
1.11 Rationale for tests under investigation 
Table 1-2 summarises the LFT’s under investigation for this thesis with respect to the 
interpretation criteria suggested.  
IOS is a theoretically promising test that is effort independent and shown to distinguish 
between health and disease.  Equipment is commercially available, relatively portable 
and requires minimal maintenance.  However, the clinical usefulness of this test is 
limited due to poor interpretation guidelines.  There are currently no standardised 
international guidelines on QC and analysis and equipment specifications for data 
handling are limited.  In particular the relatively low repeatability of Rrs over days and 
weeks may limit its applicability to longer-term follow-ups.123  Investigation of the 
methods and appropriate QC criteria may improve within-test repeatability and optimise 
the feasibility of this test.  Other limitations which need investigation include the lack of 
defined cut-off points for a positive BDR and clinically significant thresholds for the 
determination of airflow obstruction.  In addition, the reference data available needs to 
be evaluated with respect to the impact of ethnicity, and different patient groups. 
 
sRaw has been shown to be a useful research tool able to differentiate between health 
and disease, but methods and equipment are not standardised and its clinical 
usefulness is limited. The numerous different methods of data collection, outcome 
measures and QC techniques have resulted in wide variations in practice.  
Standardisation for this technique is urgently required, similarly reference data needs to 
be investigated, and software adaptations are required. 
 
Plethysmographic lung volume measurements are the gold standard for identifying 
restrictive lung disease.94 Guidelines for QC and repeatability appear to be adequately 
defined, but not verified in children.  Reference data have been reported to be 
unreliable in White children, and no Black reference data are available.  An 
investigation into reference data and appropriate interpretation in terms of identifying 
restriction/obstruction is warranted. 
 
Spirometry is the most commonly applied lung function technique.  Guidelines on QC 
are available and repeatability is well established.  Reference equations for White 
children are available; however interpretation in Black children may be limited due to 
the lack of ethnic-specific equations across all ages.  
73 
 
 
 
Table 1-2: Summary of QC, repeatability and reference data available for each LFT. 
 Quality Control Repeatability Reference Data 
IOS Limited guidelines1,39,124  
Not standardised 
Poorly defined: 
Within-test repeatability varies from 
5-15%. 
 
3 equations available for White 
children.41,62,65 
None available for Black children. 
 
sRaw Limited guidelines,  
Not standardised 
 
Well defined, but only by a single 
group78  
Predicted values have been 
defined78 
Impact of ethnicity unknown. 
 
Lung Volumes Well defined in adults94 and 
extrapolated to children 
Described in adults94 and children.125   Recommendations for the USA97 and 
the UK98 are based on White 
children.   
No ethnic specific equations are 
available 
Spirometry Well defined in adults105 and young 
children1 but some modifications 
may be required111  
Well defined in adults105 and 
children1,113 
Plethora of data,116 most 
comprehensive limited to White 
subjects.117  
One Black-specific equation for 
children >6y.5 
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1.12 Summary of introduction 
This introduction chapter has described the basic physiology of the lungs during growth 
and development and highlighted the impact of ethnicity on lung function.  It discussed 
the clinical implications of common lung diseases such as asthma and SCD and the 
importance of lung function assessments in identifying and managing these lung 
diseases from an early age.  Four LFT’s were identified for investigation and were 
reviewed in light of the interpretation steps: quality control, repeatability and reference 
data.  The limitations of these LFT’s were summarised in Table 1-2.  Further 
evaluations of the methods and interpretative strategies are required to optimise the 
use of LFT’s in the clinical management of lung diseases such as asthma and SCD. 
1.13 Research Questions, Aims and Objectives  
1.13.1 Primary aims 
i. To establish appropriate methods for the application and interpretation of lung 
function measurements in  children aged 4 to 12 years 
ii. To determine the extent of ethnic differences in lung function between healthy 
Black and healthy White children after adjusting for height, sex and age.  
iii. To determine the extent to which the various lung function outcomes (Impulse 
oscillation, Plethysmography and Spirometry) identify differences between 
healthy Black children and those with SCD  
1.13.2 Secondary aims 
i. To assess the extent to which data collection, quality control criteria and 
methods of reporting may contribute to within-test and between-test (or 
between-centre) variability of IOS, sRaw, plethysmographic lung volumes and 
spirometry in children and, if necessary, develop revised recommendations and 
quality control criteria for these lung function tests. 
ii. To investigate between-test repeatability of the various lung function outcomes 
and define thresholds for a significant bronchodilator response in school aged 
children. 
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1.14 Objectives 
The primary objectives were to evaluate whether paediatric lung function reference 
data and guidelines for the selected tests were appropriate for use in healthy children 
aged 4 to 12 years by:   
i. Recruitment of a large group of healthy children to ascertain the most 
appropriate published reference data for anthropometry, IOS, 
plethysmographic lung volumes and spirometry  for use in children of Black 
and White ethnic origin  
ii. Collation of sRaw normative data from international centres to develop new 
reference equations.   
iii. Assessment of the extent to which any bias occurred in results from healthy 
children when assessed using standardised protocols in different international 
centres or testing sites (e.g. schools vs. specialised laboratory conditions)  
 
1.15 Hypotheses 
i. All lung function outcomes are significantly different in healthy Black children 
when compared either with reference data derived from White children, or 
when directly compared to a contemporaneous group of healthy White children 
ii. Currently recommended ethnic adjustment factors for spirometry and 
plethysmographic lung volumes are inappropriate for interpreting lung function 
in Black children. 
1.16 Structure of the thesis 
This thesis has nine chapters.  Chapter 2 will describe the subjects, equipment and 
methods of the study.  This will be followed by a brief results chapter defining the study 
population, four results chapters dedicated to each lung function test under 
investigation (IOS, sRaw, plethysmographic lung volumes, and spirometry) and a final 
results chapter summarising the application of lung function tests in children with SCD.  
Chapter 9 forms the discussion of the thesis, the conclusions and directions for future 
work.  All result chapters are self-contained, with detailed descriptions of the aims and 
objectives, hypotheses, a brief description of the specific study population, results and 
interpretation of results. 
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2. Subjects, equipment and methods  
The previous chapter outlined the overall aims and objectives of the thesis.  This 
chapter will summarise the subjects, equipment and methods for conducting this study. 
Based upon the literature review in chapter one, different areas for each test will need 
to be evaluated, hence specific research questions, hypotheses and sample size 
calculations will be included within the relevant chapters.   
2.1. Inclusion criteria 
 Healthy children (White and Black children) or 
 Children with Sickle Cell Disease (SCD)  
 Age range:  4 to 12 years 
 Lung volumes age range was limited to 6 to12 years  
 All Children had fully informed consent from parents and assent from children to 
participate, which were specific to the research project through which they were 
enrolled (see Recruitment section: 2.3) 
2.2. Exclusion criteria 
 Failure to obtain consent 
 Known concomitant diagnosis of lung disease (e.g. cystic fibrosis or asthma) 
 NB: children with SCD and asthma were included in the study 
 Known heart disease that may result in surgical repair or catheter intervention after 
formal consultation with a cardiologist    
 Born <37 weeks gestation / with history of neonatal lung disease / with low birth 
weight (<2500g) 
 Any anatomical, spinal or thoracic abnormalities 
 Known congenital abnormalities 
 A recent respiratory tract infection within the last 3 weeks 
 A recent acute or any significant chronic respiratory problems that have required 
hospitalisation or medication other than brief (<2 weeks) course of oral antibiotics 
 Currently taking oral steroids 
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2.2.1. Medications to withhold and exclusion period 
 Long Acting Bronchodilators for 12 hours 
 Short Acting Bronchodilators for 8 hours 
 Anti-histamines for 72 hours 
2.3. Recruitment 
Children were recruited through various research studies, the details of which are 
described in the follow sections.   
2.3.1. SAC study 
Children with Sickle Cell Disease (SCD) were recruited from a subset of the Sleep and 
Asthma Cohort Study (SAC study) which was established in 2005  
(www.sacstudy.wustl.edu).   
 
Available lists of neonatally screened and immigrating patients were used to identify 
eligible patients. Ninety-five per cent of patients in this age group regularly attended 
clinic, and those who did not were visited at home by the sickle nurse co-ordinator.  All 
eligible children from three London hospitals (St Mary’s, North Middlesex and St 
Thomas’ were approached), thus sampling bias was minimised. The original inclusion 
criteria for this study included children aged 4 to 18 years, across three international 
centres (London (recruitment spanned three hospitals), St Louis, USA and Cleveland, 
USA.  For the purpose of this study, only those children less than 12 years old with 
SCD were included. 
 
The original SAC protocol did not have ethics to study healthy control children.  In 
2008, a substantial amendment was made to allow ethnically matched healthy control 
children to be studied to aid interpretation of the lung function results from children with 
SCD.  Healthy children of Black origin who met the inclusion and exclusion criteria 
defined above were recruited and studied at the UCL, Institute of Child Health, London 
UK and at Washington University, St Louis, USA.   
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2.3.2. SLIC study 
In 2010 the Asthma UK Size and Lung function in Children (SLIC) study commenced.  
This was a feasibility study which aimed to assess the impact of ethnicity and body 
composition on lung function in primary school children (5 to 11y).  The overall aims of 
this study were to use state-of-the-art technologies to assess lung function and identify 
parameters of body size, composition, shape and physique that can better explain 
variability in lung function in health across all ethnic groups to facilitate interpretation of 
measurements in Black and ethnic minority children with lung disease such as Sickle 
Cell Disease.  The longer term aims were to define simpler and cheaper methods of 
assessing body proportions and composition that could be routinely related to lung 
function, thereby overcoming the need for ethnic-specific reference ranges in clinical 
practice.   
 
After gaining consent from the Local Education Authority (LEA) and the head-teachers, 
two inner-city London primary schools with a predominantly Black population were 
recruited.  Science workshops were conducted for every class and all children received 
a recruitment pack (including patient information leaflets, questionnaires and consent 
forms).  The study team returned on a later date to collect consent forms and conduct 
anthropometry and spirometry measurements on all children in whom consent had 
been obtained.  At a later date, a subset of children were invited to attend the 
laboratory at the Institute of Child Health (ICH) to undergo more comprehensive lung 
function testing including measurements of impulse oscillometry (IOS), specific airways 
resistance (sRaw), plethysmographic lung volumes and repeated spirometry. 
2.3.3. Asthma UK 
The Asthma UK Collaborative Initiative was established in 2005 to develop centile 
charts and investigate the impact of sex, age and body size on interpretation of lung 
function measurements (Spirometry, Interrupter Resistance Technique and Specific 
Airway Resistance) in young children by collating existing reference data and 
methodological details from centres around the world (www.growinglungs.org.uk). 
Reference equations have been successfully developed for Spirometry126 and 
Respiratory Resistance from the interrupter technique.127  The collaboration, 
investigation of the methods and the development of reference equations for 
plethysmographic sRaw were included in this thesis and have also been published.
128 
(NB reference equations were developed by Dr Sanja Stanojevic). 
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The collaborative group was initially comprised of members of the ATS/ERS paediatric 
pulmonary function test task force.  Subsequently, collaborators were identified by 
systematically searching PubMed, advertising at international conferences, through 
membership bulletins, word of mouth and by hand searching relevant respiratory 
periodicals.   
 
sRaw data were collected in healthy children aged 3 to 11.  All participating centres 
were asked to provide detailed information about recruitment, population 
characteristics, equipment and measurement protocols. 
2.3.4. Other research projects 
In addition to the prospective recruitment of healthy Black children to facilitate the 
interpretation of the lung function measurements in Black children, lung function data 
from White children from recent research projects at ICH were also evaluated.16,104,129 
2.4. Ethics  
Full ethical approval was obtained for each research project. All participants were given 
a recruitment leaflet appropriate for their age and information leaflets were given to the 
parents.  Signed assent and parental consent was obtained from all participants.  
Examples of the patient information leaflets and assent/consent forms can be found in 
the appendix. 
2.5. Equipment 
All equipment used in this study was commercially available and met the minimum 
specification for lung function equipment as defined by the ATS/ERS taskforce.39,94,105  
In brief the following equipment utilised were: 
1) Impulse Oscillometry: IOS Jaeger Masterscreen V4.65 (Wurzburg, Germany) 
2) sRaw: Jaeger Masterscreen body box (V.5.02) 
3) Lung volumes: Jaeger Masterscreen body box V.5.02 (UK) or the 
Sensormedics V07-2B Box V6200 (USA). 
4) Spirometry: Jaeger Masterscope V4.65. 
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2.6. Protocol 
Health and safety assessments were undertaken prior to commencing each project, 
and study personnel underwent complete Criminal Records Bureau checks as well as 
attending Good Clinical Practice courses.  All lung function measurements were 
conducted in a uniform way and were either undertaken in a primary school (spirometry 
assessments only) or within the laboratory (all lung function assessments). 
2.6.1. School assessments 
Recruitment packs were given to all children in two London primary schools during a 
science workshop.  On the assessment day, those children with parental consent were 
taken out of class in groups of four.  Children were assented and asked to complete a 
respiratory health questionnaire (appendix) with the help of an investigator. 
Anthropometry and spirometry measurements were conducted. 
2.6.2. Lab assessments 
On arrival to the laboratory, the procedures were explained to the parents and to the 
children.  Information sheets had previously been sent to parents and children (see 
appendix).  Consent and assent was obtained either at the laboratory, in clinic or (if 
part of the school visit) prior to coming to the laboratory.  Anthropometry and 
measurements of IOS, sRaw, plethysmographic lung volumes and spirometry were 
conducted. 
2.6.2.1 Flow chart of laboratory lung function investigations 
 Baseline IOS measurements (minimum of three, maximum of eight sets) 
 Baseline sRaw measurements (3 sets of 10 loops) 
 15 minute rest 
 Repeat IOS measurements (minimum of three, maximum of eight sets) 
 Repeat sRaw measurements (3 sets of 10 loops) 
 Baseline spirometry measurements (minimum of three attempts, no maximum 
amount of attempts) 
 Plethysmographic Lung volumes (in children >6years; 3-6 attempts) 
 Administration of 4 puffs of a bronchodilator (BD) (400μg Salbutamol) via a spacer 
(Aerochamber) 
 15 minute rest 
 Post BD IOS (minimum of three, maximum of eight sets) 
 Post BD sRaw (3 sets of 10 loops) 
 Post BD spirometry (minimum of three attempts, no maximum amount of attempts) 
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The duration of measurements was approximately 15 minutes for baseline 
measurements (IOS and sRaw), 30 minutes for repeatability IOS and sRaw measures 
plus baseline spirometry and lung volumes, and 25 minutes for post-bronchodilator 
response (IOS, sRaw, spirometry).  Due to time constraints and the length of the 
protocol it was not possible/feasible to conduct the entire protocol in all children, and 
parents were given the option to consent to selected parts of the protocol (i.e. baseline 
measurements only, baseline + repeatability/bronchodilator response, or complete 
protocol). 
2.6.3 Anthropometry 
2.6.3.1 Weight 
Weight was measured in light clothing and without shoes to the nearest 0.1 kg using 
calibrated scales (i.e. a variety of weights were placed upon the scales to ensure 
accurate readings were made). 
All measurements were undertaken on a level floor away from objects which may 
interfere with the measurements.  
2.6.3.2 Height  
Height was measured to the nearest 0.1 cm without shoes using a calibrated 
stadiometer (Harpenden Stadiometer, Holtain Ltd., Dyfed, UK in the laboratories, or the 
portable Leicester stadiometer (Crawlea Medical, Birmingham, UK) in the school).  A 
60cm measuring rod was used to ensure the validity of the stadiometer prior to every 
assessment day.  Furthermore repeated height measures of study personnel were 
made using both stadiometers (wall-mounted (Harpenden) and portable (Leicester)) to 
ensure both stadiometers measured accurately. 
The procedure was: 
 Remove shoes and any hair ornaments which may interfere with the measurement 
 Stand with feet flat on floor and heels against heel plate 
 Back, shoulders, head, buttocks and calves against back board of stadiometer 
 Head horizontal in Frankfurt (orbito-meatal) plane (see Figure 2-1) 
 Operator placed hands under the child’s ears to assist with posture 
 Child breathed in then relaxed but remained in the tall position 
 Height was recorded to the nearest 0.1 cm  
 Measurement was repeated at least twice 
 Repeated measures were within 0.1 cm  
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2.6.3.3 Sitting height 
Where possible, measures of sitting height were obtained.  Sitting height measures 
were similar to standing height measures:  
 The subject was seated on a stool of known height  
 Spine and bottom against the back board of the stadiometer  
 Head was horizontal in Frankfurt (orbito-meatal) plane (see Figure 2-1) 
 Hands on knees 
 Child breathed in then relaxed but remained in the tall position 
 Height was recorded to the nearest 0.1 cm 
 Measurement was repeated at least twice 
 Repeated measures were within 0.1 cm  
2.6.3.4 Anthropometric reference data 
Height, weight and body mass index (BMI: weight (kg) / height (m)2) were converted to 
Z Scores based on both British White reference data,130 and American Centre for 
Disease Control data based on White and Black children.131   
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Figure 2-1: Standing position adopted during height measurements. 
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2.6.4 Impulse Oscillometry (IOS) 
2.6.4.1 Equipment set-up and calibration 
Prior to each assessment day, ambient conditions (temperature, barometric pressure 
and relative humidity) were recorded along with a volume calibration (a 3L syringe at 
multiple flows to ensure linearity of the pneumotach over a range of flows) and a 
pressure calibration with a reference impedance of 0.2 kPa∙s-1 was conducted. A 
schematic diagram of the IOS set-up can be seen in Figure 2-2.  
 
 
Figure 2-2: IOS equipment set-up 
 
The child was connected, via a mouthpiece which incorporated a bacterial filter, to a 
set-up which utilised an external oscillating pressure from a loudspeaker.  A 
pneumotachograph (PNT) measured flow (calculated from the pressure drop across a 
fixed resistance of screens), and pressure was recorded by pressure transducers.  
Both the flow created by the child as well as the pressure of the reflected waves 
coming from the lungs were recorded and the resistance (Rrs) and reactance (Xrs) of 
the respiratory system was calculated.   
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2.6.4.2 Outcome measures 
A large array of IOS outcome measures was recorded in an attempt to identify the most 
appropriate outcome measure.  The following outcomes were recorded: 
 Resistance measured at 5Hz (R5), 10Hz (R10),15Hz (R15) and 20Hz (R20) (kPa∙L
-1.s) 
 Frequency dependence of resistance between 5 and 20Hz (Fdr5-20) (kPa∙L
-1.s) 
 Reactance measured at 5Hz: X5 (kPa∙L
-1.s) 
 Resonant Frequency: Fres  (Hz) 
 Integrated area under the reactance curve: AX (kPa∙L-1) 
2.6.4.2.1 Impedance  
The concept of impedance Z with respect to the lungs is a total opposition to 
breathing/flow.   Impedance of the Respiratory System (Zrs) = Δ pressure / Δ flow  
Zrs is often considered a generalization of resistance, as it calculated by the 
pressure/flow relationship and includes the relationships of both the in-phase and out-
of-phase pressure (P) and airflow (V').  However impedance is more complex than 
resistance because it represents the net sum forces that must be overcome to 
generate flow which include the resistive, Inertance and the visco-elastic forces that 
oppose respiration. i.e. Zrs = Sum of the opposing forces (Resistance and Reactance) 
and in this thesis was expressed as either Resistance (R) or Reactance (X). 
2.6.4.2.2 Resistance 
Resistance of the Respiratory System (Rrs) is the component of the trans-pulmonary 
pressure in-phase with flow, or “real part” or the respiratory resistance.  It represents 
the sum of viscous resistances of which airway resistance is the most significant.  Low 
frequencies (5-10 Hz) penetrate the small airways (defined as bronchioles <2 mm in 
diameter), whereas high frequencies (15-20 Hz) remain in the upper airways.  
Therefore R5 and R10 are thought to reflect resistance in the periphery and the central 
airways, and R15 and R20 are more indicative of resistance in the central airways.  If 
there is significant peripheral airway oedema or bronchospasm, one would expect 
resistance in the peripheral airways to increase relative to the central airway (i.e. R5 > 
R20).  Frequency dependence of resistance between 5 Hz and 20 Hz (Fdr5-20) quantifies 
the change in resistance from the small airways to the central airways.   
2.6.4.2.3 Reactance 
Reactance of the Respiratory System (Xrs) is a complex quantity related to those 
portions of pressure oscillations out-of-phase with airflow, also termed the “imaginary 
part resistance.” Xrs is determined by the elastic and inertive properties of the lung and 
undergoes a transition from negative values at low frequencies (elastic reactance 
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dominates) and increases to positive numbers at high frequencies (inertial reactance 
dominates).   
Elastance (E) is the force required to overcome the elastic properties to expand the 
lung during inspiration.  Hooke’s Law states that the extension of a spring is in direct 
proportion with the load applied to it, in physiological terms, the elastic recoil of the 
lungs mean they spring back to their smallest size.  After flow has occurred elastic 
forces are dominant and elastic forces increase with volume: Pressure / Volume 
(inverse of compliance).  Hence, as the volume increases E becomes the dominant 
factor, and at smaller volume changes elastic forces are less important.   
Inertance (I) is the force required to overcome the inertia (tendency of an object to 
resist a change in motion) and accelerate the gas (volume of air) into and out of the 
lung. Inertance describes the relationship between pressure and volume acceleration.  
 
Elastance and Inertance may be separately visualized for clinical purposes however 
the frequency at which Reactance is zero is termed Resonant Frequency (Fres).  Fres is 
a rough dividing line, whereby the low frequencies comprising those below Fres relate 
most prominently to elastic properties of peripheral airways, and high frequencies 
comprising those above Fres relate most prominently to the inertial properties of larger 
central airways. 
 
Integrated Area of Reactance (AX) is a useful index to quantify changes in low 
frequency reactance.  It is an integrated response index for reactance developed by 
Goldman reflecting the integral of the negative values of X from 5Hz to Fres.
38  This 
value may in part reflect small airway function.   
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2.6.4.3 Measurement procedure 
The child was seated in an upright position with the head in neutral position, noseclips 
in place with the technician supporting the cheeks with their hands (to minimise upper 
airway compliance) (Figure 2-3). 
 
 
Figure 2-3: Child undergoing Impulse Oscillometry measurements. 
 
The child was instructed to perform tidal breathing for at least 30 seconds (maximum 
90 seconds).  During this time the technician encouraged and reassured the child.   
 
Online quality control included:  
 Ensuring there was no movement in the mouth (chewing, talking etc.)  
 Ensuring the tidal volume trace was stable, free from drift without hyper- or hypo- 
ventilation 
 Observing the Z5 trace to ensure consistency throughout the measurement (no 
obvious spikes in impedance that indicated swallowing, glottic closure or cough) 
 
After completing the measurement the data were played back to undergo the quality 
control measures for assessing acceptability.   
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2.6.4.4 Quality control 
An IOS QC criteria was developed to determine technical acceptability and data were 
given an over-read score according to (Table 2-1). 
The volume-time tracing was reviewed to ensure tidal breathing remained stable 
throughout data acquisition.  An example of unstable tidal breathing can be seen in 
Figure 2-4.  Sudden drifts, reduction, plateaus or interruption on the volume tracing 
were suggestive of incomplete expiration, airflow leaks (either around the mouthpiece 
or due to improper seal with the noseclip), mouthpiece obstruction, coughing, glottic 
closure, breath-holding, swallowing, or vocalization and data were rejected/edited if 
disturbed by these artefacts.  Furthermore “notching” on the volume tracing was an 
indication of airflow leak, and was detected by amplifying the volume trace.  Although 
notching was acceptable at/near end inspiration and expiration (due to slow/no 
changes in volume), it was unacceptable if present on the upslope of inspiratory 
volume or the downslope of expiratory volume, and data were rejected/edited if airflow 
leak was evident. 
 
 
Figure 2-4: Screenshot of unstable tidal breathing during IOS measurements. 
Legend: The first five breaths have a large tidal volume (900mL), next 7 breaths have small 
tidal volume.  If the normal tidal volume for this subject was known, the data could be edited to 
include the acceptable portion. 
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Optimal Breathing frequency and tidal volume was within 15-25 breaths/min and 400-
700mL respectively, however results were not rejected if outside the limits (although a 
lower QC score was awarded).  Similarly, optimal coherence function (a number 
between 0 and 1, which provided an index of causality between the input and output of 
the linear system, and was therefore decreased in the presence of nonlinearities or 
extraneous noise) was >0.7 for coherence at 5Hz and 0.9 for coherence at 10Hz. 
The shape of the resistance and reactance slopes was also reviewed during QC 
analysis.  It is physiologically implausible for R5 to be less than R10, hence if a “bump” 
in the resistance slope was observed the data were rejected.  Similarly the reactance 
curve should move from negative values at X5 to positive values after Fres.  If X5 was 
greater than X10 the slope was erroneous and was rejected.  Finally the optimal data 
acquisition time was >20s with >4 breaths, however data were still included if >12s of 
data, with >4 breaths were recorded.  Figure 2-5 illustrates unacceptable IOS 
measurements. 
 
 
Figure 2-5: Screen shot of Unacceptable IOS data. 
Legend: Poor quality measurement can be detected by the spikes in Z5 (Red trace in the top 
box) indicating movement in the mouth, irregular tidal breathing (blue trace top box) and large 
changes in flow (Red trace bottom box).   
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Table 2-1: IOS over-read scoring sheet. 
  
  
  
1 2 3 
Tidal breathing 
Free from drift, stable and regular        (2) 
    
 
Free from drift, some irregular breaths  (1) 
Irregular breaths, evidence of drift        (0) 
Notching 
Free from “notching” and leak               (2) 
    
 
Mild notching present at end expiration (1)  
Frequent notching                                 (0)  
Breathing 
Frequency (bpm) 
15-25                                                     (2)   
  
  
  
  
  
 
10-15 or 25-35                                       (1) 
<10 or >35                                             (0) 
Tidal Breathing (ml) 
400-700                                                 (2)   
  
  
  
  
  
 
250-400 or 700-850                               (1) 
<250 or >850                                         (0) 
Coherence at 10Hz 
≥0.9                                                       (2)   
  
  
  
  
  
 
0.8                                                         (1) 
≤0.7                                                       (0) 
Coherence at 5Hz 
≥0.7                                                       (2)   
  
  
  
  
  
 
0.5 - 0.6                                                 (1) 
≤0.4                                                       (0) 
R and X slopes 
expected shape 
Both curves “expected” shape               (2) 
  
  
  
  
 
One curve “abnormal” shape                 (1) 
Both curves “abnormal” shape              (0) 
Acquisition time  
≥20 sec and 4 breaths                           (2) 
    
 
12 – 20 sec or 4 breaths                        (1) 
<12 sec                                                  (0) 
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2.6.5 Specific Airways Resistance (sRaw) 
2.6.5.1 Equipment set-up and calibration 
The Jaeger Masterscreen body box (V.5.02) was used for the assessment of sRaw.  
Prior to every assessment day, ambient conditions (temperature, barometric pressure 
and relative humidity) were recorded along with a volume calibration with a 3L syringe 
at multiple flows (to ensure linearity of the pneumotach over a range of flows) (Figure 
2-6). 
 
Figure 2-6: Volume calibration at multiple flows. 
 
Box calibration consisted of a 2-minute stabilisation period with the door closed 
followed by a leak test in which the screen displayed the decaying signal which should 
be between 4 and 7 seconds (NB: if the half-life was less than 4.5 seconds, 
investigations such as checking if the door was closed properly, problem with the seal 
were conducted).  The Jaeger software automatically repeated the leak test three 
times.  If the range of half-lives from the three trials was greater than 1.5 seconds the 
calibration was repeated. 
 
Following testing of half-life, the programme automatically provided a 50mL sinusoidal 
signal three times. The screen displayed the time-base plot, a bar chart of the 3 
calibration factors (bottom right) and numerical data (top right).  Consistency of the 
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calibration was ensured (i.e. all three columns were around 1+0.25) and stability of the 
signal on the time-base plot was examined by reviewing the ‘QPB%’ (the coefficient of 
variation) and ensuring it was <2% (Figure 2-7): 
 
Figure 2-7: Box calibration. 
2.6.5.2 Measurement procedure 
The child was seated upright in the Jaeger body plethysmograph with their neck slightly 
extended to reach the mouthpiece (attached to a bacterial filter) and feet flat on the 
floor (or a step). The procedure was explained, and after one minute of rest with the 
door closed (to allow for thermal stabilisation) the child was instructed to breathe 
normally through the mouthpiece at a natural breathing frequency.  Quiet breathing 
was encouraged and animations assisted maintaining a breathing frequency of 30 to 
45 breaths/minute.  Throughout testing, the child was wearing a nose-clip and 
supporting their cheeks with the palms of their hands (Figure 2-8).  Three sets of 10 
pressure-flow loops were recorded once a stable breathing pattern had been 
established.  
 93 
 
Figure 2-8: Set-up of Body plethysmograph. 
Legend: Light panel: child undergoing plethysmographic measurements with noseclip and 
hands on cheeks.  Right panel: “Nessy” the computer animation that encourages natural 
breathing frequency. 
2.6.5.3 sRaw outcomes 
The most suitable outcome measure was under investigation since derivation of sRaw 
could be calculated from the relationship of plethysmographic (box) pressure to flow 
(P/F) in numerous ways:  Figure 2-9 is a plot of a typical sRaw loop, with change in 
respiratory flow on the Y-axis plotted against change in box (plethysmographic) volume 
(derived from box pressure) on the X-axis.  P/F changes above zero flow represents 
inspiration, and below expiration. The dotted lines indicate inspiratory and expiratory 
flow at 0.5 L.s-1.  With the exception of ‘effective resistance’ (sReff), which was 
calculated as a regression of pressure and flow over the entire breathing cycle (Figure 
2-9), the sRaw outcome is generally derived from the tangent of the slope of P/F which 
can be placed: 
 between peak inspiratory and peak expiratory flow (sRpeak). (Figure 2-10) 
 between points of maximum plethysmographic (box) pressure (total resistance, or 
sRtot) (Figure 2-11) 
 over some fixed range of flow, over the central linear portion of the breath (most 
frequently between 0-0.5 L.s-1 i.e. sR0.5) (Figure 2-12)
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Figure 2-9: Effective sRaw (sReff) 
Legend: Measured at each sample point of the breath. 
 
 
 
Figure 2-10: Peak sRaw (sRpeak) 
Legend: Measured between points of peak flow during inspiration and 
expiration. 
 
Figure 2-11: Total sRaw (sRtot) 
Legend: Measured between points of maximum pressure (i.e. box 
volume) swing during inspiration and expiration. 
 
 
Figure 2-12: sRaw at 0.5L.s
-1
 (sR0.5) 
Legend: Measured over the central, more linear, portion of the curve 
between inspiratory and expiratory flows of 0.5L.s
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2.6.5.4 Quality Control 
Measurement protocols for data collected for the Asthma UK Initiative varied according 
to centre (these differences were investigated in Chapter 5)  
In London, up to 5 trials of 10 or 5 breaths (dependent on software) were recorded with 
the aim of obtaining 3 ‘technically acceptable’ trials, as defined by the following QC 
over-read criteria (Y = 1, N = 0): 
 Respiratory rate between 30-45 bpm       Y / N 
 Breaths super-imposable (i.e. parallel slopes)      Y / N 
 Breaths of similar size and shape      Y / N 
 Breaths reasonably closed at zero flow      Y / N 
 No obvious distortions to the breath (e.g. glottic closure, cough, talking) Y / N 
 More than one acceptable trial available      Y / N 
 
Figure 2-13 illustrates an acceptable sRaw dataset which scored 6/6 on the QC score.  
Figure 2-14 and Figure 2-15 are examples of sRaw data which had undergone QC over-
reading and did not meet all the acceptability criteria, whereas Figure 2-16  is an 
example of sRaw data which failed all categories of the QC Score. 
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Figure 2-13: Example of an acceptable sRaw dataset with a QC score of 6/6 
Legend: breathing frequency within 30-45bpm = Y; Superimposable = Y; similar size and shape = Y, closed at zero = Y, No distortion of breath = Y, came 
from set of 3 trials = Y.  QC score = 6/6. 
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Figure 2-14: Example of a fast breathing frequency in sRaw measurements 
Legend: Breathing frequency within 30-45bpm = N; Superimposable = Y; similar size and shape = Y, closed at zero = Y, No distortion of breath = Y; came 
from set of 3 trials = Y. QC score 5/6 
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Figure 2-15: Example of sRaw data with a low QC score.  
Legend: Breathing frequency within 30-45bpm =N; Superimposable = N; similar size and shape = N, closed at zero =N, No distortion of breath = Y, came 
from set of 3 trials = Y.  QC score = 2/6. 
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Figure 2-16: Example of sRaw data which failed QC criteria 
Legend: Breathing frequency within 30-45bpm =N (not reported); Super-imposable = N; similar size and shape = N, closed at zero = N, No distortion of 
breath = N, came from set of 3 trials = Y.  QC score = 1 /6. Unacceptable data which should not be reported
Loops not closed at zero 
flow 
Glottic closure: distortion 
of breath 
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2.6.6 Lung volumes 
2.6.6.1 Equipment set-up and calibration 
Measurements of plethysmographic lung volumes were undertaken immediately after 
those of sRaw in the body plethysmograph, with measurement conditions the same as 
those described previously in section 2.6.4.1 
2.6.6.2 Outcome measures 
Figure 2-17 illustrates the partitioned lung volumes measured with spirometry and body 
plethysmography.  The plethysmographic lung volume outcomes reviewed were: 
 Functional Residual Capacity (FRC) (L) 
 Residual Volume (RV) (L) 
 Total Lung Capacity (TLC) (L) 
 Ratio of RV to TLC (RV/TLC)    
 
 
Figure 2-17: Spirogram identifying different lung volume levels.  
Legend: IRV = Inspiratory Reserve Volume; VT  = Tidal Volume; ERV = Expiratory Reserve 
Volume;  
IVC = Inspiratory Vital Capacity; RV = Residual Volume; IC = Inspiratory Capacity; FRC = 
Functional Residual Capacity; TLC = Total Lung Capacity 
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2.6.6.3 Measurement procedure 
Plethysmographic lung volumes were performed according to a protocol based on the 
2005 ATS/ERS recommendations.94   Prior to commencing the measurement, simple 
instructions and time to practice were provided.  The child sat within the body 
plethysmograph, after allowing for thermal stability (about one minute) the child went 
onto the mouthpiece with nose clips on his/her nose and their hands supporting their 
cheeks.  After the consistent tidal breathing was established (i.e. sRaw measurements 
were obtained), the shutter was activated at end expiratory level (FRC) and the child 
was instructed to continue breathing normally against the shutter for a series of 2-5 
“technically satisfactory breaths” (see quality control, section 2.6.6.4).  After the 
occlusion, the child took 1-2 tidal breaths and then a maximal breath to TLC, followed 
by maximal exhalation to RV, followed by another maximal breath back to TLC.   FRC 
was calculated from the mean of 3-5 technically satisfactory FRC measurements, each 
of which consisted of at least two respiratory efforts at a breathing frequency of 30-90 
breaths/min against the occlusion, with closed, superimposable loops free from 
artefact/drift).  RV was calculated as the mean FRC minus the mean of the technically 
acceptable ERV measurements, and TLC was the reported value for RV plus the 
largest of the technically acceptable Inspired VC (Figure 2-17).  
2.6.6.4 Quality Control 
To ensure data collected met published guidelines,94 and to document the quality of the 
results obtained, a plethysmographic lung volume over-read sheet was developed 
(Table 2-2).  Plethysmographic lung volumes were graded according to three 
categories:  
 Performance of FRC 
 Repeatability of FRC 
 Performance of spirometry 
Each category was graded out of three, and a minimum of one for each category was 
required to “pass”.   
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2.6.6.4.1 Performance of FRC 
 Must have a stable end expiratory level, with no obvious drift in tidal breathing prior 
to occlusion 
 At least 2 respiratory efforts against occlusion 
 Breathing frequency during occlusion must be within 30-90 breaths/min 
 Loops within each trial should be: 
 Free from artefact or drift 
 Closed and superimposable 
 FRC value for each individual loop should be similar (large differences will 
be inaccurate) 
2.6.6.4.2 Repeatability of FRC 
 Ideally >3 FRC within 5% or 100mL 
 May accept  
 2 FRC within 5%, or 
 2 FRC within 10%, or  
 FRC within 10% with comment 
2.6.6.4.3 Performance of spirometry 
 The largest IVC (>85% of the previously recorded VC in spirometry) was recorded. 
 An acceptable FVC was required to calculate accurate TLC values.  If an 
acceptable IVC was not recorded, values for TLC, VC and RV were not 
reported, however FRC could still be reported.  
 Mean ERV was calculated from the same trials as the FRC  
 If the FRC was technically unacceptable the corresponding spirometry was 
excluded due to inaccuracies in the ERV values 
 An ERV measurement was excluded if it was clearly not representative and 
very different from the other measurements. In this case the mean of the 
remaining ERVs were used to calculate RV 
 A single ERV measurement could be used ONLY in the event that the VC 
trial it came from was technically acceptable and numerically similar to that 
previously recorded during spirometry 
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Table 2-2: Quality Control scoring system for plethysmographic lung volumes 
 1) Performance of FRC (pleth) trial:  
1.1 > 3 technically acceptable trials 
(i.e. >2 respiratory efforts against the occlusion, BF 30-90 breaths/min) 
 
3 
1.2 2 technically acceptable trials 2 
1.3 1 technically acceptable trial 1 
1.4 < 1 technically acceptable trials and/or breathing frequency outside recommended range* FAIL 
 2) Repeatability of FRC (pleth) trials:  
2.1 >3 FRC values within 5% or 100mls 3 
2.2 3 FRC values within 10% 2 
2.3 2 FRC values within 5% 2 
2.4 2 FRC values within 10% 1 
 3) Performance of Spirometry measurement: 
IVC within 85% of previously recorded FVC AND….. 
 
3.1 Mean of 3 technically acceptable ERV’s 3 
3.2 Mean of 2 technically acceptable ERV’s 2 
3.3 Single ERV measurement (compatible with previous FVC) 1 
3.4 No technically acceptable VC measurement 0 
*High breathing frequencies may be associated with hyperventilation and the subsequent elevation of FRC.  Results with increased breathing frequencies 
therefore failed QC. 
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2.6.7 Spirometry 
2.6.7.1 Equipment set-up and calibration 
Spirometry measurements were obtained using identical spirometers and software in 
all sites (schools, UK laboratory and USA laboratory).  The software included incentive 
spirometry to aid adherence and displayed real-time flow-volume and volume-time 
curves. (Figure 2-18)   
 
Figure 2-18: Spirometry set-up and software incentives. 
Legend: Child undergoing spirometry testing (left panel) and the incentive software to 
encourage maximal expiration (right panel) 
 
In accordance with ATS/ERS recommendations,105 prior to every assessment day, 
ambient conditions (temperature, barometric pressure and relative humidity) were 
recorded along with a volume calibration with a 3L syringe at multiple flows (to ensure 
linearity of the pneumotach over a range of flows).  
2.6.7.2 Measurement procedure 
Each spirometry session continued until three acceptable and two repeatable attempts 
had been achieved.  The over-view protocol was published in pediatric pulmonology:111  
Quality control began with a visual inspection (rather than relying on customised 
software to “grade” the curves) to identify unacceptable curves. The following criteria 
based on the ATS/ERS 2005 guidelines,105 modified slightly for children were then 
applied. 
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Start of test: Assessed by visual inspection of the flow-volume curve to ensure sharp 
peak flow, inspection of the volume-time curve to ensure no hesitancy, and a check to 
ensure back-extrapolated volume was <5% of the FVC and <150 mL. 
Within test: Assessed to ensure the manoeuvre was free from artefact and free from 
cough within the first second. 
End of test: Assessed by a visual inspection of the volume time curve to ensure an 
end-expiratory plateau had been achieved with no sharp cessation in expiratory flow.  
A minimum Forced Expired Time (FET) was not specified at the inception of this study, 
other than that this should be at least one second in duration. 
2.6.8 Quality Assurance 
Prior to commencing the study, all physiologists undertaking anthropometric and lung 
function assessments underwent identical training and were required to demonstrate 
adherence to the study protocol by both a written and practical examination.  
Furthermore repeated measures of the same subject by different physiologists ensured 
the physiologists were adhering to the protocol and that assessments were accurate. 
 
Spirometry assessments were undertaken in three sites (London school, London 
laboratory and USA laboratory) and plethysmography was undertaken in two sites 
(London laboratory and USA laboratory).   Each site had two biological controls who 
underwent monthly assessments to ensure equipment errors did not occur.  
Unfortunately, financial constraints did not allow a biological control to visit each 
international centre to compare equipment, however the consistency of the biological 
controls and the similarity of results from healthy children studied at the different 
centres (see section 6.6 and section 7.6.1) suggests no equipment bias. 
2.6.9 Bronchodilator response  
After completion of the baseline and/or repeatability tests, a short acting bronchodilator 
(salbutamol) was administered.  The total dose was 400g (4x100g actuations) from a 
metered dose inhaler (MDI) through a spacer device (Volumatic).  Young children were 
seated wearing a nose clip and breathing quietly. The operator held the spacer and 
instructed the child to breathe on the mouthpiece with tidal breaths sufficient to cause 
the valve to ‘click’. During a normal expiration the MDI was activated and the child 
continued to take a further ten tidal breaths.  In older children the child was instructed 
to blow out until they were “empty” (i.e. RV) then take a maximal breath in and hold 
their breath for ten seconds, during the maximal breath the operator activated the MDI.  
(Figure 2-19)   
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Figure 2-19: Picture of a child taking a bronchodilator via a spacer. 
 
A 30 second rest was given before repeating the process (tidal breathing method for 
young children, or breath-hold for older children) a further three times.  Fifteen minutes 
after the bronchodilator administration “post BD” measures commenced. 
2.7 Comparison to reference data 
Published reference data for each LFT were applied to results obtained from healthy 
children to determine the appropriateness of the reference data in the healthy 
population.   
IOS reference equations under evaluation were:  
 Dencker et al (Scandinavian White children aged 2 to 11 years)41 
 Nowowiejska et al (Polish White children aged 3 to 19 years)65 
sRaw data were collated to develop new reference data as part of the Asthma UK 
Initiative (Chapter 5). 
Lung volume equations under evaluation were: 
 Rosenthal et al (British White children aged 4 to 19)98 
 Zapletal et al (Czech White children aged 6 to 17)97 
Spirometry equations under evaluation were 
 Stanojevic et al (Asthma UK, international collaboration of White subjects aged 
3 to 80)126 
 Wang et al (separate White and Black children aged 6 to 17)5 
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2.8 Data integrity and storage 
In line with the Data Protection Act, all participants were given a unique, non-identifying 
subject ID.  Contact details on study questionnaires were entered into a password 
protected database and were stored separately from the rest of the lung function data.  
In addition, all results were entered to a password protected database and double 
checked for errors.  Lung function data were backed up, and electronic copies of all 
results and questionnaires were stored on a password protected computer, whilst hard 
copies were stored in locked cabinets. 
 
Original IOS data and IOS data that had undergone “quality control analysis” were 
stored as PDF reports for each individual subject.  The PDFs were converted to 
Microsoft Excel with “able2extract” software.  Data for all subjects were merged, and 
the Data were coded by visit number (1 to 5), test status (1=pre BD, 2=post BD, 3 = 
repeatability) and attempt (3 to 5 attempts).   The data was then converted to SPSS for 
analysis.   
 
Original sRaw data that were collated from five international centres were supplied in 
Excel format, and protocols regarding QC were supplied.  Original sRaw, lung volume 
and spirometry data collected in ICH (and spirometry data collected in London schools) 
were stored on the departmental database, from which data could be extracted into 
Excel format.   
 
Original lung volume and spirometry data collected in the USA laboratories (SAC 
study) were double entered onto a database and extracted into Excel.  A direct export 
from Jaeger spirometry software to the database was possible, however the lung 
volume data was over-read and manually entered onto a spreadsheet which was then 
uploaded onto the database. 
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2.9 Statistical analysis 
Statistical analyses were performed using SPSS V18 (Chicago, USA), and Graph-Pad 
Prism V5 (San Diego, CA, USA).  Each LFT was evaluated in terms of quality control, 
repeatability and reference data as identified by the literature review in Chapter 1. 
2.9.1 Overview of analysis 
Specific over-read sheets for each LFT were developed (section 2.6) and are 
discussed in the relevant chapters.  Simple descriptive techniques were used to 
describe the over-read scores and regression analyses were used to assess the 
relationship between over-read score and age or disease.  One-way ANOVA and 
independent t-tests were applied to assess group differences in different centres, 
differences between Black and White children and differences between health and 
disease, whilst Paired t-tests and Bland and Altman plots were used to assess within-
test and between-test repeatability, and bronchodilator response.  Direct comparisons 
of reference equations were performed using paired t-tests and limits of agreement 
between reference equations were determined with Bland and Altman analysis. 
 
Statistical significance (expressed as p-values and 95% confidence intervals) identifies 
how likely that apparent differences between groups (e.g. health vs disease) are real 
and not due to chance.  In all cases statistical significance was set at 5%, thus if the p-
value was less than 0.05 the differences observed were likely to be real, and the 
chance of making a type 1 error (i.e. wrongly stating there was a difference when there 
was not a difference) was therefore 5% (1 in 20 samples).  Since there was a 5% 
chance these conclusions were incorrect, the 95% confidence interval and the 
observed value were examined in relation to clinically important values. In addition, the 
potentialclinical significance (i.e. whether or not the magnitude of the observed 
difference  was likely to be  clinically important regardless or the statistical significance) 
was reported in each results section.  The precise value of clinical significance (for 
example 0.5 Z Scores or 1 Z scores) was determined according to the specific 
research question and selected outcomes and is reported in each section.  
2.9.2 t-tests 
One sample t-tests were used to compare the mean of a continuous variable from a 
single sample against the hypothesised population mean.  For example the mean sRaw 
Z Score for healthy Black children was hypothesised to be zero. 
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Two sample t-tests were used to compare the means of two normally distributed 
populations.  These tests were paired and unpaired.  Paired t-tests were performed 
when the populations were equal, such as the mean R5 before and after a 
bronchodilator.  Unpaired/independent t-tests were performed when the samples were 
non-overlapping, for example comparing the mean FEV1 Z score in Black children 
compared to the mean FEV1 Z score White children.  The assumptions were that the 
data were normally distributed. 
2.9.3 Bland and Altman analysis 
Bland and Altman analysis assessed the agreement between two repeats of 
continuous numeric measures (e.g. repeated LFT’s) and gave the range within which 
95% of the differences are expected to lie.  The 95% limits of agreement (LA) was 
calculated as the mean difference +/- 2SD of the differences.132  Measurements that fall 
outside the 95% LA were assumed to represent a clinically significant 
change/difference.  For example if an outcome demonstrated limits of agreement of 
within +/-10% then differences exceeding 10% would provide a conservative estimate 
of a clinically relevant difference, that is, a difference that is likely to be caused by 
disease process/intervention rather than normal variability. 
 
Bland and Altman plots were calculated graphically by plotting the mean difference of 
the repeated measures against the mean of the two repeated measurements against 
the calculated 95% LA.  A clinically significant BDR was described as a response over 
and above that seen in the between-test repeatability assessment, and was estimated 
from the 95% LA determined by Bland-Altman analysis  i.e. any points which outside 
the 95% LA meet the threshold of a significant BDR. 
2.9.4 One way ANOVA 
One-way analysis of variance (one-way ANOVA) was used to compare the means of 
two or more samples.  The null hypothesis was that there is no difference between the 
groups.  The ANOVA produces an F statistic which is the ratio of the variance 
calculated among the means to the variance within the samples. If there are 
differences between the group means, the variance between the group means should 
be lower than the variance of the samples.  A higher ratio therefore implies that the 
samples were drawn from different populations and there is a difference between the 
group means.  The assumptions of this test are that data are normally distributed, and 
come from independent samples. 
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2.9.5 Regression 
Regression analysis was used to define a relationship between a dependent variable 
(e.g. lung function outcome) and one or more independent variables (e.g. age, sex, 
height, ethnicity).  More specifically, regression analysis assesses how the typical value 
of the dependent variable changes when any one of the independent variables is 
varied, while the other independent variables are held fixed (i.e. the change in FEV1 
with every cm increase in height in boys aged 8 years old). Regression analysis also 
estimates the average value of the dependent variable when the independent variables 
are held fixed. Having met the assumptions for parametric analysis (i.e. data were 
normally distributed) simple linear regression analysis was used to determine the 
relationship between lung function outcomes and age/height and, where appropriate, to 
assess the relationship between different lung function outcome measures and 
determine correction factors if applicable. 
2.9.6 Development of reference equations 
Reference equations for sRaw were developed by Dr Sanja Stanojevic using the LMS 
method.133  The LMS is an extension of regression analysis which includes three 
components: 1) the skewness (Lambda), which models the departure of the variables 
from normality using a Box-Cox transformation, 2) the median (Mu), and 3) the 
coefficient of variation (Sigma), which models the spread of values around the median 
and adjusts for any non-uniform dispersion, hence LMS. The coefficient of variation 
(CV) is defined as (100 x SD/median). The three quantities (LMS) are allowed to 
change with height and/or age, to reflect changes in the distribution as children grow.  
The LMS method was applied using the Generalized Additive Models of Location Scale 
and Shape (GAMLSS) package in the statistical program R (Version 2.6.1; R 
Foundation, http://www.r-project.org)133  Separate models were developed for males 
and females.  A detailed description of the GAMLSS technique as it pertains to 
spirometry can be found in Cole et al.(2009).134  
2.9.7 Comparison of LFT’s 
Since there was no gold standard LFT in this study, ROC (Receiver Operating 
Characteristic) analysis to determine optimal sensitivity/specificity was inappropriate.  
LFT’s were analysed to describe the correlation between tests.   
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2.10 Sample size and power calculations 
The broad research questions and hypotheses were set out in Chapter 1.  Sample size 
calculations to detect specified differences with chosen power and significance were 
performed for each research question.  The specified differences to be detected with 
confidence i.e. the minimum difference in lung function deemed to be of physiological 
importance was estimated from the literature or derived from the Bland and Altman 
Limits of Agreement calculated from repeatability data from pilot studies.  
The “clinically important difference” was dependent upon the question being answered: 
For example when estimating the clinically relevant change required to determine a 
significant bronchodilator response, knowledge of the within-subject, between test 
repeatability (standard deviation (SD)) was required, whereas when attempting to 
distinguish health from disease, the between-subject repeatability (SD) within each 
group needed to be taken into account. 
 
 A mean difference of 0.5 Z Score (0.5 SD) in lung function between tests was 
considered to be clinically significant 
 A mean difference of 1 Z score (1 SD) in lung function between healthy children 
and those with SCD was considered to be clinically significant 
 
The within-subject and between-subject SD for each LFT was required to perform the 
sample size calculations (Table 2-3) however, individual calculations for each LFT were 
not required as the calculations were based in SDs instead of absolute values.  The 
ICH Statistics and Research Methodology CD calculator, “estimating with a specified 
precision for measures of limits of agreement” was used:  A sample size of 48 was 
required to get limits of agreement within 0.5 SD with 80% power at the 5% 
significance level. 
 
Table 2-3: Within-test and between test repeatability for each lung function test  
 
 
Within-test repeatability SD Between-test repeatability SD 
IOS: R5 (kPa∙s
-1) 0.1 0.4 
sRaw: sReff (kPa∙s) 0.1 0.2 
Spirometry: FEV1 (L) 0.15 0.5 
Lung Volume: FRC (L) 0.15 0.4 
Footnote: Repeatability was based on previous publications for each lung function test: IOS;
38
 
sRaw;
78
 plethysmographic lung volumes;
98
 and spirometry
117
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All sample size calculations were based on healthy children and estimated from the 
literature or pilot studies.  Non-parametric tests would be required if the within-subject 
SD was different in disease compared to health (i.e. if the spread around the mean is 
greater in disease compared to health).  If non-parametric tests are used the sample 
size needs to be increased by 16% to accommodate this.  Therefore, a sample size of 
56 children per group was required for this study. 
 
  
  
113 
 
3. Overview of results: Study population 
3.1. Introduction: Study overview 
The overall aims of this thesis were to establish appropriate methods for the application 
and interpretation of lung function measurements in children aged four to twelve years.  
Data from several studies were evaluated and where possible, data from healthy White 
and Black children were compared to establish if ethnic differences occurred and the 
applicability of published reference data.  Given the different age ranges of studies 
included in this thesis (see section 2.1), the sample size and demographics of children 
studied varied for each lung function test.  This brief results chapter will provide an 
overview of the study population.  Four results chapters dedicated to each lung function 
test under investigation will follow, prior to a short summary results chapter. 
 
In total, 214 healthy Black children and 186 healthy White children underwent 
spirometry assessments and subgroups of differing numbers also underwent other lung 
function measurements.  In a separate retrospective study, 1908 sRaw measurements 
from healthy White children studied in five international centres were evaluated 
(Chapter 5). One hundred and eighty of these subjects were measured in London and 
had matched spirometry/lung volume measurements.  In addition to the healthy 
children assessed, 85 children with Sickle Cell Disease (SCD) from two international 
centres underwent lung function assessments (26 children underwent repeated sRaw 
measurements).   Table 3-1 summarises the subjects evaluated for each lung function 
test, and further demographic details are provided in the relevant chapters. 
 
 Table 3-1: Overview of the children who underwent each lung function test. 
*Further information regarding each project/collaboration can be found in Chapter 2, section 2.3 
 
Anthropometric outcomes (height, weight, and BMI) varied widely across the ages and 
ethnic groups (Figure 3-1).    
Test Age (years) Black (n) White (n) SCD (n) Project* 
IOS 4-11 68 0 59 SAC; SLIC 
sRaw 4-10 56 1908 99 Asthma UK; 
SAC; SLIC 
Lung Volumes 6-12 68 115 85 SAC; SLIC 
Spirometry 6-12 214 186 60 SAC; SLIC 
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Figure 3-1: Anthropometry outcomes (height, weight and BMI) according to age.   
Results based on 214 healthy Black children and 186 healthy White children.  
Note the greater variability of height, weight and BMI at any given age among Black children than their White counterparts. 
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In order to compare growth patterns in healthy White and Black children, and 
subsequently compare healthy children to those with SCD, anthropometric data 
needed to be expressed as Z Scores to adjust for age and sex. Prior to performing any 
lung function comparisons, anthropometric data from children was expressed in 
relation to two sets of commonly used anthropometric reference equations to ascertain 
which were most appropriate to use when interpreting data from Black children with 
SCD. 
3.2 Anthropometric reference data 
In the UK, the British 1990 anthropometric reference equations130 are commonly 
applied, whereas in the USA, the Centre for Disease Control and Prevention (CDC) 
2000 reference equations131 are generally used.   
 
The British equations were developed from 17 distinct surveys of White children 
representative of England, Scotland and Wales.130  Ethnic minorities were excluded “on 
the grounds that they may grow differently from White children. The alternative, of 
producing ethnic-group-specific references, is even less satisfactory, as the required 
large and representative samples are simply not available, and the definition of 
ethnicity is in any case a minefield. A better answer would be to use a series of small-
scale surveys to summarise the growth status of specific ethnic minority children in 
terms of their mean SDS on the British reference, and this could be used to recalibrate 
the reference for use with such groups.”  
 
The CDC equations were developed from five national health examination surveys 
collected from 1963 to 1994 and five supplementary data sources.131  These equations 
included ethnic minorities; the authors stated that: “One issue that received attention is 
racial differences in growth. There are differences in size and growth among the major 
racial/ethnic groups in the United States, but these appear to be small and inconsistent. 
Therefore, the revised growth charts include all infants and children in the United 
States, whatever their race or ethnicity.”  
 
The British anthropometry reference data130 are therefore based entirely on White 
children, whereas the CDC reference data131 were based on a mixture of ethnicities 
and potentially represent an “average” of Black and White children.  A comparison of 
the two sets of equations was made prior to deciding which was the most appropriate 
for use in our population. 
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3.2.1 Comparison of anthropometric reference equations 
Anthropometric data from 400 healthy children (214 Black children and 186 White) 
children were expressed as Z Scores using the British130 or the CDC131 equations.  
Regardless of the equation applied, the mean height, weight and BMI Z Scores from 
these children were significantly greater than the expected value of zero Z Scores 
(Table 3-2).  Paired t-tests of values derived from the two equations revealed 
statistically significant differences between mean height, weight and BMI Z Scores, 
however these differences (~0.1 Z Scores) were not considered to be clinically relevant 
(Table 3-2).   
 
Table 3-2: Comparison of anthropometric  reference equations in 400 children.  
  British 
1990130 
CDC  
2000131 
Mean Diff (95%CI) 
(British-CDC) 
95% limits of 
agreement 
White 
Children: 
    
Height Z Score 0.31 (0.99) 0.27 (0.93) 0.04 (0.02; 0.05) *** -0.14; 0.21 
Weight Z Score 0.39 (0.96) 0.32 (0.97) 0.07 (0.05; 0.09) *** 0.49; 0.96 
BMI Z Score 0.32 (0.97) 0.28 (0.86) 0.04 (0.02; 0.07) *** -0.26; 0.35 
Black 
Children: 
    
Height Z Score 0.80 (1.23) 0.72 (1.14) 0.08 (0.06; 0.09) *** 0.56; 1.02 
Weight Z Score 0.96 (1.15) 0.81 (1.03) 0.14 (0.13; 0.16) *** -0.14; 0.43 
BMI Z score 0.82 (1.19) 0.67 (1.00) 0.14 (0.11; 0.18) *** -0.32; 0.61 
Combined Black and White children:   
Height Z Score  0.57 (1.15) 0.51 (1.07) 0.06 (0.07; 0.05)*** -0.15 ; 0.27 
Weight Z Score 0.70 (1.11) 0.59 (0.99) 0.11 (0.10; 0.12)*** -0.17; 0.40 
BMI Z Score 0.59 (1.10) 0.49 (0.89) 0.10 (0.08; 0.12)*** -0.31; 0.51 
Unless stated otherwise, results presented as mean (SD), ***p<0.001  
Comparison based on 214 Black children and 186 White children aged 4 to 12 years. 
 
Despite the clinically insignificant mean differences between the two equations, Bland 
and Altman analyses revealed relatively wide limits of agreement and a significant 
positive bias (Figure 3-2).  Z Scores calculated by the British130 equations were greater 
than those calculated with the CDC equations,131 with the magnitude of the difference 
being greatest in those with the highest Z Scores for any outcome and in Black children 
who had significantly higher height, weight and BMI Z Scores compared to their White 
peers. 
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Figure 3-2: Bland and Altman comparison of height, weight and BMI Z Scores. 
Z Scores calculated from the British 1990
130
 and CDC 2000
131
 equations. 
Legend: Purple = White children; Green = Black children; Squares = males; circles = females. 
A positive bias occurred in all outcomes.  The bias was greatest in the children >2 Z Scores (who were generally Black).  Z Scores calculated using the British
130
 
equations were generally higher than those calculated by the CDC equations.
131
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3.2.2 Anthropometric reference data: Impact of ethnicity 
Figure 3-2 highlights the bias between the British130 and the CDC131 anthropometry 
reference equations, with the greatest differences occurring in those children with the 
highest Z Scores (who were predominantly Black children).  For example, a 9 year old 
Black girl, 165 cm tall had a calculated height Z Score of 5.0 when applying the 
British130 equations and 4.3 Z Scores using the CDC131 equations, a difference of 0.7 Z 
Scores.   A similar example using weight occurred in a 6 year old Black boy weighing 
36.8 kg where weight Z Scores were calculated as 3.5 Z and 2.9 Z Scores for British130 
and CDC131 equations, respectively.  Finally, an 11 year old Black girl with a BMI of 35 
kg/m2 had a BMI Z Score of 3.6 Z by British130 and 2.6 Z by CDC equations.131  
Independent t-tests revealed a significant ethnic difference in the mean differences 
between the two equations (Table 3-3), such that in White children either reference 
equation could be applied, whereas larger discrepancies between the two equations 
were observed in Black children. 
 
Table 3-3: Differences observed between two anthropometric reference equations.   
 Black: Mean diff 
(British-CDC) 
White: Mean Diff 
(British-CDC) 
Mean Diff (95%CI)   
(Black – White) 
Height Z Score  0.08 (0.12) 0.03 (0.09) 0.05 (0.02; 0.06)*** 
Weight Z Score 0.14 (0.15) 0.07 (0.12) 0.07 (0.05; 0.10)*** 
BMI Z Score 0.15 (0.24) 0.04 (0.15) 0.11 (0.06; 0.14)*** 
Unless stated otherwise, results presented as mean (SD), ***p<0.001 
Footnote: Anthropometric reference data based on British 1990
130
 and CDC 2000
130,131
 
equations, applied to 214 Black children and 186 White children aged 6 to 12 years. 
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3.2.3 Summary of anthropometric reference data  
Anthropometric outcomes (height, weight, and BMI) varied widely across the ages and 
ethnic groups.  Such differences could have potential clinical implications as 
anthropometry, in particular height, has been shown to have an important influence on 
lung function outcomes.8 
The British130 anthropometry reference equations were based on White children only, 
whereas the CDC131 equations included ethnic minorities.  Bland and Altman analysis 
of 214 Black children and 186 White children’ anthropometric details expressed as Z 
Scores using the two equations revealed a significant positive bias, with higher Z 
Scores being calculated with the British 1990 equations.  The largest discrepancies 
between the two equations occurred in Black children, whereas White children had 
closer limits of agreement.  In summary, the CDC 2000131 anthropometric reference 
equations were more appropriate for use in this population which included both White 
and Black children.  Therefore, the CDC 2000131 equations have been used to calculate 
anthropometric data throughout this thesis. 
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4 Impulse Oscillometry  
4.1 Introduction 
Impulse oscillometry (IOS) is an effort independent measurement of total respiratory 
resistance shown to be a useful research tool for assessing airflow obstruction45,67-71 
and bronchodilator responsiveness.37,72,73,135  The clinical usefulness of this technique 
is, however, limited due to a lack of reference data particularly  in non-White children, 
insufficient guidelines,1,39,124 and poorly defined repeatability and thresholds for 
bronchodilator responsiveness (BDR).  This chapter will review the available IOS 
reference data and evaluate the use of these data in healthy Black children and 
children with Sickle Cell Disease (SCD).  Quality control (QC), repeatability, BDR and 
other factors which may influence IOS measurements will also be investigated. 
4.2 Aims 
The primary aims were: 
i. To establish appropriate methods for the application and interpretation of 
IOS in children aged 4 to 12 years 
ii. To assess the extent to which IOS results from healthy Black children agree 
with published reference data (which is based on White children)41,65  
iii. To determine the extent to which the various IOS outcomes identify 
differences between healthy Black children and those with SCD 
The secondary aims were: 
i. To assess the extent to which data collection, quality control criteria and 
methods of reporting may contribute to the within-test and between-test 
variability of IOS and to develop revised recommendations and quality 
control criteria for IOS measurements 
ii. To investigate the between-test repeatability of the various lung function 
outcomes and define thresholds for a significant BDR in school aged 
children 
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4.3 Objectives 
The primary objectives were to evaluate whether published paediatric reference data 
(based on White children) and guidelines for IOS were appropriate for use in Black 
children.  This was done by recruiting a group of healthy Black children and a group of 
Black children with SCD and undertaking IOS measurements according to a 
standardised protocol, based on current methodological recommendations1,39,124 (see 
section 2.6.4). 
4.4 Hypothesis 
IOS data from healthy Black children will be significantly different to that predicted by 
reference data derived from White children.  
4.5 Subjects and sample size 
Impulse oscillometry data were collected in healthy Black children participating in the 
SAC study and SLIC study (described previously in chapter 2, section 2.3).  Children 
older than eleven years of age were excluded since the reference equations by 
Dencker et al were limited to children younger than eleven years.41  Power calculations 
demonstrated that IOS measurements from 64 healthy children would enable 
differences equivalent to 0.5 SD to be detected between the controls and the published 
reference data (based on White children) with 90% power at the 0.05 significance level. 
4.6 Reference data 
IOS data were collected in 68 healthy Black children (41% male, mean (SD) age: 8.2 
(1.5) years).  The following outcomes were recorded: 
 Resistance measured at 5Hz (R5), 10Hz (R10),15Hz (R15) and 20Hz (R20) 
(kPa∙L-1.s) 
 Frequency dependence of resistance between 5 and 20Hz (Fdr5-20) (kPa∙L
-1.s) 
 Reactance measured at 5Hz: X5 (kPa∙L
-1.s) 
 Resonant Frequency: Fres  (Hz) 
 Integrated area under the reactance curve: AX (kPa∙L-1)  
 
Low frequencies (5-10Hz) penetrate the small airways (defined as bronchioles <2mm 
in diameter), whereas high frequencies (15-20Hz) remain in the upper airways.  
Therefore R5 and R10 are thought to reflect resistance in the periphery (and the central 
airways) and R15 and R20 are more indicative of resistance in the central airways.   
Fdr5-20 quantifies the change in resistance from the small airways to the central 
airways.  Reactance is the out-of-phase resistance which reflects the energy storing 
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capacity of the airways.  Low frequency reactance (X5) is dominated by elastic forces 
within the airways, while the frequency at which reactance is zero (Fres) describes the 
point at which the elastic and inertial forces are equal in magnitude.  AX is the integral 
of the negative reactance values (X5 to Fres) and therefore quantifies changes in low 
frequency reactance (and hence may reflect small airway function).  Increased AX (due 
to increases in X5 and/or Fres) may reflect peripheral airway obstruction.   
 
Absolute values against height can be seen in (Figure 4-1).  A relationship between 
height and all IOS outcomes (with the exception of Fres which was relatively stable in 
this age range) was observed, therefore in order to interpret these results, a 
comparison to published reference data which adjusted for height was performed.  
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Figure 4-1: IOS outcomes plotted against height.   
Results based on 68 healthy Black children aged 6 to 11 years.  
With the exception of Resonant Frequency, all IOS outcomes were significantly, albeit weakly, correlated with height.  No Sex differences were 
observed. **p<0.01, ***p<0.001  
r = -0.415*** 
r = -0.274** r = -0.11 
r = -0.245** r = 0.418** 
r = -0.428*** 
r = -0.470*** 
r = -0.455*** 
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4.6.1 Published reference data for IOS 
Two paediatric reference equations (based on White children) by Dencker et al41 and 
Nowowiejska et al65 were evaluated.  The Dencker41 equations were developed in 2006 
from two collated populations (109 Finnish pre-school children aged 2 to 7 years, and 
251 Swedish children aged 7 to 11 years).  The calculated reference equations from all 
360 children spanned an age range of 2 to 11 years (height range: 90-160cm), and 
used height and weight to calculate predicted values for resistances measured at 5, 10, 
15 and 20Hz, reactance at 5Hz, and resonant frequency (Fres).  RSD values were 
provided to enable the calculation of Z Scores, and limits of normality were defined as 
+/-1.96 Z Scores.  Similarly, Nowowiejska et al65 provided equations and RSD values 
derived from 626 Polish children aged 3 to 19 years to calculate predicted values and Z 
Scores for the same IOS outcomes however, these equations were based on height 
alone.   
 
Neither set of equations adjusted for age, stating the use of height eliminated the need 
for age in the equation. In addition, both found that sex made no impact on the 
between-subject variation within each IOS outcome.  Nowowiejska provided sex-
specific (to match that of other lung function assessments) and sex-combined 
equations, whereas the Dencker equations only provided sex-combined equations.  No 
sex differences were observed in the investigated population (Figure 4-1).  For 
comparative purposes, the sex-combined equations were evaluated. 
NB: At the time of writing this thesis, there were no reference data available for AX or 
Fdr, and no Black-specific IOS reference data were available.   
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4.6.2 Comparison of reference data 
Two paediatric IOS reference equations41,65 could be compared using results from 68 
healthy Black children (41% male, mean (SD) age 8.2 (1.5) years).  Differences for all 
IOS outcomes were apparent, regardless of the equation applied (Figure 4-2 and 
Figure 4-3).  When applying equations by Dencker, measured values of resistance 
were on average ~0.5 Z Scores (15-20% predicted) higher than predicted.  Similarly, 
mean Fres was ~2 Z Scores (~30% predicted) higher and mean X5 was ~0.8 Z Scores 
(~40% predicted) lower than predicted.  Significantly greater differences were observed 
when the Nowowiejska65 equations were applied (Table 4-1).  
NB: Although both Dencker and Nowowiejska developed reference equations for 
reactance measurements, only the equations by Dencker produced physiologically 
plausible results, (X5 Z Scores being in the range of -30 to -8 Z Scores when calculated 
by Nowowiejska).  Comparisons between reactance Z Scores was therefore not 
possible. 
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Figure 4-2: Comparison of IOS resistance data according to two reference equations  
Legend: Results expressed as Z Scores using Dencker
41
and Nowowiejska
65
 equations.  Black lines denote mean +/-SD for the studied population.  Dashed grey 
lines indicate the limits of normality (+/-1.96SD) for the reference data.  Significant differences between Z Scores calculated from each equation were observed.  In 
all outcomes the mean was significantly higher than the expected zero Z Scores, however the majority of results fell within the expected +/-1.96 SD.
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Figure 4-3: Comparison of Fres data according to two reference equations  
Legend: Results expressed as Z Scores using Dencker
41
  and Nowowiejska
65
 equations. 
Black lines denote mean +/-SD for the studied population.  Dashed grey lines indicate the limits 
of normality (+/-1.96 SD) for the reference data 
Significant differences between the two equations were observed.  In addition, a large SD 
around the mean highlighted the extremely high variability associated with this outcome 
measure which was potentially underestimated by Nowowiejska et al 
 
Table 4-1: Comparison and limits of agreement of IOS outcomes.  
 
 
Mean (SD) 
Den 
Mean (SD) 
Now 
Mean Diff (SD) 
(Den. – Now.) 
95% Limits of 
Agreement 
R5 Z Score 0.63 (0.94) 0.85 (0.81) -0.22 (0.40)*** -1.00; 0.55 
R10 Z Score 0.63 (0.75) 0.70 (0.59) -0.07 (0.32) -0.71; 0.58 
R15 Z Score 0.54 (0.64) 0.68 (0.53) -0.14 (0.15)*** -0.43; 0.14 
R20 Z Score 0.59 (0.63) 0.70 (0.46) -0.11 (0.17)*** -0.45; 0.23 
X5 Z Score -0.81 (1.12) - - - 
Fres Z Score 1.23 (1.16) 2.01 (1.93) -0.78 (1.10)*** -2.99; 1.33 
Unless stated otherwise, results presented as mean (SD) ***p <0.001 
Results expressed as Z Scores according to Dencker (Den);
41
 and Nowowiejska (Now)
65
 
4.6.3 Bland and Altman comparisons of IOS reference data 
With the exception of R10 Z Score, statistically significant differences between the two 
equations were observed.  With the exception of Fres Z Score, these differences were 
relatively small (0.1-0.2 Z Scores) with narrow limits of agreement (Table 4-1).  The 
closest agreement occurred at higher frequencies where within-test variability (SD) was 
lowest.  Despite the small mean difference and narrow 95% limits of agreement 
observed, Bland and Altman plots for these resistances revealed a slight bias at R15 
and a greater bias at R20 suggesting the two sets of equations are not comparable 
(Figure 4-4).   
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Figure 4-4: Bland & Altman plots for IOS resistance at different frequencies. 
Legend: Results based on 68 healthy Black children aged 6 to 11 years and expressed as Z Scores using Dencker
41
and Nowowiejska
65
 equations. 
solid line denotes the mean difference. Dashed lines denote the 95% limits of agreement. 
Relatively narrow limits of agreement were observed, however, a bias was apparent in all outcomes; hence the two equations were not comparable, and results 
would be interpreted differently according to the reference equation applied.
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Larger mean differences and 95% limits of agreement where observed when 
comparing Fres Z Scores, and a large negative bias was apparent, such that in taller 
children differences of up to 4 Z Scores occurred depending on the reference equation 
applied (Figure 4-5).  
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Figure 4-5: Bland and Altman comparison of Fres. 
Legend: Results based on 68 healthy Black children aged 6 to 11 years and expressed as Z 
Scores using Dencker
41
 and Nowowiejska
65
 equations. 
solid line denotes the mean difference. Dashed lines denote the 95% limits of agreement.   
A large negative bias was observed such that a Fres result may be within the normal limits 
according to Dencker and below the normal limits according to Nowowiejska. 
 
The bias observed in R15 and R20 Z Scores may be due to the different independent 
variables in each reference equation.  Dencker41 equations were based on height and 
weight, whereas Nowowiejska65 equations were based on height alone.  The larger 
bias seen in Fres Z Scores was a result of the contradicting predicted relationships 
between height (and weight) and Fres (Table 4-2).  Dencker
41 predicted  Fres to be 
relatively stable with increasing heights, with the Fres decreasing slightly when heights 
and weights were greatest; whereas Nowowiejska65 predicted a negative association 
with height (Figure 4-6). Given such large differences in predicted values the two 
equations were not comparable.   
 
Table 4-2: Reference equations by Dencker and Nowowiejska for Fres. 
Dencker: Nowowiejska: 
11.749+(4.379*(height,cm)-3)+(0.103*weight) Exp (-0.0101*height,cm + 4.164) 
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Figure 4-6: Predicted Fres values according to two paediatric equations.  
Legend: Figure A represents predicted values based on Dencker
41
 equation which was based on height and weight and hence demonstrate increased variability. 
Figure B applies the Nowowiejska
65
 equation which was based on height alone.   
Footnote: The two equations have contrasting predicted relationships between height (and weight with respect to Dencker) and Fres.
 
A) Dencker B) Nowowiejska 
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4.6.4 Summary of reference data 
The potential applicability of two paediatric IOS reference equations derived from White 
children41,65 was examined.  Bland and Altman analysis revealed adequate, albeit with 
a slight bias, limits of agreement when comparing resistance results according to these 
two equations, but large discrepancies when comparing Fres.  These discrepancies 
were due to the contrasting relationship between height and Fres described by each 
author (Nowowiejska described a negative relationship, and Dencker described a more 
linear/slight positive relationship).  The two equations were therefore not 
interchangeable.  The relationships between IOS outcomes and height observed in the 
studied population of healthy Black children most closely reflected that described by 
Dencker et al,14 therefore these equations were selected as the most appropriate of the 
two reference data sets for use in our population.    
 
Interpretation of IOS data in healthy Black children was evaluated using a direct 
application of  the Dencker14 reference equations and the predefined limits of normality 
of +/-1.96 Z Scores.  In a normal, healthy population the mean (SD) is expected to be 0 
Z Scores (1).  The mean resistance measured at all frequencies were ~0.5 Z Scores 
higher than expected, however the narrower SD (0.6-0.9) around the mean meant that 
the majority (96%) of healthy Black children assessed fell within the predicted range 
(+/-1.96 Z Scores) for all resistance measurements.  The lower SD in the studied 
population suggests that the between-subject variability in the original reference 
population was very large. 
 
When reviewing X5 results obtained in healthy Black children, a mean (SD) reduction of 
0.8 (1.1) Z Scores was observed, and 8 children (12%) had X5 results below the lower 
limit of normal.  Z Scores calculated by Dencker14 for resistance and reactance may be 
adequate for healthy Black children so long as caution is applied when defining limits of 
normality.  Investigation of Fres in healthy Black children using the Dencker
14 equations, 
however, demonstrated a mean increase of 1.2 Z Scores.  This was accompanied by a 
large SD (1.16) which consequently resulted in 15 children (22%) falling above the 
upper limit of normal (>1.96 Z Scores).  The increase in Fres Z Score and decrease in 
X5 Z Scores could have significant clinical implications (i.e. over-diagnosis of 
abnormalities) if interpretation were directly dependent on these equations and limits of 
normality. 
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4.7 Interpretation of IOS data in healthy Black children 
Differences in IOS were observed when applying reference data based on White 
children41 to results obtained from Black children.  Furthermore, the limits of normality 
(defined as +/-1.96 SD) were not applicable in this population due to the variable SD 
observed. Interpretation of IOS data in Black children was therefore limited.  Alternative 
interpretation strategies include adjusted limits of normality (based on the mean +/-1.96 
SD of the values observed in healthy Black children), adjusted Z Scores (i.e. use of an 
ethnic adjustment factor to re-set the mean Z Scores to zero), or regression analysis to 
determine the relationship between IOS outcomes and independent variables (such as 
height, weight, age and sex).  The appropriateness and limitations of these 
interpretative strategies are described in the following sections. 
4.7.1 Adjusted limits of normality 
In a healthy, normally distributed population the mean (SD) is 0.0 (1.0) and the 95% 
limits of normality are defined as the mean +/-1.96 SD.  In the measured sample of 
healthy Black children, however, the mean was significantly different from zero, and the 
SD around the mean was <1.0 in resistance measurements and >1.0 in Fres and X5.  
The 95% limits of agreement based on these healthy Black children were therefore 
adjusted to take into consideration the different mean and SD observed for each 
outcome (Table 4-3). 
  
Table 4-3: Adjusted limits of normality for IOS data. 
 Mean (SD) LLN (95% CI) ULN (95% CI) 
R5 Z Score 0.63 (0.94) -1.21 (-1.44; -1.02) 2.47 (2.25; 2.70) 
R10 Z Score 0.63 (0.75) -0.84 (-1.02; -0.661) 2.1 (1.92; 2.28) 
R15 Z Score 0.54 (0.64) -0.71 (-0.87; -0.56) 1.79 (1.64; 1.95) 
R20 Z Score 0.59 (0.63) -0.65 (-0.79; -0.50) 1.82 (1.68; 1.97) 
Fres Z Score 1.23 (1.16) -1.04 (-1.32; -0.77) 3.50 (3.23; 3.78) 
X5 Z Score -0.81 (1.12) -2.99 (-3.24; -2.73) 1.41 (1.15; 1.66) 
LLN= lower limit of normal; ULN = upper limit of normal (calculated as: mean +/-1.96SD).  
Results expressed as Z Scores. 
41
  Based on 68 healthy Black children aged 6 to 11 years. 
R95% confidence intervals around the LLN and ULN were calculated from the standard error of 
the mean (SEM) and provide a more precise estimation of the limits of normality. Values in bold 
indicate the most conservative limits, that take the actual sample size of this study into account. 
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Table 4-3 suggests conservative limits of agreement that could be used to interpret IOS 
results in Black children.  The limits of normality differ significantly from the 
conventional +/-1.96 Z Scores and therefore limit the clinical applicability of these 
thresholds (i.e. added complication to interpretation if different limits of normality are 
applied for each outcome).  The small sample size (n=68) from which the numbers 
were derived also limited this interpretative strategy. 
4.7.2 Adjusted Z Scores 
Black-specific IOS reference equations have not been developed, yet ethnic 
differences in lung function outcomes have been identified,8 and the studied population 
of healthy Black children demonstrated a significant difference from zero Z Scores 
based on a White population.  An interim solution for interpreting IOS data obtained in 
Black children, may be to apply an ethnic adjustment factor to the measured results 
prior to applying the reference equations by Dencker.41  Table 4-4 identifies the 
calculated “adjustment” factors which were applied (i.e. the measured value was 
divided by 1.16 for R5 and R15; 1.17 for R10; 1.18 for R20; 1.28 for X5 and 1.30 for Fres) 
and hence enabled the group of healthy Black children to be “re-set” to zero Z Scores.  
Limits of normality (+/-1.96SD) were also recalculated based on the observed SD in the 
measured sample of children (Figure 4-7).  
 
Table 4-4: Ethnic adjustment factors and calculated limits of normality for IOS. 
 Adjustment LLN (95%CI) ULN (95%CI) 
R5 Z Score 1.16 -1.6 (-1.8; -1.4) 1.6 (1.4; 1.8) 
R10 Z Score 1.17 -1.3 (-1.4; -1.1) 1.2 (1.1; 1.4) 
R15 Z Score 1.16 -1.1 (-1.2; -1.0) 1.1 (1.0; 1.2) 
R20 Z Score 1.18 -1.1 (-1.2; -0.9) 1.1 (0.9; 1.2) 
Fres Z Score 1.28 -1.8 (-2.0; -1.6) 1.8 (1.6; 2.0) 
X5 Z Score 1.30 -1.6 (-1.8; -1.4) 1.6 (1.4; 1.8) 
LLN= lower limit of normal; ULN = upper limit of normal.   
Results calculated from 68 healthy Black children aged 6 to 11 years, based on Dencker 
reference equations. 
41
   Limits of normality = mean +/-1.96 SD.  95% confidence intervals 
around the LLN and ULN were calculated from the standard error of the mean (SEM) and 
provide a more precise estimation of the limits of normality. Values in bold indicate the most 
conservative limits, that take the actual sample size of this study into account. 
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Figure 4-7: IOS outcomes and calculated limits of normality. 
Results expressed as Z Scores according to Dencker
41
 equations (with an ethnic adjustment) in healthy Black children.  
Legend: Adjusted 95% limits of normality calculated as +/-1.96 SD are indicated by the dashed lines, grey shaded area indicates the 95%CI around the limits of 
normality. 
As can be seen, after adjustment 95% of healthy Black children fell within the 95% limits of agreement.
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4.7.3 Regression analysis on IOS outcomes 
Univariable linear regression analysis was performed to determine the relationship 
between independent variables and each IOS outcome in healthy Black children aged 
4 to 11 years (Table 4-5).   
Table 4-5: Univariable analysis on all IOS outcomes independent variables. 
 Height Age Sex Weight  BMI 
R5 (kPa∙L
-1.s) R
2=0.17*** R2=0.19*** R2=0.00 R2=0.12** R2=0.06* 
R10 (kPa∙L
-1.s) R
2=0.21*** R2=0.22*** R2=0.00 R2=0.17** R2=0.09* 
R15 (kPa∙L
-1.s) R
2=0.22*** R2=0.23*** R2=0.00 R2=0.19** R2=0.11* 
R20 (kPa∙L
-1.s) R
2=0.18** R2=0.22* R2=0.00 R2=0.20 R2=0.04 
X5 (kPa∙L
-1.s) R
2=0.18*** R2=0.07* R2=0.00 R2=0.18* R2=0.02 
Fres (Hz) R
2=0.01 R2=0.00 R2=0.00 R2=0.04 R2=0.02 
Fdr5-20 (kPa∙L
-1.s) R2=0.06*** R2=0.07*** R2=0.02 R2=0.04 R2=0.02 
AX (kPa∙L-1) R2=0.08*** R2=0.05 R2=0.01 R2=0.05 R2=0.02 
*p<0.05. **p<0.01; ***p<0.001 
 
Sex did not account for any variability in any of the IOS outcomes and BMI only 
contributed a small amount to the variability of R5, R10 and R15; these independent 
variables were therefore removed from further analysis.  No relationship between the 
independent variables and Fres was observed, therefore this outcome was not 
evaluated further. 
 
Multiple regression analyses were then performed using height, age and weight to 
determine which combination of independent variables accounted for the most 
variability in each IOS outcome.  Table 4-6 demonstrates the process undertaken using 
R5 as an example. 
 
Table 4-6: Combination of regression models describing the association between R5 and 
height, age and weight in 68 healthy Black children aged 4-11 years. 
Model Constant Height (cm) Age (years) Weight (kg) Adjusted R2 
1 1.620 -0.004 (0.003) -0.035 (0.022)  0.18 
2 1.795 -0.007 (0.004)  -0.001 (0.003) 0.15 
3 1.302  -0.044 (0.017) -0.003 (0.002) 0.18 
4 1.501 -0.002 (0.005) -0.036 (0.023) -0.001 (0.003) 0.20 
Data presented as ß (SE) 
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R5 had a significant (p<0.005) but weak association (r=0.45) with height, age and 
weight.  The relationship was defined as: 
R5 (kPa∙L-1.s) = 1.501 + (-0.002*height_cm)+(-0.036*age_years)+(-0.001*weight_kg) 
This relationship accounted for 20% of the variability of R5 (R
2=0.20). 
 
Similar relationships were observed in resistance measured at other frequencies: 
R10 (kPa∙L-1.s) = 1.163 + (-0.001*height_cm)+(-0.028*age_years)+(-0.002*weight_kg) 
R15 (kPa∙L-1.s) = 1.022 + (-0.001*height_cm)+(-0.024*age_years)+(-0.002*weight_kg) 
R20 (kPa∙L-1.s) = 1.005 + (-0.001*height_cm)+(-0.019*age_years)+(-0.001*weight_kg) 
However, R2 for each outcome remained low (0.22 for R10, 0.27 for R15, and 0.18 for 
R20). 
 
Multiple regression analysis with height, age and weight on the remaining IOS 
outcomes (X5, Fdr and AX), demonstrated that the addition of age or weight did not 
significantly contribute to the model.  Height was chosen in preference to age to 
prevent any bias due to restricted growth.  The relationships were defined as:  
X5 (kPa∙L
-1.s) =-0.838 + 0.004*height_cm   (R2 = 0.18) 
Fdr5-20 (kPa∙L
-1.s) = 0.626+ -0.003*height_cm (R2 = 0.06) 
AX (kPa∙L-1) = 7.06 + -0.036*height_cm  (R2 = 0.08) 
R2 was again very low for these outcomes meaning that these relationships only partly 
explain the variability seen in IOS outcomes.   
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4.8 Recommendations for interpreting IOS data in Black children  
IOS reference data specifically for Black children were not available, hence attempts to 
apply ethnic adjustment factors and adjusted limits of normality to interpret R5, R10, R15 
R20, X5 and Fres in Black children were made (reference data for AX and Fdr were not 
available).  The limits of normality varied widely for each outcome and potentially 
obscured real physiological ethnic differences, which could not be identified on the 
relatively small sample size (n=68).  In addition, the varying SD observed for each 
outcome (which differed from the expected SD of 1) may have skewed the limits of 
normality.  Adjusted Z Scores may simplify interpretation when ethnic differences vary 
according to each outcome, however the definitive adjustment factor cannot be based 
on the relatively small sample size.  These approaches to interpretation are therefore 
limited and should be used with caution.  
 
Regression analysis was also used to determine the relationship between each IOS 
outcome and the relevant determinants (e.g. height, weight, and age), but weak 
associations were observed and the independent variables only partially accounted for 
the variability seen with each IOS outcome.  In addition, the small sample size 
prevented new reference equations with limits of normality being developed.  Until 
adequate ethnic-specific reference equations are developed, the most appropriate 
method of interpreting IOS data in Black children is to make direct comparisons of Z 
Scores derived from Dencker equations41 between health and disease.  By using Z 
Scores an adjustment for height and weight, known to differ between health and 
disease,136 can be made; however limits of normality were shown to be unreliable in the 
studied population.  Although abnormalities in a given individual cannot be detected 
using this method, group differences between health and disease can be established.  
Furthermore, multiple regression analysis can be applied to identify the impact of 
disease after adjusting for any other relevent determinants.  Neither approach identifies 
individual deficits with confidence.  
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4.9 Quality control and other factors which may influence IOS 
The previous sections reviewed IOS reference equations and concluded with some 
preliminary recommendations for interpreting IOS measurements in Black children.  
Prior to applying these interpretative methods in children with SCD, quality control and 
other factors which potentially influence the variability of IOS measurements in children 
were evaluated. 
4.9.1 Reporting of results 
There are a variety of methods available with regards to reporting lung function results, 
such as expressing the mean/median of several measurements.  The extent to which 
the method of summarising data influenced reported values was examined by 
performing within-subject comparisons of IOS data from 68 healthy Black children and 
59 children with SCD (demographics of these children can be seen in Table 4-11, 
section 4.10).  No statistical differences (p<0.0001) between reporting IOS outcomes 
as mean or median of three measures were observed (Table 4-7).   
Table 4-7: Comparison of different methods of reporting IOS outcomes.  
 Mean Median Mean Diff (95% CI) 
R5 (kPa∙L
-1.s) 0.87  0.87 0.0 (-0.01; 0.01) 
R10 (kPa∙L
-1.s) 0.73 0.73 0.0 (0.00; 0.00) 
R15 (kPa∙L
-1.s) 0.67 0.68 0.0 (0.00; 0.00) 
R20 (kPa∙L
-1.s) 0.64 0.65 0.00 (-0.01; 0.00) 
Fres (Hz) 22.0 22.1 -0.09 (-0.36; 0.17) 
X5 (kPa∙L
-1.s) -0.31;  -0.30 0.0 (-0.01; 0.00) 
AX (kPa∙L-1) 2.38 2.36 0.01 (-0.02; 0.04) 
Results based on 68 healthy Black children and 59 children with SCD aged 6 to 11 years. 
4.9.2 Within-test repeatability in health and SCD 
Within-test repeatability was compared between 68 healthy Black children and 59 
children with SCD reported previously (Table 4-11).  The within-test standard deviation 
(SD) and coefficient of variation (CV) for each outcome were evaluated (Table 4-8).  
With the exception of X5 and AX, SD and CV were relatively low for all outcomes, with 
no clinically relevant differences in within-test repeatability between health and SCD 
(Table 4-8).  The greatest within-test variability was seen in the reactance 
measurements with X5 having a within-test CV of ~20%.  The most repeatable outcome 
measure was R10 which had a within-test CV of ~5%.   
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Table 4-8: Comparison of IOS within-test repeatability. 
 Standard Deviation Coefficient of Variation (%) 
SCD Health Mean Diff  (95% CI) 
(SCD- Health) 
SCD Health Mean Diff (95% CI) 
(SCD-Health) 
R5 (kPa∙L
-1.s) 0.08 (0.05) 0.06 (0.04) 0.02 (0.01; 0.09)** 8.3 (4.7) 6.6 (3.6) 1.7 (0.3; 3.2)* 
R10 (kPa∙L
-1.s) 0.04 (0.03) 0.04 (0.02) 0.0 (0.00; 0.01) 5.7 (3.9) 5.1 (3.5) 0.6 (-0.3; 1.6) 
R15 (kPa∙L-1.s) 0.04 (0.03) 0.03 (0.02) 0.01 (0.00; 0.02) 6.5 (4.6) 5.0 (3.6) 1.5 (0.0; 3.0)* 
R20 (kPa∙L
-1.s) 0.04 (0.03) 0.03 (0.02) 0.01 (0.00; 0.02)* 7.6 (4.8) 5.5 (3.3) 2.1 (0.0; 4.6) 
Fres (Hz) 1.28 (1.76) 1.78 (1.89) -0.50 (-1.15; 0.16) 6.2 (10.8) 8.6 (10.5) -2.4 (-6.2; 1.3) 
X5 (kPa∙L
-1.s) 0.08 (0.06) 0.06 (0.04) 0.02 (-0.06; 0.61) 19.6 (17.8) 19.8 (14.9) -0.2 (-5.6; 6.2) 
AX(kPa∙L-1) 0.46 (0.35) 0.40 (0.31) 0.06 (-0.06; 0.18) 12.1 (7.8) 18.7 (12.2) -1.8 (-10.3; 3.0) 
Unless stated otherwise, results presented as mean (SD) *p<0.05, **p<0.01  
Results based on 68 healthy Black children and 59 children with SCD
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4.9.3 Over-read scores 
All results reported in this chapter were based on data that had undergone quality 
control (QC) analysis.  The QC criteria were based on current literature1,39,124 and on 
consultation with Dr Michael Goldman (leading expert at the time of analysis).38,124  An 
“acceptable” IOS measurement was “scored” against several categories and given a 
score of 2 if the criterion was met; one if partially met and zero if it failed to meet that 
criterion.   
 
The acceptability categories were as follows: 
 
1) Stable tidal breathing without drift  (1 point if small amount of drift) 
2) No evidence of notching (air-flow leak) (1 point if small amount of leak) 
3) Breathing Frequency within 15-25 bpm (1 point if 25-35 bpm or 10-15 bpm) 
4) Tidal Volume within 400-700 mL  (1 point if 700-850 mL/250-400 mL) 
5) Coherence at 10Hz >0.9   (1 point if 0.7-0.9) 
6) Coherence at 5Hz >0.7   (1 point if 0.5-0.7) 
7) Reactance curves and resistance curves physiologically acceptable 
shape (no inflexion of curves)  (1 point if one curve slight 
abnormality) 
8) Data acquisition greater than 20 sec and 4 breaths. (1 point if 12-20s) 
 
A minimum of three and a maximum of eight trials were undertaken, after visual 
inspection of the results, the best three trials were selected and the above acceptability 
criteria were applied.  The maximum acceptability score was therefore 48 per 
measurement session (16 per trial).  In addition the following repeatability criteria were 
applied: 
1) 3 superimposable AX curves all within 20% of the largest recorded AX  
(1 point if 2 within 20%) 
2) 3 superimposable R10 curves all within 10% of the largest recorded R10  
(1 point if 2 within 10%) 
NB: If only one trial was deemed acceptable the measurement session was considered 
a fail (this did not occur in any of the children undertaking IOS measurements).  Where 
only two trials were acceptable, data were included in the overall analysis (i.e. the 
comparison between health and SCD), but excluded from the total QC analysis.   
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Sixty-eight healthy Black children and 59 SCD underwent IOS measurements.  No 
child failed the measurements; however five healthy children (7%) and eight children 
with SCD (14%) only had two acceptable measures and were therefore excluded from 
the total QC analysis.  Thus 189 baseline measurements from 63 healthy Black 
children and 153 baseline measurements from 51 children with SCD were evaluated 
(Table 4-9).  The majority of children scored maximum points in stable breathing, 
airflow leak, coherence at 10Hz and “normal shape” indicating that these criteria are 
fully achievable in this age group.  The largest failures occurred in quantifying 
coherence at 5Hz and breathing frequency where 36% and 21% of children with SCD 
respectively failed to achieve the recommended range.  This was in contrast to healthy 
children who had relatively few measurements that “failed” in any category (Table 4-9).  
Despite some “failures” in some categories, no data were excluded due to low QC 
scores. 
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Table 4-9: Frequency table of IOS QC over-read scores.   
 SCD Healthy Black children 
2 points 1 point 0 points 2 points 1 point 0 points 
Stable tidal breathing 86.4 12.5 1.0 87.5 12.5 0 
No airflow leak 87.7 11.8 0.5 95.5 4.5 0 
Breathing frequency 37.3 42.2 20.5 54.5 36.6 8.9 
Tidal volume 57.5 37.3 5.1 63.4 32.1 4.5 
Coherence at 10Hz 83.4 15.3 1.3 84.8 15.2 0 
Coherence at 5Hz 23.5 40.4 36.1 84.8 15.2 0 
Curves: Normal shape 82.4 14.6 3.1 95.5 3.6 0.9 
Acquisition 54 42.5 3.6 75.9 23.2 0.9 
AX repeatability 60.7 36.3 4 62.4 32.6 5 
R10 repeatability 81.4 16.4 2.2 87.9 11.1 1 
Results based on 51 children with SCD and 63 healthy Black children aged 6 to 11years
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4.9.3.1 Validation of over-read scores 
A subset of IOS data from 49 children (22 healthy children and 27 children with SCD 
with demographics similar to the entire group) were extracted and reverted back to the 
raw format (i.e. pre editing/QC analysis).  A comparison of data pre- and post-QC was 
performed using paired t-tests.  No significant differences in the absolute values or SD 
occurred after QC analysis; however there was a trend towards a reduction in within-
test SD after edits/QC analysis was applied (Table 4-10). 
 
Table 4-10: Within-subject comparisons of raw and QC data. 
 Raw data 
(no edits) 
QC data Mean Diff (raw-QC)  
(95%CI) 
R5 (kPa∙L
-1.s) 0.87 0.87 0.00 (-0.02; 0.03) 
R10 (kPa∙L
-1.s) 0.72 0.72 0.00 (-0.02; 0.02) 
R15 (kPa∙L
-1.s) 0.64 0.64 0.00 (-0.02; 0.01) 
AX (kPa∙L-1.s) 2.51 2.52 -0.01 (-0.20; 0.19) 
R5 (kPa∙L
-1.s)SD 0.11 0.08 0.03 (-0.03; 0.07) 
R10 (kPa∙L
-1.s)SD 0.08 0.05 0.03 (-0.08; 0.15) 
R15 (kPa∙L
-1.s)SD 0.06 0.04 0.02 (-0.05; 0.01) 
AX (kPa∙L-1)SD 0.7 0.6 0.1 (-0.3; 0.6) 
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4.9.4 Summary of quality control in IOS 
Factors which may influence IOS results were examined.  Reporting results as the 
mean or the median of three measures made no significant difference to the final 
outcome.  Of the children assessed, the majority could achieve the current 
recommendations of at least three measurements.39 Within-test, within-occasion 
repeatability was assessed and found to be low, with the most repeatable outcome 
being R10 (with a coefficient of variation of ~5%).  Results were reviewed according to 
QC criteria (derived from Dr Michael Goldman, unpublished work), which demonstrated 
that the majority of children could achieve these criteria, however the tidal volume 
criterion (400-700mL) was too high for the young children and should be modified if 
applied in the future.  The impact of applying the QC criteria revealed no significant 
difference in raw data and edited data, however results may have been biased as all 
data were obtained by trained physiologists (JK, LW, KL and RB) who endeavoured to 
obtain data that met the QC criteria and hence online QC (i.e. encouraging the child to 
adopt the “acceptable” breathing pattern) occurred.  Despite the trend towards a 
slightly decreased within-test SD post QC, the time spent grading each measurement 
(about 10 minutes per measurement) makes it clinically impractical.  Online visual QC 
and editing is recommended, but a QC grade is not necessary. 
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4.10 Applications of IOS in SCD 
The previous sections have investigated reference data and methods of qualtiy control 
and defined within-test repeatability.  This final section applies these methods and 
evaulates the use of IOS in 59 children with SCD in comparison to 68 healthy Black 
children.  The children with SCD were significantly shorter and lighter than their healthy 
peers despite a similar age range (Table 4-11).   
 
Table 4-11: Comparison of 59 children with SCD and 68 healthy Black children. 
 SCD Healthy 
Black 
Mean Diff (SCD-health) 
(95%CI) 
n (% male) 59 (54%) 68 (41%)  
Age (years) 7.5 (1.1) 8.2 (1.5) -0.7 (-1.3; -0.1)* 
Height Z Score 0.1 (1.1) 0.6 (1.0) -0.5 (-0.9; -0.2)** 
Weight Z Score 0.1 (1.1) 0.8 (1.2) -0.7 (-1.1; -0.3)*** 
BMI Z Score -0.6 (1.1) 0.0 (0.9) -0.6 (-1.0; -0.2)** 
Unless stated otherwise, results presented as mean (SD) *p<0.05, **p<0.01   
Demographics expressed as Z Scores
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Multiple regression analysis was used to determine the impact of SCD after adjusting 
for any other relevant determinants (e.g. height, weight, age) for each IOS outcome.  
The relationships are described in (Table 4-12).  After adjusting for age and height, 
having SCD did not have a significant impact on the R5 and R10 values (which reflect 
resistance in the small airways), however R15 and R20 (which reflect resistance in the 
more central airways) were significantly lower in the presence of SCD (mean reduction 
(95%CI): -0.06 (-0.10; -0.02) kPa∙L-1.s and -0.09 (-0.13; -0.05) kPa∙L-1.s respectively).  
Multiple regression also revealed X5 (a measure of energy storage/elastic forces in the 
small airways) to be significantly more negative (mean reduction (95%CI): -0.09 (-0.14; 
-0.05) kPa∙L-1.s) in the presence of SCD, after adjusting for height.   
 
The outcomes affected most by SCD were AX (mean (95% CI) increase of 1.08 (0.59; 
1.57) kPa∙L-1) and Fdr5-20 (mean (95%CI) increase of 0.14 (0.09; 0.19) kPa∙L
-1.s).  
Given AX quantifies changes in low frequency reactance, and Fdr5-20 quantifies 
changes from low to high frequency resistance it is not surprising that subtle changes 
in reactance/resistance at any frequency can have larger changes in these outcomes. 
(Table 4-12). 
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Table 4-12: The relationship between height, weight and age and the impact of SCD on each IOS outcome.   
 Regression equation 
(height in cm; age in years; weight in kg; SCD: 1=SCD, 0 = health) 
SCD coefficient  
(95% CI) 
R5 (kPa∙L
-1.s) 1.777+ (-0.005*height) + (-0.032*age) + (0.059*SCD) 0.059 (0.00; 0.123)* 
R10 kPa∙L
-1.s) 0.381+ (-0.004*height) + (-0.020*age) + (-0.012*SCD) -0.012  (-0.059; 0.035) 
R15 (kPa∙L
-1.s) 1.175+ (-0.003*height) + (-0.010*age) + (-0.001*weight) + (-0.059*SCD) -0.059  (-0.100; -0.017)** 
R20 (kPa∙L
-1.s) 1.137+ (-0.003*height) + (-0.008*age) + (-0.087*SCD) -0.087  (-0.126; -0.048)*** 
X5 (kPa∙L
-1.s) -1.142 + (0.006*height) + (-0.094*SCD) -0.094 (-0.137; -0.051)*** 
AX (kPa∙L-1.s) 9.730 + (-0.057*height) + (1.080*SCD) 1.080  (0.592; 1.568)*** 
Fdr5-20 (kPa∙L
-1.s) 0.834 +(-0.005*height) + (0.138*SCD) 0.138  (0.091; 0.185)*** 
*p<0.05, **p<0.01, ***p<0.001 
 Result based on 68 healthy Black children and 59 children with SCD aged 4 to 11 years.
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When results were adjusted for height alone and expressed as Z Scores using the 
Dencker equations,41 similar results were found: With the exception of R10 Z Scores, 
independent t-tests showed significant group differences in all IOS outcomes (Table 
4-13, Figure 4-8 and Figure 4-9). 
 
Table 4-13: Comparison of IOS outcomes in 59 SCD and 68 healthy Black children.  
 SCD Healthy 
Black 
Mean Difference (SCD-health) 
(95%CI) 
R5 Z Score 0.99 (0.90) 0.63 (0.94) 0.36 (0.04 ; 0.69)* 
R10 Z Score 0.48 (0.81) 0.63 (0.75) -0.15 (-0.42 ; 0.13) 
R15 Z Score -0.02 (0.83) 0.54 (0.64) -0.56 (-0.82 ; -0.31)*** 
R20 Z Score -0.18 (0.80) 0.59 (0.63) -0.77 (-1.02; -0.52)*** 
X5 Z Score -2.13 (1.58) -0.79 (1.06) -1.3 (-1.81; -0.87)*** 
Fres Z Score 1.58 (0.69) 1.23 (1.16) 0.35 (0.01; 0.69)* 
AX 3.78 (1.54) 2.25 (1.43) 1.53 (1.00; 2.04)*** 
Fdr5-20 0.40 (0.14) 0.22 (0.13) 0.18 (0.13; 0.22)*** 
Unless stated otherwise, results presented as mean (SD) *p<0.05, ***p<0.001   
Results expressed as Z Scores,
41
 and based on 59 children  with SCD and 689 healthy Black 
children.
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Figure 4-8: Comparison of resistance measured at 5, 10 15 and 20Hz 
Results based on 68 healthy Black children and 59 children with SCD.   
Legend: Results expressed as Z Scores.
41
 Black lines denote mean +/-SD for the studied 
population.  Solid and dashed grey lines indicate the mean and limits of normality (+/-1.96 SD) 
for the reference data. 
R5 (a measure of resistance in small airways) was significantly elevated in SCD; there was no 
difference in R10 between health and SCD and R15 and R20 (measures of resistance in the 
larger/central airways) were significantly lower in the presence of SCD. 
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Figure 4-9: Comparison of X5, Fres, AX Z Scores and Fdr5-20.  
Results based on 68 healthy Black children and 59 children with SCD aged 4 to 11 years.   
Legend: Black lines denote mean +/-SD for the studied population.  Solid and dashed grey 
lines indicate the mean and limits of normality (+/-1.96SD) for the reference data (not available 
for AX or Fdr). 
Significant differences in all outcomes were observed.  The reduced X5 and increased Fres in 
SCD both contribute to the elevated AX observed in SCD which reflects changes in the 
periphery.  The elevated Fdr5-20 reflects changes in both the periphery (increased R5) and the 
central airways (reduced R20).
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R5 Z Score was significantly increased in SCD compared with the healthy children. In 
addition, when reviewing the relative changes in resistance measured at low 
frequencies (which represent the small airways), to resistance measured at high 
frequencies (which represent the central airways) a frequency dependence was 
observed in the SCD group.  Resistance in the healthy children however, remained 
relatively stable regardless of the frequency at which it was measured (as expected), 
albeit with a larger spread around the mean (Figure 4-10).  This frequency dependence 
of resistance was also highlighted by the t-tests on Fdr which revealed children with 
SCD to have significantly higher Fdr5-20 when compared to healthy Black children 
(p<0.0005, mean difference (95% CI): 0.18 kPa∙L-1.s (0.13; 0.22)) (Figure 4-9).  These 
results may be indicative of peripheral airway obstruction; however they only became 
apparent because the SCD group had a mean reduction in resistance at high 
frequency in comparison to healthy children (mean difference: -0.77 Z Scores) as well 
as a slight increase in resistance at low frequency (mean difference: +0.4 Z Scores).  
Such results may suggest the SCD group have reduced resistance within the central 
airways, and a relative increased resistance in the peripheral airways. However, the 
large SD around the mean observed in health limits the interpretation of these findings. 
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Figure 4-10: Frequency dependence of Resistance in health and SCD 
Legend: Left panel (green) = 68 healthy Black children;  Right Panel (Blue) = 59 children with 
SCD. Black lines denote mean for the studied population.  Solid and dashed grey lines indicate 
the mean and limits of normality (+/-1.96SD) for the reference data. 
41
 
In health, resistance remains relatively stable regardless of the frequency at which is measured.  
In SCD there is a slight increase in resistance in the small airways (low frequency resistance) 
and a larger reduction in resistance in the central airways (high frequency resistance), and thus 
a relative increase in Fdr is observed.  However the large spread around the mean observed in 
health limits the confidence with which these results can be interpreted. 
 
Healthy Black       SCD 
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4.10.1 Summary of IOS results in SCD 
Fifty-nine children with SCD were compared with 68 healthy Black children of the same 
age (4 to 11 years).  Interpretation on an individual basis was restricted due to the lack 
of adequate reference data and limits of normality, however multiple regression 
analysis revealed SCD had a significant impact on high frequency resistance (R15 and 
R20), X5, AX and Fdr after adjusting for height, age and weight (where applicable).  
These statistically significant differences were small (0.09 kPa∙L-1.s in R20), equating to 
less than one SD per outcome.  Similarly, direct comparisons of health and SCD when 
results were expressed as Z Scores revealed significant group differences.  R5 was 
slightly elevated in SCD, whereas R15 and R20 were significantly reduced.   
 
Results suggest a decreased resistance in the more central airways relative to the 
periphery in SCD.  This may suggest peripheral airway obstruction, and/or reflect 
increased traction and hence increased airway calibre in the central airways in the 
presence of restrictive lung disease.  Further interpretation of these results is only 
possible in the light of other lung function assessments and clinical symptoms.  The 
clinical usefulness of IOS in combination with other lung function tests and respiratory 
symptoms will be examined further in Chapter 8. 
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4.11 Repeatability and the bronchodilator response 
The previous section investigated the applications and interpretation of IOS in 
distinguishing between health and disease.  In addition to identifying group differences 
in baseline IOS measurements, IOS has been proposed as a useful outcome measure 
in the assessment of bronchodilator response (BDR).37,72,73,135    Appropriate 
interpretation of the BDR first requires knowledge of the between-test, within-occasion 
repeatability in health and disease, and whether or not healthy children exhibit a BDR.  
The following section will first review the between-test repeatability in health and in 
SCD, then determine the thresholds for defining a significant BDR before finally 
assessing the clinical role IOS plays in assessing  BDR in children with SCD.  Outcome 
measures analysed included R5, R10, R20 AX and Fdr5-20. 
4.11.1 Between test repeatability in health and SCD 
Twenty-two healthy Black children (mean (SD) age: 10.1 (2.1) years ) and 27 children 
with SCD (mean (SD) age: 10.4 (2.6) years) underwent baseline measures of IOS and 
repeated measures after a 15 minute interval with no intervention.  Paired t-tests 
revealed no significant difference between the two measurement sessions, and the 
between-test repeatability was the same in all outcomes in both health (Table 4-14) 
and SCD (Table 4-14), although between-test repeatability in AX was far greater (but 
not statistically significant) in SCD. 
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Table 4-14: Between test repeatability and limits of agreement of IOS in health. 
 Baseline (A) Repeated (B) Mean Diff (B-A) 
(95% CI) 
95% Limits of Agreement 
Lower limit (95% CI) Upper limit (95% CI) 
R5 (kPa∙L
-1.s) 0.72 (0.15) 0.72 (0.15) 0.00 (-0.03; 0.04) -0.15 (-0.19; -0.12) 0.16  (0.13; 0.19) 
R10 (kPa∙L
-1.s) 0.61 (0.12) 0.62 (0.13) 0.01 (-0.02; 0.04) -0.12 (-0.15; -0.09) 0.14 (0.11; 0.17) 
R20 (kPa∙L
-1.s) 0.57 (0.12) 0.58 (0.12) 0.01 (-0.02; 0.04) -0.11 (-0.14; -0.09) 0.10 (0.07; 0.12) 
Fdr5-20 (kPa∙L
-1.s) -0.14 (0.06) -0.14 (0.05) 0.00 (-0.01; 0.01) -0.11 (-0.14; -0.09) 0.10 (0.08; 0.12) 
AX (kPa∙L-1) 1.50 (0.76) 1.43 (0.85) -0.07 (-0.32; 0.19) -1.19 (-1.38; -0.99) 1.04 (0.85; 1.24) 
Unless stated otherwise, results presented as mean (SD) 
Results based on 22 healthy Black children aged 6 to 11 years. 
95% confidence intervals around the LLN and ULN were calculated from the standard error of the mean (SEM) and provide a more precise estimation of the 
limits of normality. Values in bold indicate the most conservative limits, that take the actual sample size of this study into account. 
 
Table 4-15: Between test repeatability of IOS in SCD.   
 Baseline (A) Repeated (B) Mean Diff (B-A) 
(95% CI) 
R5 (kPa∙L
-1.s) 0.73 (0.21) 0.70 (0.21) -0.03 (-0.06; 0.00) 
R10 (kPa∙L
-1.s) 0.63 (0.16) 0.60 (0.17) -0.03 (-0.05; 0.00) 
R20 (kPa∙L
-1.s) 0.58 (0.13) 0.55 (0.14) -0.03 (-0.05; 0.00) 
Fdr5-20 (kPa∙L
-1.s) 0.15 (0.02) 0.15 (0.02) 0.00 (-0.02; 0.03) 
AX (kPa∙L-1) 1.81 (1.45) 1.63 (1.41) -0.18 (-0.36; 0.02) 
Unless stated otherwise, results presented as mean (SD).  Results based on 25 children with SCD.
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4.11.2 Bronchodilator response in health 
Twenty-five healthy Black children (mean (SD) age: 8.6 (1.3) years) underwent BDR 
measurements.  Bland and Altman analysis on the between-test repeatability was 
performed to calculate the 95% limits of agreement from which the thresholds for a 
significant BDR could be determined (i.e. results which fell outside these limits 
constituted a significant change from baseline) (Table 4-14).  Each IOS outcome post 
BD was plotted using the limits of repeatability defined in Table 4-14, thus allowing the 
BDR in health to be examined.  All outcomes identified a trend towards a slight BDR in 
health, with R5 and R10 identifying six children in whom a significant BDR was observed 
(Figure 4-11).  Four of these children also demonstrated a significant reduction in R20 
(Figure 4-12), whereas AX and Fdr only picked up two of these children (Figure 4-13). 
 
The extent to which BDR occurs in health should be taken into account when 
assessing BDR in disease.  Six healthy children demonstrated a significant BDR when 
using R5 and R10 as the main outcome measures, and many of the other healthy 
children demonstrated some, albeit statistically insignificant, bronchodilator 
responsiveness (seen by the overall trend for a decrease in IOS outcomes post BD) 
(Figure 4-11, Figure 4-12 and Figure 4-13).  Bland and Altman analysis of baseline and 
post BD measurements in health were performed and the 95% limits of agreement 
were used as the threshold for determining a positive BDR in children with SCD (Table 
4-16). 
 
Table 4-16: 95% Threshold for a bronchodilator response using IOS.  
 95% Limits of agreement: 
Lower limit (95% CI) Upper limit (95% CI) 
R5 (kPa∙L
-1.s) -0.47 (-0.54; -0.41) 0.18 (0.12; 0.25) 
R10 (kPa∙L
-1.s) -0.30 (-0.34; -0.26) 0.09 (0.06; 0.13) 
R20 (kPa∙L
-1.s) -0.25 (-0.29; -0.21) 0.13 (0.09; 0.17) 
Fdr5-20 (kPa∙L
-1.s) -0.29 (-0.33; -0.25) 0.12 (0.08; 0.16) 
AX (kPa.L-1) -3.74 (-4.28; -3.20) 1.76 (1.22; 2.30) 
Results based on 25 healthy Black children. 95% confidence intervals around the LLN and ULN 
were calculated from the standard error of the mean (SEM) and provide a more precise 
estimation of the limits of normality. Values in bold indicate the most conservative threshold for 
a BDR, that take the actual sample size of this study into account. 
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Figure 4-11:Between test repeatability and BDR of R5 & R10 healthy Black children.  
Legend: Test A = baseline; Test B = repeatability; Test C = post bronchodilator.  Dashed lines denote 95% limits of agreement calculated from the between 
test repeatability (grey shaded area denotes the 95%CI around these limits).  Red dots indicate those children in whom a significant BDR was observed (i.e. 
results below the lower limit of repeatability).   Six healthy children were identified as a having a significant BDR 
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Figure 4-12: R20 between test repeatability and BDR healthy Black children. 
Legend: Test A = baseline; Test B = repeatability; Test C = post bronchodilator.  Dashed lines denote 95% limits of agreement calculated from the between 
test repeatability (grey shaded area denotes the 95%CI around these limits).  Red dots indicate those children in whom a significant BDR was observed (i.e. 
results below the lower limit of repeatability).   
R20 only identified a significant BDR in 3 healthy children (compared to the 6 that were identified by R5 and R10). 
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Figure 4-13: AX and Fdr5-20 between test repeatability and BDR in healthy Black children  
Legend: Test A = baseline; Test B = repeatability; Test C = post bronchodilator.  Dashed lines denote 95% limits of agreement calculated from the between 
test repeatability (grey shaded area denotes the 95%CI around these limits).  Red dots indicate those children in whom a significant BDR was observed (i.e. 
results below the lower limit of repeatability).  The same two children were identified as having a significant BDR with these outcomes, however, an additional 
4 children were identified by R5 and R10.
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4.11.3 Bronchodilator response in SCD 
Fifty-four children with SCD (mean (SD) age: 7.6 (2.0) years) underwent baseline and 
BDR assessment using IOS measurements.  With the exception of R20 in SCD, a 
statistically significant BDR was observed in all outcomes in both healthy children and 
children with SCD (Table 4-17). 
 
A clinically significant BDR, however, is a change over and above that seen in healthy 
children of the same age.  The thresholds for a significant BDR for each IOS outcome 
were derived from Bland and Altman analysis on baseline and BDR measures in health 
(Table 4-16).  The BDR in SCD was plotted next to the BDR in health to examine the 
extent to which BDR occurred in SCD.  There were no significant differences between 
the BDR in health and SCD when R5 (Figure 4-14), R10 and R20 were the outcome 
measures (Figure 4-15).  Fdr5-20 identified five children with SCD with a significant BDR 
(over and above that seen in health).  There was a significant difference between the 
absolute change post BD seen in SCD and health (mean difference (SCD-health): -
0.08 kPa∙L-1.s (p<0.005, 95%CI: -0.13; -0.03) (Figure 4-16).  AX only identified one 
child with SCD with a clinically significant BDR; however the mean difference in BDR in 
health and SCD was not significant (Figure 4-16). 
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Table 4-17: Comparison of baseline and post bronchodilator results in 25 healthy Black children and 59 children with SCD aged 4 to 11 years. 
 Healthy Black SCD 
 Baseline Post Mean diff (95% CI) Baseline Post Mean diff (95% CI) 
R5 (kPa∙L
-1.s) 0.82 (0.19) 0.68 (0.10) -0.14 (-0.21;-0.08)*** 0.97(0.22) 0.84 (0.20) -0.13 (-0.17; -0.10)*** 
R10 (kPa∙L
-1.s) 0.69 (0.12) 0.59 (0.08) -0.10 (-0.06; -0.01)*** 0.76 (0.15) 0.68 (0.15) -0.08 (-0.11; -0.06)*** 
R20 (kPa∙L
-1.s) 0.63 (0.10) 0.57 (0.07) -0.06 (-0.10; -0.02)** 0.65 (0.12) 0.68 (0.15) 0.03 (0.00; 0.06) 
Fdr5-20 (kPa∙L
-1.s) 0.19 (0.11) 0.11 (0.06) -0.08 (-0.13; -0.02)** 0.33 (0.13) 0.17 (0.07) -0.16 (-0.20; -0.14)*** 
AX (kPa.L-1) 2.19 (1.60) 1.20 (0.73) -0.99 (-1.56; -0.42)** 3.78 (1.58) 2.71 (1.30) -1.07 (-1.35; -0.80)*** 
Mean diff (Post-Baseline); Unless stated otherwise, results presented as mean (SD) *p<0.05, **p<0.01, ***p<0.001   
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Figure 4-14: BDR measured by R5 in health and in SCD  
Legend: Dashed lines denote 95% limits of agreement calculated from the bronchodilator response observed in health (grey shaded area denotes the 95%CI 
around these limits).  Red dots indicate those children in whom a significant BDR was observed (results below the lower limit of normal). 
Health        SCD 
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Figure 4-15: BDR in health and in SCD using R10 and R20 as the outcomes.    
Legend: Dashed lines denote 95% limits of agreement calculated from the bronchodilator response observed in health (grey shaded area denotes the 95%CI 
around these limits).   
Health       SCD 
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Figure 4-16: BDR in health and in SCD using Fdr5-20 and AX as the outcomes.    
Legend: Dashed lines denote 95% limits of agreement calculated from the bronchodilator response observed in health (grey shaded area denotes the 95%CI 
around these limits).  Red dots indicate those children in whom a significant BDR was observed (results below the lower limit of normal). 
Health       SCD 
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4.11.4 Summary of IOS and the bronchodilator response 
Impulse oscillometry was used as an outcome measure in the assessment of BDR in 
59 children with SCD.  A statistically significant BDR was seen in all outcomes, in both 
healthy children and children with SCD, however only five children with SCD were 
identified as having a significant BDR (over and above that seen in health) when using 
Fdr5-20 as the main outcome primarily due to the reduction in R5 in these children post 
bronchodilator.  Resistance measured at 5Hz and 10Hz in isolation did not identify any 
clinically important BDR in SCD.  The results suggest that as a group, children with 
SCD do not demonstrate a clinically relevant response to bronchodilator.  Those 
children with some BDR observed in Fdr changes are investigated further in 
combination with other lung function tests and the clinical status in Chapter 8. 
 
In summary, IOS can be used in the assessment of BDR, however the bronchodilator 
response observed in health must be taken into account prior to interpreting BDR in 
lung disease.  R20 did not identify a clinically relevant change from baseline and should 
not be used as an outcome measure for assessing BDR.  R5 and R10 may be used, but 
a clinically relevant BDR would be a fall >0.15kPa∙L-1.s (15%).  These results suggest 
that Fdr5-20 may be the most useful outcome measure in monitoring response to 
bronchodilator with IOS, as it does  not detect many healthy children, but picks up a 
few children with SCD.  The benefit of Fdr5-20 as an outcome measure is that it reflects 
resistance over a range of frequencies and therefore describes the change in 
resistance across the bronchial tree, rather than at discrete frequencies.  The 
thresholds for Fdr and AX are larger at 0.1kPa∙L-1.s (40%) and 1.0kPa∙L-1 (40%) 
respectively.  Further work with a larger sample size and other disease groups are 
required to elucidate the appropriate threshold for BDR if this measurement is applied 
in the future. 
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4.12 Summary 
This chapter has demonstrated discrepancies between the two reference datasets 
available for IOS in White children and significant differences of +0.5 Z Scores in 
resistance at all frequencies and -0.8 Z Scores in X5 were observed in Black children.  
The differences observed are thought to be due to ethnic differences in lung function. 
However, the assessment of IOS in White children was not included in the SAC 
protocol and therefore a direct comparison between White and Black children could not 
be undertaken and the differences observed in Black children cannot be assumed to be 
entirely due to ethnicity.  Attempts were made to adjust the limits of normality and apply 
ethnic adjustment factors to enable interpretation in Black children but these were 
found to be limited due to the sample size upon which they were based.   
 
The clinical usefulness of IOS was assessed by making group comparisons between 
health and SCD.  Multiple regression analysis was used to determine the impact of 
SCD after adjusting for the relevant determinants, and significant differences between 
SCD and healthy Black children of the same age were observed.  Low frequency 
resistance (reflecting the small airways) was slightly increased in children with SCD 
compared to the healthy children however, more significantly, high frequency 
resistance (reflecting the central airways) was reduced in children with SCD, 
suggesting lower resistance within the central airways, possibly relating to restrictive 
lung disease (see Chapter 6: ‘Plethysmographic lung volumes’). 
 
Finally, IOS was evaluated as an outcome measurement for BDR.  The between-test, 
within-occasion repeatability, and BDR was first established in health, prior to 
assessing it in SCD.  As a group, children with SCD did not exhibit BDR over and 
above that seen in health.  Further work on recommendations and the development of 
reference equations are required, before IOS can be used clinically.   
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5 Specific Airways Resistance 
5.1 Introduction 
Plethysmographic specific airways resistance (sRaw) has proved to be a feasible and 
useful outcome measure in clinical research studies of preschool children with cystic 
fibrosis and wheezing disorders.82,86,87,91,137-139  However its use as a valid outcome 
measure in clinical management has been limited by the lack of consensus with 
regards to equipment, measurement conditions, data collection, analytical strategies 
and reference data.  Although sRaw is internally adjusted for differences in lung volume 
and it is likely that ethnic differences do not exist, this has not been elucidated; thereby 
limiting interpretation of sRaw in Black children. 
 
This chapter will describe the collation of healthy sRaw data from international centres; 
the subsequent investigation of methodological differences between these centres and 
the development of recommendations and reference equations for sRaw measurements 
in children.  These results have been published in the European Respiratory Journal.128  
An evaluation of these recommendations in healthy Black children is undertaken to 
determine if ethnic differences exist.  This is followed by an assessment of the potential 
use of sRaw as an outcome measure in the clinical management of children with Sickle 
Cell Disease (SCD). 
5.2 Aims  
The primary aim was to establish appropriate methods for the application and 
interpretation of sRaw measurements in young children and to develop reference data. 
 
The secondary aims were to: 
i. To determine the extent of ethnic differences in sRaw between healthy Black and 
healthy White children after adjusting for height, sex and age.  
ii. To evaluate the extent to which sRaw detects lung disease in children with SCD. 
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5.3 Objectives 
The primary aim was to improve interpretation of sRaw in young children; this was 
achieved by 
i. Collating available reference data for sRaw in young children  
ii. Developing reference equations and recommendations for use of sRaw in 
children 
iii. Assessment of the extent to which any bias occurred in results from healthy 
children when assessed using standardised protocols in different international 
centres 
5.4 Hypothesis 
The primary aim here was to collate normative data and generate reference equations; 
therefore this part of the study was not hypothesis driven.  Regarding the application of 
sRaw in healthy Black children, the hypothesis is that there are no ethnic differences in 
sRaw between Black and White children. 
5.5 Subjects and sample size 
The Asthma UK initiative (see Chapter 2, section 2.3.3) provided the majority of the 
data for this chapter: Plethysmographic sRaw data from healthy children aged 2 to 11 
years were collated from five international centres, all of whom had published studies 
reporting the measurement of sRaw in healthy children.
16,86,104,129,140-142 Healthy Black 
children were recruited from the SLIC and SAC study and the children with SCD were 
recruited from the SAC study (see Chapter 2, section 2.3).  Age was limited to <10 
years since the reference equations were also limited to this age range. 
 
Based on the literature,16,86,104,129,140-142 the Asthma UK initiative estimated that 
differences in sRaw of 0.2kPa∙s between centres or 0.1k Pa∙s within-subject would be 
clinically or physiologically significant, such differences approximating one standard 
deviation (SD) for between and within-subject variability respectively.143  To determine 
group differences (i.e. differences between Black and White children, or between 
health and disease) a sample size of 64 children in each group would enable 
differences of 0.5 SD to be detected with 80% power at the 5% significance level. 
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5.6 Collation of reference data 
The Asthma UK Collaborative Initiative was established in 2005 to develop centile 
charts and to investigate the impact of sex and age on interpretation of lung function 
measurements.  Further details of data collection and data cleaning can be found  in 
chapter 2 (section 2.6.5) In brief, sRaw data were collected in healthy children aged  2 
to 11 years.  All participating centres were asked to provide detailed information about 
recruitment, population characteristics, equipment and measurement protocols.   
 
Five centres contributed 2,872 sets of sRaw data from 2,347 children measured 
between 1995 and 2008.  Population characteristics can be found in Table 5-1. 
 
Table 5-1: Population characteristics in 2,872 healthy children in whom sRaw 
measurements were collated 
 Centre 1 Centre 2 Centre 3 Centre 4 Centre 5 
n (% boys) 38 (58%) 40 (50%) 828 (55%) 472 (51%) 1494 (53%) 
Age (years) 7.1 (1.1) 4.5 (1.0) 5.1 (1.0) 6.6 (2.1) 4.2 (1.0) 
Height Z  0.2 (0.9) 0.8 (1.3) 0.4 (1.1) 0.2 (1.0) 0.2 (1.0) 
Weight Z 0.5 (1.4) 0.4 (0.6) 0.2 (1.3) 0.2 (1.1) 0.2 (1.0) 
BMI Z  0.5 (1.6) -0.1 (1.0) -0.1 (1.0) 0.1 (1.1) 0.1 (1.) 
% White: 100% 100% 100% 77% 93% 
% Non-White: - - - 3% 6% 
% Unknown ethnicity: - - - 20% 1% 
Footnote: Anthropometry measurements were expressed as Z Scores according to equations 
by the CDC.
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White subjects of European descent contributed 2531 (88%) of the data points; 93 data 
points (3%) were recorded as “non-White”, whereas ethnicity was not recorded in 248 
(9%) subjects (Table 5-1 and Figure 5-1). The limited data in non-White subjects 
precluded analysis according to ethnic origin; hence these subjects were excluded from 
the reference equations (although impact of ethnicity was investigated in section 5.10). 
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Figure 5-1: sRaw Vs. height (A) and age (B) in children aged 3 to 11 years studied in five international centres 
The majority of the data came from White children.  The small amount of sRaw data from “non-White” and unknown ethnicities did not appear to differ 
from the White children (A).  Sex differences were not apparent (B)
B) A) 
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In total, sRaw data from 2,347 children were evaluated. Individual sRaw values ranged from 
0.21 - 2.82kPa∙s, with the mean (SD) sRaw from these five centres ranging from 0.55 (0.18) 
to 1.29 (0.30)kPa∙s.  One-way ANOVA analysis revealed significant between centre 
differences (p<0.0001) (Figure 5-2).   
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Figure 5-2: sRaw in children aged 3 to 11 years from five international centres. 
Significant between centre differences were observed.  The difference between the highest and the 
lowest mean sRaw was 0.74kPa∙s. 
NB: Two centres (1 & 4) reported sReff and the remaining centres reported sRtot.  A definition of the 
different sRaw outcomes can be found in the section 5.6.2.1, and the impact of different methods of 
reporting sRaw investigated in section 5.6.2.3  
 
The significant inter-centre differences prompted an investigation into methodological 
differences between each centre.  Where differences in methodology were observed, sub-
analyses were conducted to establish the potential impact of these differences, and 
resulted in the exclusion of two centres (centres 1 and 3).  A final dataset of 1908 sRaw 
measurements were collated and sRaw reference equations were developed (section 5.7).  
Further analyses into other factors which may influence sRaw were undertaken before 
developing recommendations for use (section 5.8.6). 
 
The following section identifies the inter-centre differences and the sub-analyses 
undertaken which led to the exclusion of two centres, and the collation of data from three 
centres to generate reference equations. 
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5.6.1 Inter-centre differences 
The Asthma UK initiative collated 2,872 sets of sRaw data from five centres, however the 
individual sRaw values ranged from 0.21 - 2.82kPa∙s and significant inter-centre differences 
were observed.  There was a spread of age across the five collaborating centres (Table 
5-1), and one-way ANOVA analysis revealed significant differences in age across the five 
centres.  The impact of age, sex and centre were investigated using regression analysis. 
5.6.1.1 Influence of age 
Simple linear regression on sRaw and age revealed a strong significant (p<0.0001) 
correlation between the two variables (Figure 5-1B).  Nine percent of the variance seen in 
sRaw could be explained by age (r
2 = 0.09), and the relationship was defined as: 
sRaw = 1.179 + -0.021*age_years 
Thus with every year increase in age, sRaw decreases by 0.02 kPa∙s, such that the sRaw 
predicted at 3, 7 and 10 years is 1.11 kPa∙s, 1.03 kPa∙s and 0.97 kPa∙s respectively.    
Given the marked between subject variability at any given age, these differences were not 
physiologically significant, however, age was taken into consideration in the final reference 
equations (Table 5-5, section 5.7). 
5.6.1.2 Regression of age, sex and centre 
Multiple regression analysis was used to determine how much of the variance in sRaw 
could be explained by age alone (section 5.6.1.1) and by age, sex and centre in 
combination.  The coefficient for age, sex and centre was -0.16, -0.06 and 0.59 
respectively.  Thus, although all three variables made a significant unique contribution to 
sRaw (p<0.0001), only centre contributed a physiologically significant difference.  The 
relationship of sRaw and age, sex and centre was therefore defined as: 
 sRaw = 0.455 + 0.044*age + -0.036*sex + -0.41*centre 
(where: centre = coefficient attributed to each centre, age = years, and sex is: 1=male and 
2=female). 
After adjustment for centre, sex and age were independently associated with sRaw; sRaw 
decreased with age (β: -0.044 kPa∙s, p<0.0001), and was slightly lower in females (β: -
0.030 kPa∙s, p<0.0001). Centre explained the most variability (partial r2 = 11%), compared 
to 6% for sex and 4% for age.  After adjustment for centre, sex and age, sRaw was 
independent of height (β: 0.002, p=0.94). The inter-centre differences contributing to the 
potentially physiologically significant difference (pre-defined as 0.2 kPa∙s) in sRaw 
outcomes are investigated in the following sections. 
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5.6.2 Methodological differences 
Details regarding equipment and methodology are summarised in Table 5-2.   
The Jaeger Masterscreen body plethysmograph (Wurzburg, Germany) was used by all 
collaborating centres; however a variety of software versions and equipment 
(masks/mouthpieces/bacterial filters) were used.  Due to the retrospective nature of the 
data collection, the equipment differences could only be investigated in small studies on 
adults.  Software differences and the use of mask/mouthpieces were not thought to 
contribute to inter-centre differences, whereas neglecting to use a filter appeared to reduce 
sRaw values (see appendix).  Although the investigations of equipment differences were 
limited, investigations into the impact of applying different methods of data selection and 
reporting were feasible and are described in detail in the following sections. 
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Table 5-2: Equipment and methodology used by five collaborating centres. 
Centre 
Equipment  (Jaeger): Quality 
control: 
(selection of 
tangent) 
sRaw 
outcomes
# 
Reporting of results Software 
Version 
Mask or 
mouthpiece 
Use of 
Filter 
1 V4.1 mouthpiece 
Sometimes
## 
computer & 
manual 
sRtot & 
sReff 
Weighted mean 
2 
V4.22 & 
V4.34 
Specialised 
mask 
No Computer sRtot Mean of Median 
3 V4.34 mouthpiece No Manual sRtot 
Median of first set of 
acceptable loops 
4 
V4.65 & 
5.01 
mouthpiece Yes Computer 
sRtot & 
sReff 
Weighted Mean, mean 
of medians & median 
5 
V4.34 & 
4.65 
mask Yes Computer sReff Mean of Median 
#
Definitions of the difference sRaw outcomes are available in section 5.6.2.1 
##
Filters were used in specific patient groups (e.g. cystic fibrosis), but not in healthy children. 
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5.6.2.1 Manual or automatic tangent selection 
With the exception of ‘effective resistance’ (sReff), which is calculated as a regression of 
pressure and flow over the entire breathing cycle, the sRaw outcome is generally derived 
from the tangent of the slope of pressure/flow curve (P/F) which can be placed: 
 between points of maximum plethysmographic (box) pressure (total resistance, or 
sRtot)  
 between peak inspiratory and peak expiratory flow (sRpeak)  
 over some fixed range of flow or over the central linear portion of the breath (most 
frequently between 0-0.5L.s-1 i.e. sR0.5)  
The most common sRaw outcomes in children are sRtot and sReff, however with the 
numerous outcomes available, it is essential to specify which sRaw outcome is being 
reported, and whether any manipulation of the tangent has occurred, as each outcome 
represents resistive changes over a different portion of the curve (see section 2.6.5.3 for 
the different calculations on sRaw outcomes.)   
 
The sRaw tangent of P/F can be selected automatically by the computer software, or can 
be manually selected/adjusted by the operator as demonstrated in Figure 5-3.  Three 
centres accepted the computer generated tangent between peak to peak box pressure 
(sRtot).  One centre (centre 1) manually adjusted the tangent periodically when the 
operator felt it was necessary.  The final centre (centre 3) applied a very specific protocol 
for selecting sRaw loops which involved reanalysing the tangent post data collection and 
modifying each loop to ensure that the tangent was measured over the central linear 
portion of the curve, generally at flows at or below 0.5L.s-1.   
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Figure 5-3: Methods for selecting sRaw slope/tangent 
A) Computer generated tangent.  B) Operator adjusted tangent to represent the central/linear portion of the loop.   
sRtot in A was calculated as 0.83kPa∙s, whereas sRtot in example B was 0.67 kPa∙s  
 
B) A) 
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To investigate the effect of manually adjusting the tangent, a subset of 187 randomly 
selected sRaw measurements were re-analysed by manually adjusting the tangent to 
measure just the central linear portion of the inspiratory loop (now defined as sRmid).  
The within-subject comparisons of sRtot (computer generated) and sRmid (manual 
adjustment) showed sRtot was significantly higher than sRmid (mean difference (95%CI): 
0.41 kPa∙s (0.38; 0.44)). 
 
A significant correlation (r2 = 0.76, p<0.0001) between sRtot and sRmid was observed 
(Figure 5-4A), and Bland and Altman analysis revealed no bias as sRaw increased.  The 
mean % difference was 38.2% (95% LA: -65.8 ; -10.2%) (Figure 5-4B).  Despite the 
relatively high correlation between sRmid and sRtot, linear regression revealed that sRtot 
accounted for just 57% of the variation in sRmid (adjusted r
2 = 0.573).  Marked between-
subject variability in this relationship (up to 80% in some cases), together with potential 
between–operator variability in tangent placement precluded the use of sRmid data, or 
data which had been manipulated to such an extent.  Centres 1 and 3 were therefore 
excluded from further analysis.
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Figure 5-4: Correlation (A) and within-subject comparisons (B) of sRtot (computer generated) and sRmid (manual adjustment).   
Legend: (B): Black line indicates the mean difference; dashed lines indicate the 95% limits of agreement.   
sRtot and sRmid were significantly correlated (r
2
=0.76), however the large within-subject variation (B) precluded the use of sRmid data.
B) A) 
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5.6.2.2 Over-read scores 
Prior to the final collation of reference data, the three included centres underwent quality 
control (QC) analysis to ensure data were acceptable.  A random sample of 10-20 P/F 
curves from children studied at each centre were requested to enable a central QC over-
read.  P/F curves were graded out of 6, with one point given for each of the following 
criteria achieved:  
i. Respiratory rate 30-45 bpm;  
ii. Breaths super-imposable (i.e. parallel tangents);  
iii. Breaths similar size and shape;  
iv. Breaths reasonably closed at zero flow;  
v. No obvious distortions (e.g. glottic closure, cough, talking)  
vi. Availability of at least two acceptable trials  
The over-read sheet and examples of applying the over-read system can be found in 
Chapter 2, section 2.6.5.4. 
 
Table 5-3 summarises the details of the over-read score from the three centres included in 
the final dataset.   One of these centres did not include breathing frequency on the P/F 
curve print-outs, but confirmed that the protocol always maintained breathing frequency 
between 30-45 bpm, so were scored appropriately for this criterion.  No data were 
excluded on the basis of poor over-read scores. 
 
Table 5-3: Summary of QC scores for sRaw loops from the three included centres. 
 Centre 2 Centre 4 Centre 5 
Number analysed 10 70 18 
Resp. Rate = 30-45bpm 8 (80%) 70 (100%) 18 (100%)a 
Breaths super-imposable 9 (90%) 65 (93%) 18 (100%) 
Loops similar size and shape 5 (50%) 60 (86%) 7 (39%) 
Loops closed at zero flow 6 (60%) 6 (60%) 0 (0%) 
No distortion 7 (70%) 59 (84%) 11 (6%) 
>1 set available b 10 (100%) 70 (100%) 18 (100%) 
Over-all score 5/6 5/6 3/6 
Footnote: Results represent the number (%) of subjects from each centre that achieved each QC 
criteria. 
a
 Reported to maintain all recordings within 30-45bpm, but not recorded on printouts.
 b
 i.e. at 
least 2 technically acceptable trials.  
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5.6.2.3 Use of different sRaw outcomes: sRtot or sReff? 
Two centres were excluded from analysis due to the protocol they adopted which allowed 
manual adjustment of the tangent (section 5.6.2.1).  Of the three remaining centres, one 
reported sRtot, one reported sReff and another reported both sRtot and sReff.  The potential 
impact of reporting different outcome measures for sRaw was investigated by reanalysing a 
subset of 228 paired sReff and sRtot measurements and making within-subject 
comparisons. 
 
 Although a strong correlation (r2 = 0.98) between these two variables was observed, 
(Figure 5-5A), sRtot was significantly higher than sReff (mean difference (95%CI): 0.16 
(0.15; 0.16) kPa∙s)) (Figure 5-5B), hence the two outcomes were not interchangeable.  
Linear regression of these data revealed the following relationship:   
sRtot = 0.09 + 1.07 * sReff_ kPa∙s   
The validity of the equation was verified using another dataset which had both sReff and 
sRtot measurements.  sRtot was calculated from sReff by applying the regression equation 
cited above.  The newly calculated sRtot (sRtot_calc) was highly correlated with the original 
sRtot values (r
2 = 0.96), with no significant difference between them (mean difference (95% 
CI): 0.007 (-0.01; 0.02)).  The validated regression equation enabled adjustment factors to 
be applied to sReff and sRtot and allowed a direct comparison of the values (Table 5-4).  
Values of sReff and sRtot were similar between the centres, as was the between-subject 
variability.    
 
Table 5-4: The mean (SD) sRaw values for all included centres. 
Centre sReff 
Mean (SD) 
sRtot 
Mean (SD) 
2 1.13 (0.3)# 1.29 (0.3) 
4 1.09 (0.2) 1.20 (0.3) 
5 1.15 (0.2) 1.32 (0.2)## 
Footnote: # sReff: calculated by applying a correction factor to sRtot data: (sReff = -0.03 +0.9 *sRtot) 
##sRtot: calculated by applying a correction factor to sReff data: (sRtot = 0.09 +1.07*sReff) 
 
In summary, both sRtot and sReff are useful outcome measures and are highly correlated 
with one another.  To enable future collaboration of sRaw data, future studies should record 
both outcomes.  
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Figure 5-5: Relationship between sRtot and sReff compared by linear regression (A) and Bland and Altman analysis (B) 
Legend: (B): Dashed lines indicate the mean difference and the 95% limits of agreement.   
Footnote:  sRtot and sReff were significantly correlated (r
2
=0.98), and within subject agreement was low (B).  sRtot was significantly higher than 
sReff. 
A) 
B) 
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5.6.2.4 Different methods of reporting  
The collaborating centres demonstrated a variety of methods with regards to reporting 
results that included:   
i. the weighted mean, i.e. the sum of all ‘acceptable’ sRaw  values, after rigorous 
QC, divided by the total number of acceptable values87  
ii. the mean of the median sRaw  from three trials, prior to any exclusions 
iii. the ‘median’, as represented by the median value of sRaw from the most 
representative (i.e. ‘median’) trial (Figure 5-6) 
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Figure 5-6:  Example of different methods of QC and reporting. 
Left-hand panel has 3 measurements of 10 sRaw loops.  Right-hand panel includes the same measurements but after undergoing 
rigorous QC.  
sReff with no QC in each measurement was 0.79kPa∙s, 0.78kPa∙s and 0.80kPa∙s (red circles). Median sReff = 0.79 kPa∙s, and the mean-
median=0.79kPa∙s. Weighted mean is the sum of the acceptable loops (purple circle) divided by the total (n=19) and is calculated as 0.78kPa∙s. 
No Quality Control Quality Control (excluding “unacceptable” loops 
Median sReff: 0.79 kPa∙s 
Median sReff: 0.78 kPa∙s 
Median sReff: 0.80 kPa∙s 
Weighted mean sReff: 0.78kPa∙s 
([0.83+0.78+0.77+0.78+0.74+0.8+0.74/7) 
Weighted mean sReff: 0.78kPa∙s 
([0.78+0.76+0.79+0.84+0.71+0.78]/6) 
Weighted mean sReff: 0.79kPa∙s 
([0.8+0.79+0.86+0.71+0.78+0.81]/6) 
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The extent to which the method of summarising data influenced reported values was 
examined by recalculating a subset of 297 sets of results so that both the median and the 
weighted mean could be compared.   Within-subject comparisons revealed no statistical 
differences between weighted-mean vs. mean-of-median sReff (mean difference: 0.003 
(95%CI -0.001; 0.006) kPa∙s) (Figure 5-7).  Similar analysis between 101 mean-of-median 
and median-median sReff data sets revealed similar results: mean difference: -0.02 
(95%CI: -0.07; 0.075) kPa∙s . 
 
 
Figure 5-7: Bland and Altman plot comparing methods for reporting results.  
Legend: Dotted lines indicate the mean difference +/- 95% limits of agreement. 
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5.6.3 Summary of the methodological differences 
In summary, significant inter-centre methodological differences were observed, which 
prompted sub-analyses to investigate these differences:  The impact of sRaw slope 
selection was significant across the collaborating centres, with two centres found to adjust 
the tangent.  Despite a significant correlation between sRmid (the value found after 
adjusting the tangent) and sRtot (computer generated slope) the marked between-subject 
variability in this relationship, together with potential between–operator variability in 
tangent placement precluded the use of sRmid data, or data which had been manipulated to 
such an extent.  Subsequently, two centres were excluded from the final collation.  The 
remaining centres underwent specific quality control over-read analysis.  Some variation in 
the QC scores attained between the three centres was observed, however no data were 
excluded on the basis of poor QC. 
 
The use of different sRaw outcomes and the methods of reporting were then evaluated.  
sRtot and sReff were the most common outcomes and were found to correlate well with one 
another.  Although sRtot was significantly higher than sReff, linear regression enabled the 
relationship to be defined so that the outcomes could be calculated from one another.  In 
contrast to the significant impact of manually adjusting the slope, the method of reporting 
results as weighted mean, mean of median or median-median did not impact the final 
outcome, thus the least time consuming method (median-median) is recommended for 
future reports, especially as this is more objective and not subject to inter-observer 
variability. 
 
Data from three centres were collated and reference equations were developed (section 
5.7).  Further analysis on retrospective data collected at the UCL Institute of Child Health 
(ICH) to ascertain additional factors which may influence sRaw outcomes were examined 
prior to generating recommendations in section 5.9. 
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5.7 Development of reference equations 
The Asthma UK initiative collated sRaw data from five international centres.  After a 
thorough investigation of the methodology, two centres (centres 1 & 3) were excluded from 
the final collation, thus 1908 sRaw measurements from three international centres were 
available to enable reference equations to be constructed.  The equations were 
constructed by Dr Sanja Stanojevic using the LMS method133 described in Chapter 2, 
section 2.9.6.  Separate models were developed for males and females, and smoothly 
changing curves, which explain the age related changes, were developed. The reference 
equations were limited to children aged 3 to 10 years to avoid edge effects and were 
created with the prerequisite that measurements were performed under the 
recommendations described in section 5.9. 
 
Z Scores can be obtained by substituting the values for M, S and L from Table 5-5 into the 
following equation:   
Z Score = [(Measurement/M)L - 1] / [L x S] 
 
Table 5-5: Reference equations for sRtot and sReff for children aged 3 to 10 years.  
 M S L 
sRtot 1.308 - 0.0001648*age
3 - 0.037*sex  exp(-1.727 -0.00428*age2) 0.048 
sReff 1.143 - 0.0001369*age
3 - 0.038*sex exp(-1.651 -.003786*age2) 0.088 
Age is in decimal years; for sex enter 1 for males and 2 for females; exp (exponentiate).  
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Figure 5-8: Predicted values of sRaw (kPa·s) with upper and lower limits of normal. 
(a) sReff  and (b) sRtot for children aged 3 to 10 years. Solid lines represent equations for 
boys, whereas dotted lines represent equations for girls. 
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5.8 sRaw: Influence of breathing pattern 
Previous sections have described the collation of sRaw data in healthy children and the 
development of reference equations.  Prior to developing recommendations to accompany 
these reference equations, further analysis was conducted to investigate other factors that 
could potentially influence sRaw outcomes. 
 
Breathing frequency has previously been demonstrated to have a marked impact on 
measured values of sRaw.
81  The true impact of breathing pattern, however may relate 
more to flows attained, which can vary markedly while maintaining identical breathing 
frequency, than to respiratory rate per se.   Figure 5-9 demonstrates the impact of 
breathing pattern in an individual subject.  In this case, breathing frequency was doubled 
but no change in sRaw occurred when the same flows were maintained (Figure 5-9 A&B), 
however when flows and breathing frequency were increased there was a large increase 
in sRaw (Figure 5-9 C&D).   
 
Systematic investigation of breathing pattern in the Asthma UK collated data was impeded 
by the fact that flows were not available as outcome variables within the plethysmographic 
program, such that readings would need to be taken from print-outs, which were too small 
to be reviewed.  The impact of flows was therefore reviewed retrospectively in children 
studied at ICH.  Additional adult data were used to answer questions difficult to address in 
children.
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Figure 5-9: Impact of breathing frequency and flows on sRaw.  
sRaw remains relatively the same when flows are maintained at -1.0 L∙s
-1
 to +1.0L∙s
-
 even when breathing frequency is increased from 35bpm (A) 
to ~80bpm (B).  By contrast when flows are approximately doubled, sRaw is also doubled (C and D).
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5.8.1 Evaluation of breathing pattern in children 
A retrospective analysis of flows obtained during sRaw measurements of 180 White 
children studied at ICH from five research projects was reviewed.  One-way ANOVA 
analysis revealed significant differences in age across the five projects (p<0.0005), 
however no significant difference was observed in height, weight and BMI when 
expressed as Z Scores131 (Table 5-6).  As a group, the mean (SD) age, and height, 
weight and BMI Z Score was 8.3 (2.0) years; 0.2 (0.9); 0.3 (0.8) and 0.3 (0.9) 
respectively.  
 
Table 5-6: Comparison of demographics, sRaw and breathing pattern.  
 1: 2: 3: 4: 5: 
Year: 2004-06129 2006-0716 2006-08104 2009-10144 2011 
n (% male) 23 (57%) 53 (59%) 54 (50%)  40 (48%) 10 (50%) 
Age (yrs) 7.5 (0.7) 11.0(0.5) 7.9 (1.2) 6.0 (0.7)*** 7.3 (1.8) 
Height Z Score 0.4 (1.0) 0.2 (0.9) 0.2 (1.0) 0.0 (0.9) 0.4 (0.8) 
Weight Z Score 0.5 (0.8) 0.2 (1.0) 0.2 (0.8) 0.3 (0.7) 0.4 (0.6) 
BMI Z Score 0.4 (0.7) 0.2 *1.0) 0.2 (0.8) 0.5 (0.7) 0.3 (1.0) 
sRtot Z Score 0.3 (1.0) 0.4 (0.6) 0.5 (0.9) -0.6 (1.0)*** 0.0 (0.7) 
sReff Z Score 0.0 (1.2) NA 0.5 (0.9) -0.7 (1.0)*** 0.0 (0.7) 
BF (bpm) 42.4 (10.8) 33.4(3.7) 43.9(7.8) 37.1 (4.5)*** 36 (1.5) 
Netflow (L∙s-1) 1.2 (0.5) 1.2 (0.4) 1.1 (0.4) 0.8 (0.2)*** 1.0 (0.3) 
Unless stated otherwise, results presented as mean (SD) ***p<0.001  
Results based on five research studies conducted at ICH between 2004 and 2011.  
BF = Breathing Frequency.  Netflow was calculated as ((PIF-PEF)/2) Demographics and sRaw 
were expressed as Z Scores according to reference equations by the CDC
131
 and Kirkby et al
128
 
respectively 
 
Since no quantitative measure of peak expiratory flow (PEF), peak inspiratory flow 
(PIF) or average flow were reported within the sRaw program, an estimation of PEF and 
PIF was approximated from the flow axes on scaled printouts and calculating the 
average flow (“net-flow”: (PIF – PEF)/2) for each sRaw measurement (Figure 5-10) 
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Figure 5-10: sRaw loops from which “net-flow” was calculated. 
Legend: Dashed lines identify the estimated peak inspiratory (red) and expiratory (blue) flow, 
from which “net-flow” was calculated. 
 
All children studied had sRtot measurements within the normal range (+/- 2 Z Scores as 
defined by section 5.7).  However, despite the use of identical protocols and equipment 
during all projects, significant group differences between projects were observed; these 
differences being of potential clinical/physiological relevance.  
 
Subsequent investigations into the inter-project differences were undertaken:  Project 4 
was a preschool project, in which the children were significantly younger, and the flows 
attained by these children were significantly lower than those children measured in the 
other projects.  After excluding project 4, one-way ANOVA analysis of the remaining 
four projects revealed no significant group differences in sRtot Z Scores (p=0.09) or 
netflow (p=0.16), however significant differences in breathing frequency were still 
observed (p<0.0005).  The impact of breathing pattern (breathing frequency and flows 
attained) and age are investigated in the following sections. 
5.8.2 Association of breathing frequency and netflow 
Figure 5-9 demonstrated that breathing frequency can vary markedly whilst sRaw 
values can remain constant as long as flows are maintained relatively constant.  As can 
be seen in Figure 5-11 there was no correlation between netflow and breathing 
frequency during sRaw measurements (p=0.73).  The majority of children aged 4 to 11 
years adopted a breathing pattern which has a netflow <1.5 L∙s-1 and breathing 
frequency <50bpm.   
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Figure 5-11: Breathing pattern adopted sRaw measurements. 
Results based on 180 healthy White children.   
No association between netflow ((PIF-PEF)/2)) and breathing frequency was observed (p=0.73) 
 
5.8.3 Adult verification: influence of breathing pattern on sRaw 
The impact of breathing pattern on sRaw was investigated in 12 healthy adults (age 17 
to 56 years).  Repeated sRaw measures at either 30bpm or 60bpm at low flows (i.e. 
quiet, natural breathing) or high flows (i.e. forced breathing) were performed in a 
random order.  Paired t-tests were used to determine the impact of flow and BF on 
sReff. 
 
When flows were doubled from approximately ±1 L∙s-1 to ~±2 L∙s-1, while maintaining a 
constant breathing frequency there was a significant increase in sRaw: mean difference 
(95%CI): 0.3 kPa∙s (0.2; 0.4) p<0.0001) (Figure 5-12A).  By contrast, when breathing 
frequency was doubled while maintaining a constant flow there was no significant 
change in sRaw: mean difference (95%CI): 0.06 kPa∙s (0; 0.1), p=0.21) (Figure 5-12B). 
  191 
Low flow High flow
0.0
0.5
1.0
1.5
(A)
s
R
e
ff
 (
k
P
a
-s
)
30bpm 60bpm
0.0
0.5
1.0
1.5
(B)
s
R
e
ff
 (
k
P
a
-s
)
 
Figure 5-12: Within-subject changes in sReff when breathing pattern is altered. 
a)Flows are doubled but breathing frequency remains constant at 30bpm, b) flows remain 
relatively constant but breathing frequency is doubled.   
Doubling flows results in a significant increase in sReff, whereas doubling the breathing 
frequency makes little difference to sReff. 
 
5.8.4 Impact of breathing frequency  
Projects which commenced data collection prior to 2006 (projects 1 and 3) were not 
subjected to the strict quality control and breathing frequency criterion to the same 
extent as those which started at a later date.  Consequently some of these children had 
adopted a breathing frequency >45bpm (Figure 5-13 A).  Despite the variability in 
breathing frequency across the projects, sRtot Z score remained relatively constant.  
Although a significant (p=0.018), but weak correlation between breathing frequency 
and sRtot Z Score was observed (r=0.177), it was unlikely to bear any clinical 
significance (Figure 5-13 B).  
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Figure 5-13: Breathing frequency adopted during sRaw measurements in 180 healthy White children according to project.   
A) Comparison between breathing frequency and age. B) Comparison between breathing frequency and sRtot  Z score.   
A significant but weak correlation between sRtot Z Score and breathing frequency was observed. 
 
 
A B
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5.8.5 Impact of netflow 
The shallower breathing pattern (i.e. lower netflows) in pre-school children (project 4) 
compared to the older children is illustrated in Figure 5-13.  The pre-school children 
also had significantly lower sRaw Z Scores. Figure 5-14 plots netflow against age and 
sRtot Z Score.   Pearsons correlation revealed significant (p<0.0001), but weak 
correlations between age and netflow (r = 0.39), albeit that the majority of children 
measured in the age range adopted a netflow of <1.5 L∙s-1 (Figure 5-14 A).  In addition 
netflow was also weakly correlated with sRtot Z Score (r = 0.46, p <0.0001) (Figure 5-14 
B). 
 
Multiple regression analysis was used to determine how much of the variance in sRtot 
could be explained by netflow alone, and by netflow, breathing frequency and age in 
combination.  The coefficient for netflow, breathing frequency and age was 0.43, 0.26 
and 0.06 kPa∙s respectively.  Thus only netflow and breathing frequency made a 
significant, clinically relevant contribution to sRaw (p<0.0001).   
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Figure 5-14: Flows attained during sRaw measurements in 180 healthy White children according to project.   
A) Comparison between netflow and age. B) Comparison between netflow and sRtot Z score.   
The majority of children adopt a netflow of <1.5L∙s
-1
, however there is a weak correlation between age and netflow (A).  Higher netflows are also associated 
with increased sRtot Z Scores. 
  
A B
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5.8.6 Summary of the influence of breathing pattern 
An investigation into the impact of breathing patterns on sRaw Z Scores was conducted 
after the Asthma UK collation of sRaw data and reference equations were developed.  
Retrospective analysis of data collected at ICH plus adult verification studies suggest intra-
subject variability of sRaw was more related to flows attained than to breathing frequency 
per se, with higher sRaw values being associated with increased flows.   
 
The majority of children aged 4 to 11 years adopted a breathing pattern which had a 
netflow <1.5 L∙s-1 and breathing frequency <50bpm, however results suggest that healthy 
children may breathe at higher breathing frequencies without increasing sRaw values.  
Emphasis on breathing pattern may therefore be of more importance than breathing 
frequency alone.  To reduce variability between subjects, and further standardise 
recordings, subjects should be encouraged to breathe quietly and naturally during sRaw 
measurement. 
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5.9 Recommendations for sRaw measurements 
Based on the data collated from five international centres, the subsequent exclusion of two 
centres, and further retrospective analysis of data from different projects within one centre, 
recommendations for data collection and analysis were developed.  These 
recommendations, together with the reference equations developed by Dr Sanja 
Stanojevic were published in the European Respiratory Journal.128 The main conclusions 
were as follows:  
i. As software and equipment change, it is recommended that laboratories always 
validate any major software releases by within-subject comparisons in biological 
controls.  Results of such biological validation should be collated by manufacturers and 
placed in the public domain.  Validation studies should be performed under identical 
conditions as that in clinical practice 
ii.  While we were unable to directly compare results obtained with a modified mask and 
mouthpiece, previous studies have found no difference between these methods.145 In 
order to standardise methodology we recommended an appropriately sized 
mouthpiece and noseclip be used since these are now used routinely for many 
preschool lung function  tests1 as well as in older children and may be more readily 
available 
iii.  Manual adjustment of the tangent for sRaw should be avoided as this is a subjective 
method of QC and may impact on the results 
iv.  It is recommended that for future studies, sReff be the primary outcome measure since 
this calculates sRaw from multiple points throughout the breathing cycle.  However, 
recording both sReff and sRtot is advisable for future collaboration of sRaw data 
v.  Reporting the median breath from the median trial appears to be the most robust 
approach as it is not influenced by outliers, and avoids the subjective and time-
consuming nature of excluding “inadequate” loops  
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Demographics:  
The following test details should be recorded whenever collecting reference data: 
 Measured standing height (+sitting height where possible): Recorded to nearest 
0.1cm 
 Calculated age: Recorded as (date of test) – (date of birth), in years to 1 decimal 
place. 
 Measured weight : Recorded to the nearest 0.1kg 
 Sex: recorded and coded consistently 
 Gestational age: Recorded as completed weeks 
 Birth weight: Recorded to nearest 0.1kg 
 Ethnicity: Consensus required for definition 
Equipment:  
 Make, model and software version needs to be recorded.   
o A biological validation should be performed prior to upgrading software or 
equipment 
 Use an appropriately sized mouthpiece and noseclip. (a modified mask may also 
be used if that is current practice, though many centres now report equal success 
with a mouthpiece) 
 Always use a bacterial filter 
o Ensure calibrations are performed with filter in situ, and internal settings 
have accounted for the filter 
Data Collection:  
 Ensure the child is sitting upright, with no leak between the lips and mouthpiece 
 Cheek supported with child’s hands. 
o NB, while not strictly necessary if no occlusion manoeuvres are performed, 
this is good practice for when plethysmographic assessments include 
measures of FRC. 
 Natural breathing pattern within the specified range of 30-45bpm, avoiding either 
shallow panting or hyperventilation. 
 Collect at least 3 sets of ‘technically acceptable’ data during with no gross 
distortion. 
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Quality Control:  
 Use the automatic computer selected tangent. 
Use the sRaw over-read sheet in section 2.6.5.4 to “grade” the quality of the measurement 
sRaw outcomes: 
 Report sReff as the main outcome measure 
o  sRtot should be recorded where available, to facilitate comparisons with 
published data and provide objective evidence regarding most discriminative 
outcome in future clinical trials 
o Breathing frequency, peak expiratory and inspiratory flow (PEF and PIF 
respectively) should be recorded as QC outcomes 
 Report the Median of the median: Select the median (middle) breath from the 
median trial of 3 technically acceptable  sets of  5 or 10 breaths   
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5.10 Applications in healthy Black children 
The Asthma UK reference equations developed and presented in section 5.7 were 
developed for White children aged 3 to 10 years.  Ethnic differences were not expected, 
however the limited data from non-White children at the time precluded an investigation 
into ethnic differences. 
 
To determine the impact of ethnicity on sRaw, 56 healthy Black children aged 4 to 10 years 
underwent plethysmographic sRaw measurements in accordance with the 
recommendations suggested in section 5.9 and results were compared with those from 
148 healthy White children previously assessed at ICH.  The age range was limited to 4 to 
10 years to reflect the age range for which reference equations had been developed.  
Black children were significantly older, taller, and heavier and had a higher BMI compared 
to their White peers (Table 5-7).   
 
Table 5-7: Demographics of healthy children undergoing sRaw measurements. 
 Black  
  
White  
 
Mean Difference  
(Black –White) (95%CI) 
n (% male) 56 (64%) 148 (50%)  
Age (years) 8.3 (1.1) 7.3 (1.4) 1.0 (0.05; 1.4)*** 
Height Z score 0.8 (1.1) 0.2 (1.0) 0.6 (0.4; 0.9)*** 
Weight Z score 0.9 (1.1) 0.3 (0.8) 0.6 (0.4; 0.9)*** 
BMI Z score 0.8 (1.0) 0.3 (0.8) 0.5 (0.2; 0.8)*** 
Unless stated otherwise, results presented as mean (SD) ***p<0.001  
Demographics expressed as Z Scores according to the CDC anthropometric reference equations
131
 
 
Despite the demographic differences, and a significant difference in breathing frequency, 
there were no significant differences in sReff measurements obtained from Black and White 
children (Table 5-8 and Figure 5-15). 
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Table 5-8: Comparison of sRaw results in healthy children aged 4 to 11 years. 
 Black  
  
White 
 
Mean Difference  
(Black –White) (95%CI) 
sReff (kPa∙s) 1.1 (0.2) 1.2 (0.3) -0.1 (-0.2; 0.0)* 
sReff Z Score
128 -0.1 (0.8) 0.1 (1.0) -0.2 (-0.5; 0.1) 
Netflow (L.s-1) 0.9 (0.3) 0.9 (0.4) 0.0 (-0.2; 0.1) 
Breathing frequency (bpm) 35.4 (3.8) 42.2 (9.3) -6.7 (-0.3; -4.2)*** 
Unless stated otherwise, results presented as mean (SD) *p<0.05, ***p<0.001 
Results based on 56 healthy Black children and 148 healthy White children aged 4 to 11 years. 
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Figure 5-15: Comparison of sReff Z Scores in healthy White and Black children.   
Legend: Black lines denote mean +/-SD. 
No significant difference was observed (p=0.22)  
 
In summary, the sRaw reference equations based on healthy White children appear to be 
applicable for use in healthy Black children of the same age. 
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5.11 Applications of sRaw in SCD 
The previous sections described the development of sRaw reference data for White 
children, and demonstrated the applicability of these reference equations in healthy Black 
children.  The following section will describe the use of sRaw measurements in children with 
SCD.  All measurements were undertaken under the conditions described in section 5.9 
and the reference equations described in section 5.7 were used.   
 
Ninety-nine children with SCD less than 10 years of age were compared with 56 healthy 
Black children (previously evaluated in section 5.10).  The children with SCD were 
significantly shorter, lighter and had lower BMI than healthy children of the same ethnicity 
(Table 5-9).   
 
Table 5-9: Comparison of demographics of 56 healthy Black children and 99 children with 
SCD aged 4 to 10 years in whom sRaw measurements were obtained. 
 Healthy 
Black  
SCD Mean Difference  (SCD-health) 
(95%CI) 
n (% male) 56 (64%) 99 (45%)  
Age (years) 8.3 (1.1) 7.6 (1.8) -0.7 (-1.2; -0.2)** 
Height Z score 0.8 (1.1) 0.1 (1.0) -0.7 (-1.0; -0.3)*** 
Weight Z score 0.9 (1.1) 0.1 (1.0) -0.9 (-1.2; -0.6)*** 
BMI Z score 0.8 (1.0) 0.0 (1.0) -0.7 (-1.1; -0.4)*** 
Unless stated otherwise, results presented as mean (SD) **p<0.01, ***p<0.001 
Demographics expressed as Z Scores according to the CDC anthropometric reference equations
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Other than a slight trend towards children with SCD adopting a gentler breathing pattern 
(netflow difference: -0.1L∙s-1  (p=0.06)), there were no significant differences in sRaw 
outcomes (Table 5-10 and Figure 5-16).   
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Table 5-10: Comparison of sRaw measurements in 56 healthy Black children and 99 children 
with SCD aged 4 to 10 years. 
 Healthy Black SCD Mean Difference (SCD-health) 
(95%CI) 
sRtot (kPa∙s) 1.1 (0.2) 1.1 (0.3) 0.0 (-0.1; 0.1) 
sRtot Z Score -0.1 (0.8) -0.3 (1.0) -0.2 (-0.5; 0.1) 
sReff (kPa∙s) 1.0 (0.2) 1.0 (0.3) 0.0 (-0.1; 0.1) 
sReff Z Score -0.1 (0.9) -0.3 (1.1) -0.3 (-0.6; 0.1) 
Netflow (L.s-1) -0.9 (0.2) -0.8 (0.2) 0.1 (0; 0.2) 
BF (bpm) 35.4 (3.8) 37.6 (7.9) 2.1 (-0.1; 4.3) 
Unless stated otherwise, results presented as mean (SD)  
Healthy Black SCD
-4
-2
0
2
4
s
R
e
ff
 Z
 S
c
o
re
 
Figure 5-16: Comparison of sReff Z Scores in healthy Black children SCD. 
Results based on 56 healthy Black children and 99 children with SCD aged 4 to 10 years.   
There was no significant difference in sReff Z Scores
128
 between healthy Black children and children 
with SCD.  The two outliers in the SCD group (with elevated sReff had concurrent reduction in FEV1) 
 
These results suggest that baseline sRaw values are unaffected by SCD with just two 
children with SCD (1%) demonstrating elevated sReff.  Baseline sRaw assessments may not 
be a useful outcome measure to assess group differences in lung function between 
healthy children and children with SCD. 
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5.12 Repeatability and the bronchodilator response 
The chapter so far has described the development of recommendations and reference 
data for sRaw, and demonstrated no differences in sRaw outcomes between healthy Black 
and White children, and no differences between healthy Black children and those with 
SCD.  A further potential application of sRaw measurements would be as an outcome 
measure for the assessment of bronchodilator response (BDR).  Establishing a clinically 
relevant BDR requires knowledge of the between-test, within-occasion repeatability in 
health and disease, and the extent to which (if any) a BDR occurs in healthy children.  The 
following section first reviews the within-test, within occasion repeatability, and then 
reviews a subset of healthy children and children with SCD who underwent repeated sRaw 
measurements at ICH with and without a bronchodilator.  
5.12.1 Within-test repeatability 
The sRaw protocol includes reporting the median of three baseline measurements.  The 
within-test, within-subject repeatability of these three repeated measures at baseline was 
defined in terms of absolute differences (maximum sReff minus the minimum sReff) in 
kPa∙s; percent difference (([highest-lowest]/highest)*100); and the coefficient of variation 
(CV) (Table 5-11).  Due to the uneven distribution of the data, non-parametric tests were 
performed:  Mann Whitney comparisons between healthy Black and White children 
revealed no significant differences in any of the outcomes (p=0.2; 0.7; and 0.5 for absolute 
difference, % difference, and CV respectively).  In addition, a comparison between healthy 
children and children with SCD revealed no significant differences in within-test 
repeatability when defined as absolute difference (p= 0.24), % difference (p= 0.9), or CV 
(p= 0.7).  No significant correlation between age and within-test repeatability was observed 
in this age group (Figure 5-17 and Figure 5-18).  Similarly increased within-test 
repeatability was not associated with increased sReff Z Scores (Figure 5-18B). 
 
Table 5-11: Within-test repeatability of sReff measurements in health and SCD. 
 
 
 
 
 
 
Results presented as median (inter-quartile range) 
 Absolute 
difference (kPa∙s)  
Absolute Percent 
difference (%) 
Coefficient of 
variation (%) 
Healthy Black 0.14 (0.08; 0.18) 11.9 (6.6; 15.0) 6.4 (3.6; 8.6) 
Healthy White 0.16 (0.10; 0.22) 11.8 (8.0; 17.6) 6.8 (4.5; 10.6) 
SCD 0.13 (0.09; 0.21) 11.7 (9.9; 16.4) 6.8 (4.8; 9.8) 
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Figure 5-17: Within-test repeatability expressed as A) absolute difference and B) % difference in healthy children and children with SCD. 
Legend: Solid Black line indicates the median, dashed lines indicate the inter-quartile range. 
No significant correlation between age and absolute difference (p=0.4; r=-0.06) and age and % difference (p=0.5; r=-0.05) was observed
A B 
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Figure 5-18: A) sRaw within-test repeatability expressed as the coefficient of variation (CV). B) Association of CV and sReff Z Scores. 
Legend: Solid Black line indicates the median, dashed lines indicate the inter-quartile range. 
No significant correlation between age and within test CV (p=0.4; r=-0.05) was observed.  Similarly an increased CV was not associated with increase 
sReff Z Scores.  There was no difference according to ethnic group or clinical status.
A B 
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5.12.2 Between-test repeatability and BDR in health  
Between-test sRaw repeatability (i.e. repeated measures 15 minutes after baseline without 
any intervention) was measured in 20 healthy Black children with a mean age (SD) of 8.7 
(1.3) years.  Mean (SD) sReff was 1.28 (0.20) kPa∙s at baseline and 1.20 (0.20) kPa∙s 
when repeated 15 minutes later (without any intervention).   There was no significant 
difference between the two repeated measurements (mean (SD) difference (repeat-
baseline) was -0.08 kPa∙s (0.15) or -2.0% (3.4)) (Table 5-12).  Bland and Altman analyses 
were used to calculate the 95% limits of agreement for the between test repeatability 
(Figure 5-19A). 
 
Twenty-three healthy children (mean age: 8.3 (1.3) years) underwent BDR assessments 
with sReff as the main outcome.  Paired t-tests revealed a statistically significant mean 
difference post bronchodilator (mean (SD) difference: -0.32 kPa∙s (0.19)).  The 95% limits 
of agreement established from the between-test repeatability (Table 5-12) were used to 
identify those children in whom a clinically significant BDR was observed. Eight (35%) of 
the healthy children demonstrated a clinically significant BDR (i.e. results fell below the 
95% limits of agreement established from the between-test repeatability), and all children 
demonstrated a trend for lower sReff results post bronchodilator (Figure 5-19B). 
 
Table 5-12: Between test repeatability and BDR of sRaw in healthy children. 
 Mean Diff(SD) 
from baseline 
(kPa.s) 
95% Limits of Agreement 
Lower limit 
(95%CI) 
Upper limit  
(95% CI) 
Between-test repeat 
sReff (kPa∙s) 
 
-0.08 (0.15) 
 
-0.36 (-0.43; -0.30) 
 
0.21 (0.14; 0.27) 
Post bronchodilator 
sReff (kPa∙s) 
 
-0.32 (0.19)*** 
 
-0.69 (-0.77; -0.61) 
 
0.05 (-0.03; 0.13) 
 ***p<0.001   
Results based on 20 healthy children (between test) and 23 healthy children (BDR) aged 4 to 12 
years.  95% confidence intervals around the lower and upper limit of normal were calculated from 
the standard error of the mean (SEM) and provide a more precise estimation of the limits of 
normality. Values in bold indicate the most conservative limits, that take the actual sample size of 
this study into account. 
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Figure 5-19: A) sRaw between-test repeatability and B) BDR in healthy children  
Legend: Dotted lines indicate the mean +/- 95% limits of agreement, grey shaded area indicate 95% CI around the upper and lower limits of 
agreement based on the between-test repeatability in health.  Values that fall below these lines in B (red symbol) denote a significant BDR. 
The majority of healthy children demonstrated a trend towards a decrease in sReff post BD.  Eight (35%) healthy children demonstrated a 
significant bronchodilator response (results below the 95% LA established by between-test repeatability).
A B 
  208 
5.12.3 Bronchodilator response in SCD 
A subset of 37 children (49% male) with SCD underwent BDR assessments using sReff as 
an outcome measure.  Although slightly older than the entire population, mean (SD) age 
was 9.1 years (1.1), demographics were similar to the main group (Table 5-9).  The mean 
(SD) sReff was 1.1 (0.3) kPa∙s at baseline and 0.9 (0.20) kPa∙s post BD.  Paired t-tests 
revealed a statistically significant mean difference (95% CI) of -0.21 kPa∙s (-0.30; -0.04) 
(p<0.0001).  If expressed as percent change the mean (SD) change post bronchodilator in 
children with SCD was -16.3 (20.7)%, whereas in healthy the mean (SD) BDR was 19.8 
(23.4)% 
 
Although a statistically significant BDR in children with SCD was observed, the clinical 
relevance of this could only be interpreted when comparing it to the BDR observed in 
healthy children of similar age and ethnicity.  A clinically significant BDR is a response 
over and above that seen in health, and was estimated from the 95% limits of agreement 
determined by Bland-Altman analysis on baseline and post BD results in healthy children 
(Table 5-12).  A conservative threshold for the significant BDR (including the 95% CI, 
which adjusted for sample size), was therefore estimated as -0.77 kPa∙s (Figure 5-20A).  
Only one child with SCD (and concurrent asthma symptoms) fell below the BDR threshold, 
whilst the remaining children demonstrated little bronchodilator responsiveness (Figure 
5-20B). 
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Figure 5-20: A) Between-test sRaw repeatability and corresponding 95% limits of agreement. B) BDR in SCD.   
Legend: The threshold for a clinically significant bronchodilator response is defined by the limits of agreement in A. 
A) The dashed lines indicate the 95% limits of agreement, and the grey shaded area is the 95%CI around them. 
B) Red symbol identifies the child in whom a significant bronchodilator response was observed (i.e. results fell below the lower 95% LA 
established in healthy children).   
 
 
A) Health 
B) SCD 
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5.12.4 Repeatability and BDR: Summary 
Within-test repeatability was described in healthy White and Black children as well as 
children with SCD and was defined in terms of absolute and percentage differences 
(frequently used in the clinical scenario when the technician requires a quick 
calculation to determine if results are within acceptable repeatability criteria) and 
coefficient of variation (CV), which is more commonly used in epidemiological studies 
to describe the repeatability of a group of subjects.  No ethnic differences or differences 
between health and disease were observed.  Based on these results repeated baseline 
measures of sRaw should be within 0.2 kPa∙s or 16% of the highest value (this equates 
to a CV of 9%). 
 
Between-test repeatability was described in twenty healthy children as ~0.1 kPa∙s 
(2%).  The 95% limits of agreement were used to ascertain bronchodilator 
responsiveness in health, and subsequently 35% of the healthy children assessed 
were found to have a physiologically significant BDR.  The 95% limits of agreement 
were therefore calculated based on the baseline and post BD sReff results and used to 
define the thresholds for reversibility in SCD.  Only one child with SCD demonstrated a 
significant BDR, with the rest demonstrating bronchodilator responsiveness similar to 
that seen in health.  These results are investigated further, in combination with the 
other lung function tests and the clinical status in Chapter 8. 
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5.13 Summary 
The Asthma UK initiative comprised the largest collation of paediatric sRaw data from 
healthy controls to date.  A comprehensive review of the different methodologies 
across the five collaborating centres was undertaken which revealed significant 
between centre differences and necessitated exclusion of data from two centres.  
Results from the study enabled the development of a quality-control over-read sheet 
and recommendations for future measurements.  Furthermore, preliminary sex-specific 
reference equations which adjusted for the minimal age-related changes in sReff and 
sRtot were developed.  This study demonstrated that collation of healthy data and 
subsequent development of reference equations is possible, but highlighted the 
potential for increased inter-centre variability unless data collection/conditions are 
standardised.   
 
In addition to developing recommendations and reference equations, sRaw 
measurements were applied in healthy Black children and children with SCD.  No 
differences in sRaw between healthy White and Black children were observed, thus 
enabling the reference equations to be applied and interpreted with some confidence in 
Black children with suspected lung disease.  sRaw measurements did not, however 
distinguish children with SCD from healthy controls, nor was it shown to be a useful 
outcome measure in bronchodilator responsiveness assessments in this group of SCD 
patients.   
 
This study demonstrates that sRaw measurements in Black children with suspected 
lung disease are feasible and can be interpreted using published reference data. 
However, sRaw measurements do not appear to be a useful outcome measure in the 
clinical management of SCD.  The combination of sRaw measurements with other lung 
function tests are investigated further in Chapter 8. 
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6 Plethysmographic Lung Volumes 
6.1 Introduction 
Plethysmographic lung volume measurements are the gold standard for identifying 
restrictive lung disease.94  Interpretation of these measurements in non-White children 
however, may be limited due to the fact that the published reference data, based on 
White children only,97,98 have been shown to be unreliable.16,99,104 In addition, to our 
knowledge, there are no plethysmographic reference data available for Black children.  
Furthermore, while guidelines for quality control (QC) and repeatability have previously 
been defined in adults,94 the appropriateness of these QC criteria in children have not 
been formally assessed.   
 
This chapter will evaluate the available paediatric reference data in healthy Black and 
White children, and assess the impact of ethnicity on lung volumes.   These data have 
been published in Pediatric Pulmonology.146  The use of plethysmographic lung 
volumes in children with regards to applying the adult QC criteria and repeatability 
measures94 will then be reviewed, prior to the development of recommendations for 
applying these measurements in children with suspected lung disease.  These 
recommendations are then applied in children with Sickle Cell Disease (SCD) to 
evaluate the clinical role of plethysmographic lung volume measurements in these 
children.   
6.2 Aims 
The primary aims were:  
i. To evaluate published paediatric plethysmographic lung volume reference 
data97,98 
ii. To investigate potential ethnic differences in plethysmographic lung volumes 
and develop recommendations for interpreting plethysmographic lung volumes 
in Black children 
iii. To evaluate the extent to which plethysmographic lung volume measurements 
detect lung disease in children with SCD  
The secondary aims were:  
i. To determine within-test repeatability in healthy children and children with lung 
disease 
ii. To develop and apply a QC over-read scoring system and assess the 
feasibility of current guidelines2 
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6.3 Objectives 
The primary objective was to compare lung volume data in healthy Black children to 
published reference data based on White children.97,98  To achieve this objective, data 
were collected in two international centres (London and St Louis, USA) and inter-centre 
comparisons were undertaken to determine if data could be combined.  Secondary 
objectives were to over-read lung volume data in healthy children and children with 
SCD to ascertain the appropriateness of applying adult QC and repeatability criteria in 
children and develop recommendations for future plethysmographic lung volume 
measurements. 
6.4 Hypothesis 
Lung volume data from healthy Black children will be significantly lower than that 
predicted by reference data derived from White children.  
6.5 Subjects and sample size 
Plethysmographic lung volumes were collected in healthy Black children aged 6 to 12 
years from two international centres (The UCL Institute of Child Health, London, UK 
and Washington University, St Louis, USA) as part of the SAC study and SLIC study 
(described previously in chapter 2, section 2.3). In addition, data collected from healthy 
White children of the same age from previous on-going research projects were 
collated.16,104,129  
 
A sample size of 64 children in each group (Black and White children) were required to 
determine differences in outcomes equivalent to 0.5SD (which equates to ~5% 
predicted in FRC and TLC) with 90% power at the 5% significance level. 
6.6 Collation of lung volume data: Inter-centre comparisons 
Plethysmography was performed in 68 healthy Black children (40 from ICH and 28 
from the USA).  The plethysmographic lung volume outcomes reviewed were: 
 Functional Residual Capacity (FRC) (L) 
 Residual Volume (RV) (L) 
 Total Lung Capacity (TLC) (L) 
 Ratio of RV to TLC (RV/TLC) 
Unpaired t-tests revealed that the Black children measured in the USA were 
significantly older than those measured in the UK, however, when results were 
adjusted for age and sex, there were no significant differences in height, weight and 
BMI Z Scores131 (Table 6-1). 
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Table 6-1: Demographics of 68 healthy Black children in whom plethysmographic lung 
volumes were obtained, according to measurement site. 
 UK Lab  
 
USA Lab 
  
Mean Diff (UK - USA) 
(95%CI) 
n (% male) 40 (40%) 28 (46%)  
Age (years) 9.4 (1.4) 10.7 (1.2) -1.3 (-1.9; -0.6)*** 
Height Z Score 0.8 (1.1) 0.4 (1.1) 0.4 (-0.2; 0.9) 
Weight Z Score 0.8 (1.1) 0.8 (1.0) 0.0 (-0.5; 0.5) 
BMI Z Score 0.6 (1.1) 0.8 (0.9) -0.2 (-0.7; 0.3) 
Unless stated otherwise, results presented as mean (SD) ***p<0.001 
Demographics were expressed as Z Scores according to the CDC reference equations
131
 
 
There were no significant differences in plethysmographic lung volumes between the 
two centres in absolute values or when corrected for sex and height (based on 
Rosenthal reference equations98) (Table 6-2).  
  
Table 6-2: Comparison of Plethysmographic lung volume data in healthy Black children 
from the UK and the USA. 
 UK Lab 
 
USA Lab 
 
Mean Diff (UK-USA) 
95% CI  
n (% male) 40 (40%) 28 (46%)  
FRC Z Score -0.65 (0.67) -0.83 (0.70) 0.18 (-0.15; 0.50) 
FRC % predicted 88.2 (11.4) 83.4 (13.8) 4.9 (-1.3; 11.0) 
RV Z Score 0.18 (0.73) 0.10 (0.72) 0.08 (-0.27; 0.44) 
RV % predicted 104.4 (19.9) 102.7 (20.4) 1.8 (-8.1; 11.7) 
TLC Z Score -0.50 (0.81) -0.59 (0.90) 0.09 (-0.32; 0.50) 
TLC % predicted 95.1 (9.0) 92.9 (10.8) 2.3 (-2.6; 7.1) 
RV/TLC Z Score 0.56 (0.93) 0.54 (1.06) 0.26 (-0.45; 5.02) 
RV/TLC % predicted 109.7 (17.3) 110.8 (21.5) -1.1 (-10.5; 8.3) 
Unless stated otherwise, results presented as mean (SD). All lung volume results expressed as 
percent predicted and Z Scores based on reference equations by Rosenthal et al
98
 
 
In summary, results from the inter-centre comparison demonstrated that with strict 
adherence to a standardised protocol and prospective over-reading (see section 6.8), 
no bias in plethysmographic data collected in different laboratories in the UK and USA 
occurred, thus enabling data to be combined and used to compare to: 
 published reference data:97,98 section 6.7.1  
 healthy White children of the same age: section 6.7.3 
 children with SCD: section 6.11.3 
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6.7 Reference data 
Plethysmographic lung volume data were collated from 68 healthy Black children 
(section 6.6) and 115 healthy White children aged 6 to12 years (Table 6-3).   
Significant differences in height, weight and BMI Z Scores were observed, with Black 
children being taller, and heavier than their White peers of same sex and age (Table 
6-3).    
Table 6-3: Comparison of demographics in Black and White children in whom 
plethysmography measurements were obtained. 
 Black  White  
 
Mean Diff (Black-White) 
(95%CI) 
n (% male) 68 (46%) 115 (45%)  
Age (years) 10.0 (1.5) 8.9 (1.7) 1.0 (0.6; 1.5)*** 
Height Z Score 0.6 (1.1) 0.3 (1.0) 0.3 (0.0; 0.7)* 
Weight Z Score 0.8 (1.1) 0.3 (0.9) 0.6 (0.2; 0.8)*** 
BMI Z Score 0.7 (1.0) 0.2 (0.8) 0.6 (0.2; 0.7)** 
Unless stated otherwise, results presented as mean (SD) *p<0.05, **p<0.01, ***p<0.001 
Demographics were expressed as Z Scores according to the CDC reference equations
131
 
 
The absolute partitioned lung volumes (FRC, RV, TLC, and RV/TLC) versus height are 
shown in Figure 6-1. Since there is a strong relationship between FRC, RV and TLC 
with height and age, and a decrease in RV/TLC with height and age, and known sex 
differences,147 all lung volume outcomes needed to be adjusted for these factors to 
enable comparison between groups of healthy Black and White children, and between 
healthy children and children with lung disease.  Two paediatric reference equations 
were used to adjust for height and sex:  Those by Zapletal97 expressed results as 
percent predicted, whereas those by Rosenthal98 expressed results as both percent 
predicted and Z scores.  For the purpose of comparing the two equations, results will 
be expressed as % predicted.   
NB: The original equations by Rosenthal did not include a calculation for RV/TLC, 
however personal correspondence provided us with the equations subsequently used 
by this group.148 
 
The following section will first compare the two reference equations in healthy children 
(section 6.7.1), then investigate their suitability in healthy Black and White children 
(section 6.7.3).  Quality control and repeatability measures are investigated (section 
6.8) prior to developing recommendations for interpreting plethysmographic lung 
volumes (section 6.10) and applying them in children with SCD (section 6.11). 
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Figure 6-1: Absolute lung volumes against height in healthy children 
Results based om 68 Black children and 115 White children aged 6 to 12 years.  
With the exception of RV, significant ethnic differences were observed: White children had 
greater values for FRC and TLC, and lower RV/TLC value 
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6.7.1. Comparison of reference equations 
Results from 183 Healthy Black and White children were available with which to 
compare the two paediatric plethysmography equations (although all subsequent 
analyses were performed separately for each ethnic group).   Bland and Altman 
comparisons between the two equations revealed good agreement for FRC (mean 
difference (Zapletal-Rosenthal): 2.1% (95% LA -8.5; 12.7), however larger 
discrepancies for other lung volumes were observed: Mean difference (95% LA): 7.5   
(-8.6; 23.7), -5.1 (-12.2; 2.1) and 13.3 (-0.2; 26.8) for, RV, TLC and RV/TLC 
respectively (Table 6-4 and Figure 6-2). 
 
Table 6-4: Bland & Altman comparison of 2 plethysmographic reference equations 
 Mean Difference   
(Zap - Ros) 
95% Limits of Agreement 
FRC % predicted 2.1 
7.5 
-5.1 
13.3 
-8.5; 12.7 
-8.6; 23.7 
-12.2; 2.1 
-0.2; 26.8 
RV % predicted 
TLC % predicted 
RV/TLC % predicted 
Zap = Zapletal
97
, Ros = Rosenthal
98
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Figure 6-2: Bland & Altman plots for lung volume outcomes expressed as % predicted using two paediatric reference equations. 
Results based on 183 healthy children aged 6 to 12 years. 
Legend: Reference equations by Zapletal
97
 and Rosenthal.
98
 Solid line denotes the mean difference; dashed line denotes the 95% limits of agreement. 
Small mean differences in FRC were observed, however larger discrepancies in other outcomes mean that these two equations are not interchangeable.  
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6.7.2 Interpretation according to different reference equations 
In this study, we found significant differences in % predicted of lung volumes, 
particularly with respect to RV and hence the RV/TLC ratio.  Interpretation of lung 
volumes can therefore vary widely depending on which equation is applied, potentially 
resulting in significant clinical implications. Figure 6-3 shows the changes in predicted 
values for lung volume outcomes in a boy of “normal” height (i.e. a height Z Score of 
zero131) for the two equations.   
 
 
 
Figure 6-3: The changes in lung volumes predicted values in a boy with a height Z Score 
of zero.  
Legend: Solid black lines are predicted values calculated by Zapletal
97
 and dashed grey lines 
are calculated by Rosenthal
98
   
Predicted values differ for all outcomes at all ages with significant cross-over at the start of 
puberty (~14 years where the Rosenthal equation switches at 162.5cm to post-puberty 
equations) 
 
Up to about the age of ~13 years (i.e. pre-puberty) the equations are relatively similar, 
but some cross-over is apparent.  At 165.5cm the Rosenthal98 equations switch to new 
equations which supposedly take pubertal changes into account.  The impact of 
puberty was not investigated in this study due to the restricted age limit (primary school 
children aged 6 to 12 years). 
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6.7.2.1 Case studies: Interpretation according to different reference data 
Two case studies of healthy children are reviewed in Table 6-5.  Both children were 
healthy but interpretation differed depending on the reference data applied. In both 
case studies, TLC % predicted was similar, and within the normal range (i.e. no 
evidence of restrictive lung disease), however FRC % predicted was 10% greater, and 
RV % predicted dramatically lower when calculated using the Zapletal equations.   
 
Table 6-5: Case Studies: Difference in lung volume interpretation. 
 Case Study A Case Study B 
Demographics: White Male, 6.3y,  
Height Z Score: -0.44 
Black Female, 7.8y, 
Height Z Score: -0.79 
Lung Volumes % 
Predicted:  
Rosenthal98:  Zapletal97 Rosenthal98:  Zapletal97 
 FRC % Predicted 98                     108 95                   105 
 RV % Predicted 75                      92  150                 175   
 TLC % Predicted 100                    96 112                 112 
 RV/TLC % Predicted 74                      97 130                  160 
 
A difference of 10% predicted in FRC potentially has clinical implications, but this did 
not alter the interpretation in these examples.  The differences in RV however, and 
consequently, differences in RV/TLC, potentially changed the interpretation of these 
two cases depending on the equation applied. 
 Case study A: All results were within normal limits according to Zapletal 
equations.97  When expressing results as % predicted using Rosenthal 
equations,98 a significantly reduced RV (and consequently RV/TLC) was 
observed.  These results were not consistent with a “healthy child” 
 Case study B: When results were expressed according to Zapletal equations97 
the RV and RV/TLC were severely elevated consistent with obstructive lung 
disease.  The Rosenthal equations98 also presented an elevation in RV and 
RV/TLC but only mildly. 
The larger discrepancies observed in case study B are probably due to ethnic 
differences which have not been accounted for in either of the reference equations.  
The impact of ethnicity is investigated in section 6.7.3. 
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6.7.2.2 Case study: The impact of height on interpretation 
The influence of height was investigated in a ten year old White boy with restrictive 
lung disease in whom results were adjusted to represent a child short for age (-2 Z 
Scores), “normal” height for age (0 Z Scores) or tall for age (+2 Z Scores)131 (Table 
6-6). 
 
At a “normal” height (0 Z Scores) differences between the two equations were minimal.  
Larger discrepancies however, were observed in the growth restricted (-2 Z Scores) 
example where FRC and RV/TLC were 10% higher, and RV 17% higher when 
interpreted using the Zapletal,97 suggesting that Zapletal under-estimates predicted 
values (thus inflates % predicted values) in comparison to the Rosenthal equations.98  
These results have important clinical implications as growth restriction is common in 
lung disease.136  In addition, the scenario of a “tall-for-age” child (commonly observed 
in healthy Black children compared to their White peers (Table 6-3)) differences in 
calculated RV and TLC % predicted differed by ~6% in opposite directions resulting in 
large discrepancies in RV/TLC % predicted, which also has important clinical 
implications. 
 
In summary, interpretation of lung volumes can vary widely depending on which 
equation is applied.  The two equations examined are not interchangeable and caution 
should be applied when reviewing results from different laboratories which may have 
used different reference equations for interpretation.  Zapletal equations97 were 
developed over 40 years ago using equipment which is now obsolete and were based 
on a relatively small sample size (173 children), and appear to generate greater 
extremes in the interpretation.  The Rosenthal equations98 were developed more 
recently (1993) with modern equipment and a larger sample size (772 children), 
however age was not taken into consideration in the reference equations and the 
impact of height has potential clinical implications (discussed further in the main 
discussion, Chapter 9).  The following sections review the applications of these 
equations in healthy Black children and, after further analysis of QC and repeatability, 
recommendations for applying and interpreting lung volume reference data are 
developed in section 6.10. 
 222 
 
Table 6-6: Case Study: The impact of height on predicted value for lung volumes. 
 Height: -2 Z Scores Height: 0 Z Scores Height: +2 Z Scores 
 Rosenthal Zapletal Rosenthal Zapletal Rosenthal Zapletal 
FRC % Pred. 115 125 86 87 79 78 
RV % Pred. 107 124 89 87 84 78 
TLC % Pred. 107 105 77 73 71 66 
RV/TLC % Pred. 108 118 121 124 116 127 
Footnote: Example based on a 10 year old boy with an FRC of 1.5L, RV of 0.8L, TLC of 2.6L and RV/TLC of 0.31. 
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6.7.3 Comparison of lung volumes in Black and White children 
Plethysmographic lung volume data from 68 healthy Black children and 115 healthy 
White children aged 6 to 12 years (Table 6-3) were compared.  With the exception of 
RV, there were significant differences between Black and White children for all lung 
volume outcomes, but the magnitude and direction of these differences varied 
markedly according to outcome and equation selected (Table 6-7 and Figure 6-4).  
Thus, while there were no ethnic differences in RV by either equation, FRC % 
predicted was 6-9 % lower in Black children, whereas % predicted RV/TLC ratio was ~ 
12% higher among Black children.   
 
Table 6-7:Comparison of Plethysmographic outcomes according to two reference 
equations. 
 Black children  
(B) 
White children 
 (W) 
Mean Difference 
(95%CI; B-W)  
n (% male) 68 (43%) 115 (45%)  
By Zapletal:97    
FRC % predicted  86.6 (12.3) 95.1 (15.6) -8.5 (-12.8; -4.1)*** 
RV % predicted 109.0 (21.8) 107.8 (24.5) 1.2 (-5.9; 8.2) 
TLC % predicted 88.6 (9.2) 96.9 (10.0) -8.2 (-11.2; -5.3)*** 
RV/TLC % predicted  122.5 (21.2) 110.8 (20.1) 11.8 (5.5; 18.1)*** 
By Rosenthal:98    
FRC % predicted  86.2 (12.6) 91.2 (15.4) -5.8 (-10.1; -1.4)* 
RV % predicted 103.7 (20.0) 99.0 (23.4) 4.7 (-2.0; 11.4) 
TLC % predicted 94.2 (9.8) 101.7 (11.0) -7.5 (-10.6; -4.3)*** 
RV/TLC % predicted 110.2 (19.0) 96.9 (19.0) 13.2 (7.5; 19.0)*** 
Unless stated otherwise, results presented as mean (SD), *p<0.05, **p<0.01, ***p<0.001 
Footnote: Equations by Zapletal and Rosenthal are based on White children.  No ethnic 
adjustment was applied in this table. 
 
Even among the White children, when results were compared to those predicted by 
Zapletal, there was a significant bias which exceeded 5% for all outcomes except TLC.  
By contrast, with the exception of FRC, where mean values were 9% (0.4 Z Scores) 
lower than the expected mean of 100% (0 Z Scores), the Rosenthal equations provided 
a reasonable fit for the White children aged 6 to 12 years.  Interpretation of 
plethysmographic lung volumes in Black children is limited when applying either 
equation.  An interim solution is to apply an ethnic adjustment factor and interpret with 
caution.  Interpretation strategies are investigated in the following section.   
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Figure 6-4: Comparison of % predicted for different lung volume outcomes for White and Black children according to two reference equations.  
Legend: Reference equations by Rosenthal
98
 and Zapletal.
97
 Purple = White children, Green = Black children.  Black lines denote the mean and SD.  Dashed 
red line denotes 100% predicted for each outcome. 
With the exception of RV which was relatively the same for White and Black children in both equations, differences between White and Black children 
occurred, but the magnitude and direction of the differences was dependent on the outcome and the reference data applied.  Of interest, there was a large 
SD around the mean in RV, possibly reflecting the technical difficulty in measuring this outcome.
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6.7.4  Applications of plethysmographic reference data 
In the USA, the Zapletal plethysmographic equations are used most commonly,97  
whereas in the UK, the British Thoracic Society recommend reference equations by 
Rosenthal et al.98  The Zapletal equations97 were derived from a small sample (173) of 
White children aged 6 to 17 years, measured over 40 years ago, and, when compared 
to Rosenthal equations,98 demonstrated large discrepancies, in particular in the 
extremes of height Z Scores.  Rosenthal equations98 were based on a much larger 
sample (772 White children aged 4 to 19 years) and developed some 20 years later, 
and are considered to be more appropriate of the two equations.  The Rosenthal 
equations98 most closely reflected the predicted results in our White population.  In 
addition the Rosenthal equations98 have the added advantage of calculating Z Scores 
(calculated as: (observed-predicted)/(SD-predicted), thus quantifying how far from the 
mean an individual observation is).  For these reasons, reference data by Rosenthal et 
al98 was deemed to be the more appropriate of the two.  The following sections will 
review the feasibility of applying Rosenthal plethysmographic reference equations98 in 
White and Black children.   
6.7.4.1 Rosenthal equations in White children 
Rosenthal plethysmographic reference equations are based on White children.98  In 
this study, with the exception of FRC, the Rosenthal equations demonstrated good 
agreement with the healthy White children (Table 6-7).  FRC was over-estimated by 
~0.4Z Scores (~9% predicted) (i.e. mean Z Score in our sample was -0.4 Z (91% 
predicted) rather than the expected 0 Z Scores/100% predicted).  This discrepancy 
may reflect a change in protocol during recent years, whereby subjects are no longer 
required to pant rapidly during airway occlusions for thoracic gas volume manoeuvres, 
a practice that may in the past have led to elevated resting lung volumes.  This 
discrepancy has important implications since clinical evidence of hyperinflation or gas 
trapping may be missed unless this bias is taken into account, as reported 
previously.16,104   In order to apply the Rosenthal equations appropriately in White 
children, we recommend an adjustment factor of 0.91 for FRC measures (i.e. FRC 
should be divided by 0.91 before applying the Rosenthal equations) (Table 6-8). 
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Table 6-8: Plethysmographic lung volume data and calculated limits of normality from 
115 healthy White children aged 6 to 12 years.   
 Mean (SD) LLN (95%CI) ULN (95%CI) 
FRC % predicted 91.2 (15.4) 61 (58; 64) 121 (118; 124) 
*FRC % predicted* Adjustment  factor: 0.91 68 (65; 70) 134 (131; 137) 
RV % predicted 99.0 (23.4) 53 (48; 57) 145 (141; 149) 
TLC % predicted 101.7 (11.0) 80 (78; 82) 123 (121; 125) 
RV/TLC % predicted 96.9 (19.0) 60 (56; 63) 134 (131; 138) 
    
FRC Z Score -0.4 (0.8) -2.0 (-2.1; -1.8) 1.2 (1.0; 1.3) 
*FRC Z Score Adjustment factor 0.91 -1.8 (-1.9; -1.6) 1.8 (1.6; 1.9) 
RV Z Score 0.0 (0.8) -1.6 (-1.7; -1.4) 1.6 (1.4; 1.7) 
TLC Z Score 0.1 (0.9) -1.6 (-1.8; -1.5) 1.9 (1.7; 2.0) 
RV/TLC Z Score -0.1 (0.9) -1.9 (-2.0; -1.7) 1.7 (1.5; 1.8) 
Lung volume results corrected for sex and height using Rosenthal reference equations
98
 
LLN= lower limit of normal; ULN = upper limit of normal. Based on: mean+/-1.96 SD 
95% confidence intervals around the LLN and ULN were calculated from the standard error of 
the mean (SEM) and provide a more precise estimation of the limits of normality. Values in bold 
indicate the most conservative limits, that take the actual sample size of this study into account.  
6.7.4.2 Interpretation of lung volumes in White children 
In the current study, after adjusting FRC by dividing the absolute result by 0.91, lung 
volume outcomes in healthy White children centred around 0 Z Scores (100% 
predicted) (Table 6-8).  The lower and upper limits of normality (LLN and ULN) are 
calculated as +/-1.96 SD, and therefore vary depending on the SD of each outcome.   
For example, when expressing results as % predicted, RV had the largest SD (23.4%) 
and therefore limits of normality were 48% predicted to 149% predicted, whereas TLC 
had a much smaller SD (11%), such that the limits of normality were much narrower 
(78% to 125% predicted).  Given the relatively small sample size, the 95% confidence 
interval for which we can estimate these limits of normality offers a more conservative 
estimate of the LLN / ULN (Table 6-8, Figure 6-5). 
 
Using Z Scores minimises the problems associated with differing SD according to 
different outcomes, as limits of normality (for plethysmography) are defined as +/-1.96 
Z Scores. (Further explanations of limits of normality for different lung function 
outcomes can be found in section 1.5.1.3).  In the current study the SD around the 
mean was <1 Z Score for all outcomes, hence minor adjustments to the limits of 
normality were made to account for these slight differences (Table 6-8, Figure 6-6). 
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Figure 6-5: Lung Volume outcomes and calculated limits of normality presented as % predicted according to Rosenthal equations, in healthy 
White children. 
Legend: Limits of normality calculated as +/-1.96 SD are indicated as the dashed lines, grey shaded area indicates the 95%CI around the limits of normality.  
NB: FRC was adjusted by 0.91, all other outcomes remain unadjusted.  
Limits of normality varied for each outcome as they were dependent on the SD of each outcome.  RV had a large SD around the mean, hence limits of 
normality (+/-1.96 SD) were relatively wide, whereas TLC had a low SD around the mean resulting in relatively narrow limits of normality.
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Figure 6-6: Lung Volume outcomes and calculated Limits of Normality presented as Z Scores according to Rosenthal equations, in healthy White 
children. 
Legend: Limits of normality calculated as +/-1.96 SD are indicated as the dashed lines, grey shaded area indicates the 95%CI around the limits of normality.  
NB: FRC was adjusted by 0.91, all other outcomes remain unadjusted.  
With the exception of FRC (which was adjusted), all outcomes centred ~0 Z Scores.  The SD around the mean however was <1 Z Score, hence the limits of 
normality (+/-1.96 SD) where slightly narrower than the conventional +/-1.96 Z Scores.   
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6.7.4.3 Rosenthal equations in Black children 
Rosenthal plethysmographic reference equations,98 based on White children were 
applied in 68 healthy Black children and significant discrepancies were observed: FRC 
and TLC were 0.7 Z Scores (14%) and 0.5 Z Scores (6%) lower in Black children than 
White children when predicted by these equations, whereas RV and RV/TLC 
respectively were 0.1 Z Scores (4%) and 0.5 Z Scores (10%) higher.  In order to 
interpret results from Black children using these equations, the limits of normality were 
adjusted to take into consideration the fact that the results were not centred around 0 Z 
Scores or 100% predicted (Table 6-9).  However, a more appropriate method of 
interpretation would be to apply an ethnic adjustment factor prior to applying the 
Rosenthal reference equations (Table 6-10, section 6.7.4.4). 
 
Table 6-9: Plethysmographic lung volume data with no ethnic adjustment and calculated 
limits of normality from 68 healthy Black children aged 6 to 12 years.   
 Mean (SD) LLN (95%CI) ULN (95%CI) 
FRC % predicted 86.2 (12.6) 62 (59; 65) 111 (108; 114) 
RV % predicted 103.7 (20) 65 (56; 29) 143 (138; 148) 
TLC % predicted 94.2  (9.8) 75 (73; 77) 113 (111; 116) 
RV/TLC % predicted 110.2 (19.0) 73 (69; 78) 147 (143; 152) 
    
FRC Z Score -0.7 (0.6) -1.9 (-2.0; -1.7) 0.5 (0.3; 0.6) 
RV Z Score 0.1 (0.7) -1.3 (-1.5; -1.1) 1.5 (1.3; 1.7) 
TLC Z Score -0.5 (0.8) -2.1 (-2.3; -1.9) 1.1 (0.9; 1.3) 
RV/TLC Z Score 0.5 (0.9) -1.3 (-1.5; -1.0) 2.3 (2.0; 2.5) 
Lung volume results corrected for sex and height using Rosenthal reference equations
98
 
LLN= lower limit of normal; ULN = upper limit of normal. Based on: mean+/-1.96SD 
95% confidence intervals around the LLN and ULN were calculated from the standard error of 
the mean (SEM) and provide a more precise estimation of the limits of normality. Values in bold 
indicate the most conservative limits, that take the actual sample size of this study into account. 
6.7.4.4 Interpretation of lung volumes in Black children 
Ethnic adjustment factors of ~12% for TLC and RV and ~7% for FRC have been 
described in the ATS/ERS 2005 Interpretative strategies for lung function tests,2 whilst 
many lung function software offer a blanket 12% reduction for all lung function 
outcomes.  The current study however, suggests measured values would need to be 
divided by 0.86 (FRC), 1.04 (RV), 0.94 (TLC) or 1.10 (RV/TLC) prior to expressing 
results in relation to predicted values to adjust for the observed ethnic differences 
(Table 6-10). 
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Table 6-10: Plethysmographic lung volume data with an ethnic adjustment factor, and 
calculated limits of normality from 68 healthy Black children aged 6 to 12 years.   
 Ethnic 
Adjustment 
Mean 
(SD) 
LLN 
(95%CI) 
ULN 
(95%CI) 
FRC % pred. 0.86 100.3 (14.6) 72 (68; 75) 129 (126; 133) 
RV % pred. 1.04 99.7 (19.3) 62 (57; 67) 138 (133; 142) 
TLC % pred. 0.94 100.2 (10.4) 80 (77; 82) 120(118; 123) 
RV/TLC % pred 1.10 100.2 (17.2) 66 (62; 71) 134 (130; 138) 
     
FRC Z Score 0.86 0.0 (0.7) -1.4 (-1.6; -1.2) 1.5 (1.3; 1.7) 
RV Z Score 1.04 0.0 (0.7) -1.4 (-1.5; -1.2) 1.4 (1.2; 1.5) 
TLC Z Score 0.94 0.0 (0.9) -1.7 (-1.9; -1.5) 1.7 (1.5; 1.9) 
RV/TLC Z Score 1.10 0.0 (0.8) -1.6 (-1.8; -1.4)  1.7 (1.5; 1.9) 
Lung volume results corrected for sex and height using Rosenthal reference equations
98
 
LLN= lower limit of normal; ULN = upper limit of normal. Based on: mean+/-1.96 SD 
95% confidence intervals around the LLN and ULN were calculated from the standard error of 
the mean (SEM) and provide a more precise estimation of the limits of normality. Values in bold 
indicate the most conservative limits, that take the actual sample size of this study into account. 
 
As previously described in White children (section 6.7.4.2), use of percent predicted is 
associated with varying limits of normality dependent upon the SD of the outcome 
under investigation (Figure 6-7).  Expressing the results as Z Scores simplifies the 
limits of agreement, albeit they have been amended slightly to account for the lower SD 
of each outcome (Table 6-10 and Figure 6-8).  
 
In summary, two commonly used paediatric plethysmographic equations were 
evaluated and found to have marked discrepancies between them, however those by 
Rosenthal et al appeared to be the more reliable of the two.  Ethnic differences in 
plethysmographic lung volumes were observed, and varied depending on the outcome.  
Reference equations based on White children are therefore not appropriate for use in 
Black children unless suitable adjustments both to the predicted values and limits of 
normality are implemented and interpretation is undertaken with caution.  The following 
section evaluates the use of quality control criteria and repeatability measures prior to 
developing recommendations for the application and interpretation of plethysmographic 
lung volumes in children. 
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Figure 6-7: Lung Volume outcomes and calculated Limits of Normality presented as % predicted according to Rosenthal equations, in healthy Black 
children. 
Legend: Limits of normality calculated as +/-1.96SD are indicated as the dashed lines, grey shaded area indicates the 95%CI around the limits of normality. Ethnic 
adjustments were made: Measured values were divided by 0.86 (FRC), 1.04 (RV), 0.94 (TLC) and 1.10 (RV/TLC) prior to expressing results 
With the exception of TLC which has narrow limits of normality, wide limits of normality for all outcomes were observed (a reflection of large SD). 
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Figure 6-8: Lung Volume outcomes and calculated Limits of Normality presented as Z Scores according to Rosenthal equations, in healthy Black 
children. 
Legend: Limits of normality calculated as +/-1.96SD are indicated as the dashed lines, grey shaded area indicates the 95%CI around the limits of normality.  Ethnic 
adjustments were made: Measured values were divided by 0.86 (FRC), 1.04 (RV), 0.94 (TLC) and 1.10 (RV/TLC) prior to expressing results 
Expressing results us adjusted Z Scores simplifies interpretation as 95% of the healthy population falls with +/-1.96 Z Scores. 
  
 
 
233 
 
6.8 Quality Control 
Measurements of plethysmographic lung volumes are technically difficult to perform, 
and only one outcome (FRC) is directly measured, whilst the other outcomes (RV, TLC 
and RV/TLC) are derived from combining different outcomes (described below).  
Quality control assessments are therefore particularly pertinent in this effort dependent 
measurement.   
 
Plethysmographic lung volumes were performed according to a standardised protocol 
described in chapter 2, section 2.6.6).  In brief: FRC was calculated from the mean of 
2-5 technically satisfactory FRC measurements (each of which consisted of at least two 
respiratory efforts at a breathing frequency of 30-90 breaths/min against the occlusion, 
with closed, super-imposable loops free from artefact/drift).  RV was derived from the 
mean FRC minus the mean of the technically acceptable Expiratory Reserve Volume 
(ERV) measurements, and TLC was derived from the reported value for RV plus the 
largest technically acceptable Inspired Vital Capacity (IVC).   
 
To ensure data collected met published guidelines,94 and to document the quality of the 
results obtained, a plethysmographic lung volume over-read sheet was developed.  
Plethysmographic lung volumes were graded according to three categories:  
 Performance of FRC,  
 Repeatability of FRC, and  
 Performance of spirometry 
Each category was graded out of three, and a minimum of one for each category was 
required to “pass”.  The over-read sheet and instructions are available in the methods, 
section 2.6.6.4 and the scoring table can be seen in (Table 6-11). 
6.8.2 Over-read score 
A random sample of lung volume data from 60 healthy Black children (mean (SD) age 
10.0 (1.4) years)), 60 healthy White children (mean (SD) age 9.3 years (1.8)) and 60 
children with SCD (mean (SD) age 9.9 (1.7)) were reviewed.  A maximum of five FRC 
measures per child were reviewed.  None of the data reviewed were failures (i.e. <1 
acceptable FRC measurement). 
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Table 6-11: Quality Control scoring system for plethysmographic lung volumes 
 Performance of FRC (pleth) trial:   
1.1 > 3 technically acceptable trials   
(i.e. >2 respiratory efforts against the occlusion, BF 30-90 breaths/min) 
 
3 
1.2 2 technically acceptable trials 2 
1.3 1 technically acceptable trial 1 
1.4 < 1 technically acceptable trials and/or breathing frequency outside recommended range* FAIL 
 Repeatability of FRC (pleth) trials:  
2.1 >3 FRC values within 5% or 100mls 3 
2.2 3 FRC values within 10% 2 
2.3 2 FRC values within 5% 2 
2.4 2 FRC values within 10% 1 
 Performance of Spirometry measurement: 
IVC within 85% of previously recorded FVC AND….. 
 
3.1 Mean of 3 technically acceptable ERV’s 3 
3.2 Mean of 2 technically acceptable ERV’s 2 
3.3 Single ERV measurement (compatible with previous FVC) 1 
3.4 No technically acceptable VC measurement 0 
*High breathing frequencies may be associated with hyperventilation and the subsequent elevation of FRC.  Results with increased breathing frequencies 
therefore failed QC. 
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Table 6-12: Lung Volume over-read scores in health and SCD.   
Results based on 60 healthy Black children, 60 healthy White children and 60 children with SCD aged 6 to 12 years.
 FRC performance score: 
Frequency (%) achieving: 
1                2               3 
FRC Repeatability score: 
Frequency (%) achieving: 
0         1           2            3 
Spirometry score: 
Frequency (%) achieving: 
0         1           2          3 
Overall score:  
Frequency (%) achieving: 
  3       4         5        6       7      8       9 
Healthy Black 0              22              78 3        13         53          30 0         10        38         52   2       2       12      26       7      23     28 
Healthy White 0              38              62 0        10         47          43 0          7         28         65   0       2       10      13       5      30     40 
SCD 2              43              55 2         13        55          30 0          15       33         52   0       3        17     20      12     28     20 
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Figure 6-9: Frequency plots of lung volume over-read scores. 
Results based on 60 healthy White children, 60 healthy Black children and 60 children with SCD 
aged 6 to 12 years. 
The majority (>80%) of children reviewed achieved an overall score of >6.  There was no 
difference in QC scores between health and disease. 
 
 
Sixty-two percent of the White children, 78% of the Black children and 55% of the 
children with SCD performed three or more technically acceptable FRC measures and 
therefore scored a three for FRC performance.  The FRC repeatability scores varied, 
with the majority scoring two (3 FRC measures within 10% or 2 FRC measures within 
5%), whereas the majority of spirometry performance scores were three.  The total 
over-read scores were similar in health and disease, with >80% of the children in all 
groups achieving 6 or more in the total score (Table 6-12 and Figure 6-9).  
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6.8.3 Summary of QC criteria 
The QC criteria in Table 6-11, based on published recommendations, appear to be 
suitable for children aged 6 to 12 years undergoing these measurements.  The majority 
of those reviewed performed two measures of FRC within 5% or three measures within 
10%.  However it is estimated that ~5% of children aged 6 to 12 are unable/refuse to 
perform an FRC measurement.  These results were therefore not included in the 
review.  Given that absolute lung volumes in children are lower than that observed in 
adults, the repeatability criteria in the over-read sheet, which is based on adult data 
and dependent on absolute volume differences, may be too lenient for children.  
6.9 Repeatability 
The QC criteria included a pre-defined repeatability criterion based on adults,94 which 
the majority (80%) of the children reviewed achieved.  Of the four main outcomes 
measured in plethysmographic lung volumes (FRC, RV, TLC and RV/TLC) only FRC is 
measured directly (the rest are derived from other measurements), hence the within-
test repeatability of these measures may be influenced by many factors.  This section 
will review the within-test repeatability of the FRC measurement in terms of absolute 
differences (maximum-minimum (mL)) and percent (([highest-lowest]/highest)*100), as 
well as the within-test SD and CV.  The influence of age will also be evaluated. 
6.9.2 FRC within-test repeatability 
The literature suggests an absolute maximum within-test FRC repeatability of 150mL in 
adults94 and 160mL in children.149  In the current study, the median FRC within-test 
repeatability was ~ 90mL or 7% in healthy children and slightly lower (80mL or 6%) in 
children with SCD (Table 6-13).  Non-parametric tests to determine group differences 
(Kruskal-Wallis Tests) revealed no significant differences between the three groups.  
The within-test FRC SD and CV for children aged 6 to 12 years can therefore be 
assumed to be around 50mLs and 3.5% respectively, this is slightly lower than 
previously reported in adults94 and children.149 
Table 6-13: Within test repeatability of FRC.   
Results presented as median (inter-quartile range) Results based on 60 healthy White children, 
60 healthy Black children and 60 children with SCD aged 6 to 12 years. 
 Absolute 
difference (mL)  
Absolute % 
difference  
SD 
(mL) 
Coefficient of 
variation (%) 
Healthy Black 90 (43-130) 6.9 (3.4-10.9) 50 (25-70) 3.6 (2.0-5.6) 
Healthy White 95 (50-130) 6.6 (3.9-10.2) 47 (27-71) 3.5 (2.2- 5.3) 
SCD 80 (50-110) 5.8 (4.1-8.9) 42 (26-64) 3.3 (2.2-5.1) 
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6.9.3 Influence of age and within-test repeatability 
The literature suggests an absolute maximum within-test FRC repeatability of 150mL in 
adults94 and 160 mL in children,149 however the current study investigated younger 
children aged 6 to 12 years and found within-test FRC repeatability to be lower (Table 
6-13).  Pearson’s Correlation revealed no correlations between absolute difference 
(mL) and age (r=0.07, p=0.3); a significant, but weak correlation between % difference 
and age (r = -0.17, p = 0.02); and no correlation between SD and age (r=0.09, p=0.25) 
or CV and age (r= -0.14, p = 0.06) (Figure 6-10).  The within-test repeatability criteria 
defined above (SD:50 mLs or CV: 3.5%) can therefore be considered to be applicable 
to all children aged 6 to 12 years. 
6.9.4 Summary of repeatability 
FRC within-test repeatability in children aged 6 to 12 years is slightly lower than that 
previously quoted in the literature which may reflect the strict QC criteria applied.  
There was no influence of age or lung disease on FRC repeatability in this age range; 
however changes during puberty (not investigated) may have a more significant 
impact. 
 
Due to the nature of the test, between-test repeatability and bronchodilator 
responsiveness was not feasible to assess in this study. 
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Figure 6-10: With-test repeatability of FRC in health and in SCD 
 
Legend: Repeatability was expressed as absolute difference (mL or % difference between 
maximum and minimum) or as the SD (mL) or CV.  Dashed line indicates the median for all 
children assessed.   
No correlation between age and within-test FRC repeatability was observed regardless how 
repeatability was expressed.  The median within-test FRC repeatability in healthy children and 
children with SCD was 90mL (absolute difference); 6.7% (percent difference); 49mL (SD) or 
3.8% (CV).
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6.10 Recommendations for plethysmographic lung volumes in children  
Based on the results of this study the most appropriate published paediatric reference data for plethysmographic lung volumes are those by 
Rosenthal et al.98  Ethnic adjustments for Black children should be applied (Table 6-14): 
Table 6-14: Recommended Limits of normality using % predicted and Z Scores based on Rosenthal’s plethysmographic reference equations 
Outcome Ethnicity Adjustment 
factor 
% Predicted 
LLN (95%CI) 
% Predicted 
ULN (95%CI) 
Z Score 
LLN (95%CI) 
Z Score 
ULN (95%CI) 
FRC Black 0.86 72 (68; 75) 129 (126; 133) -1.4 (-1.6; -1.2) 1.5 (1.3; 1.7) 
RV  1.04 62 (57; 67) 138 (133; 142) -1.4 (-1.5; -1.2) 1.4 (1.2; 1.5) 
TLC  0.94 80 (77; 82) 120(118; 123) -1.7 (-1.9; -1.5) 1.7 (1.5; 1.9) 
RV/TLC  1.10 66 (62; 71) 134 (130; 138) -1.6 (-1.8; -1.4) 1.7 (1.5; 1.9) 
FRC White 0.91 68 (65; 70) 134 (131; 137) -1.8 (-1.9; -1.6) 1.8 (1.6; 1.9) 
RV  NA 53 (49; 57) 145 (141; 149) -1.6 (-1.7; -1.4) 1.6 (1.4; 1.7) 
TLC  NA 80 (78; 82) 123 (121; 125) -1.6 (-1.8; -1.5) 1.9 (1.7; 2.0) 
RV/TLC  NA 60 (56; 63) 134 (131; 138) -1.9 (-2.0; -1.7) 1.7 (1.5; 1.8) 
LLN= lower limit of normal; ULN = upper limit of normal.  NA = Not applicable. 
95% confidence intervals around the LLN and ULN were calculated from the standard error of the mean (SEM) and provide a more precise estimation of the 
limits of normality.  
Values in bold indicate the most conservative limits, that take the actual sample size of this study into account 
 
CAUTION: While these thresholds may provide a useful guide until more appropriate reference equations can be developed, they must be 
interpreted with caution, given the relatively small numbers of children in the current study and can only be applied to children aged 6 to 12 
years.  Furthermore, it is recommended that all results undergo a QC over-reading process (Table 6-11), with good quality data scoring >6.   
Within-test repeatability for children aged 6-12 years should be within 90mL (max-min) or 7% (this equates to a CV of 3.5%, or a SD of 50 mL).
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6.11 Applications in disease 
The previous sections have described and validated a suitable method for applying a 
QC over-read system to plethysmographic lung volume measurements, defined within-
test repeatability and suggested adjustment factors that allow published reference data 
to be applied in Black or White children aged 6 to 12 years.  The following section will 
investigate the use of plethysmographic lung volume measurements in children with 
SCD, and compare results to healthy Black children. 
6.11.2 Subjects with SCD 
Lung volume data were collected in children with SCD recruited as part of the SAC 
study (described in Chapter 2, section 2.3.1).  Age was limited to 6 to 12 years to 
match the healthy Black control group.  Data were collected in three sites (one at ICH 
and two in the USA).  One-way ANOVA analysis of the three groups revealed a 
significant difference in height Z Scores, but differences in weight and BMI Z Scores 
did not reach significance (Table 6-15).   
Table 6-15: Comparison of demographics in 98 children with SCD aged 6 to 12 years from 
3 different locations 
 UK 
(ICH) 
USA  
(St Louis) 
USA  
(Cleveland) 
n (% male) 59 (46%) 26 (67%) 13 (69%) 
Age (years) 9.9 (1.8) 9.8 (1.8) 9.8 (1.8) 
Height Z Score 0.0 (1.0) 0.2 (2.1) -1.0 (1.1)* 
Weight Z Score -0.2 (1.0) 0.0 (1.3) -0.6 (1.2) 
BMI Z Score -0.2 (1.0) -0.1 (1.1) 0.0 (1.1) 
Unless stated otherwise, results presented as mean (SD) *p<0.05  
Demographics were expressed as Z Scores according to the CDC reference equations
131
 
 
Children with SCD measured in Cleveland, USA demonstrated a significant difference 
in height Z Scores and the trend towards a difference in weight Z Scores.  In addition, 
no control children were measured in this centre.  Therefore children from this centre 
were excluded from further analysis. 
 
In the two remaining centres (UK and St Louis, USA) there were no significant 
differences (mean difference (95%CI)) in age (0.2 years (-1.0; 0.7)); height Z Score 
(0.2 Z (-0.4; 0.9)); weight Z Score (0.3Z (-0.4; 0.7)) or BMI Z Score (0.2Z (-0.4; 0.6)). 
Thus data from these two centres could be combined and compared to healthy Black 
children from the same centres. 
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6.11.3 Comparison of lung volumes in SCD and healthy Black children 
The 68 healthy Black children in whom reference data were investigated were 
compared to 85 children with SCD aged 6 to 12 years to determine if differences in 
demographics (Table 6-16) or plethysmographic lung volumes (Table 6-17) were 
observed.  Despite no differences in age, children with SCD were significantly shorter 
and lighter than the healthy control children (Table 6-16). 
 
Table 6-16: Comparison of demographics in 68 healthy Black children and 85 children 
with SCD aged 6 to 12 years. 
 SCD Healthy Black 
(HB) 
Mean Diff  (SCD-HB) 
(95% CI) 
n (%male) 85 (52%) 68 (43%)  
Age (years) 9.8 (1.8) 10.0 (1.5) -0.2 (-0.7; 0.4) 
Height Z Score 0.1 (1.4) 0.6 (1.1) -0.5 (-1.0; -0.1)* 
Weight Z Score -0.1 (1.1) 0.8 (1.1) -0.9 (-1.2; -0.5)*** 
BMI Z Score -0.2 (1.1) 0.7 (1.0) -0.8 (-1.1; -0.5)*** 
Unless stated otherwise, results presented as mean (SD) *p<0.05, **p<0.01, ***p<0.001 
Demographics were expressed as Z Scores according to the CDC reference equations
131
 
 
With the exception of TLC, there were no statistical group differences in lung volume 
outcomes between children with SCD and healthy Black children (Table 6-17).  The 
statistical group difference in TLC of -0.8 Z Scores (91% predicted) has significant 
clinical implications suggestive of restrictive lung disease in children with SCD.  The 
extent and number of children with SCD in whom the TLC measurements fell outside 
the limits of normality are investigated further in the following sections. 
Table 6-17: A comparison of plethysmographic lung volumes in 88 children with SCD and 
68 healthy Black control children aged 6 to 12 years. 
 SCD Healthy Black 
(HB) 
Mean Diff  (SCD-HB) 
(95% CI) 
FRC Z Score 0.0 (1.0) 0.0 (0.7) 0.0 (-0.3; 0.3) 
RV Z Score -0.2 (0.8) 0.0 (0.7) -0.2 (-0.4; 0.1) 
TLC Z Score -0.8 (1.0) 0.0 (0.9) -0.8 (-1.1; -0.5)*** 
RV/TLC Z Score 0.3 (1.1) 0.0 (0.8) 0.3 (0.0; 0.6)† 
Unless stated otherwise, results presented as mean (SD) 
† 
p=0.05, ***p<0.001   
All lung volume outcomes were expressed as Z Scores according to Rosenthal reference 
equations
98
 and the ethnic adjustments derived in from Table 6-14. 
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6.11.4 Interpretation of lung volumes in children with SCD 
Lung volume measurements are the gold standard for identifying restrictive lung 
disease, and are useful measurements in determining obstructive lung disease.94 A 
TLC below the LLN is indicative of restrictive lung disease in an individual, whereas 
elevated RV, FRC or RV/TLC above the ULN indicates obstructive lung disease.  Table 
6-17 highlighted a statistically significant and clinically relevant group reduction in TLC 
in children with SCD compared to healthy Black children.  Furthermore, the SCD group 
demonstrated a slight elevation in RV/TLC (p=0.05) in comparison to the healthy Black 
children.   
 
Although group differences were identified, interpretation on an individual basis is 
dependent upon whether or not a result falls within the limits of normality (+/-1.96 SD).  
The number of children with SCD and the extent to which they fall outside the limits of 
normality are investigated in conjunction with the different methods of interpretation: 
1) Direct application of reference equations (based on White children) with no 
ethnic adjustment 
2) Using the lung function software adjustment of 12% for all outcomes (i.e. all 
results are divided by 0.88 prior to applying reference equations)  
3) Applying ethnic adjustments recommended by the ATS/ERS2: 12% (0.88) for 
RV, TLC and RV/TLC ratio, and 6% (0.94) for FRC 
4) Applying the ethnic adjustments based on the current study:  FRC (0.86), RV 
(1.04), TLC (0.94) RV/TLC (1.10) and interpreting the results using: 
a. Mean Z Scores +/-1.96 SD based on the actual SD in the healthy Black 
children 
b. Z Scores and the conventional limits of normality (+/-1.96 Z Score) 
 
The different methods of interpretation and the impact of over/under-diagnosis of lung 
disease is described in Table 6-18 and illustrated in the Figure 6-11, Figure 6-12, 
Figure 6-13 and Figure 6-14) 
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Table 6-18: Number of children with SCD with results outside the limits of normality 
depending on different interpretative strategies. 
Method of Interpretation: 
Number (out of 85) with results 
outside the limits of normality 
 ↑FRC ↑RV ↓TLC ↑RV/TLC 
No ethnic adjustment: 1 0 11 14 
Software adjustment (12% for all outcomes): 3 5 3 27 
ATS/ERS2: (7% for FRC, 12% for all others):  3 5 3 27 
Ethnic adjustment based on current study: 
FRC:0.86; RV:1.04; TLC:0.94; RV/TLC:1.10 
    
 Z Scores (+ adjusted limits of normality)  4 1 30 7 
 Z Scores (+conventional limits of 
normality)  
3 0 6 7 
 
The majority of children with SCD had FRC and RV measures within the normal range, 
and the different methods of interpretation did not significantly impact on the 
interpretation of FRC (Figure 6-11) whilst there was a slight difference in the numbers 
identified with a raised RV when applying the 12% adjustment advised by the 
ATS/ERS2 and implemented by the software (Figure 6-12).  When reviewing TLC 
results in SCD, applying the 12% adjustment (advised by the ATS/ERS2 and 
implemented by the jaeger lung function equipment) resulted in the potential under-
diagnosis of restrictive lung disease with just three children being identified by this 
method of interpretation. This compared to 11 children being identified when not 
applying any adjustment; six children when applying the 6% adjustment suggested by 
this study, and 30 children if using the ethnic adjustment and adjusted limits of 
normality suggested by this study (Figure 6-13).  An evaluation of RV/TLC found that 
not applying an ethnic adjustment identified 14 children with a raised RV/TLC 
(consistent with obstructive lung disease).  An apparent over-diagnosis of obstructive 
lung disease (when defined by an elevated RV/TLC) occurred when applying the 12% 
adjustment, however, using the ethnic adjustment suggested by the current study only 
seven children were found to have an elevated RV/TLC ratio. 
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Figure 6-11: Comparison of FRC Z Scores in health and SCD. 
Legend:Results based on 85 children with SCD and 68 healthy Black controls.   
Black dashed line denotes the limits of normality (+/-1.96 SD).  Red dotted line denotes the 
adjusted limits of normality based on the measured SD. 
2-3 children with SCD were identified as having an elevated FRC.  Interpretation did not differ 
significantly when applying different interpretative method
A) No Ethnic adjustment B) -12%adjustment (equipment) 
C)-7% adjustment (ATS/ERS)  D) -14% adjustment (current study) 
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Figure 6-12: Comparison of RV Z Scores in health and SCD.   
Legend: Results based on 85 children with SCD and 68 healthy Black controls.   
Black dashed line denotes the limits of normality (+/-1.96 SD).  Red dotted line denotes the adjusted limits of normality based on the measured SD. 
When no ethnic adjustment made, or the adjustment factor derived from the current study was applied all children fell within the normal limits.  Following 
ATS/ERS recommendations (and the option available in the equipment) of 12% adjustment resulted in 5 children with SCD having an elevated RV (although 
4 healthy children also had an elevated RV).  There was no significant difference in RV measurements in health or SCD. 
 
C) +4% adjustment (current study) A) No Ethnic adjustment B) -12% adjustment (equipment + ATS/ERS) 
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Figure 6-13: Comparison of TLC Z Scores in health and SCD. 
Legend: Results based on 85 children with SCD and 68 healthy Black controls.   
Black dashed line denotes the limits of normality (+/-1.96 SD).  Red dotted line denotes the adjusted limits of normality based on the measured SD. 
When no ethnic adjustment was made 11 children with SCD had a TLC below the lower limit of normal.  Following the ATS/ERS recommendations (and the 
option available in the equipment) of 12% adjustment resulted in a potential under-diagnosis of restriction with just 3 children being identified.  Using the 
ethnic adjustment based on the current study 6 children with SCD had a reduced TLC using the conventional limits of normality, and a further 24 children 
were identified using the adjusted limits of normality. 
 
 
 
A) No Ethnic adjustment B) -12% adjustment (equipment + ATS/ERS) C)-6% adjustment (current study) 
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Figure 6-14: Comparison of RV/TLC Z Scores in health and SCD.   
Legend: Results based on 85 children with SCD and 68 healthy Black controls.   
Black dashed line denotes the limits of normality (+/-1.96 SD).  Red dotted line denotes the adjusted limits of normality based on the measured SD. 
When no ethnic adjustment was made 14 children with SCD had an elevated RV/TLC.  Following the ATS/ERS recommendations (and the option available in 
the equipment) of 12% adjustment resulted in a potential over-diagnosis of obstructive lung disease with 27 children with SCD being identified with an 
RV/TLC above the ULN.  Using the ethnic adjustment based on the current study, just 7 children with SCD had a RV/TLC above the ULN. 
. 
A) No Ethnic adjustment B) -12% adjustment (equipment + ATS/ERS) C)+4% adjustment (current study) 
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6.12 Summary 
Plethysmographic lung volume measurements are the gold standard for identifying 
restrictive lung disease,94 however the interpretation of these measurements in non-
White children was limited due to the lack of Black specific reference data, and a 
dearth of paediatric specific guidelines. 
 
Two commonly used paediatric plethysmographic equations97,98 based on White 
children were evaluated and found to have marked discrepancies between them.  The 
equations by Rosenthal seemed to be  more reliable of the two; however discrepancies 
in FRC of ~9% in White children were still observed.  In addition, significant ethnic 
differences were observed: FRC was 0.7 Z Scores and TLC was 0.5 Z Scores lower in 
Black children than White children when predicted by these equations, whereas RV 
and RV/TLC respectively were 0.1 Z Scores and 0.5 Z Scores higher.  These equations 
were therefore unsuitable for use in Black children unless an adjustment was applied.  
Ethnic adjustments and further recommendations regarding quality control and within-
test repeatability were developed, however it should be noted that these 
recommendations are based on a relatively small sample size of 68 healthy Black 
children aged 6 to 12 years.  Further studies with a larger sample size and greater age 
range are required before definitive recommendations can be made. 
 
Subsequent to developing recommendations for applying plethysmographic lung 
volumes in Black children, the measurements were performed in a group of 85 children 
aged 6 to 12 years with SCD.  When compared with the healthy Black children of the 
same age, the children with SCD were found to have a significantly reduced TLC (-0.8Z 
Scores) and borderline significantly elevated RV/TLC (0.3Z Scores higher than the 
controls).  Different methods of interpretation were evaluated: Failure to apply ethnic 
adjustments resulted in the possible over-diagnosis of raised RV/TLC, but little impact 
on the interpretation of the other outcomes.  Applying the 12% reduction recommended 
by the ATS/ERS2 and implemented by the equipment underdiagnosed restrictive lung 
disease (reduced TLC) and over-diagnosed RV/TLC.  Applying the ethnic adjustments 
developed as a result of the current study appeared to be the most robust method in 
identifying children with lung disease.  These measurements are evaluated in 
comparison to the other lung function assessments described in Chapters 4,5, and 7 
and in relation to the clinical status in Chapter 8. 
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7 Spirometry 
7.1 Introduction 
Spirometry is the most common lung function test available and is used extensively in 
both clinical practice and research studies with well established guidelines for both 
adults,105 and children.1  However, since ethnic differences in lung function are known 
to exist,150 accurate interpretation of spirometry in children from different ethnic 
backgrounds is not feasible without using appropriate reference data.151  The most 
comprehensive spirometric reference data to date are the “All-Age” equations by 
Stanojevic et al,126 which are available for White subjects aged 3 to 80 years of age 
whereas the only Black-specific paediatric spirometry reference data are those by 
Wang et al.5  (NB: NHANES also provided multi-ethnic data from the age of 8 years;107 
however these were not reviewed in this thesis, since many of the children studied 
below the age range of these reference data).  This chapter will evaluate the 
practicality of using either the All-Age126 equations or the Black-specific Wang5 
equations in healthy Black children, and then apply these reference data to Black 
children with Sickle Cell Disease (SCD).  Some of the data presented in this chapter 
have been published in Pediatric Pulmonology.146  
7.2 Aim 
The primary aims were: 
i. To establish appropriate methods for interpreting spirometry data in healthy Black 
children and Black children with SCD  
ii. To determine the extent of ethnic differences in lung function between healthy 
Black and White children 
iii. To evaluate the extent to which spirometry detects lung disease and bronchodilator 
responsiveness in children with SCD 
7.3 Objectives 
The primary objectives were to collate spirometry data obtained from healthy children 
in different centres and compare them to published reference data.  A secondary 
objective was to establish whether inter-centre differences occurred. 
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7.4 Hypothesis 
Healthy Black children will generate different predicted values and lower limits of 
normal for spirometry in comparison to those defined by previously published reference 
data based on White children.126 
7.5 Subjects and sample size 
Spirometry data were collected in healthy Black and White children recruited into the 
SAC and SLIC studies (described previously in chapter 2, section 2.3).  Power 
calculations demonstrated that spirometry measurements from 64 healthy children 
would enable differences equivalent to 0.5 SD (~5% predicted in FEV1 and FVC) to be 
detected between the healthy children and published reference data with 90% power at 
the 5% significance level. 
7.6 Reference data 
A plethora of spirometry reference data in children were available151 with the most 
comprehensive reference data to date being the All-Age equations.126  These equations 
were continuous from 3 to 80 years and took into account the between-subject 
variability, such that an age-dependent lower-limit of normal could be defined.  At the 
time of writing, these equations were limited to White subjects only.  For Black children, 
the only paediatric reference data available were those by Wang et al.5  These were 
created from the 6 cities study which included 989 Black children aged 6 to 18 years 
(NB: Equations from 1630 White children were also developed by the same authors).  
The Wang5 equations were not continuous (i.e. there were 13 equations (one for each 
year (6 -18 years), for each sex and each outcome), and there was a fixed lower limit of 
normal which was defined as the percent predicted corresponding to the 5th percentile, 
which was equivalent to -1.64 SD.   
The All-Age126 and Wang5 equations were directly compared to one another using 
spirometry data obtained in healthy Black children from this study.  Prior to comparing 
the reference equations, prospective spirometry data obtained from healthy Black 
children at three different centres, collected using identical protocols, were compared 
and inter-centre comparisons were made to establish if data could be combined. 
7.6.1 Inter-centre comparisons 
Healthy Black children aged 6 to 12 years underwent spirometry measurements in 
three centres: London primary schools, The UCL Institute of Child Health respiratory 
laboratory (UK) and the Washington University respiratory laboratory (USA).   
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7.6.1.1 Demographic comparisons 
Independent samples t-tests between children measured in London schools and the 
UK laboratory revealed no statistical differences in the demographics of these children.  
However, significant differences in the demographics of children measured in the USA 
were observed.  After adjusting for age and sex using the CDC anthropometry 
reference equations,131 unpaired t-tests revealed children in the UK to be significantly 
taller for age (mean difference (95% CI) Height Z Score: 0.8 (0.1; 1.4)) (Table 7-1).   
Table 7-1: Demographics of healthy Black children in undergoing spirometry. 
 School  UK lab USA lab 
n (% male) 140 (39%) 49 (38%) 25 (48%) 
Age (yrs) 8.7 (1.7) 8.9 (1.5) 10.2 (1.4) 
Height (cm) 136.2 (13.1) 137.9 (13.2) 140.7 (11.9) 
Height Z Score 0.8 (1.0) 0.9 (1.2) 0.1 (1.4) 
Weight (kg) 35.4 (12.2) 36.6 (12.4) 40.0 (11.2) 
Weight Z Score 0.8 (1.0) 0.9 (1.1) 0.6 (1.0) 
BMI 18.6 (3.7) 18.8 (3.6) 19.9 (3.5) 
BMI Z Score 0.6 (1.0) 0.7 (1.0) 0.8 (0.8) 
Results presented as mean (SD) 
Z Scores for weight, height and BMI were based on CDC growth charts.
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7.6.1.2 Spirometry comparisons 
Despite the slight somatic differences, one way ANOVA analysis of spirometric 
outcomes revealed no significant differences between the three centres when adjusted 
for height, sex and age according to ethnic specific Wang reference equations5 (Table 
7-2). 
 
Table 7-2: Spirometry results in healthy children according to measurement site.   
 School UK Lab USA Lab 
n (% male) 140 (39%) 49 (38%) 25 (48%) 
FEV1 % Predicted 101.1 (12.4) 100.1 (11.1) 99.8 (12.8) 
FVC % Predicted 104.5 (13.0) 101.5 (12.0) 105.0 (12.9) 
FEV1/FVC  % predicted 97.1 (7.7) 99.1 (8.2) 95.3 (5.6) 
Results presented as mean (SD)  
NB: Wang reference equations
5
 calculate % predicted only, Z Scores were not available. 
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7.6.1.3 Summary of inter-centre comparisons 
Results from this study demonstrated that with strict adherence to protocol and 
prospective over-reading with rapid feedback (described in the methods, section 
2.6.7.2) there was no bias between results collected in different laboratories in the USA 
and UK, or between spirometry results collected in London schools when compared to 
those measured in a specialised paediatric lung function laboratory.   
7.6.2 Comparison of spirometry reference data 
Spirometry data from 400 healthy children (214 healthy Black children (described in 
section 7.6.1) and 186 healthy White children previously assessed within the UK 
laboratory) were used to compare two spirometry reference equations and elucidate 
the impact of ethnicity.  Black children were slightly older than their White peers.  After 
correcting for age and sex, there was a significant difference in height, weight and BMI 
Z Scores with Black children being taller and heavier (Table 7-3). 
 Table 7-3: Demographics of healthy children undergoing spirometry measurements 
 Black  
(B)  
White  
(W)  
Mean Difference 
(95%CI; B –W) 
n ( % male) 214 (40%) 186 (50%)  
Age (yrs) 8.9 (1.7) 8.4 (1.6) 0.5 (0.2; 0.8)* 
Height Z Score 0.7 (1.1) 0.3 (0.9) 0.5 (0.2; 0.7)*** 
Weight Z Score 0.8 (1.0) 0.3 (0.9) 0.5 (0.3; 0.7)*** 
BMI Z Score 0.7 (1.0) 0.3 (0.9) 0.4 (0.2; 0.6)*** 
Unless stated otherwise, results presented as mean (SD), *p<0.05 ***p<0.001  
Z Scores for weight, height and BMI were based on CDC growth charts.
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Spirometry results were expressed as percent predicted according to Wang,5 using the 
Black or White equations as appropriate, and the Stanojevic All-Age126 equations, 
which are based on White children.  Both Wang (White-specific) and All-Age equations 
described the White population well, with Bland and Altman analysis revealing close 
agreement between the two equations (FEV1: mean difference (95% limits of 
agreement): 2.1% (-3.8 to 8.0)).  The Wang Black-specific equations also described the 
current Black population well, with both mean FEV1 and FVC % predicted centred on 
100% predicted (Figure 7-1).  When compared with their White peers using the All-Age 
equations, results from Black children were ~15% lower for FEV1 and ~13% lower for 
FVC (Table 7-4). 
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Table 7-4: Comparison of spirometric outcomes between healthy Black and White 
children according to two reference equations 
 Black  
(B) 
White  
(W) 
Mean Difference 
(95%CI, B-W)  
n (% male) 
Wang et al:5 
214 (40%) 186 (50%)  
FEV1 % pred.  99.9 (12.4) 104.4 (12.9) -4.3 (-6.8; -1.8)** 
FVC% pred.  103.0 (13.0) 104.4 (12.9) -1.4 (-4.0; -1.1) 
FEV1/FVC % pred.  97.4 (7.6) 99.8 (6.9) -2.5 (-3.9; -1.1)** 
All-Age:126     
FEV1 % pred.  86.6 (10.2) 102.1 (12.5) -15.5 (-17.7;-13.3)*** 
FVC % pred.  90.1 (11.2) 103.5 (12.3) -13.5 (-15.8;-11.2)*** 
FEV1/FVC % pred.  95.4 (7.6) 97.7 (6.6) -2.3 (-3.7; -0.9)** 
Unless stated otherwise, results presented as mean (SD), **p<0.01, ***p<0.001 
Footnote: Wang et al equations have ethnic specific equations and were calculated 
respectively.   
All-Age equations are based on White subjects; no ethnic adjustment was made in this table. 
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Figure 7-1: Comparison of spirometric outcomes in 400 healthy children 
Results expressed as % predicted calculated by two reference equations. 
5
 
126
 
 
Wang equations (left panel) demonstrate good agreement for both White (purple) and Black (green)children (results approximating 100% predicted).  All-Age 
equations demonstrate good agreement for White children, but a reduction by ~15% predicted in both FEV1 and FVC, and hence no difference in FEV1/FVC 
for healthy Black children.  
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7.6.2.1 Interpretation of Wang reference equations 
Evaluation of the two reference equations revealed the equations by Wang et al5 to be 
the most appropriate for interpreting spirometry results in the studied population of 
Black children aged 6 to 12 years.  The wide SD around the mean, however, may have 
an impact on the expected limits of normality.  Wang et al5 described the lower limit of 
normal (LLN) to be 82-83% predicted for FEV1 and FVC (corresponding to the 5
th 
percentile (-1.64 SD)). However, a more conservative approach would be to define the 
LLN as the 2.5th percentile (-1.96 SD) as used in other lung function outcomes in 
children.   Based on the investigated healthy population, the 95% limits of normality 
(i.e. +/-1.96 SD) have been calculated (Table 7-5).  For example the LLN for FEV1 in a 
Black child has been estimated to be 78% predicted.   
Table 7-5: Limits of normality for Black and White children using % predicted based on 
Wang spirometry reference equations. 
Outcome Ethnicity LLN (95%CI) ULN (95%CI) 
FEV1 Black 80 (78; 80) 120 (119; 122) 
FVC  82 (80; 83) 124 (123; 126) 
FEV1/FVC  85 (84; 86) 110 (109; 111) 
FEV1 White 82 (81; 80) 120 (124; 127) 
FVC  83 (82; 85) 126 (124; 127) 
FEV1/FVC  89 (88; 89) 111 (110; 112) 
LLN= lower limit of normal; ULN = upper limit of normal.  NA = Not applicable. 
95% confidence intervals around the LLN and ULN were calculated from the standard error of 
the mean (SEM) and provide a more precise estimation of the limits of normality. Values in bold 
indicate the most conservative limits, that take the actual sample size of this study into account. 
7.6.2.2 Ethnic “adjustments” for spirometry 
The Wang5 equations may be suitable for interpreting spirometry data in Black children 
aged 6 to 12 years; however subjects that fall below this age range do not have 
suitable reference data. The observed differences in spirometric outcomes between 
healthy Black children and those predicted using the All-Age126 equations (~13% for 
FEV1 and ~10% for FVC (Table 7.4)) were therefore used as “ethnic adjustments.” i.e. 
measured results from the Black children were divided by 0.87, 0.90 and 0.95 for FEV1, 
FVC and FEV1/FVC respectively before calculating predicted values according to the 
All-Age equations.  Once these adjustment factors had been applied, Bland and Altman 
analysis revealed no bias across the age group studied between % predicted results 
calculated according to Wang et al5 and those calculated from the All-Age126 (adjusted) 
equations:  The mean difference (95% limits of agreement) between Wang minus All-
Age-adjusted was 0.3% (-9.7; 10.3) for FEV1, 2.8% (-8.2, 13.8) for FVC and -3.7% (-
10.4; 3.0) for FEV1/FVC. 
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7.6.2.3 Summary of reference data comparisons 
Two paediatric spirometry reference equations were reviewed.  The All-Age126 
spirometry equations demonstrated excellent agreement with White children, as 
described previously,32,152 but were not appropriate for Black children unless ethnic 
adjustments were applied.  The ethnic-specific spirometry equations by Wang et al5 
also proved a good fit for White and Black children respectively, with mean results from 
our healthy children approximating 100% predicted (Table 7-4).  The Wang equations 
are, however, limited to 13 step-wise sex-specific equations for each year of age from 6 
to 18 years for each ethnic group.  This step-wise approach to adjust for age potentially 
limits the accuracy of deriving predicted equations.  Quanjer et al have recently 
demonstrated that neglecting to use decimalised age results in errors of up to 10%.153  
Furthermore extrapolating beyond these age ranges is not recommended,125 hence 
these equations are not suitable for the increasing number of preschool children now 
undertaking such tests.1  A temporary solution to this problem could be to use the 
Stanojevic equations with appropriate adjustment factors for Black children less than 6 
years, albeit with caution due to the known potential problems which may occur when 
switching between reference equations.151,154 
 
Caution should be used when interpreting spirometry using the Wang equations.  The 
lower limit of normal (LLN) quoted by Wang et al as 81.3%, 81% and 90% (based on 
+/-1.64 SD) for FEV1, FVC and FEV1/FVC respectively may over diagnose abnormality, 
since the LLN of normal was demonstrated to be slightly lower in this study at 75.2%, 
74% and 84.8%, respectively.  Varying LLNs for each outcome, and age group have 
been described previously,155 and can complicate interpretation.  A solution to this 
would be to present the results as Z Scores instead of % predicted.  Z Scores take into 
account the variability of the measurement.  The LLN can be set at -1.96 Z Scores 
(equivalent to 2.5th percentile) or -1.64 Z Scores (equivalent to the 5th percentile, often 
used in adult lung function).155  Z Scores were not available for the Wang equations, 
therefore all results were presented as percent predicted.  The limitations observed in 
the Wang equations are not present in the All-Age equations, which are based on 
White subjects aged 3 to 80 years of age and provide smoothly changing curves to 
describe the transition between childhood and adulthood, whilst accounting for the age-
dependent range of normal.126  Multi-ethnic equations across all ages that allow the 
calculation of Z Scores are expected to be released in 2012 (www.lungfunction.org).    
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7.7 Applications: Spirometry in SCD 
The previous sections have evaluated the available reference data for spirometry and 
identified which are the most appropriate for use in Black children.  The following 
section applies these reference data to 60 children with SCD, and compares children 
with SCD to 214 healthy Black children.  
Independent t-tests demonstrated that the children with SCD were significantly shorter 
and lighter for age compared with the healthy Black children (Table 7-6).   
Table 7-6: Comparison of demographics in 214 healthy Black children and 60 children 
with SCD aged 6 to 12 years. 
 Healthy 
Black 
SCD Mean Diff (SCD – Black) 
(95% CI) 
n (% male) 214 (43.3%) 60 (39.3%)  
Age (years) 8.9 (1.7) 9.2 (2.1) 0.3 (-0.2; 0.8) 
Height Z 0.7 (1.1) -0.2 (1.1) -0.9 (-1.2; -0.6)*** 
Weight Z 0.8 (1.0) -0.3 (1.0) -1.1 (-1.4; -0.8)*** 
BMI Z 0.7 (1.0) -0.3 (0.9) -0.9 (-1.2; -0.6)*** 
Unless stated otherwise, results presented as mean (SD) ***p<0.001 
Z Scores for weight, height and BMI were based on CDC growth charts.
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Spirometry results were expressed as percent predicted to adjust for age, height and 
sex differences.5  Group differences between SCD and health were observed (Figure 
7-2):  FEV1 and FVC were significantly lower in SCD than in health; however they were 
reduced in equal proportions, such that there was no difference in the FEV1/FVC ratio 
(Table 7-7).  
Table 7-7: Comparison of spirometry obtained in 214 healthy Black children to 60 
children with SCD aged 6 to 12 years. 
 Healthy Black SCD Mean Diff (SCD – Black) 
(95% CI) 
FVC (% pred) 103.9 (12.8) 90.1 (14.9) -13.8 (-17.6; -10.0)*** 
FEV1 (% pred) 100.7 (12.1) 88.8 (13.9) -12.0 (-15.6; -8.4)*** 
FEV1/FVC  (% pred) 97.3 (7.7) 98.9 (7.4) 1.6 (-0.6; 3.8) 
Unless stated otherwise, results presented as mean (SD) ***p<0.001  
Z Scores for weight, height and BMI were based on CDC growth charts.
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Comparisons of age, height and height Z Scores8 and spirometry results expressed as 
% predicted demonstrated no bias according to age or height in the age group studied.  
Thus, spirometry results in children who were small for age (i.e. with low height Z 
Scores) were no worse than in taller/older children who were “normal” height for age 
(Figure 7-3 and Figure 7-4). 
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Figure 7-2: Comparison of spirometric outcomes in 214 healthy Black children and 60 children with SCD aged 6 to 12 years.  
Legend: Black lines denote mean (SD). Red dashed line represents 100% predicted. 
FEV1 and FVC were significantly (p<0.0001) lower in SCD than in health; however they were reduced in equal proportions, such that there was no significant 
difference in the FEV1/FVC ratio 
 
p<0.0001 p<0.0001 p=0.15 
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Figure 7-3: Comparison of FEV1 % predicted and age, height and height Z Scores in 60 children with SCD.   
Legend: Red dashed line represents 100% predicted. 
No correlation between decreased FEV1 percent predicted and age, height or height Z Score was observed.
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Figure 7-4: Comparison of FVC and FEV1/FVC percent predicted and age, height and height Z Score in 60 children with SCD.   
Legend: Red dashed line represents 100% predicted. 
No correlation between decreased FEV1 percent predicted and age, height or height Z Score was observed 
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7.7.1 Bronchodilator response (BDR) 
Between-test repeatability has previously been defined as <150mL in FVC and FEV1, 
with a slightly tighter criteria of <100mL if the FVC is <1.0L.105  Several studies have 
demonstrated that these criteria are achievable in children,1,105,108,111,113,114 thus 
between-test repeatability was not investigated further in this study.  Criteria for 
defining a significant BDR has also been defined previously as a 12% and/or 200mL 
increase in FEV1 from baseline.
2  The extent to which children with SCD responded to 
bronchodilators was evaluated.  Prior to evaluating spirometry and  BDR in children 
with SCD,  BDR in health was examined. 
7.7.1.1 Bronchodilator response in health 
A subset of 50 healthy children (11 Black and 39 White) underwent BDR assessments 
with spirometry data as the outcome measure.  The demographics and baseline 
spirometry of these healthy children were similar to the main group (Table 7-3 and 
Table 7-4), and there was no significant difference between the BDR observed in 
healthy White children and healthy Black children when expressed as absolute change 
or percent change from baseline (mean difference (Black-White), (95%CI): 42.6mL (-
32.8; 118.0) and 2.0% (-2.2; 6.1) respectively).  Results from these children were 
therefore combined and used as a reference for interpreting bronchodilator 
responsiveness in SCD (i.e. a clinically relevant BDR would be a change greater than 
that seen in health). 
7.7.1.2 Comparison of bronchodilator response observed in health and SCD 
Fifty-five children with SCD and 50 healthy children underwent BDR assessments.  The 
demographics of these children were similar to the main group (Table 7-6).  As 
observed previously, the children with SCD were significantly shorter and lighter than 
the healthy children (Table 7-8). 
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Table 7-8: Comparison of demographics in healthy children and children with SCD in 
whom BDR using spirometry were undertaken. 
 SCD  Healthy  Mean Diff (SCD- Health) 
(95% CI) 
n (% male) 55 (48)  50 (46)  
Ethnicity: % Black 100  80  
Age (yrs) 9.4 (2.0)  8.6 (2.2) 0.7 (-0.1; 1.6) 
Height Z -0.2 1.1)  0.3 (1.0) -0.5 (-0.9; -0.1)* 
Weight Z -0.3 1.0)  0.2 (0.9) -0.6 (-1.0; -0.3)*** 
BMI Z -0.3 0.1)  0.2 (0.9) -0.6 (-0.9; -0.2)*** 
Unless stated otherwise, results presented as mean (SD), *p<0.05,***p<0.001 
Z Scores for weight, height and BMI were based on CDC growth charts.
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Paired t-tests revealed a statistically significant (p<0.0001) change between baseline 
and post bronchodilator FEV1, in both healthy children (mean difference (95%CI): 49 
(20; 80) mL) and children with SCD (mean difference (95%CI): 60 (40; 90) mL).  
However, when compared in terms of absolute change or percentage change from 
baseline, the differences observed were not clinically relevant and group differences 
between health and SCD were not observed (Table 7-9).   
 
Table 7-9: Comparison of  BDR expressed as absolute change, or percentage change in 
50 healthy children and 55 children with SCD aged 6 to 12 years. 
Change from 
baseline 
SCD Healthy Mean Diff (SCD – Health) 
(95% CI) 
FEV1 (mL) 66 (84) 49 (11) 17 (-20; 55) 
FEV1 (%) 5.0 (7.3) 3.1 (6.0) 1.9 (-0.7; 4.5) 
FVC (mL) 28 (11) 3 (15) 25 (-27; 77) 
FVC (%) 2.6 (8.3) 0.5 (7.8) 2.1 (-1.0; 5.2) 
Unless stated otherwise, results presented as mean (SD), No significant differences. 
 
No significant relationship between age and BDR was observed (Figure 7-5).   
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Figure 7-5: Relationship between age and change in FEV1 post bronchodilator in 50 
healthy children and 55 children with SCD 
Results presented as absolute (L) or percent change.  Red dashed line indicates the published 
threshold for reversibility (12% or 200 mL). 
There was no significant relationship between age and absolute change post BD (r=0.07) or 
percent change post BD (r=0.01). 
 
The mean change post bronchodilator +/-1.96 SD seen in health was used to define 
the thresholds of reversibility, and demonstrated no significant BDR in the group of 
children with SCD (Figure 7-6). 
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Figure 7-6: BDR in health and SCD for FEV1 and FVC. 
Legend: Dashed lines denote 95% limits of agreement calculated from the pre and post bronchodilator values obtained in health.  The grey shaded area 
denotes the 95% CI around these limits.  Red dots indicate those children in whom a significant BDR was observed (i.e. change outside the limits agreement 
determined in health). 
 
a) Health b) SCD 
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7.8 Summary 
The ethnic-specific spirometry equations by Wang et al,5 alongside a healthy, ethnically 
matched control group provided adequate reference data with which to interpret 
spirometry data obtained in children with SCD.  There was a clinically significant 
reduction in FEV1 and FVC in children with SCD in comparison to healthy children; 
however they were reduced in equal proportions, such that there was no difference in 
the FEV1/FVC ratio.  Assessments of bronchodilator responsiveness revealed that 
children with SCD had no increased BDR compared with that seen in health.  Baseline 
spirometry results and the lack of BDR suggest either the presence of restrictive lung 
disease or physiologically reduced lung capacity secondary to poor growth in children 
with SCD. These results are evaluated alongside the other lung function 
measurements reviewed previously and the clinical symptoms in the next chapter. 
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8 Correlation of lung function tests with respiratory morbidity 
in children with SCD 
8.1 Introduction 
The previous four results chapters in this thesis have reviewed the methodology and 
interpretation of four commercially available lung function tests (Impulse Oscillometry 
(IOS), specific airways resistance (sRaw), plethysmographic lung volumes and 
spirometry) in children aged four to twelve years.  After developing recommendations 
for the applications and interpretation for each test, each individual test was applied in 
children with SCD.   This final results chapter summarises the results obtained so far 
and compares the various lung function outcomes from these tests to one another and 
in relation to the clinical symptoms.   
8.2 Aim 
The primary aim of this chapter was to ascertain the most appropriate combination of 
lung function tests for the clinical monitoring of children with SCD with suspected lung 
disease. 
8.3 Objectives 
The primary objectives were   
i. To compare results obtained from each lung function test and delineate 
correlations between the measurements 
ii. To evaluate the clinical symptoms in combination with the lung function results 
iii. To determine the most appropriate combination of lung function outcomes to 
detect lung disease in children with SCD 
8.4 Hypothesis 
All lung function techniques of interest in this thesis will detect differences between 
healthy children and children with SCD with pulmonary manifestations. 
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8.5 Subjects with matched lung function assessments  
Due to the nature of the protocol and the age limits involved for each assessment, not 
all children underwent the entire protocol.  To describe the most appropriate 
combination of lung function measurements for monitoring SCD and the relationship 
between various outcomes, matched measurements conducted in the same children 
were evaluated. 
Fifty-nine children with SCD had matched measurements of IOS, sRaw and spirometry 
measurements on the same occasion, and 53 children had matched spirometry and 
lung volume measurements (only 20 of these children had sRaw measurements).  
There were no significant differences between the demographics for each of these 
subgroups either when compared with each other or to the main study group; however 
the children who underwent plethysmographic lung volume measurements were 
slightly older than those in whom matched IOS, sRaw and spirometry results were 
obtained (Table 8-1). 
 
Table 8-1: Demographics of the subsets of children with SCD in whom matched lung 
function measurements on the same test occasion were obtained. 
 
Matched data for IOS, 
sRaw and spirometry 
Matched data for Lung volumes 
and spirometry 
n (% male) 59 (54%) 53 (43%) 
Age (yrs) 7.5 (2.1) 9.8 (1.8) 
Height Z  0.1 (1.1) 0.0 (1.1) 
Weight Z 0.0 (1.0) -0.1 (1.1) 
BMI Z 0.0 (1.0) -0.1 (1.1) 
Demographics of entire population studied can be found in Table 3-2 
 Height, weight and BMI were expressed as Z Scores according to the CDC growth charts
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8.6 Summary of previous results chapters 
Each lung function test was reviewed independently in the relevant chapter.  The 
principle findings from each chapter were: 
 Significant differences in IOS reference data based on White children41 and healthy 
Black children occurred 
 R15 and R20 were lower in the presence of SCD compared with healthy Black 
children 
 No significant differences in sRaw outcomes occurred between healthy Black and 
White children, nor between healthy Black children and children with SCD 
 Significant ethnic differences in lung volumes occurred however the magnitude and 
direction of the differences were dependent on outcome: 
 FRC and TLC were 0.7 Z Scores (14%) and 0.5 Z Scores (6%) lower in 
Black children than White children  
 RV/TLC was 0.5 Z Scores (10%) higher in Black children 
 RV was 0.1 Z Scores (4%) higher in Black children (not significant). 
 Interpretative strategies (ethnic adjustments) recommended by the ATS/ERS2 were 
not appropriate for interpreting lung volumes in Black children. 
 When compared with the healthy Black children of the same age, the children with 
SCD were found to have a significantly reduced TLC (-0.8 Z Scores) and borderline 
significantly elevated RV/TLC (0.3 Z Scores higher than the controls). 
 Ethnic-specific spirometry equations by Wang5 were suitable for interpreting 
spirometry in Black and White children 
 There was a clinically significant reduction in FEV1 and FVC in children with SCD in 
comparison to healthy Black children  
 BDR observed in SCD was similar to that seen in health, and was therefore 
clinically insignificant. 
 
The following section summarises the main conclusions for each lung function test and 
the main findings are collated in Table 8-2, whilst the retrospective power calculations 
based on the actual number of children assessed can be seen in Table 8-3. 
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8.6.1 Summary of IOS results 
In chapter 4, two paediatric IOS reference equations based on White children41,65 were 
evaluated and found to differ from one another in such a way that they were not 
interchangeable.  Furthermore, marked differences between predicted values and 
those measured were observed: Healthy Black children had, on average, resistance 
and reactance measurements that were ~0.6 Z Scores higher and 0.8 Z Scores lower 
than predicted (based on White children) which could potentially be due to ethnic 
differences.  The most appropriate method of interpreting IOS data in Black children 
was found to be direct comparisons between health and disease using Z Scores 
derived from Dencker equations,41 although true limits of normality could not be 
defined.   Multiple regression analyses and direct comparisons demonstrated that, after 
adjusting for age and height, having SCD did not have a significant impact on the R5 
and R10 values; however R15 and R20 were lower in the presence of SCD.  X5 was also 
significantly more negative in the presence of SCD after adjusting for height, whilst the 
outcomes affected most by SCD were AX and Fdr5-15, which were both significantly 
elevated (commonly associated with peripheral airway obstruction). 
 
There were no significant differences between the BDR in health and SCD when R5 
and R10 were compared, however there was a significant increase in R15 post BD in 
some children with SCD thus contributing to the differences seen in Fdr5-15, which 
identified five children with SCD with a significant BDR (over and above that seen in 
health).  AX identified just one child with SCD with a clinically significant BDR.   
8.6.2 Summary of sRaw results 
Chapter 5 (sRaw) comprised the largest collation of paediatric sRaw data from healthy 
controls to date.  A comprehensive review of the different methodologies across the 
five collaborating centres was undertaken, and results from the study enabled the 
development of a quality-control over-read sheet and recommendations for future 
measurements.  Furthermore, preliminary sex-specific reference equations, which 
adjusted for the minimal age-related changes in sReff and sRtot, were developed.
128  
These reference equations, although developed for White children, were shown to be 
applicable in Black children, since no ethnic differences were observed.  Other than a 
slight trend towards children with SCD adopting a lighter breathing pattern, there were 
no significant differences in baseline sRaw outcomes or response to bronchodilator 
between SCD and healthy children. 
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8.6.3 Summary of Plethysmographic Lung Volume results 
Chapter 6 consisted of an assessment of plethysmographic lung volumes in children to 
assess the extent to which pre-defined QC criteria were applicable and the impact of 
ethnicity.  Published QC recommendations appeared to be suitable for children 
undergoing these measurements, and within-test repeatability was similar to that 
previously reported.94,149  Two reference equations based on White children were 
reviewed,97,98 and ethnic differences were observed, however the magnitude and 
direction of the differences were dependent on the lung volume outcome and the 
reference equation selected.  Predicted values described by Rosenthal et al98 
appeared to be the more reliable method of interpretation; however they could only be 
used in Black children if suitable adjustments both to the predicted values and limits of 
normality were implemented.  Finally plethysmographic lung volumes were measured 
in children with SCD and results compared to those from healthy Black children of 
similar age (6 to 12 years).  With the exception of TLC, which was significantly reduced 
in the SCD group (indicating restrictive lung disease), there were no statistical group 
differences in lung volume outcomes between children with SCD and healthy Black 
children.  Lung volumes were not used as an outcome measure for bronchodilator 
responsiveness. 
8.6.4 Summary of spirometry results 
The spirometry results chapter (chapter 7) reviewed the most comprehensive 
spirometric reference data to date (the “All-Age” equations by Stanojevic et al,126) along 
with the Black specific reference data by Wang et al.5  As expected ethnic differences 
in spirometry were observed, and the ethnic-specific spirometry equations by Wang,5 
alongside a healthy, ethnically matched control group proved to be the most feasible 
method of interpreting spirometry data from Black children at the time of writing this 
thesis.  A comparison of children with SCD, to healthy Black children of the same age 
demonstrated a clinically significant reduction in FEV1 and FVC in children with SCD in 
comparison to healthy children; however these outcomes were reduced in equal 
proportions, such that there was no difference in the FEV1/FVC ratio.  In addition, 
assessments of bronchodilator responsiveness revealed that children with SCD 
exhibited no increased BDR compared with that seen in health when assessed using 
spirometry. 
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Table 8-2: Summary of the lung function tests undertaken in healthy Black children and children with SCD. 
Test Children assessed: Lung function 
outcome 
Mean Diff  
(SCD-health) 
(95% CI) 
BDR: change from baseline 
SCD 
(n) 
Control 
(n) 
Age 
(yrs) 
SCD Control  Mean Diff  (95%CI) 
(SCD – health) 
IOS 59   68 4-11 R5 Z Score
a
 0.4 (0.0 ; 0.7)* -0.9 (0.8) Z -1.1 (1.2) Z 0.1 (-0.3; 0.6) 
    R10 Z Score
a 
-0.2 (-0.4 ; 0.1) -0.8 (0.9) Z -1.1 (1.0) Z 0.3 (-0.2; 0.7) 
    R15 Z Score
a
 -0.6 (-0.8 ; -0.3)*** 0.3 (1.1) Z -0.7 (1.1) Z 1.0 (0.4; 1.5)*** 
    AX (kPa∙L
-1
) 1.5 (1.0; 2.0)*** -1.1 (1.0) kPa∙L
-1
  -1.0 (1.4) kPa∙L
-1
 -0.1 (-0.6; 0.5) 
    Fdr5-15 (kPa∙L
-1
.s) 0.2 (0.1; 0.2)*** -0.2 (0.1) kPa∙L
-1
.s -0.1(0.1) kPa∙L
-1
.s -0.1 (-0.1; -0.00)*** 
sRaw 99  56 4-10 sRtot Z Score
b 
-0.2 (-0.5; 0.1) -0.7 (0.9) Z -1.2 (0.7)Z 0.5 (0.1; 1.0) 
sReff Z Score
b 
-0.3 (-0.6; 0.1) -0.8 (0.8) Z -1.3 (0.7)Z 0.5 (0.1; 0.8) 
Lung 
Volumes 
85 68 6-12 FRC adjusted
 
Z
c 
0.0 (-0.3; 0.3) Not applicable 
RV adjusted
 
Z
c
  -0.2 (-0.4; 0.1) 
TLC adjusted Z
c
  -0.8 (-1.1; -0.5)*** 
RV/TLC adjusted Z
c 
0.3; (0.0; 0.6)
†
 
Spirometry 60  214 6-12 FEV1 % pred.
d 
-12.0 (-15.6; -8.4)*** 5.0 (7.3)% 3.1 (6.0) % 1.9 (-0.7; 4.5) 
FVC % pred.
d 
-13.8 (-17.6; -10.0)*** 2.6 (8.3)% 0.5 (7.8) % 2.11 (-1.0; 5.2) 
FEF25-75 % pred.
d 
-12.8 (-21.6; 4.1)*** 19.4 (31.4)% 19.1 (23.9) % 0.3 (-10.6; 11.3) 
FEV1/FVC % pred.
d 
1.6 (-0.6; 3.8) 2.7 (6.6) % 3.4 (7.7) % -0.7 (-3.5; 2.1) 
†
p=0.52, *p<0.05, **p<0.01, ***p<0.001 Results in bold also indicate significance.
 
Where applicable, published reference equations were applied to each outcome: IOS
a
=Dencker
41
; sRaw
b
=Kirkby
128
; Lung volumes
c
=Rosenthal (with ethnic 
adjustment described in chapter 5)
98
 and spirometry
d
 = Wang
5
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Table 8-3: Retrospective sample size calculation on baseline measurements obtained in healthy children and children with SCD 
 Actual sample size:                                Retrospective power calculation:  
 SCD Control Power Significance Difference in SD (absolute values) 
IOS 59 68 80% 0.05 0.52 SD  (0.05 kPa∙L-1.s in Fdr5-15 or 0.52 kPa∙L
-1
 in AX) 
sRaw 99 56 80% 0.05 0.53 SD (0.1kPa∙s in sReff) 
Lung Volumes 85 68 80% 0.05 0.48 SD (6%pred in FRC; 9.6% pred in RV; 4.7% pred. in TLC; 
or 9.1% pred.  RV/TLC) 
Spirometry 60 214 80% 0.05 0.2 SD (or 2.4% predicted).  
1 SD is equivilent to 1 Z Score.  Therefore with these numbers there is sufficient power to detect a difference of 0.2 Z Scores in spirometric 
outcomes, but only ~0.5 Z Scores for IOS and plethysmography outcomes.  
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8.7 Symptoms and Doctor Diagnosis of Asthma in children with 
SCD 
In addition to the combination of lung function measurements undertaken, respiratory 
symptoms were documented.  The following questions from the health questionnaire 
(see appendix) were analysed to determine respiratory symptoms/ history of asthma: 
 
1. Does the child cough on most days (>4 days per week)? 
2. Does the child wheeze on most days (>4 days per week)? 
3. Has a doctor ever said the child has asthma? 
4. Does the child take asthma medication? 
 
All of the healthy children included in the study were free from respiratory symptoms, 
and none had a doctor diagnosis of asthma or received any medication for asthma (i.e. 
they answered “no” to all the above questions) (Table 8-4). 
 
Table 8-4: Frequency of children with a positive response to the respiratory health 
questionnaire 
 Cough most 
days 
Wheeze most 
days 
Asthma 
diagnosis 
Asthma 
medication 
Health (n=68) 0% 0% 0% 0% 
SCD (n=59) 50% 14% 12% 14% 
 
Half of the 59 children with SCD, in whom three lung function measurements were 
obtained, reported cough on most days.  Eight children (14%) reported wheeze most 
days, seven (12%) had a doctor diagnosis of asthma and a further eight (14%) were 
receiving asthma medication at the time of assessment (Table 8-4).  In total 10 (17%) 
of the children with SCD had answered yes to at least one of the questions: wheeze 
most days, doctor diagnosis of asthma and/or asthma medication.  “Cough most days” 
was excluded from the “respiratory symptom” coding criteria, as it was impossible to 
identify differences with such a large proportion complaining of cough.  Of the ten 
children reporting respiratory symptoms other than cough, seven had been referred to 
a specialist respiratory physician, and a further eight children who did not complain of 
respiratory symptoms were reviewed in a respiratory clinic, regardless of symptoms.  
Thus 25% of the children with SCD reviewed in this study were receiving specialist 
follow-up with a respiratory physician.  In addition, 30% of the children with SCD had 1 
or 2 hospital admissions due to acute chest syndrome (ACS), and a further 13% had 3 
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or more episodes of ACS, however at the time of writing this thesis the ACS 
information could not be paired with the lung function data. 
 
In light of the respiratory symptoms/respiratory follow-up, the various lung function 
outcomes were reviewed in combination with one another to elucidate the nature of the 
underlying pathophysiology of SCD, to determine concordance and to identify which 
lung function outcomes detected the most abnormalities. Table 8-5 shows the 
correlation of each individual lung function outcome against one another and 
respiratory symptoms.   
IOS and sRaw outcomes demonstrated significant but weak correlations (r =0.36 and 
0.35 for sReff Vs. AX and sReff Vs. Fdr, respectively), whereas the strongest correlations 
occurred between spirometry and lung volume outcomes (Table 8-5).  The various 
combination of assessments, along with cross comparisons are investigated further in 
the following sections. 
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Table 8-5: Pearsons correlation of differing lung function outcomes and respiratory symptoms in children with SCD aged 4 to 12 years.   
 AX 
kPa∙L-1 
Fdr 
kPa∙L-1.s 
sReff 
Z Score 
FEV1 
%Pred 
FVC 
%Pred 
FEV1/FVC 
%Pred 
FRC 
Z Score 
RV 
Z Score 
TLC 
Z Score 
RV/TLC 
Z Score 
Resp. 
symptoms 
AX(kPa∙L-1)  0.89*** 0.36** -0.20 -0.21 0.20 0.08 0.16 0.01 -0.18 0.21 
Fdr (kPa∙L-1.s)   0.35** -0.20 -0.22 0.18 -0.16 -0.33 -0.15 -0.3 0.19 
sReff Z Score    0.16 0.24 -0.03 0.58* 0.22 0.6** -0.12 -0.17 
FEV1 %Pred     0.92*** 0.08 0.56* 0.02 0.77*** -0.54** 0.19 
FVC %Pred      -0.02 0.71** 0.08 0.86*** -0.55* -0.44** 
FEV1/FVC %Pred       0.0 -0.08 -0.02 -0.11 0.16 
FRC Z Score        0.13 0.67** -0.32 -0.26 
RV Z Score         0.49** 0.66** 0.09 
TLC Z Score          -0.23 -0.28 
RV/TLC Z Score           0.18 
Resp. symptoms            
*p<0.05; **p<0.01; ***p<0.001. 
Footnote: Lung function outcomes were compared in children with matched results.  59 children had matched IOS, sRaw and spirometry results and 53 
children had matched spirometry and lung volume results.  Since there were only 19 matched datasets of lung volumes and IOS and lung volume and sRaw, 
these results are highlighted in blue italics as sample size prevents a conclusion on these results. 
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8.8 Combination of lung function assessments 
Chapter 4 investigated the best methods of interpreting IOS results and found severe 
limitations in the reference data.  Consequently direct comparisons of AX and Fdr5-20 
were made as these outcomes take into account changes in reactance and resistance 
across a range of frequencies.  Limits of normality for AX and Fdr5-20 however, have yet 
to be established.  Furthermore the conventional methods for calculating limits of 
normality (mean +/-1.96 SD) were inappropriate since AX and Fdr5-20 were not normally 
distributed.  The two outcomes were therefore plotted against one another and an 
upper limit was estimated by drawing a line across the plot where the majority of 
healthy subjects fell below these lines.  A crude estimate for an upper limit of normality 
was 0.45 kPa∙L-1.s for Fdr and 5.0kPa∙L-1 for AX (Figure 8-1). 
 
Figure 8-1: Comparison of IOS outcomes in 68 healthy Black children and 59 children 
with SCD.   
Legend: Estimates of the upper limit of normality were made by adding a reference line for 
each outcome denoting the point whereby 95% of healthy children fell below that value.  Upper 
limit for Fdr5-20 was estimated as 0.45kPa∙L
-1
.s and AX was estimated as 5.0kPa∙L
-1
. 
 
Using the estimated upper limits defined in Figure 8-1, IOS outcomes could be 
compared with spirometry (Figure 8-2) and sRaw outcomes (Figure 8-3). 
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Figure 8-2: Comparison of FEV1 % predicted and IOS outcomes (AX and Fdr5-20) in 59 children with SCD and 68 healthy Black children aged 4-11y.   
Legend: Vertical black dotted line indicates the lower limit of normal for FEV1 % predicted, and the horizontal grey dashed line indicates a visual estimate of 
the upper limit of normal for AX (where the majority of healthy children fall below this line). Results in the upper left quadrant are abnormal for both 
measurements  
AX results in SCD and health significantly overlap, and there was no correlation between FEV1 and AX (p=0.15, r=-0.2).  AX is not useful for establishing 
abnormality in individual cases.  
 
 
R= -0.2 R= -0.2 
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Figure 8-3: Comparison of sReff Z Score and IOS (AX and Fdr5-20) in 59 children with SCD and 68 healthy Black children aged 4-11y.   
Legend: Vertical black dotted line indicates the upper and lower limit of normal for sReff Z Score (+/-1.96SD), and the horizontal grey dashed line indicates a 
visual estimate of the upper limit of normal for AX (where the majority of healthy children fall below this line). Results in the upper right quadrant are abnormal 
(increased resistance) for both measurements, whereas results in the lower left quadrant are consistent with reduced airways resistance. 
Weak correlations between IOS outcomes and sReff were observed.  The majority of children with SCD had sReff results within the normal limits, with a few 
children presenting with unexpectantedly reduced sReff and concordant lower AX and Fdr. 
 
(k
P
a
/L
) 
R= 0.36 R= 0.35 
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A comparison of IOS outcomes (AX and Fdr) and FEV1 revealed a trend toward those 
children with lower FEV1 % predicted also having higher AX or Fdr values, thus 
supporting the evidence of mild airway obstruction in these children (Figure 8-2).  
Similarly there was a tendency for those children with respiratory symptoms to have 
higher AX and Fdr and lower FEV1, although this did not reach statistical significance.  
Despite these trends, IOS outcomes failed to provide any additional information 
regarding possible pathology other than already identified by spirometry and the 
respiratory health questionnaire. 
 
Figure 8-3 plots IOS outcomes against sReff. There was a weak correlation between 
these outcomes with concordant results between low sReff and low AX and Fdr, and 
one child with concordant elevated sReff Z Score and elevated AX and Fdr (i.e. this 
child’s results fell in the top right quadrant for both plots).  This child had reported 
significant respiratory symptoms, significant bronchodilator responsiveness and was 
undergoing respiratory follow-up with the specialist respiratory physician (i.e. results 
consistent with obstructive lung disease).  The associated reduced IOS outcomes and 
sReff may be suggestive of reduced resistance in the central airways (noted by the 
decreased resistance at high frequencies (R20) measured in IOS (chapter 4)) which 
may be the consequence of restrictive lung disease (discussed further in section 9.4.6) 
 
Further comparisons of sReff and spirometry (FEV1) were made (Figure 8-4).  No 
significant differences in sReff between health and SCD where observed, and the 
majority of sReff results fell within the normal limits.  Five children (8%) with SCD fell 
below the lower limits of normal for sReff. Two of these children reported respiratory 
symptoms, but neither were being reviewed in the respiratory clinic.  On comparison to 
FEV1 % predicted, the few children with low sReff did not have any evidence of 
increased expiratory airflows (Figure 8-4) and a similar pattern was seen in other 
spirometry outcomes (Table 8-5).  Contrary to the expectation that an elevated sRaw 
may be associated with reduced flows, there was no correlation between sReff Z Score 
and FEV1 % predicted (p=0.3, r = 1.55), or sReff.  In summary, more abnormalities (i.e. 
results falling outside the limits of normality) were detected by spirometry than sReff.  
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Figure 8-4: Comparison of sReff Z Score and FEV1 % predicted in 59 children with SCD 
and 68 healthy Black children aged 4-11y.   
Legend: Horizontal dotted line indicates the upper and lower limit of normal for sReff Z Score 
(+/-1.96SD), and vertical dotted line indicates the lower limit of normal for FEV1 % predicted. 
There was no correlation between FEV1 % predicted and sReff Z Score.  More children with 
abnormal results were identified by FEV1 than by sReff. 
 
Matched sReff and lung volume results were available in 20 children with SCD (the 
children from St Louis did not undergo sRaw measurements, and initial lung volume 
measurements in London were not accompanied by sRaw measurements).  Despite the 
limited numbers a significant correlation between FRC and sReff (r=0.58) and TLC and 
sReff (r=0.6) was observed.  No child with SCD had elevated sReff, whereas five 
children, including two symptomatic children had low sReff, however these were not the 
same children in whom FEV1 was reduced (suggesting restriction).  Those with the 
lowest TLC Z Score also had the lowest sReff Z Score, suggesting low sRaw 
measurements are associated with restrictive lung disease, potentially due to the low 
FRC values observed in restrictive lung disease. (Figure 8-5). 
 
Further evidence of restriction was shown in Figure 8-6 which demonstrated highly 
significant correlations between spirometry and lung volume outcomes. 
 
R= 0.16 
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Figure 8-5: Comparison of sReff Z Score and Lung volumes (FRC and TLC Z Scores) in 20 children with SCD aged 6-12y 
Legend: Dotted line indicates the lower limit of normal  
The two outcomes are significantly correlated; however there was no relationship between those reporting respiratory symptoms and the lung function results.  
NB: Interpretation is limited due to the relatively small sample of children in whom concordant measures were obtained. 
R= 0.58 R= 0.6 
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Figure 8-6: Comparison of FEV1 and FVC %pred and FRC, TLC and RV/TLC Z Scores in 53 children with SCD and 68 healthy Black children.  
Legend: Dotted line indicates the lower limit of normal.  Significant correlations were seen in all outcomes
R= 0.77 R= 0.56 R= -0.54 
R= 0.86 R= 0.71 R= -0.55 
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Spirometry and lung volume outcomes were compared.  No significant correlation 
between RV and any spirometric outcomes were observed (Table 8-5), hence these 
results were not plotted.  Highly significant correlations between FEV1 % predicted and 
TLC Z Score (r=0.77, p<0.0001) and FRC (r=0.56, p<0.05) were observed with an 
even greater correlation when comparing FVC % predicted with these two outcomes 
(r=0.86 and 0.71 for TLC and FRC respectively) (p<0.01).  In addition, a significant 
correlation between FEV1 and FVC % predicted and RV/TLC was observed (r =-0.54 
and -0.55 respectively) (Table 8-5 and Figure 8-6).  Those children with low FEV1 and 
FVC % predicted had concurrent reduced lung volumes (TLC and FRC) indicative of 
restriction, whereas those children with an elevated RV/TLC also had reduced FEV1 
and FVC % predicted. 
8.9 Summary 
In summary, four commercially available lung function tests were evaluated in healthy 
children aged 4 to 12 years and then applied in children with SCD to determine the 
extent to which these children had lung disease/abnormalities in lung function.  A 
respiratory health questionnaire was administered and all lung function outcomes were 
reviewed in light of the clinical symptoms.  Fifty percent of the children with SCD 
reported cough on most days, whilst 25% had been reviewed by a specialist respiratory 
consultant in the three months previous to the assessments.  Despite the relatively high 
proportion of respiratory symptoms reported, the proportion of children with lung 
function results falling outside the limits of normal was relatively small:  FEV1 % 
predicted in children with SCD was significantly reduced compared to that in control 
children, with 15% of children with SCD assessed falling below the limits of normality.  
FVC however, was reduced to a similar extent, indicative of a restrictive rather than 
obstructive pattern.  Concurrently, a group reduction in TLC was observed in children 
with SCD, and a comparison of the two lung function tests revealed those children with 
low TLCs also had reduced FEV1 and FVC % predicted. Around 20% of children with 
SCD were identified as having restrictive lung disease (defined by a reduced TLC).94   
Although lung volumes are the gold standard for identifying restrictive lung disease94 
the measurement is technically more difficult to perform, and every child with a reduced 
TLC had concurrently low FEV1 and FVC % predicted.  Thus, in this study, the use of 
plethysmographic lung volumes helped to confirm diagnosis, rather than add further 
information to the clinical picture.   
 
Whilst no group differences in sRaw were detected between healthy children and 
children with SCD, there was a trend for a slightly reduced sRaw in SCD which correlate 
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with the low lung volumes observed in these children. However, measurements of sRaw 
were not found to discriminate between healthy children and those with SCD.  
Similarly, measurements of IOS were not a useful adjunct to the lung function testing, 
as interpretation was limited due to the lack of well-defined limits of normality.  Despite 
a rough estimate of the upper limit of normal (based on the healthy children) and 
significant group differences between health and SCD, IOS outcomes did not yield any 
additional clinical information, and results did not correlate with clinical symptoms.  
 
In summary, the combination of four lung function measurements, a respiratory 
questionnaire, and a healthy control group of children of the same age and ethnicity 
revealed children with SCD to have reduced TLC, with concurrent reductions in FEV1 
and FVC.  No differences in sRaw were observed and IOS outcomes proved to be of 
limited value due to poorly defined limits of normality, and the huge scatter around the 
mean.  The highest proportion of abnormal results was detected by spirometry, and the 
only outcome that was significantly associated with respiratory symptoms was FVC.  
Children with SCD did not demonstrate clinically significant bronchodilator 
responsiveness regardless of the outcome measured.  The results from this study 
suggest a pattern of restrictive lung disease in children with SCD.   Of the outcomes 
assessed in this thesis, spirometry appears to be the most useful outcome measure for 
routine assessment of lung disease in SCD. 
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9 Discussion 
9.1 Introduction 
The overall aims of this thesis were to improve the application and interpretation of lung 
function measurements in young children and to determine the extent to which ethnic 
differences in lung function occurred between healthy Black and healthy White children 
after adjusting for height, sex and age.  A series of investigations of four commercially 
available lung function tests (Impulse oscillometry (IOS), specific airways resistance 
(sRaw), plethysmographic lung volumes, and spirometry) involving a total of 214 healthy 
Black and 186 healthy White children aged 4 to 12 years were undertaken.  In addition, 
2,872 sets of sRaw data from 2,347 children were collated as part of the Asthma UK 
Initiative to develop sRaw reference equations.   
 
As a result of the study, recommendations for the application (in terms of data 
collection and measurement conditions) and interpretation (in terms of appropriate 
reference data, limits of normality and ethnic adjustments) for each lung function test 
were made.  The lung function tests were then applied in a group of up to 85 children 
with Sickle Cell Disease (SCD) to determine the extent to which each outcome 
measure identified lung function abnormalities in these children.  Each lung function 
test was reviewed in isolation, and then in combination with the other lung function 
assessments and the clinical status of the child.  This final discussion chapter will 
summarise the principal findings of the thesis, identify the strengths and weaknesses of 
the study, compare findings with published literature, highlight the implications of the 
results and explore areas for future research. 
9.2 Principal findings reported in this thesis 
Chapter 8 summarised the principal findings of the thesis with regards to development 
of recommendations for the application and interpretation of four commonly used lung 
function tests and the application of these measurements in children with SCD, both as 
stand-alone assessments and in combination with other lung function tests and clinical 
symptoms derived from a questionnaire.   
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9.2.1 Novel findings 
This thesis comprised the largest collation of paediatric sRaw data from healthy controls 
to date, and developed preliminary sex-specific reference equations which adjusted for 
the minimal age-related changes in sReff and sRtot, along with recommendations for 
their use.128  Additional novel findings of the thesis were: 
 Resistance within the central airways was lower (significant reduction in R15 and 
R20) in children with SCD compared with healthy Black children. 
 Considerable misinterpretation of plethysmographic lung volume data from Black 
children would occur if current paediatric reference data and recommended ethnic 
adjustments were applied.  New ethnic adjustments for interpreting lung volumes in 
Black children were developed146 
 Spirometry and plethysmographic lung volumes were the most useful lung function 
assessments for monitoring children with SCD. 
9.2.2 Comparison of results to main hypotheses 
9.2.2.1 Chapter 4 hypothesis 
IOS data from healthy Black children will be significantly different to that predicted by 
reference data derived from White children 
Discrepancies between IOS predicted values based on White children41 and healthy 
Black children were observed: resistance at all frequencies were ~0.5 Z Score higher, 
and X5 was ~0.8 Z Score lower in Black children.   
9.2.2.2 Chapter 5 hypothesis 
There are no ethnic differences in sRaw between Black and White children. 
No significant differences were observed between sRaw Z Scores
128 obtained from 
healthy Black and White young children. 
9.2.2.3 Chapter 6 hypothesis 
Lung volume data from healthy Black children will be significantly lower than that 
predicted by reference data derived from White children. 
Significant ethnic differences in lung volumes occurred however the magnitude and 
direction of the differences were dependent on outcome, such that considerable 
misinterpretation of lung disease would have occurred had interpretation been based 
on White reference data98 or using the simple ethnic adjustments recommended by the 
ATS/ERS.2  There were no significant differences in RV between healthy Black and 
White children, however, TLC was found to be ~8% lower in Black children.  A 12% 
adjustment in these outcomes would have over-estimated the predicted values for RV 
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and TLC in Black children and potentially over-diagnosed obstructive lung disease 
(indicated by a raised RV) and under-diagnosed restrictive lung disease (defined by a 
reduced TLC).   Furthermore, despite the difference in FRC between Black and White 
children being similar to that indicated by the ATS/ERS2 (~6% lower in Black children), 
predicted values for FRC based on Rosenthal equations98 were found to be over-
estimated for White children, thus the extent of hyperinflation (identified by an elevated 
FRC) would be potentially misdiagnosed in these children, furthermore the degree of 
restrictive lung disease may be under-estimated. 
9.2.2.4 Chapter 7 hypothesis 
Healthy Black children will generate different predicted values and lower limits of 
normal for spirometry in comparison to those defined by previously published reference 
data based on White children.126 
The All-Age126 spirometry equations demonstrated excellent agreement with White 
children, but were not appropriate for Black children unless ethnic adjustments were 
applied.  Wang et al ethnic specific spirometry equations5 were shown to be adequate 
for interpreting spirometry in children aged 6 to 12 years.   
9.2.2.5 Chapter 8 hypothesis 
All lung function techniques of interest in this thesis will detect differences between 
healthy children and children with Sickle Cell Disease with pulmonary manifestations. 
There were no significant group differences in sRaw, although there was a tendency for 
sRaw to be lower in SCD compared to health. Furthermore, there was no significant 
difference in resistance measured at low frequencies by IOS (reflecting more peripheral 
airway calibre), whilst IOS resistance at high frequencies, which tends to reflect more 
central airway calibre, were significantly lower than that seen in health, resulting in 
increased frequency dependence of resistance (Fdr) in those with SCD.  This Fdr was 
not, however, due to the normal pattern of increased peripheral airway resistance more 
commonly seen in obstructive lung disease.   
Spirometric and plethysmographic lung volume results revealed significant group 
differences between children with SCD and healthy Black children, with FEV1, FVC and 
TLC being significantly lower in the children with SCD thus indicating a pattern of 
restrictive lung disease.  Despite a relatively high proportion of respiratory symptoms 
reported in SCD, few were on anti-asthma medication and BDR was not detected, nor 
was there evidence of airway obstruction or increased airways resistance.  Results 
suggested a pattern of restrictive lung disease in SCD and that spirometry and 
plethysmographic lung volumes were the most useful lung function tests in assessing 
children with SCD. 
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9.3 Strengths and weaknesses  
The strengths of the study include the large number of healthy Black and White 
children that undertook a series of lung function measurements which enabled an 
evaluation of the differing methods of quality control and interpretation and the 
subsequent development of recommendations for their use in children.  Furthermore by 
recruiting a large group of children with SCD of the same age it was possible to apply 
the tests and ascertain the clinical usefulness of these measurements in this disease 
group.  A major limitation of the study was the restricted age range (4 to 12 years) 
which prevented the impact of puberty on lung function being investigated.  The 
strengths and weaknesses of the study are reviewed in detail in the following sections. 
9.3.1 Study population 
The recruitment of healthy control children was a major strength of the study.  Two 
hundred and fourteen healthy Black children and 186 healthy White children aged four 
to twelve years underwent spirometry assessments and subgroups of these children 
underwent the other selected lung function tests.  The healthy Black children were 
either recruited in London schools (with a wide range of socio-economic status) or in 
the laboratory at ICH or St Louis, USA (primarily consisting of siblings/friends of 
children with SCD).  The healthy White children came from a range of previous studies 
based at ICH,16,104,129,144 and were again primarily siblings or friends of children 
attending Great Ormond Street Hospital for a range of clinical and epidemiological 
studies, and came from within a 2 hour travelling distance from London.  The exclusion 
criteria were the same for all control children:  Children with Cystic Fibrosis or SCD 
were excluded as were those with a history of asthma (doctor diagnosis or current 
(within last 3 months) bronchodilator therapy); prematurity (less than 37 completed 
weeks of gestation), previous hospitalisation with a respiratory complaint, or a past 
history of pneumonia, tuberculosis or whooping cough.  Measurements were 
postponed if the child had had a respiratory infection within 3 weeks of the 
appointment.  The standardised inclusion/exclusion criteria for all healthy control 
children and the range of projects from which they came, minimised selection bias and 
made the results more generalisable.   
 
A limitation of the study population was that ethnicity was simply defined as either 
“White” or “Black,” and Asian children were not included.  Whilst lung function 
reference data based on height and sex tend to be applicable in White European 
children of the same age and sex,126 larger differences in anthropometry have been 
observed between children of Black African and Black Caribbean backgrounds, with 
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African children being smaller and hence having a lower absolute FEV1 than their 
Caribbean peers.8  FEV1 has been shown to be 13-14% lower in Caribbean children 
and 15-17% lower in African children compared with White children of the same age 
and sex.8 These differences have been attributed to anthropometric differences in 
trunk/leg ratios between these ethnic groups,8 although chest wall dimensions are also 
thought to contribute to these differences.9  Ethnic differences in anthropometry and 
lung function have also been reported in Asian children, with FEV1 reported to be 
around 7% lower than in White children of the same age and sex.2,8 The inclusion of 
healthy Asian children however, was beyond the scope of the thesis as a primary aim 
was to interpret lung function in children with SCD (a disease predominantly associated 
with Black subjects).  Furthermore, whilst dividing the Black children into sub-groups of 
African or Caribbean origins may have provided more information regarding ethnic 
differences in growth and lung function amongst Black children, the modest sample 
size meant there was not enough power to achieve this.  The challenges surrounding 
the impact of ethnicity (and the many different ethnic groups) will be addressed further 
in section 9.6. 
 
In addition to the healthy children reviewed in this study, a large cohort of children with 
SCD was also recruited:  All eligible children from three London hospitals (St Marys, 
North Middlesex and St Thomas’) were approached, therefore sampling bias was 
minimised.  A detailed respiratory questionnaire and information regarding 
hospitalisation was documented (see appendix 6 for details), however it was beyond 
the scope of this thesis to compare extensive clinical details with the lung function 
assessments (future research directions include more comprehensive investigations of 
clinical details and lung function assessments during serial studies (section 9.6)).  The 
children with SCD presented with a range of respiratory symptoms (12% had a doctor 
diagnosis of asthma at the start of the study, however 50% reported cough on most 
days), thus enabling the lung function tests (and newly developed recommendations for 
use and interpretation) to be interpreted in conjunction with some basic knowledge of 
the clinical status of the child.   
 
The study population of both healthy children and children with SCD was a major 
strength of the study.  The healthy control group enabled investigations of current 
published reference data and guidelines to be undertaken,1,2,5,39,41,78,97,98,105,126,147 and 
where reference data and/or guidelines were unavailable or inappropriate they were 
developed,128,146 whilst the SCD group enabled the clinical applicability of these 
measurements and newly developed recommendations to be assessed.  The inclusion 
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of healthy Black children, was particularly pertinent for identifying group differences 
between health and SCD as significant misinterpretation would have occurred had 
interpretation been based solely on published reference data from White 
children,41,65,97,98,126 even after using the ethnic adjustments suggested by the 
ATS/ERS.2  The clinical implications of using reference data based on White children, 
and the appropriateness of ethnic adjustments are discussed further in section 9.5. 
9.3.2 Sample size 
Table 8-3 in chapter 8 summarises the number of children who underwent each lung 
function test at baseline, and describes the magnitude of difference that the study was 
powered to detect for each test depending on the precise sample size.  For all baseline 
measures, the number of children assessed enabled differences of 0.5 SD (Z Score) to 
be detected with 80% power at the 5% significance level, hence the significant 
differences between healthy Black children and predicted values based on White 
children in IOS outcomes, and the ethnic differences detected in plethysmographic lung 
volumes and spirometry were adequately powered, whilst the difference of 0.2 Z 
Scores between healthy Black and White children in sRaw outcomes was not 
significant.  The large sample (1908) of sRaw data from healthy White children meant 
there was sufficient power to develop reference equations for this outcome.128   
 
Reference equations for all other outcomes however could not be developed based on 
the sample size available since at least 300 local healthy controls (150 males and 150 
females) would be needed to validate published reference equations with any degree 
of certainty, as in smaller sample sizes differences of up to 0.5 Z Scores may arise 
purely by chance.156  Although the development of reference equations for IOS and 
plethysmographic lung volumes was not an aim of the study, the lack of adequate 
reference equations was a limitation to the interpretation of results. 
 
Since discrepancies between IOS results and the predicted values based on reference 
data were observed, multiple regression analysis was used to determine the impact of 
SCD on each IOS outcome.  SCD had a significant impact on IOS outcomes with 
increases in R5 values, and decreases in R15 values of ~0.06 kPa∙L
-1.s (equating to~ 
0.5 SD), and greater differences for R20, Fdr and AX was observed.  Thus, IOS was 
sufficiently powered to detect the group differences observed. However, since there 
was not enough power to develop reference equations and/or limits of normality, IOS 
could not be interpreted on an individual basis, as the limits of normality could not be 
reliably established. 
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Further limitations in IOS were found when reviewing within-subject, between-test 
repeatability and bronchodilator responsiveness.  Twenty-two healthy Black children 
underwent between-test repeatability measures, this meant there was 80% power to 
detect differences of 0.85 SD (0.102 kPa∙L-1.s in R5 values) at the 5% significance 
level, however there was no significant difference in between test repeatability (mean 
difference) of 0.0 kPa∙L-1.s in health and SCD.  Twenty-five healthy Black children 
underwent measures of BDR.  This sample size meant a difference of 0.8 SD could be 
detected with 80% power at the 5% significance level.  The difference in R5, R10 and 
R20 post bronchodilator was ~0.07 kPa∙L
-1.s (~0.5 SD).  This was neither a clinically or 
statistically significant change.   Thresholds for BDR were therefore calculated using 
Bland and Altman analysis and 95% CI were calculated for both the upper and lower 
limits of agreement to ensure that conservative limits of agreement were derived.  BDR 
was found to be of similar in both healthy children and children with SCD.  Similar 
numbers for repeatability and BDR were used in sRaw, and a similar level of BDR in 
health and SCD was observed (i.e. no significant group differences).   
 
BDR assessments were also conducted with spirometry as an outcome measure.  The 
sample size of 50 children assessed meant that a difference of 0.56 SD (equivalent to 
6.7% predicted or 22 mL) could be detected with 80% power at the 5% significance 
level.  Whilst statistically significant changes from baseline were observed in both 
health and SCD, they were not clinically relevant, nor did they meet the thresholds of 
significance (12% change from baseline and/or 200 mL increase in FEV1) 
recommended by the ATS/ERS.105  Finally there was no significant difference in BDR 
observed between health and SCD.  In summary, despite the limited numbers of 
children undergoing BDR assessments using IOS and sRaw outcomes, an adequate 
number of children underwent BDR assessments with spirometry.  All three lung 
function assessments demonstrated a similar extent of BDR in health and SCD, 
therefore demonstrating that BDR is not a common feature in those children with SCD 
assessed in this study. 
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9.3.3 Anthropometry 
Anthropometric differences between Black and White children are known to exist.8  In 
particular the trunk: leg ratio has been shown to be higher in White European children 
in comparison to children of Black origin, resulting in lung volumes being larger in 
White children compared to Black children of similar sex and standing height.4-8,150,157  
The current study demonstrated that Black children were taller, heavier and had a 
higher BMI when compared with White children of the same age (Figure 3-1).  Given 
the known anthropometric differences between Black and White children and the 
potential impact this has on lung function, it was essential to express anthropometry on 
a common scale (i.e. as Z Scores) which adjusted for differences in sex and age.  An 
advantage of this study was that it provided an opportunity to evaluate the 
anthropometric reference data available for children of different ethnic origins.   
 
In the UK, the British 1990 anthropometry reference equations based on White children 
are commonly applied,130 whereas the USA commonly use the CDC 2000 growth 
charts131 which include Black, White and Hispanic children and therefore represent an 
average from all these children.  Regardless of the equation applied, the mean height, 
weight and BMI Z Scores in the healthy children under review were significantly higher 
than the expected value of zero Z Scores (White children centred around 0.3 Z Scores, 
whilst Black children centred around 0.8 Z Scores).  This offset from zero had 
significant implications in defining the limits of normality for growth in children of this 
age group.  For example a “normal range” (defined as mean+/-1.96 SD) of -1.66 Z to 
+2.26 Z for White children, and -1.16 Z to +2.76 Z for Black children may be more 
suitable (see section 3.2.3).  Without the control group, growth restriction in children 
with SCD would have been missed as their values centred around zero, yet were 
significantly lower than the Black controls. 
 
Statistically significant mean differences between the two anthropometric equations 
were observed (mean difference ~0.1 Z Scores).  Although these differences may have 
minimal clinical significance, the Bland and Altman analysis revealed clinically 
significant wide limits of agreement (~1 Z Score) and a positive bias, with Z Scores 
calculated by the British equations130 generally being higher than those calculated with 
the CDC equations.131 The largest discrepancies between values predicted by the two 
equations were observed in Black children, who had significantly increased height, 
weight and BMI Z Scores compared to their White peers.  The discrepancies in Z 
Scores between the two equations were not surprisingly more prominent in the Black 
children when using the British 1990 equations,130 since these were based entirely on 
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White children.  The inadequacies of expressing anthropometry based on White 
reference data have been described before by Wang et al.158  These findings highlight 
the importance of selecting the most appropriate reference data as the two equations 
were not interchangeable.  Whilst the British 1990 anthropometry equations130 may be 
adequate for UK studies on White children only (for example Cystic Fibrosis 
research104), multi-ethnic  and multi-centre research studies such as the SAC study 
should use the CDC 2000131 reference equations, and ensure the same reference data 
are applied during longitudinal studies.  The offset from zero observed in this study 
should be taken into consideration when attempting to identify either growth restriction 
or evidence of obesity in children. 
 
It has been reported that White people have higher fat free masses, higher inspiratory 
and expiratory muscle pressures and wider chests than those from the other races.159  
Slight anthropometric differences between healthy Black and White children were 
observed despite using equations that included both Black and White children in the 
reference data, and expressing results as Z scores which adjusted for age and sex.131  
Despite the slight increase in height, weight and BMI Z Scores of ~0.5 Z Scores in 
Black children, there was no correlation between BMI Z Score and lung function 
outcomes.  The challenges in expressing anthropometric differences between Black 
and White children may be minimised if lung function is expressed in relation to body 
size and shape rather than just standing height.  Although now standard practice, at the 
time when most of these measurements were undertaken we did not measure the ratio 
of sitting to standing height which may contribute to ethnic differences in lung 
function.160  Protocols have since been amended to include sitting height in all future 
lung function assessments and further work including body size and composition 
studies has commenced (see section 9.6). 
 
Another possible limitation to the study were the slight differences in height Z Scores in 
healthy Black children studied in the UK compared to those studied in the USA (British 
children were ~0.4 Z Scores taller) despite identical measuring techniques.  This 
observation may represent real physiological differences between healthy children in 
the two different countries which could be a consequence of several factors including 
diet and genetic ancestry (i.e. the difference between Black-British and African-
American) which could not be investigated in the current study but will be investigated 
in the future.  Despite these anthropometric differences, no difference in lung function 
was observed once results were adjusted for height, age and sex.  
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9.3.4 Age range 
Ideally the research questions should have been addressed in a wider age range to 
encompass children from 3 to 18 years of age. However, practical limitations restricted 
the age range assessed.  The Asthma UK initiative was a collaborative study which 
collated normative data in children aged 2 to 11 years and the subsequent reference 
data and recommendations were based on children aged 3 to 10 years, hence the 
study of contemporaneous healthy Black children and children with SCD had to be 
limited to a similar age range.  Similarly the IOS reference data by Dencker et al41 were 
also limited to young children less than 11 years of age (the Nowowiejska equations,65 
which extended to 18 years, were found to be unreliable (chapter 5)).  Finally, there 
was an opportunistic approach in combining healthy children recruited for the SLIC 
study (which was limited to primary school children to minimise education disruption).  
While results from this study are not applicable to adolescence where considerable 
growth and development of the respiratory system occur,3 data describing ethnic 
differences in lung function during adolescence are available.157  We therefore 
focussed on age groups where measurements were most challenging and information 
most lacking. 
 
The lower age limit in the study differed depending on the lung function test studied, 
hence interpretation of some pre-school lung function was limited. Objective 
assessments of lung function in the pre-school years are important for understanding 
normal growth and development of the respiratory system as well as the evolution and 
natural history of disease processes.  Furthermore, lung function has been shown to 
track throughout childhood,161 hence early identification of lung abnormalities are 
essential for optimising clinical management.  IOS and sRaw measurements included 
children as young as four years of age.  Spirometry has been demonstrated to be a 
feasible outcome measure in pre-school children,1,83 and was successfully undertaken 
in all children greater than four years of age. However, interpretation of spirometry in 
children less than six years of age was not possible because of the lack of ethnic 
specific reference data (Wang equations reported results down to six years only5).  
Similarly, despite the apparent successes of some groups obtaining successful 
plethysmographic lung volume measurements in pre-school children,162 it was not 
attempted in children less than six years of age due to the technically challenging 
nature of the test, especially when a complex protocol was being undertaken.  Black 
pre-school children assessed in this study therefore only undertook two of the four 
investigated lung function tests (IOS and sRaw).  Neither measurement proved useful in 
the assessment of children with SCD.   
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Spirometry results from children aged six years upwards in this study revealed 
significant differences between healthy children and children with SCD (FEV1 and FVC 
were significantly lower amongst children with SCD).  Spirometry may yet prove to be 
the most useful test to assess pre-school children with SCD, but this cannot be 
ascertained until the Global Lungs multi-ethnic equations are released 
(www.lungfunction.org).  Until that time a temporary solution was proposed in terms of 
using an ethnic adjustment of 0.85 for FEV1 and 0.87 for FVC (i.e. dividing the results 
by 0.85 or 0.87 respectively before applying the All-Age Stanojevic equations).126  
Bland and Altman analysis revealed no bias among the older subjects studied between 
percent predicted results calculated according to Wang et al5 and those calculated from 
the All-Age126 (adjusted) equations.  Results would, however, need to be interpreted 
with caution especially when switching to Wang equations at six years of age due to 
the known potential problems which may occur when switching between reference 
equations.151,153,154   
 
The upper age limit for the study of the healthy children was 12 years.  With the 
exception of sRaw, which demonstrated minimal age-related changes, the upper age 
restriction limited interpretation in all measurements.  In IOS significant frequency 
dependence of resistance (Fdr) was observed in both health and SCD, however it was 
more pronounced in children with SCD.  Fdr is generally associated with peripheral 
airway obstruction in adults,124 however Fdr is also a common feature in healthy 
young/small children since it reflects the relative increase in peripheral airway 
resistance compared with resistance in the more central airways.  This may be a 
reflection of the dysanaptic growth occurring in which lung volume (alveolar growth) 
increases at a greater rate than airway size,3 however the magnitude of flow/pattern of 
flow and the involvement of turbulent flow can also contribute to the differences 
between peripheral and central airways resistance. Several studies (based on White 
subjects) have demonstrated that significant Fdr occurs naturally in healthy young 
children, however by ~13 years IOS resistance values are similar to that found in 
adults, with no evidence of Fdr in healthy adults.38,51,52,57  Since anthropometric 
differences were observed between both healthy White and Black children, and healthy 
Black children and children with SCD, it was not possible to determine whether the Fdr 
observed in SCD had some pathophysiological basis (i.e. greater peripheral airway 
obstruction) or was simply a function of these anthropometric differences.  The lack of 
appropriate reference data for IOS across the ages and ethnicities was a further 
limitation of this measurement. 
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There was no relationship between the calculated Z Scores for spirometric or 
plethysmographic outcome measures and age in the healthy children assessed 
suggesting the reference equations applied were appropriate across the age range 
studied (6 to12 years).  The important physiological changes that occur during the 
pubertal growth spurt, and their potential implications on lung function, could not be 
assessed in the current study, but have been described recently.3  Quanjer et al 
compared FEV1/FVC ratio against age in 22,412 healthy subjects aged 4 to 20 and 
found a “kink” at puberty, which was thought to reflect changes in chest dimensions 
and respiratory mechanics during puberty.3  This age dependence of lung volumes was 
also observed in RV/TLC, and similar patterns of growth and development were 
observed across different ethnic groups, however there was a notable offset, 
highlighting the importance of using ethnically appropriate reference equations.  
Although the reference equations used in the current study appeared to be adequate 
(with the exception of FRC which required some adjustment factors), the applicability of 
these equations in older children, where rapid changes in airway properties, body 
proportions, thoracic shape and respiratory muscle function are occurring could not be 
assessed.  Furthermore it was likely that some of the children in this study would have 
already entered puberty.  Although pubertal staging was not included in the original 
part of the protocol, future studies will include Tanner stage pubertal questionnaires57,58 
and further comparisons of teenage children and investigations into the relationships 
between lung and somatic growth are currently being undertaken (see section 9.5.2.1). 
 
Despite the limited age range, results from the study improved the application and 
interpretation of the selected lung function tests in young children.  Whilst the 
interpretation strategies are limited to the age-range studied, recommendations for 
applying each lung function test may prove to be a useful starting point for developing 
recommendations which encompass all ages. 
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9.3.5 Study protocol 
A major strength of the study was the standardised protocols used for all 
measurements which enabled direct comparisons between healthy children and 
children with SCD and ensured that any differences detected were real physiological 
differences, and not simply a consequence of differing methodology.  The following 
sections describe the strengths and weaknesses surrounding the study protocol, 
paying particular attention to the quality assurance that enabled inter-centre 
comparisons together with justification for why specific lung function tests were 
selected, while others were omitted. 
9.3.5.1 Quality assurance 
The stringent quality assurance applied to all measurements was of considerable 
advantage for this study.  Where guidelines, standards or information were missing, 
investigations were conducted so that new or amended guidelines could be developed.  
Strict adherence to protocol has been a policy at ICH for several years, and therefore 
enabled data from healthy White children previously studied at ICH to be included in 
the comparisons without creating a bias. 
 
The importance of biological controls, and standardising equipment and internal 
settings was demonstrated by Poorisrisak et al, who recruited seven young children 
aged 4.9 to 6.6 years to act as biological controls to repeat plethysmographic 
measurements in six centres and found sRaw results to be significantly lower in two 
centres due to a difference in factory settings.163  Although it was not possible to have 
international biological controls, within-centre adult biological controls served as a 
verification of equipment accuracy, and a central over-read process enabled a rapid 
response to any potential equipment/protocol problems.  In contrast to a recent report 
which found subtle inter-centre differences in lung volumes despite identical 
protocols,164 no between-centre differences were detected in this study, despite the use 
of different plethysmographs (UK utilised Jaeger, whilst the USA utilised the Sensor 
Medics body box). 
 
Anthropometric differences in healthy children studied between centres were observed 
despite identical measurement protocols, equipment and regular calibration.  After 
making adjustments for height, age and sex, there were no differences in lung function 
amongst the healthy children assessed in different centres, thus suggesting the 
observed anthropometric differences reflect real population differences rather than 
differing measurement techniques.  The importance of accurate measures of height 
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and of expressing anthropometry in Z Scores using appropriate reference data, was 
recently highlighted by Quanjer et al who recently re-calculated predicted FEV1 and 
FVC values from 26,321 healthy White children (51% male) aged 6 to 19 years using 
whole numbers for age (years) and height (cm) compared with decimal age and height.  
They demonstrated that inaccurately entering age and height into prediction equations 
led to considerable additive errors in predicted lung function values such that a 1 cm 
error in height resulted in errors in spirometric outcomes varying between 1.2 and 
3.0%.153 All stadiometers underwent regular verification checks with a standard 
measuring rod, and staff were trained to ensure accurate measures of height were 
obtained.   
9.3.5.2 Inter-centre comparisons 
Results from this study demonstrated that with strict adherence to protocol, within-
centre biological controls and prospective over-reading with rapid feedback; there was 
no bias between results collected in different laboratories in the USA and UK, and 
between spirometry results collected in London schools when compared to those 
measured in a specialised paediatric lung function laboratory.  The inter-centre 
comparisons proved to be vital in demonstrating the generalisability of the results, and 
added confidence that results obtained in this study can be applied in other centres, 
providing protocols are adhered to. 
 
In addition to the prospective data collection, and inter-centre comparisons (London 
school Vs. London laboratory Vs. St Louis Laboratory (section 7.6.1)), retrospective 
sRaw data collated from five international centres were compared as part of the Asthma 
UK Initiative to develop reference equations.  This was the largest collation of sRaw 
normative data to date.  The advantages of this study were that it allowed different 
methods of data collection and analysis to be scrutinised, and consensus 
recommendations to be developed.  The disadvantage of this study was that the 
retrospective nature of the data collection meant that two centres had to be excluded 
due to methodological differences.  Interim recommendations and reference equations 
were however developed which were important for the prospective data collection 
which followed, and further recommendations will be made in the near future (see 
future work, section 9.6). 
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9.3.5.3 Limitations of the study protocol 
The study protocol was devised by the SAC team and took approximately 90 minutes 
to undertake the lung function assessments in addition to the study questionnaire and 
included assessments of children with SCD and healthy Black children.  Of the four 
lung function tests under investigation, IOS was the only assessment which was new to 
ICH and hence had no retrospective controls (Black or White) to validate the methods.  
The lack of a White control group limited the interpretation of IOS results in Black 
children since the differences observed could not be proved to be due to ethnic 
differences alone.  IOS was part of the SAC protocol which originally only assessed 
children with SCD.  A further limitation of IOS was associated with data management.  
Despite the potential usefulness of IOS in differentiating asthma from healthy White 
children,45,47,67,68 the limitations surrounding data extraction and reference data means 
that IOS is not considered to be a useful clinical test for children with SCD at the 
present time. 
 
In addition to the lung function assessments evaluated in this thesis, the children with 
SCD also underwent echocardiograms, over-night sleep studies, methacholine 
challenges, and blood tests (results not included in this thesis).  Whilst extending the 
lung function assessments to include multiple breath washout technique (MBW), 
resistance measured by the interrupter technique (Rint), Diffusion capacity of the lung 
with carbon monoxide (DLCO) and measurements of exhaled nitric oxide (eNO) may 
have enhanced the clinical picture, lengthening the protocol was not feasible.  
Justification for the selection of the four lung function tests which were investigated can 
be found in the introduction (section 1.11).   Ideally measurements of DLCO, and KCO 
(gas transfer per unit lung volume) would have been included as they have been 
shown to distinguish between healthy Black children and SCD,165 however the 
technique is difficult to perform in children less than eight years, and paediatric 
guidelines are limited.120 Furthermore, reference data have been shown to be 
inappropriate in White children16 and ethnic differences have yet to be delineated.  It 
was beyond the scope of this thesis to develop new guidelines and reference data for 
this technique.   
 
Measures of airway inflammation (e.g. eNO39,40) and hyper-responsiveness (e.g. 
methacholine challenge testing166) were not included in this thesis, however a subset of 
the SCD children had undergone these measurements as part of the SAC study.  While 
over half the children assessed demonstrated significant airway hyper-responsiveness, 
this was not related to the typical characteristics of asthma (i.e. respiratory symptoms, 
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markers of inflammation (eNO), positive response to skin tests to aeroallergens, and 
reduced FEV1), suggesting a different pathophysiology from common childhood 
asthma.167  Whilst performing measures of DLCO and methacholine challenges in 
children with SCD may elucidate the pathophysiological mechanisms in SCD, these 
measures were beyond the scope of the thesis which was primarily to improve the 
application and interpretation of four commercially available lung function tests that are 
commonly applied in young children. 
 
SCD is associated with repeated lung injury, and further characterised by haemolysis, 
endothelial cell dysfunction, vascular disorders and leucocytosis.  There is also much 
evidence that acute chest syndrome (ACS) is associated with a reduction in lung 
function,168  with repeated episodes of ACS resulting in scattered areas if lung 
fibrosis,169 and evidence of restrictive lung defects in adults.169,170  Although details 
regarding these symptoms were collected as part of the SAC study, these details were 
not available at the time of writing this thesis and will be reviewed in the future.  Despite 
the limitations described previously, this study described appropriate measures of data 
collection and analysis and, by standardising these methods, proved that these 
methods can be reliably applied in other centres.   
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9.4 Comparison of results from current study with previous 
literature 
The overall aim of the thesis was to improve the application and interpretation of 
paediatric lung function tests.  The following sections compare the results obtained in 
this study with those published in the literature and focuses on published 
guidelines/recommendations, and normative data for each lung function test.  
Repeatability and the bronchodilator response for each outcome are then evaluated 
followed by a comparison of the lung function results obtained in the SCD children 
studied for this thesis with those reported in elsewhere. 
9.4.1 Impulse Oscillometry 
9.4.1.1 IOS: Published guidelines 
Impulse Oscillometry (IOS) is a commercially available, effort-independent lung 
function test which measures respiratory mechanics.  Whilst there are some published 
guidelines available which generally describe how to optimise data quality by observing 
the real-time volume/time display to identify data corruption (i.e. airflow leak due to 
talking, chewing, swallowing etc),1,39 there is no international consensus on quality 
control.38  Some research groups exclude entire measurements if there was any 
evidence of airflow leak36 whereas others suggest editing/selecting “acceptable” 
segments.41 The current study developed an over-read criteria based on the literature 
and personal correspondence from the late Dr Michael Goldman.  Results from the 
majority of children met the specified criteria, however since the physiologists were 
specially trained to perform online QC (i.e. coaxing the child) and were aware of the 
QC criteria that would be applied after the measurement, our ability to assess the true 
impact of applying such criteria to more naïve investigators was somewhat limited. It is 
expected that fewer children would meet the QC criteria, or data would have required 
more editing had the measurements been undertaken by less experienced 
physiologists.   
 
 A comparison of results before and after carefully applying the QC criteria revealed no 
difference in the results, and just a small reduction in the within-test SD.  Whilst 
minimising within-test SD is potentially useful for research studies, the small difference 
to SD observed in the current study was probably not clinically relevant, and the time 
spent applying this quality criteria (about 10 minutes per measurement session) would 
not be clinically feasible for routine use.  The overall recommendations for performing 
IOS based on the current study and the published literature are to ensure 
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measurements are undertaken by an experienced, trained operator and undertake as 
much online QC as possible (i.e. coaxing the child into a gentle breathing pattern as 
described in the methods section 2.6.4.4). 
9.4.1.2 IOS: reporting results 
A secondary aim when reviewing IOS was to describe the most appropriate method of 
summarising the results and to ascertain appropriate outcome measures.  Whilst the 
average of three44 to five171 IOS measurements (i.e. up to 90s continuous recording of 
tidal breathing) have been suggested, the current set-up of IOS software displays just 
one measurement at any given time, and subsequent attempts are stored as separate 
measurements thereby limiting the ease with which reports can be generated.  
Reporting the median of three measures was the simplest and fastest method of 
reporting IOS results as it was relatively easy to select the “middle” result of three (or 
five) measurements, and no statistical differences (p<0.0001) were observed between 
reporting IOS outcomes as mean or median of three measures. 
 
IOS outcomes can be measured at several different frequencies (5-35Hz), with the 
general assumption that high frequency oscillations (e.g.>20Hz) remain  in the upper 
airway and hence reflect  resistance in the more central airways, whereas low 
frequency oscillations (5Hz) can be transmitted through the upper airways towards the 
lung periphery and therefore reflect  a combined resistance of the peripheral and 
central airways.38  Whilst this potentially provides useful information regarding different 
regions of the respiratory system, and it is common to describe resistance and 
reactance at discrete frequencies,67,172-174 more informative outcomes may be those 
which describe the difference between R20 and R5 (Fdr5-20) and the area under the 
reactance curve from X5 to Fres (AX).  Where Fdr5-20 may help to discriminate peripheral 
resistance from the central resistance (as R5 reflects information on both central and 
peripheral airways), and AX represents an average of all the low frequency reactance 
applied, both outcomes have the advantage of exaggerating subtle changes in 
resistance or reactance at different frequencies and therefore represent more 
discriminative outcomes.  These outcomes have been used in a few recent 
studies124,175,176 and have been proposed as the better indicators of uncontrolled 
asthma, compared to resistance measured at discrete frequencies.176  In the present 
study Fdr5-20 and AX identified larger group differences between healthy Black children 
and children with SCD than when reporting resistance and reactance at discrete 
frequencies, and were more repeatable measures.  Fdr and AX were therefore 
suggested as the preferred IOS outcome measures. 
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9.4.1.3 IOS: Normative data 
To date five IOS reference equations have been published,41,62-65 none of which were 
based on Black children.  When attempting to  select the most appropriate reference 
equation to apply, the Chinese63 and Iranian64 reference data were excluded from the 
outset as they used linear stepwise multiple regression to develop the reference 
equations i.e. separate equations for each year group which potentially introduces 
errors when “progressing” to another age/reference equation.177 In addition, the authors 
specified that these equations were “suitable for children in their local area” and hence 
they were not considered to be appropriate for the Black population in this study.   
Since reference equations by Frei et al62 were considered too restricted in terms of 
height range (100-150cm), only two equations based on White children were 
reviewed.41,65  Discrepancies between these two equations meant they were not 
interchangeable.  Despite divergences from the expected mean zero Z Score observed 
in the healthy Black children, the investigations suggested that the equations by 
Dencker et al41 were the more appropriate, although still limited by the lack of  
equations for AX, and Fdr.  Furthermore the lack of IOS data from healthy White 
children prevented the impact of ethnic differences to be determined. 
 
As described earlier, Fdr is significant in early childhood,51,52 however, by ~15 years of 
age all Fdr disappears and resistance in a healthy adult is considered to be constant 
(~0.25 kPa∙L-1.s) at all frequencies.178  For this reason, many adult studies make direct 
comparisons between absolute results from subjects of the same age without 
expressing results as Z Scores.38,179  Comparison of absolute values rather than Z 
Scores in children is however, inappropriate because of the known age-dependent Fdr.  
An example of this inappropriate interpretation comes from Shi et al, who, despite 
describing significant correlations between IOS outcomes and height and age, and 
referencing the five reference equations described above, chose to interpret results 
based on absolute values merely stating “caution should be exercised in using absolute 
values for cut points in children who differ in age or height.”176 Despite the limitations of 
currently available IOS reference data, an effort to express results as Z Scores (and 
therefore make some adjustment for differing height and age) should be made. 
 
IOS is considered to be less technically demanding than spirometry, and has been 
shown to discriminate asthmatic children from healthy children.45,47,67,68 It is also argued 
that IOS provides more information about the peripheral airways which is not provided 
by spirometry.  However, given the limited use in SCD and the fact that success rates 
are similar to spirometry, its use in clinical practice remains doubtful. 
 305 
 
 
The current study has advanced the field of impulse oscillometry measurements 
in children by: 
 Developing recommendations for the application and data reporting of IOS 
measurements 
 Highlighting the inadequacies of current reference data.  
 
9.4.2 Specific airways resistance 
9.4.2.1 sRaw: published guidelines 
Plethysmographic Specific Airways Resistance (sRaw) is a measurement of airway 
resistance corrected for lung size, which is measured during tidal breathing from the 
relationship between simultaneous measurements of airflow and the change in 
plethysmographic pressure (as a reflection of alveolar pressure) without the need for 
any special breathing manoeuvres against an airway occlusion.77  The equipment is 
commercially available and the feasibility of applying this effort-independent 
measurement in young children is very good.78  No children participating in this study 
were excluded due to “unacceptable” results. 
 
Prior to the inception of this thesis, there were no official guidelines for sRaw 
measurements, consequently, reported values of sRaw had been collected under a 
variety of differing measurement conditions such as use of a re-breathing bag or 
panting technique to achieve body temperature, pressure, and water vapour saturated 
(BTPS) conditions80 versus quiet tidal breathing with subsequent electronic 
compensation for changes in temperature and humidity throughout the breathing 
cycle;79 modified masks82 vs. mouthpieces;83 use of bacterial filters or not; and a variety 
of breathing patterns and frequencies.81  Furthermore differences in selecting/modifying 
the pressure-flow loop, methods of reporting86,87 and the use of different outcome 
measures for sRaw were apparent.
78,180-182  The current study collated and evaluated 
sRaw data from five international centres which all used the same equipment (Jaeger, 
Carefusion).   
 
Recommendations for standardising measurements of  sRaw in children were 
developed.128  These included using equipment that encompasses electronic 
compensation, (since methods of achieving true BTPS conditions are largely redundant 
in the modern age), and using bacterial filters with appropriately sized mouthpieces and 
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noseclips (rather than a  modified mask82) since these are now used routinely for many 
preschool lung function  tests1 as well as in older children.  Although not undertaken as 
part of this study, direct comparisons between results obtained with a modified mask 
and mouthpiece found no difference,145  findings that were supported by the similar 
values of sRaw (within 0.1 kPa∙s) between centre 4 (mouthpiece) and centres 2 and 5 
(mask) in the current study.  Previous studies in children have reported statistically 
significant, though clinically unimportant, alterations in spirometric flows and interrupter 
resistance when filters are used.183,184  To adjust for the potential change in resistance 
provided by a filter, the Jaeger equipment has a checkbox in the internal settings to 
confirm a filter is in situ.  Although the effect of filters was only investigated in a 
relatively small group of adults in this study (see appendix 3), there was a clear 
increase in sRaw with the filter in situ. With an average FRC of 3.1L in these adults and 
a mean increase in sRaw of 0.19 kPa∙s, this equated to a change in Raw of 0.06 
kPa∙L -1.s, which was in keeping with the manufacturer’s claim that bacterial filters add 
no more than 0.1 kPa∙L -1.s to the resistance (Air Safety LTD, Lancashire, UK).  
Nevertheless, the impact on sRaw equated to 1 SD of between-subject variability in 
health which could result in overestimation of sRaw and potential over-diagnosis if filters 
are used without adjusting the internal settings to specify for a filter in situ in patients 
with lung disease (as most infection control policies now dictate), but not in the healthy 
controls from whom reference data are derived.   
 
One of the most significant findings of the sRaw study was the impact of changes in 
breathing pattern and airflow on the results.  It has been suggested that breathing 
frequency can have a marked impact on measured values of sRaw,
81 thus all 
collaborating centres adhered to the sRaw recommendations for breathing frequency 
(30 and 45bpm).  However, an elevation of breathing pattern in terms of flows attained 
and breathing frequency demonstrated that the majority of children aged 4 to 11 years 
adopted a breathing pattern which had a netflow <1.5L∙s-1 and breathing frequency 
<50bpm, and results suggested that healthy children may breathe at higher breathing 
frequencies without increasing sRaw values.   
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9.4.2.2 sRaw: reporting results 
Various outcome measures and the method of reporting these were investigated.  
Whilst sReff was the preferred outcome because it is calculated as a regression of 
pressure and flow over the entire breathing cycle and may therefore provide more 
information than sRtot (calculated between points of maximum plethysmographic (box) 
pressure) it was demonstrated that they were highly correlated and that one could be 
predicted from the other.  Given that in the past different research centres have 
reported sRaw as either sReff or sRtot 
83,129,141 and the limited evidence as to which is the 
most discriminative in various disease processes, it was recommended that both 
outcomes be reported for the foreseeable future. 
9.4.2.3 sRaw: Normative data 
Part of this thesis was dedicated to the development of sRaw reference equations 
(created by Dr Sanja Stanojevic).128  The new equations, however, included the caveat 
that they could only be applied to populations that had been measured using the same 
methodology and similar demographics (e.g. White children aged 3 to 10 years), and 
were for these reasons an interim solution.  Nevertheless, these preliminary equations 
were far more appropriate than those currently available in Jaeger equipment. The 
“Jaeger-kids” for children aged 4 to18 years, and “Jaeger” for those >18 years were 
based on data collected under BTPS conditions over 30 years ago80 and have identical 
predicted values for sReff and sRtot, whereas we found sReff to be significantly lower than 
sRtot. Furthermore the ‘Jaeger-kids’ predicted values of 0.51 kPa·s for girls and 0.53 
kPa·s for boys <18 years significantly under-estimated the actual values observed in 
healthy children in this study, which were collected using electronic compensation. If 
the interpretation had been based on the default reference data within the equipment, 
serious over-estimation of the degree of airway obstruction in children with lung 
disease would have occurred.  Whilst we observed a very gradual decline in the 
predicted values with age, the Jaeger equations suggest that there is a sudden (and 
physiologically implausible) increase in predicted values to 0.96 kPa·s for females and 
1.18 kPa∙s for males from 18 years of age onwards.   
 
In contrast to other lung function outcomes, ethnic group did not appear to influence 
measures of sRaw.  This lack of ethnic differences in sRaw has been reported previously 
for Asian preschool children185 and was an expected finding since sRaw is the product 
of FRC and Raw, and therefore internally adjusts for any ethnic differences in resting 
lung volume.  sRaw could therefore be interpreted with some confidence in children with 
 308 
 
SCD.  To date there are no other published studies of young children with SCD 
undergoing sRaw measurements.   
 
This study advanced the field in sRaw measurements in children by: 
 Providing the most comprehensive guidelines and reference equations to 
date.128  
 Demonstrating that ethnic differences in sRaw do not exist.   
 Providing confidence that sRaw data can be reliably applied and interpreted in 
young Black children using the recommendations and reference data 
developed.128  
 
9.4.3 Plethysmographic Lung Volumes 
9.4.3.1 Lung Volumes: Published guidelines 
Plethysmographic lung volume assessments measure the total volume of gas in the 
lungs at end expiration, including any gas trapped behind closed airways and are the 
gold standard for diagnosing restrictive lung disease.2  The full assessment protocol 
can be found in the methods section 2.6.6.  Given the challenging nature of breathing 
against an occlusion, the measurement is rarely performed below the age of six years.  
 
International guidelines for the application of lung volumes are based on adults,94 and 
no modifications to these guidelines have been made to adjust for potential differences 
in children.  The evaluation of the applicability of these international standards in 
children undertaken in this thesis found that total over-read scores were similar in 
health and disease, and across the age range assessed, therefore no modifications to 
these standards were made.  These results supported findings by Vilozni et al who 
investigated the feasibility of performing plethysmographic lung volumes in very young 
children (aged 3 to 7)162 and found that adult acceptability guidelines were sufficient for 
this age group, with a reported 70% success rate.162  Adequate training time (Vilozni 
reported~15 minutes to teach the child the complex techniques), equipment 
modifications (such as adjusting the chair height and ensuring the flow sensor was 
accurate at low flows) and reference data in very young children are the main keys to 
accurate measurements and appropriate interpretation of results when using this 
technique.162  Given the use of lung volumes in identifying restrictive lung disease, 
particularly in SCD, further work to establish ethnic-specific normative data is 
warranted. 
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9.4.3.2 Lung Volumes: Normative data 
Lung volume reference data in children are limited and ethnic differences are not well 
defined.2   Although plethysmographic lung volumes are considered to be  the gold 
standard lung function test when diagnosing restrictive lung disease,2 interpretation 
was shown to vary widely depending on which equation was applied (i.e. those by 
Zapletal et al97 (commonly used in the USA) or those by Rosenthal et al98 (currently 
recommended by the British Thoracic Society)).  The equations by Zapletal97 were 
considered to be the least reliable of the two reference equations as they were derived 
from a small sample of White children (86 boys and 87 girls) measured over 40 years 
ago before international guidelines regarding standardised protocols had been 
published, and using equipment that is no longer available.  Results from the current 
study were therefore expressed as Z Scores (and % predicted) according to equations 
derived by Rosenthal et al, which were based on 772 White children aged 4 to 18 years 
and modern equipment.98  
 
As expected, results from this study demonstrated good agreement with the reference 
data for RV and TLC in the White children assessed, however FRC was found to be 
over-estimated by ~9% (i.e. mean % predicted FRC in our sample was only 91%).  
This discrepancy has been reported previously,16,99,104 and has important implications 
since clinical evidence of hyperinflation or gas trapping may be missed unless this bias 
is taken into account.  The difference in FRC observed may reflect a change in protocol 
during recent years, whereby subjects are no longer required to pant rapidly for airways 
resistance measurements immediately prior to the airway occlusion for thoracic gas 
volume manoeuvres, a practice that may, in the past have led to elevated resting lung 
volumes.   
 
The difficulties in interpreting plethysmographic lung volume data are further 
complicated when investigating Black children.  FRC and TLC were found to be 14% 
and 6% lower respectively in Black children than predicted by Rosenthal equations, 
such that measured values would need to be divided by 0.86 and 0.94 respectively 
prior to calculating % predicted values, whereas RV and RV/TLC respectively were 4% 
and 10% higher.  Ethnic differences in lung function have been described 
previously,150 with lung function reported to vary between 10% to 25%.10 The 
ATS/ERS 2005 Interpretative strategies for lung function tests suggest ethnic 
adjustment factors of ~12% reductions for TLC, FEV1 and FVC and ~7% for FRC in 
Black subjects,2 whilst most commercial lung function devices simply apply a fixed 
ethnic adjustment of 12% reduction on all parameters for Black children.  Results from 
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this study demonstrated that ethnic differences differed in magnitude and direction and 
were dependent on the outcome investigated.  Using the Rosenthal98 reference 
equations directly, without an ethnic adjustment would have resulted in an over-
diagnosis of obstruction/gas trapping (elevated RV/TLC) in SCD.  By contrast, 
application of the 12% reduction (as recommended by the ATS/ERS2 and 
implemented by the equipment) would have resulted in the under-diagnosis of 
restrictive lung disease (reduced TLC) and over-diagnosed obstruction (raised 
RV/TLC) in SCD.  Although currently based on a relatively small sample size, the 
ethnic adjustments derived from the healthy Black children assessed in this study 
appeared to be the most robust method of identifying changes in lung volumes 
amongst children with lung disease.  Given the limitations of ethnic adjustment 
factors107 there is an urgent need to establish new plethysmography lung volume 
equations which span all ages (like the All-Age spirometry equations126).  
 
This study advanced the field of plethysmographic lung function measurements 
in children by: 
 Providing further evidence that young children can perform the 
measurements and meet adult standards94   
 Quantifying ethnic differences for each lung volume outcome146  
 Preventing under-diagnosis of restrictive lung disease which would have 
occurred had current guidelines been followed94 
 
9.4.4 Spirometry 
9.4.4.1 Spirometry: Published guidelines 
Spirometry is a commercially available, effort-dependent lung function test shown to be 
feasible in children from three years and older in both health and disease.83,111,186-188  
Published guidelines for both adult105 and  pre-school children1 were available for 
spirometry at the inception of this thesis, and modifications of these guidelines were 
made to ensure they were applicable for children assessed in the current study.111  No 
child assessed in the current study had unacceptable spirometry, and no further 
recommendations regarding quality control and repeatability for spirometry were made 
as a result of this study.  Although data were not scored, all measurements underwent 
a central over-read process by an experienced respiratory physiologist (JK and PB (St 
Louis)), and future work will involve scoring spirometry in the manner suggested by 
Enright et al.106 
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The importance of over-reading spirometry was highlighted recently by Hankinson et al, 
who reviewed the appropriateness of the spirometry QC criteria defined by the 
ATS/ERS105 by comparing spirometry QC scores derived automatically from a 
computer with scores determined by an experienced physiologist. Spirometry results 
from 1456 healthy adults previously accepted into the NHANES107 dataset were re-
reviewed by Hankinson.  Whereas the computer rejected around a third of results 
primarily due to failure of end of test criteria (FET >6s or no change in volume (<25mL) 
for >1s), the human over-view only rejected 3-5%.189 These results highlight the 
potential problems with relying on computers/strict guidelines to determine acceptability 
of spirometry data and stress the importance of ensuring an experienced reviewer 
over-reads all results. All spirometry results in this study met the standards described in 
the methods (section 2.6.7) and are published in Pediatric Pulmonology.111 
9.4.4.2 Spirometry: Normative data 
A plethora of spirometry reference data for children are available151 with the most 
comprehensive reference data to date being the All-Age equations.126 For Black 
children reference data for children aged 6 to 18 years by Wang et al5 are available, 
additionally NHANES III equations for Black children >8 years107 can be applied, 
however those would have excluded a large proportion of the population studied and 
were therefore not used. 
 
The ethnic-specific spirometry equations by Wang et al5 proved a good fit for White and 
Black children, with mean results from our healthy children approximating 100% 
predicted in the age range assessed.  The Wang equations are, however, limited to 13 
step-wise sex-specific equations for each year of age from 6 to 18 years for each 
ethnic group.  Extrapolating beyond these age-ranges is not recommended,125  and 
therefore these equations are not suitable for the increasing number of preschool 
children now undertaking such tests.1  A temporary solution to this problem could be to 
use the Stanojevic equations with appropriate adjustment factors for Black children less 
than 6 years, albeit with caution due to the known  potential problems which may occur 
when switching between reference equations.151 A recent letter to the ERJ highlighted 
the importance of continuous reference equations by describing the case of an 18 year 
old male with cystic fibrosis who had serial spirometry measurements post lung 
transplantation.154  His progress post-transplant had been generally good, with only one 
instance of severe respiratory compromise aged 17 years when his FEV1 had dropped 
to 57% predicted.   Upon turning 18 years of age, the default spirometry reference 
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equations within the spirometer automatically converted from paediatric (Rosenthal190) 
to adult (ECCS112) reference ranges, resulting in an apparent clinically significant 
decrease in FEV1 percent predicted (82% predicted to 58% predicted) which would 
normally trigger an urgent admission and invasive evaluation.  The observed 
differences occurred because the paediatric spirometry reference equations used by 
Rosenthal190 were based on height alone with different equations pre and post puberty 
(pubertal break points at 152.5cm for girls and 162.5cm for boys).  If a child is 
particularly short for age, their results may be calculated on the “pre-pubertal” 
equations, with under-estimation of their predicted value.154 Given that many children 
with lung disease have some degree of growth restriction, as found in the current study 
and elsewhere,136 the potential for under-estimating predicted (and hence over-
estimating  percent predicted) values using spirometry reference equations based on 
height alone (e.g. those by Rosenthal190) or step-wise equations which have distinct 
“break-points” at each age (e.g. those by Wang5) limits the use of these equations and 
highlights the importance of the All-Age126 reference equations which provide smoothly 
changing curves to describe the transition between childhood and adulthood and adjust 
for both height and age.    
 
The current study has advanced the field of spirometry in children by: 
 Highlighting the challenges of interpreting spirometry in non-White children 
 Developing recommendations for interpreting spirometry in Black children146  
9.4.5 Repeatability and the bronchodilator response 
Within-test repeatability reflects the consistency of the subjects effort (e.g. used to 
determine if flow limitation is achieved during spirometry assessments); the instability 
of intrinsic biological factors (e.g. a stable breathing pattern to determine FRC) and the 
precision of the LFT device used.  A strength of the study lay in the fact that each lung 
function measurement was repeated several times at baseline which enabled the 
within-test repeatability to be calculated and compared to that previously published. 
 
Within-test repeatability may be expressed in absolute terms, as a within-subject SD or 
as the coefficient of variation (CV), which is the SD expressed as a percentage of the 
mean.  In IOS assessments, the most repeatable outcome measure was R10 which had 
a within-test CV of ~5%.  This finding was much lower than recent findings by Shi et al, 
who suggested that a within-test CV of 10% for R10 to be adequate
176  but similar to 
that reported by Dr Goldman.43,124  The lower CV reported in the current study, and 
studies by Dr Goldman et al, may be the result of strict QC (which was derived in 
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consultation with Dr Goldman) and was shown to minimise within-test variability.  
Careful attention to within-test QC in sRaw and plethysmographic lung volumes also 
resulted in lower within-test repeatability to that previously reported:  Within-test 
repeatability in sRaw was 7%, compared to the 8-11% described in pre-school 
children,54 whereas the within-test FRC repeatability was 90mL, which was much lower 
than the published recommendations of 150mL in adults94 and 160mL in children.149   
 
Within-test repeatability of spirometry measures was not investigated in the current 
study as it has been described elsewhere,105 however all spirometry results included in 
this study had a within-test repeatability of <150 mL.  Recently, Hankinson et al 
evaluated the impact of applying different repeatability measures to spirometry 
outcomes and found that the mean results were minimally influenced if there were at 
least 2 measures within 200 mL, however if repeatability was >200 mL (grade D) mean 
values were significantly reduced,189 which study supports the findings in the current 
study. 
 
Within-subject, between-test repeatability in IOS and sRaw was undertaken in a sub-
group of healthy children and children with SCD.  Knowledge of the between-test 
repeatability was required for both tests to enable the threshold for a significant BDR to 
be determined.  Within-subject, between-test repeatability was not attempted in 
spirometry or lung volumes since this was relatively well established in the literature 
and would have been an unnecessary additional burden on parents and children 
involved in the study.  Furthermore, the repeated deep inspiration required in the 
spirometry and lung volume assessments potentially would have confounded the IOS 
and sRaw results as the deep breaths may have fatigued the child or modified the 
results. 
 
Between-test repeatability in IOS outcomes was similar to that seen in the within-test 
repeatability (CV~5%), and the same in health and SCD.  These results were 
consistent with another study which evaluated IOS outcomes (R5, R20 and X5) in 
triplicate at baseline and after a placebo in 33 asthmatic preschool children (aged 3-6 
years) and found the baseline repeatability for R5 to be 4.1%.
44   Mean between-test 
repeatability in sRaw was also found to be similar to the within-test repeatability and 
similar in health and SCD, and much lower (absolute mean (SD) between-test 
repeatability: 0.08 kPa∙s (0.15)) than that previously reported by Bisgaard et al (which 
ranged between 0.19-0.20 kPa∙s).78   
 
 314 
 
The purpose of assessing between-test repeatability was to evaluate the thresholds for 
a BDR, whereby a significant BDR was a result over and above that seen in the 
between-test repeatability.  In IOS, healthy children demonstrated significant reductions 
in R5 and R10 of 15% whilst the thresholds for BDR in Fdr and AX (which reflect subtle 
changes over a range of frequencies, and hence physiological changes in the 
peripheral and more central airways) were much larger at 40%. Two children with SCD 
were identified with a significant BDR by changes in Fdr and AX, this was not detected 
with any other outcome.  The different thresholds for BDR in each outcome reflect the 
different areas of the lung that are being measured and the intrinsic variability of each 
outcome.  Low frequencies (5-10Hz) penetrate the small airways (defined as 
bronchioles <2mm in diameter), whereas high frequencies (15-20Hz) remain in the 
upper airways which have less muscle and are less likely to respond to an inhaled 
bronchodilator.  Unsurprisingly, this study revealed that outcomes that reflect the more 
peripheral airways demonstrated greater BDR. 
 
The thresholds for the BDR in IOS derived in the current study were slightly lower than 
that reported in previous studies which found reductions in R5 post bronchodilator to 
range from 20-25%47,48 up to 40%,135 whilst significant changes in R10 have ranged 
from 15-20%48 up to 30%.50  In addition reductions of up to 65% have been described 
for AX,37 and up to 50% for Fdr5-20.
176  These higher thresholds however, were based 
on preschool children who were slightly younger than the children assessed in the 
current study.  Preschool children have greater variability (higher SD) in all lung 
function outcomes (hence a larger range in a clinically significant change from 
baseline) and have been shown to demonstrate increased bronchodilator 
responsiveness.47  
 
Bronchodilator responsiveness was also assessed using sRaw as an outcome.  Based 
on the between-test repeatability measures, and after calculating the 95% CI around 
the limits of agreement (to take into account the small sample size (see section 9.3.2)) 
the conservative threshold for a significant BDR was estimated as -0.77 kPa∙s (45% 
reduction in sRaw).  This threshold was greater than that suggested by Nielsen et al 
who proposed a cut-off level of a 25% decrease in sRaw after bronchodilator 
administration based on 29 healthy pre-school children.90  The differences observed in 
the current study may be the result of more conservative limits of agreement (i.e. 
calculating 95% CI) and that a slightly different age range was assessed.  
Nevertheless, there was no significant difference in the level of BDR seen in the 
healthy children and the children with SCD regardless of the outcome used. 
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9.4.6 Comparison of LF results in SCD in this thesis to the literature 
SCD is a genetic disorder which predominantly affects children of Black African and 
Afro-Caribbean origin, and frequently results in significant respiratory morbidity.14  
Several pulmonary complications have been associated with SCD, including airway 
hyper-reactivity, acute chest syndrome, chronic sickle lung disease, pulmonary 
hypertension, and sleep disordered breathing,14 with studies also suggesting SCD 
progresses from an obstructive lung defect in childhood24 to a predominantly restrictive 
defect in adulthood.25  The main lung function tests used in the assessment of SCD are 
spirometry, lung volumes and measurements of diffusion capacity (DLCO, discussed in 
section 9.3.5.3).  IOS has been used as a secondary outcome in one study which 
demonstrated an increased Rrs that was associated with reduced expiratory flow rates 
and an increase in the number of ACS episodes,76 however sRaw has not been used 
previously as an outcome measure in SCD.  This section of the discussion compares 
and contrasts the main findings of this thesis with that found in the published literature 
with particular emphasis on spirometry and plethysmographic lung volumes in subjects 
with SCD. 
 
The principal findings were that children with SCD had significantly lower values of 
TLC, FEV1, and FVC, a normal FEV1/FVC ratio and similar bronchodilator 
responsiveness compared with healthy Black children of the same age.  Despite the 
relatively young age, results from this study suggested a pattern of restrictive lung 
disease in SCD, although some concurrent obstruction was also indicated by the raised 
RV/TLC, and the relative increase in R5 in the SCD children compared with healthy 
Black children.  These results are consistent with findings by Maclean et al, 25 and 
Sylvester et al,102 who both reported significant differences in FEV1 and FVC from 
predicted values (based on NHANES III African-American spirometry reference 
data107), and an unaffected FEV1/FVC (consistent with restrictive lung disease) in 
children with SCD.   
 
A recent study by Knight-Madden et al on 80 young adults with SCD and 80 ethnically 
matched controls (mean age: 23 years) also found a high prevalence of restrictive lung 
disease in SCD,168 however, 36% of the healthy Black adults measured were also 
diagnosed with restrictive lung disease.  These results suggest that the normative data 
used (Jamaican dataset) in the Knight-Madden study over-compensated for ethnic 
differences since it is unlikely that 36% of an apparently healthy population of young 
Black adults would have restrictive lung disease.  This study emphasises the 
importance of including a control group, since despite the inappropriate diagnosis of 
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restrictive lung disease in the healthy group, a significantly greater proportion (60%) of 
adults with SCD were diagnosed with restrictive lung disease.168 Although the severity 
of restriction appears to have been over-diagnosed in this study, the use of a control 
group did identify significant group differences between healthy Black adults and adults 
with SCD, consistent with the findings in this thesis.   
 
Longitudinal studies are important for determining the pathogenesis of abnormal lung 
function in children with SCD, however it was beyond the scope of the thesis to explore 
longitudinal changes in SCD.   A few studies have investigated the impact of somatic 
growth and lung function in children: Maclean et al performed at least two spirometry 
measures on 413 children with SCD.  At eight years of age they found 96.5% of the 
SCD children had normal lung function (confirmed by comparing results to NHANES III 
reference equations for Black children107), 0.9% had an obstructive defect and 2.6% 
had a restrictive defect.  By 17 years of age 81.3% still had normal lung function, none 
were obstructive and 18.7% were restrictive.25  Studies by Koumbourlis et al also found 
a decline in lung function over time that developed into a predominantly restrictive 
defect that was not associated with growth,191 however the restrictive defect observed 
in these children was evident at the earlier age of 10 years.192  Another study included 
a retrospective review of 79 children with SCD aged 6 to 19 years with at least two 
spirometry results (mean length of time between assessments: 3.5 years) and 
demonstrated that FEV1 increased at a lower rate in children with SCD than the healthy 
children, in the same way that FEV1 has been reported to increase at a lower rate in 
cystic fibrosis.193  While there was no correlation between the reduction in TLC and age 
in the current study,  the incidence of restrictive lung function has been previously 
reported to be greater in older than younger children with SCD, albeit findings based on 
cross-sectional data.10  Future studies will include longitudinal assessments of lung 
function in subjects with SCD. 
 
Further pulmonary complications in SCD have been described in the literature: Caboot 
and Allen reported “convincing evidence that asthma is a significant comorbidity in 
children with SCD.”14  This suggestion of asthma was because of the high incidence of 
airway-hyperreactivity (AHR) that has been reported,14,167,194-196 along with a frequency 
of respiratory symptoms.23,197,198  Boyd et al reported 17% if their cohort to be 
asthmatic,199  however this is a similar frequency to that observed in the general 
population,200 and the current study.  Furthermore, bronchodilator responsiveness and 
high levels of expired nitric oxide (FeNO)  are cardinal features of asthma,201,202 
however BDR was not detected in the current study, nor in other published 
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studies,168,203,204 and FeNO levels in SCD have been reported to be normal.102,167,168   
Thus, although asthma-like-symptoms in SCD have been reported in this study and  in 
the literature, and the current study demonstrated a raised RV/TLC and R5 (suggestive 
of obstruction) in some children, the absence of a BDR, reduced FeNO levels and 
evidence of accompanying restrictive changes (decreased FVC, normal FEV1/FVC and 
reduced TLC suggest that there is a different pathophysiological pathway causing  
elevated AHR than that usually ascribed to typical childhood asthma. 
 
Results from this study suggest a restrictive lung defect, which may be the result of 
repeated lung injury since the incidence of acute chest syndrome and reduced FVC 
has been demonstrated elsewhere,168 however it was beyond the remit of the thesis to 
investigate the cause of the restrictive lung disease (i.e. if restriction was a 
consequence of repeated lung injury or more simply a function of restricted growth).  
These areas will be addressed in the future. 
9.4.7 Interpretation of lung function results in SCD 
When interpreting lung function, whether or not a result falls outside the lower or upper 
limits of normality (LLN or ULN) is often of greater clinical significance than the precise 
percent predicted value. Depending on outcome, these limits of normality may be 
defined either as those encompassing 90% of the healthy population, in which case the 
LLN and ULN are based on the 5th and 95% centiles (i.e. ±1.64 SDs)  or alternatively 
encompassing 95% of the population, whereby the LLN and ULN represent the 2.5th 
and 97.5th centiles (±1.96 SD) respectively. Conventionally, a LLN derived from -1.64 
SD is used for outcomes such as FEV1 and FVC where only reductions in measured 
values are clinically relevant.  By contrast, for outcomes such as FRC or RV/TLC 
where either reduced or elevated values may be clinically significant with respect to 
defining restrictive or obstructive lung disease, then the 95% limits should apply.  When 
results are expressed as SD (or Z) scores, it is self-evident as to whether or not a result 
lies outside these limits, however interpretation of results when expressed as percent 
predicted is more complex due to the wide range of between-subject variability (i.e. SD) 
according to outcome.32,151   The current study calculated limits of normality based on 
95% limits of normality (+/-1.96 SD) regardless of the outcome (i.e. including 
spirometric outcomes) as this gives more conservative limits of normality and 
minimises over-diagnosis.  The use of 95% limits of normality is common practice when 
interpreting lung function in paediatrics.1,16,111,144 
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A variety of interpretation methods have been employed when interpreting spirometry 
in Black children. The majority of studies on SCD have used the ethnic-specific 
NHANES III reference equations205 to interpret spirometry,24,25,191,206 however these 
equations were not suitable for the young children assessed in the current study as 
they did not extend lower than eight years of age.  The Quanjer reference equations 
(based on White children)207 with a 12% reduction to account for ethnicity has also 
been used,208 but this method of interpretation was also inappropriate since the current 
study demonstrated that ethnic adjustments of 0.87 and 0.9 for FEV1 and FVC 
respectively would be more appropriate.  The use of the Wang equations5  was 
investigated and found them to be adequate for the children assessed in this study, 
however results were then limited to being expressed as percent predicted (with 
varying limits of normality) and could not be interpreted in children under six years of 
age.  The interim solution for children <6 years  was to use the All-Age equations126 
(based on White children) with an ethnic adjustment.   
 
The use of the All-Age reference equations126 plus an ethnic adjustment of 12% was 
used in a recent study by Tassel et al.  They studied 184 children with SCD (mean age 
12.6 years) and expressed results as Z Scores using -1.64 Z to define the lower limit of 
normal.203  With this method of interpretation, Tassel et al found that the prevalence of 
obstructive lung disease was only 5% which was much lower than that previously 
reported.76,192  The lower rate of obstructive lung disease in SCD was accredited to the 
fact that they used the All-Age equations with appropriate lower limits of normal. They 
reported that had they used the <80% predicted to define obstruction the frequency of 
obstruction in their cohort would have risen to 20%.203  Although the method for 
identifying obstruction may have been appropriate, the use of an ethnic adjustment of 
12% potentially under-estimated the degree of restriction (reported as 14%),203 since 
we found an adjustment factor of 10% for FVC and 6% for TLC to be more appropriate.   
 
Interpretation of lung volumes in children to date has been challenging.  This study 
demonstrated differences between two commonly used paediatric reference 
equations97,98 and recommended reference equations by Rosenthal et al98 with ethnic 
adjustments to be the most appropriate interim method for reporting lung volumes in 
children with SCD.  The results were consistent with findings by Sylvester et al7 who 
evaluated the interpretation of lung volumes in 80 Afro-Caribbean children aged 4 to 17 
years.  Predictive values based on standing and sitting height and 90% or 77% of lung 
volumes predictive values from Rosenthal98 and Cotes209 were evaluated in these 
children and the authors found that healthy Afro-Caribbean children had significantly 
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different lung volumes than those values predicted from White reference ranges based 
on standing height, with the magnitude of the difference dependent on the reference 
equation used.7  Sylvester et al, conducted further investigations to assess lung 
function in children with SCD, however they used their own healthy control data to 
make group comparisons rather than attempt to use published data with 
unconfirmed/unreliable ethnic adjustments.7,10 
 
An interesting example of possible misinterpretation of lung volumes in SCD was a 
study by Maclean et al who used the 1969 plethysmographic Wang equations210 
(based on height and sex) without ethnic adjustments to interpret lung volumes “as 
validated race-corrected lung volume prediction equations were not available.”25  The 
lack of any ethnic adjustment may have over-estimated restrictive lung disease slightly 
(as we found ethnic differences of ~6%), and the adjusted threshold to define 
restriction of TLC<70% predicted used in their study (rather than the 80% cut-off 
suggested by the ATS/ERS taskforce2) potentially over-estimated restriction further.  In 
addition Maclean et al reported RV/TLC in absolute values and suggested that the 
“decline” in the mean RV/TLC ratio at 8 years of age to 17 years of 0.3 to 0.21 
respectively was supportive of early injury or inflammation resulting in progressive 
changes in lung volumes across age.25 Their conclusion is not correct, as changes in 
RV/TLC during childhood are a consequence of considerable changes in airway 
properties, body proportions, thoracic shape and respiratory muscle function that occur 
during growth.3 Hence the results were unlikely to represent the progression of lung 
disease from an obstructive to restrictive lung disease, moreover, they simply reflect 
the change in RV/TLC that occurs with growth.  The study by Maclean et al,25 and 
Sylvester et al26,86 emphasise the importance of using a healthy control group and 
highlight the need for ethnically matched prediction equations in clinical practice. 
9.5 Implications of findings 
The overall findings of the study demonstrated significant ethnic differences in 
spirometric and plethysmographic lung volumes between healthy Black and White 
children, differences in IOS results obtained from Black children compared to predicted 
values, but no ethnic differences in sRaw.  Furthermore, significant group differences in 
TLC, FVC and FEV1 between healthy Black children and children with SCD were 
observed.  The main implications of these findings are that considerable 
misinterpretation of lung function results would have occurred had it not been for the 
inclusion of the control group and the “adjustments” or acknowledgement of ethnic 
differences in lung function that were made.  This study highlighted the importance of 
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measuring healthy children and has important implications on the clinical applications 
and interpretation of these lung function tests. 
9.5.1 Importance of controls 
The use of healthy White and Black control children enabled lung function methods and 
published reference data to be evaluated and, with the exception of spirometry, 
identified serious limitations in current paediatric lung function reference data.  Two 
paediatric reference equations for IOS were evaluated however neither was suitable for 
interpreting IOS data obtained from Black children (assessment in White children was 
not performed, see section 9.3.5.3).  Had the Dencker41 equations (based on White 
children) been applied directly to the IOS results from the SCD children, all results 
would be considered to be within the normal limits (+/-1.96).  However by comparing 
the results to the healthy Black children of the same age, significant differences both in 
absolute terms, and in the pattern of results (i.e. frequency dependence of resistance) 
could be identified.  Although IOS assessments could not be interpreted on an 
individual basis because of the lack of defined limits of normality, the inclusion of a 
healthy control group enabled group differences to be detected. 
  
The collation of sRaw data from healthy White children was the primary aim for the 
Asthma UK Initiative and enabled the development of the most comprehensive 
reference data for sRaw to date,
128 thus study of healthy control children were 
imperative to improve interpretation of sRaw measurements.  Moreover, it was essential 
that prospective controls (both White and Black children) were recruited to investigate 
the various factors that influence sRaw results and to confirm that ethnic differences do 
not occur.  sRaw did not prove to be a useful outcome measure when investigating lung 
function in SCD, however, the findings in this thesis mean that sRaw can be reliably 
interpreted in Black children with suspected lung disease. 
 
Further evidence of the importance of measuring healthy control children came in the 
assessment of plethysmographic lung volume measurements.  The two paediatric 
reference equations were evaluated and interpretation of lung volumes was shown to 
vary widely depending on which equation was applied.  The equations by Rosenthal et 
al98 were the more appropriate of the two (since they were based on a larger sample 
size and on modern equipment), however there were still inaccuracies with estimating 
the predicted FRC values in White children.  Had the healthy White children not been 
studied, the extent of hyperinflation (elevated FRC) would potentially have been mis-
diagnosed in these children.  Furthermore, use of healthy Black controls added to the 
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evidence that ethnic differences in lung volumes exist, but demonstrated that 
magnitude and direction of the difference were dependent on the outcome investigated.  
Had standard guidelines for interpreting plethysmographic lung volumes been used as 
opposed to using healthy control children, restrictive lung disease would have been 
over-estimated in SCD. 
 
Finally, given that ethnic differences in lung function have been attributed to differences 
in anthropometry,8,9,211 the use of healthy control children proved to be a vital inclusion 
in the study when describing anthropometry.  Despite the careful selection of the 
anthropometric reference data, important differences in anthropometry would have 
been missed had a control group not been recruited. Height, weight and BMI Z Score 
(according to the CDC growth charts131) in healthy White children averaged around 
0.3Z, whereas the Black children were slightly taller, heavier and had a higher BMI than 
the White children of the same age (with an average Z Score for all outcomes of 0.75).  
Although the Black children were “bigger” than White children at any given age, lung 
volumes (TLC) were smaller compared to their White peers.  Since restrictive lung 
disease is associated with obesity,212 the reduced lung volumes observed in the 
healthy Black children in comparison to their White peers could potentially be attributed 
to the higher BMI in these children, however a difference of 0.5Z Scores in BMI is 
unlikely to reduce lung volumes to such an extent.212  A more conceivable explanation 
is the trunk: leg ratio which was not recorded in the current study but will be evaluated 
in the future.  
 
A further important advantage of including healthy control children in this study lay in 
the fact that without a control group the relative growth restriction seen in SCD would 
not have been detected.  The mean height and weight Z Score (according to the CDC 
growth charts131) in the SCD group was ~0.1 Z which would have been considered to 
be completely “normal” had it not been for the fact that it was on average 0.5 Z Scores 
lower than the healthy Black children measured.  The significant anthropometric 
differences between SCD and health may in part be the reason for the lung restriction 
observed in SCD, however, whether the restrictive defect observed was a direct 
consequence of growth restriction overall or a result of repeated lung injury could not 
be determined in this study and was beyond the remit of the thesis to investigate small 
children with SCD with and without a history of repeated acute chest syndrome (ACS) 
insults. 
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9.5.2 Impact on future lung function studies 
Results from this study have significant clinical implications with regards to the 
application and interpretation of lung function tests in children.  Despite proving to be of 
little clinical use in the assessment of lung function in SCD, IOS and sRaw methods 
were thoroughly investigated and guidelines for their application and interpretation in 
children were improved, particularly with respect to sRaw.
128  In contrast, spirometry and 
plethysmographic lung volume assessments proved to be vital in the assessment of 
lung function in SCD and results were consistent with restrictive lung disease.  Given 
the added complexity of performing lung volume measurements, spirometry may be 
used as a screening measurement, and lung volumes performed when restrictive lung 
disease is suspected (i.e. reduced FEV1 and FVC with a normal/elevated FEV1/FVC).   
 
As yet, there is no evidence as to whether incorporating spirometry and lung volumes 
into the clinical care of SCD improves patient outcomes, however a number of children 
assessed in this study have now been referred to a respiratory specialist, and future 
work will include an audit of interventions and lung function outcomes. 
 
Overall findings from this study highlight the importance of both applying and 
interpreting results appropriately and ensuring that the choice of lung function test is 
tailored to the individual disease process as the ability of specific tests to detect 
abnormalities varies according to the underlying pathophysiology.  SCD is 
characterised by lung restriction,24 (hence measurements of lung volumes and 
spirometry were required), and has been associated with obstruction and “asthma-like” 
symptoms14 (hence the inclusion of IOS as an assessment of peripheral airway 
obstruction and sRaw as an effort independent assessment of airways resistance).  The 
interpretative methods and adjustments for ethnicity developed in this thesis can be 
applied in different disease groups, however given the sample size upon which these 
recommendations were based results should still be compared to a prospective, 
ethnically matched control group, and all future studies should include the 
measurement of sitting height as this potentially more relevant than standing height 
alone. 
 
In addition to the change in management of the children with SCD participating in this 
study (i.e. regular lung function assessments with reports to a respiratory specialist), 
the study has also changed clinical practice at the UCL Institute of Child Health.  All 
children now undergo sitting height measurements and anthropometric results are 
expressed using the CDC 2000 growth charts.131  Furthermore the study has raised 
 323 
 
awareness regarding both lung function abnormalities in SCD, and the importance of 
using appropriate reference data for interpreting lung function results in children (see 
introduction (page 21) for a summary of publications). 
9.5.2.1 Summary of lung function tests suggested for monitoring SCD 
Measurements of spirometry and lung volumes are essential to identify restrictive lung 
disease, furthermore measurements of IOS and sRaw may be useful to identify the 
obstructive lung disease sometimes observed in SCD.  Given the technical difficulties 
associated with performing lung volumes, the lack of reference data for IOS, and the 
confounding effects restriction may have on sRaw the primary lung function test 
recommended for monitoring SCD in young children is spirometry.  This should be 
performed at least annually and more frequently if significant symptoms suggest 
abnormalities.  If spirometry indicates a restrictive pattern (i.e. reduced FEV1 and FVC 
but normal FEV1/FVC ratio) plethysmographic lung volumes should be considered.  If 
spirometry identifies an obstructive pattern (i.e. reduced FEV1 and/or reduced 
FEV1/FVC) bronchodilator responsiveness should be assessed.  In addition to 
measurements of spirometry, assessments of Transfer factor may also elucidate 
additional important information regarding the pathophysiology of SCD in children old 
enough to complete such measurements satisfactorily. 
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9.6 Future research directions 
The following areas of research are either currently being undertaken or will be 
addressed in the future: 
9.6.1 Longitudinal studies of SCD 
The children with SCD assessed in this study were recruited as part of the SAC study 
and analysis was limited to cross-sectional data only.  The SAC study is funded until 
2015 and will continue to take annual measurements of lung function (spirometry and 
plethysmography) in all children included in this study as well as healthy control 
children.  Measurements of sitting height and respiratory questionnaires will also be 
undertaken in all of these children.  In addition funding will be sought and the ethics 
committee will be contacted to include the measurement of diffusion capacity of the 
lung for carbon monoxide (DLCO).  This should explain the underlying pathophysiology 
of the disease and determine the impact of restrictive growth on lung function. 
9.6.2 Assessment of anthropometry in health 
Many of the healthy children included in this thesis were recruited as part of the SLIC 
study.  This study has funding until 2014 and is currently undertaking detailed 
measurements of body shape, size and composition in 1600 primary school children of 
all ethnicities.  Assessments will be repeated after one year to determine the extent to 
which the known variability in lung function between children of different ethnic groups 
is explained by differences in body physique (size, shape and composition) 
(www.ucl.ac.uk/slic). 
9.6.3 Global lungs Initiative 
The Global Lungs Initiative (GLI) aims to develop improved ‘All-Age’ lung function 
reference equations across several ethnic groups and to recommend a global 
approach to the interpretation of spirometry data (www.lungfunction.org).  A manuscript 
describing the new GLI 2012 equations has been submitted to the ERS and future work 
will involve re-analysing the spirometry data within this thesis using the new Global All-
Age reference data to assess the extent to which the new GLI equations are 
appropriate for Black children.   
 
Phase 2b of the GLI taskforce remit involved re-evaluating QC criteria for children.  The 
analysis of spirometry data from two international centres was completed recently by 
five expert reviewers including the author of this thesis, on-going work on appropriate 
QC guidelines for spirometry will continue. 
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9.6.4 Application for ATS/ERS taskforce status for sRaw  
The aim of the taskforce will be to focus on improving the applicability of 
plethysmographic sRaw measurements in both clinical practice and research, including 
collecting evidence-based information to underpin standardisation of data collection 
and analysis.  This taskforce will be lead by Jane Kirkby and Dr Paul Robinson 
9.6.5 Liaison with manufacturers to improve lung function equipment 
As a result of the findings in this thesis and previous studies, communication with the 
manufacturers of lung function equipment has commenced: Software issues 
surrounding data extraction and reporting of IOS data have impeded the progress of 
this technique.  Despite limitations surrounding the reference equations for IOS, there 
are currently no published IOS reference data incorporated into the Jaeger V4.65 
device.  Communication with the manufacturers has resulted in an agreement that 
reference equations will be improved in newer software versions.  Similarly with sRaw, 
software modifications to enable accurate measures of flow and implementation of the 
reference equations128 need to be achieved to improve the use of this technique in 
children. 
 
In the field of spirometry, the implications of using inappropriate reference equations 
was highlighted in a recent letter to the ERJ by the author of this thesis.154   There has 
been some delay in ensuring the All-Age126 reference equations are implemented into 
the software but progress is being made and a current list of the manufacturers which 
have implemented these equations can be found at www.lungfunction.org. Further 
work will need to be done to ensure the new 2012 equations are incorporated into the 
spirometers once they become available. 
9.6.6 Extend the measurements to older children/other disease groups  
Finally, the study will be extended to include older healthy children and children with 
SCD to elucidate the impact of puberty on these important measurements.  
Measurements in both healthy White and Black children of all ages and ethnicities are 
required to enable these measurements to be successfully applied and interpreted in 
other disease groups. 
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9.7 Conclusions 
The work presented in this thesis has advanced the field in the application and 
interpretation of lung function measurements in children.  Comprehensive guidelines 
and reference data for sRaw have been developed and published.
128  Furthermore the 
extent of the ethnic differences occurring in plethysmographic lung volumes and 
spirometry was identified and interpretative recommendations were developed.146  
Despite developing recommendations for IOS the use in the clinical monitoring of lung 
function in SCD was limited, and sRaw failed to differentiate children with SCD from 
healthy children.  Spirometry and plethysmographic lung volumes however, proved to 
be extremely useful in differentiating lung function in children with SCD from health and 
demonstrated a restrictive lung disease pattern in the children with SCD assessed.  
Despite the high prevalence of respiratory symptoms, and the suggestion of airway 
obstruction in some studies, this thesis demonstrated that asthma is not a common 
feature of SCD.  Furthermore, the new interpretation strategies developed in this thesis 
will facilitate better interpretation of lung function in Black children.  
 
To date, this is the only study which has investigated the application and interpretation 
of IOS, sRaw, spirometry and lung volumes in healthy Black and White children aged 4 
to 12 years.  Moreover, no other study has applied all four lung assessments in SCD.  
The study highlighted the importance of including an appropriate control group since 
the extent of both growth restriction and the pattern of restrictive lung disease in SCD 
would not have been detected had comparisons been made directly to published 
reference data.  Results from this study therefore improve the overall standards for 
using these lung function tests in children.  Furthermore, results from this study may be 
transferred to different settings (i.e. additional laboratories, schools, and other field 
settings) and can be used to inform on both power calculations and suitable outcome 
measures for clinical trials/observation studies.   
 
A unique cohort of children with SCD with ethnically matched control children has been 
established as result of this thesis and, with continued funding and improvements to 
the applications and interpretation of lung function tests in children, respiratory 
management of children with SCD and other lung diseases will hopefully be enhanced. 
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Appendix 3: Pilot studies  
Specific airways resistance: The impact of bacterial filters. 
Two centres routinely used bacterial filters, and one only used filters for specific patient 
groups (e.g. cystic fibrosis).  To establish the impact of using bacterial filters, paired 
sets of sRaw measurements were obtained in 9 adults using a mouthpiece and noseclip 
with and without a bacterial filter in situ at a breathing frequency of 30bpm within a 10 
minute interval.  The equipment was calibrated with a filter in situ and the “filter check 
box” within the software was checked for all measurements i.e. the software had an 
internal adjustment that corrected for the added resistance created by the filter at all 
times, therefore the absolute difference of not having a filter in situ could be measured. 
The measurements were not taken in a random order as infection control policies 
meant that the pneumotach had to be disinfected after measurements which did not 
include a filter in situ.  All measurements were obtained by the same operator and 
analysed by a different operator who was masked to the measurement condition.  
Paired t-tests were used to determine the differences with and without filters.   
Results: sRtot was significantly higher when filters were used; mean difference 
(95%CI): 0.19kPa∙s (0.13; 0.25) (Figure A). 
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Figure A: Comparison of sRtot when recorded with or without a bacterial filter. 
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Appendix 4: Patient information sheets  
 SAC parent invitation letter 
 SAC parent information leaflet 
 SAC child information leaflet 
 
 SLIC parent invitation letter 
 SLIC parent information leaflet 
 SLIC child information leaflet 
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Appendix 5: Consent forms 
 SAC consent form 
 SLIC consent form 
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Appendix 6: Respiratory questionnaire 
 SAC health questionnaire 
 SAC screening questionnaire for healthy controls  
 SLIC health questionnaire 
 
 
